{"PMC7302248": [["IntroductionNetwork embedding, as one of network representation learning methods, has been successfully applied in a wide variety of network-based analysis tasks, such as link prediction, network reconstruction, node classification, etc. Different from traditional adjacency matrix representation, which suffers from high dimensionality and data sparsity, network embedding aims to represent each node in a given network as a vector in a low-dimensional latent space.", [["node", "ANATOMY", 212, 216], ["node", "ANATOMY", 397, 401], ["node", "MULTI-TISSUE_STRUCTURE", 212, 216], ["IntroductionNetwork embedding", "TREATMENT", 0, 29], ["based analysis tasks", "TEST", 141, 161], ["network reconstruction", "TREATMENT", 188, 210], ["node classification", "TREATMENT", 212, 231], ["traditional adjacency matrix representation", "PROBLEM", 253, 296], ["high dimensionality and data sparsity", "PROBLEM", 317, 354], ["each node", "PROBLEM", 392, 401], ["node classification", "OBSERVATION", 212, 231], ["traditional", "OBSERVATION_MODIFIER", 253, 264], ["adjacency matrix", "OBSERVATION", 265, 281], ["high dimensionality", "OBSERVATION_MODIFIER", 317, 336], ["node", "OBSERVATION", 397, 401]]]], "0f83a01bcd8c649d13f80855b129ad67044d1662": [["COVID-19: the current situation in AfghanistanOn March 11, 2020, WHO declared the outbreak of coronavirus disease 2019 (COVID-19), which originated in Wuhan, China, and has since spread around the world, a global pandemic.", [["coronavirus disease", "DISEASE", 94, 113], ["COVID-19", "CHEMICAL", 120, 128], ["coronavirus", "ORGANISM", 94, 105], ["coronavirus disease", "PROBLEM", 94, 113], ["COVID", "TEST", 120, 125], ["a global pandemic", "PROBLEM", 204, 221], ["coronavirus disease", "OBSERVATION", 94, 113], ["global", "OBSERVATION_MODIFIER", 206, 212], ["pandemic", "OBSERVATION", 213, 221]]], ["As of March 25, 2020, 413 467 cases of COVID-19 have been confirmed in more than 180 countries and territories and at least 18 000 deaths have been reported from around the world.", [["deaths", "DISEASE", 131, 137], ["COVID", "TEST", 39, 44]]], ["COVID-19 is now establishing a foothold in impoverished, war-torn nations, such as Afghanistan.", [["torn", "OBSERVATION", 61, 65]]], ["1 Although the health-care system in Afghanistan has improved over the past 17 years, we question its preparedness for a prompt and functional response to the COVID-19 outbreak.", [["the COVID", "TEST", 155, 164], ["improved", "OBSERVATION_MODIFIER", 53, 61]]], ["Afghanistan is now seeing a rapid rise in COVID-19 cases.", [["COVID", "TEST", 42, 47], ["rapid", "OBSERVATION_MODIFIER", 28, 33], ["rise", "OBSERVATION_MODIFIER", 34, 38]]], ["On Feb 24, 2020, the Afghanistan Ministry of Public Health reported on one individual with confirmed COVID-19 from the western province of Herat.", [["COVID", "TEST", 101, 106]]], ["The number of confirmed cases of COVID-19 in Afghanistan has since increased.", [["COVID-19", "CHEMICAL", 33, 41], ["COVID", "TEST", 33, 38], ["increased", "OBSERVATION_MODIFIER", 67, 76]]], ["As of March 25, 2020, there were 75 confirmed cases of COVID-19 across 12 provinces of Afghanistan, one death attributed to COVID-19, a 40-year-old man in Balkh province with no previous travel history, and two people reported to have recovered.", [["COVID", "DISEASE", 55, 60], ["death", "DISEASE", 104, 109], ["man", "ORGANISM", 148, 151], ["people", "ORGANISM", 211, 217], ["man", "SPECIES", 148, 151], ["people", "SPECIES", 211, 217], ["COVID", "TEST", 55, 60], ["COVID", "TEST", 124, 129]]], ["Controlling the epidemic in Afghanistan will be complicated by a diverse set of problems, including the influx of Afghan refugees from neighbouring Iran.", [["epidemic", "OBSERVATION_MODIFIER", 16, 24]]], ["Officials from the western province of Herat have documented thousands of people passing the border from Iran every day.", [["people", "ORGANISM", 74, 80], ["people", "SPECIES", 74, 80]]], ["Another concern is low public awareness of COVID-19 and low health literacy, exemplified by one individual with confirmed COVID-19, and 37 people with suspected COVID-19, leaving quarantine, risking the transmission of COVID-19 through communities.", [["people", "ORGANISM", 139, 145], ["people", "SPECIES", 139, 145], ["COVID", "TEST", 43, 48], ["COVID", "TEST", 122, 127], ["COVID", "TEST", 161, 166], ["COVID", "TEST", 219, 224], ["low", "OBSERVATION_MODIFIER", 19, 22]]], ["Furthermore, the cultural norms of shaking hands and hugging, community gatherings in mosques that still largely remain open, and the paucity of masks and effective handwashing technique will aggravate the crisis.", [["shaking hands", "PROBLEM", 35, 48], ["effective handwashing technique", "TREATMENT", 155, 186], ["the crisis", "PROBLEM", 202, 212], ["open", "OBSERVATION", 120, 124]]], ["Because of this dependency, any border restrictions put in place will not be as effective in controlling transmission.COVID-19: the current situation in AfghanistanAfghanistan is home to 31\u00b76 million people, 71\u00b75% of whom live in rural areas.", [["people", "ORGANISM", 200, 206], ["people", "SPECIES", 200, 206], ["this dependency", "PROBLEM", 11, 26], ["any border restrictions", "TREATMENT", 28, 51]]], ["Only one central public health laboratory in Afghanistan's capital, Kabul, is currently doing diagnostic tests for COVID-19, with a maximum capacity of 50 tests per day, costing US$1600 per diagnostic kit.", [["diagnostic tests", "TEST", 94, 110], ["COVID", "TEST", 115, 120], ["a maximum capacity", "TEST", 130, 148], ["one", "OBSERVATION_MODIFIER", 5, 8], ["central", "OBSERVATION_MODIFIER", 9, 16]]], ["The absence of local laboratories to do diagnostic tests for COVID-19 creates considerable delays in treating and isolating patients in hospitals in distant parts of the country.", [["COVID-19", "CHEMICAL", 61, 69], ["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 124, 132], ["diagnostic tests", "TEST", 40, 56], ["COVID", "TEST", 61, 66]]], ["There are only 9\u00b74 skilled health professionals, and 1\u00b79 physicians, per 10 000 individuals in Afghanistan; physicians are disproportionately distributed across the country, with 7\u00b72 physicians per 10 000 people in urban areas and as few as 0\u00b76 physicians per 10 000 in rural areas.", [["people", "ORGANISM", 205, 211], ["people", "SPECIES", 205, 211]]], ["5 According to WHO's Global Health Workforce Alliance, 22\u00b78 skilled health workers per 10 000 people are required for most countries to execute all essential health interventions.", [["people", "ORGANISM", 94, 100], ["people", "SPECIES", 94, 100]]], ["5 High levels of financial insecurity and low levels of personal safety in some remote provinces will have a large, direct negative effect on the provision and coverage of health services for both the general public and the health-care staff.", [["financial insecurity", "PROBLEM", 17, 37], ["large", "OBSERVATION_MODIFIER", 109, 114]]], ["With an overall literacy rate of 31\u00b774% in Afghanistan, 6 community awareness of imperative public health, sanitation, and hygiene practices and more efficient infection prevention strategies must be raised by an alternative method to the written word.COVID-19: the current situation in AfghanistanAccording to WHO reports, 7 almost 45 800 people have been displaced by conflicts and 24 500 people have been affected by natural disasters in Afghanistan in 2020 alone.", [["infection", "DISEASE", 160, 169], ["people", "ORGANISM", 340, 346], ["people", "ORGANISM", 391, 397], ["people", "SPECIES", 340, 346], ["people", "SPECIES", 391, 397], ["an overall literacy rate", "TEST", 5, 29], ["sanitation", "TREATMENT", 107, 117], ["hygiene practices", "TREATMENT", 123, 140], ["more efficient infection prevention strategies", "TREATMENT", 145, 191], ["infection", "OBSERVATION", 160, 169]]], ["Afghanistan is still endemic for emerging infectious diseases such as poliomyelitis and measles.", [["infectious diseases", "DISEASE", 42, 61], ["poliomyelitis", "DISEASE", 70, 83], ["measles", "DISEASE", 88, 95], ["emerging infectious diseases", "PROBLEM", 33, 61], ["poliomyelitis", "PROBLEM", 70, 83], ["measles", "PROBLEM", 88, 95], ["endemic", "OBSERVATION_MODIFIER", 21, 28], ["infectious", "OBSERVATION", 42, 52], ["poliomyelitis", "OBSERVATION", 70, 83]]], ["Because of inadequate health-care services in Afghanistan, many ill people will try to seek medical care oversees while wide travel restrictions and flight suspensions come into force in the country.COVID-19: the current situation in AfghanistanAs of March 25, 2020, the International Organization for Migration reports that approximately 136 400 Afghans have returned from Iran with a high risk of having COVID-19; however, Afghan authorities have locked down three cities on the Afghanistan-Iran border.", [["people", "ORGANISM", 68, 74], ["people", "SPECIES", 68, 74], ["COVID", "TEST", 406, 411]]]], "9e4b4b8070067c5652c75a06459b71642f3e4877": [["BackgroundThrombospondin-1 (TSP-1), a multimodular Ca 2+ -binding trimeric matricellular glycoprotein, is secreted by a wide array of cells such as platelets, fibroblasts, macrophages, dendritic cells, vascular smooth muscle cells, keratinocytes, epithelial cells, endothelial cells, and several cancer cells [1] [2] [3] .", [["cells", "ANATOMY", 134, 139], ["platelets", "ANATOMY", 148, 157], ["fibroblasts", "ANATOMY", 159, 170], ["macrophages", "ANATOMY", 172, 183], ["dendritic cells", "ANATOMY", 185, 200], ["vascular smooth muscle cells", "ANATOMY", 202, 230], ["keratinocytes", "ANATOMY", 232, 245], ["epithelial cells", "ANATOMY", 247, 263], ["endothelial cells", "ANATOMY", 265, 282], ["cancer cells", "ANATOMY", 296, 308], ["Ca", "CHEMICAL", 51, 53], ["cancer", "DISEASE", 296, 302], ["Ca 2+", "CHEMICAL", 51, 56], ["Thrombospondin-1", "GENE_OR_GENE_PRODUCT", 10, 26], ["TSP-1", "GENE_OR_GENE_PRODUCT", 28, 33], ["cells", "CELL", 134, 139], ["platelets", "CELL", 148, 157], ["fibroblasts", "CELL", 159, 170], ["macrophages", "CELL", 172, 183], ["dendritic cells", "CELL", 185, 200], ["vascular smooth muscle cells", "CELL", 202, 230], ["keratinocytes", "CELL", 232, 245], ["epithelial cells", "CELL", 247, 263], ["endothelial cells", "CELL", 265, 282], ["cancer cells", "CELL", 296, 308], ["Thrombospondin-1 (TSP-1", "PROTEIN", 10, 33], ["multimodular Ca 2+ -binding trimeric matricellular glycoprotein", "PROTEIN", 38, 101], ["platelets", "CELL_TYPE", 148, 157], ["fibroblasts", "CELL_TYPE", 159, 170], ["macrophages", "CELL_TYPE", 172, 183], ["dendritic cells", "CELL_TYPE", 185, 200], ["vascular smooth muscle cells", "CELL_TYPE", 202, 230], ["keratinocytes", "CELL_TYPE", 232, 245], ["epithelial cells", "CELL_TYPE", 247, 263], ["endothelial cells", "CELL_TYPE", 265, 282], ["cancer cells", "CELL_TYPE", 296, 308], ["BackgroundThrombospondin-1", "TEST", 0, 26], ["TSP", "TEST", 28, 31], ["a multimodular Ca 2+ -binding trimeric matricellular glycoprotein", "PROBLEM", 36, 101], ["a wide array of cells", "PROBLEM", 118, 139], ["platelets", "TEST", 148, 157], ["fibroblasts", "PROBLEM", 159, 170], ["macrophages", "PROBLEM", 172, 183], ["dendritic cells", "PROBLEM", 185, 200], ["vascular smooth muscle cells", "PROBLEM", 202, 230], ["keratinocytes", "PROBLEM", 232, 245], ["epithelial cells", "PROBLEM", 247, 263], ["endothelial cells", "PROBLEM", 265, 282], ["several cancer cells", "PROBLEM", 288, 308], ["matricellular glycoprotein", "ANATOMY", 75, 101], ["fibroblasts", "ANATOMY", 159, 170], ["macrophages", "ANATOMY", 172, 183], ["dendritic cells", "OBSERVATION", 185, 200], ["vascular", "ANATOMY", 202, 210], ["smooth muscle cells", "OBSERVATION", 211, 230], ["epithelial cells", "OBSERVATION", 247, 263], ["endothelial cells", "OBSERVATION", 265, 282], ["several", "OBSERVATION_MODIFIER", 288, 295], ["cancer", "OBSERVATION", 296, 302]]], ["Alterations in TSP-1 expression levels have been implicated in the pathophysiology of several clinical conditions including diabetes, cancer, renal failure, and cardiovascular diseases [4] [5] [6] .", [["cancer", "ANATOMY", 134, 140], ["renal", "ANATOMY", 142, 147], ["cardiovascular", "ANATOMY", 161, 175], ["diabetes", "DISEASE", 124, 132], ["cancer", "DISEASE", 134, 140], ["renal failure", "DISEASE", 142, 155], ["cardiovascular diseases", "DISEASE", 161, 184], ["TSP-1", "GENE_OR_GENE_PRODUCT", 15, 20], ["cancer", "CANCER", 134, 140], ["renal", "ORGAN", 142, 147], ["TSP", "PROTEIN", 15, 18], ["Alterations in TSP", "PROBLEM", 0, 18], ["diabetes", "PROBLEM", 124, 132], ["cancer", "PROBLEM", 134, 140], ["renal failure", "PROBLEM", 142, 155], ["cardiovascular diseases", "PROBLEM", 161, 184], ["cancer", "OBSERVATION", 134, 140], ["renal", "ANATOMY", 142, 147], ["failure", "OBSERVATION", 148, 155], ["cardiovascular", "ANATOMY", 161, 175]]], ["TSP-1 possesses interacting domains for a variety of proteins, which relay signals regulating a diverse range of cellular functions such as cytoskeletal organization, migration, cell-cell interaction, cell proliferation, autophagy, and apoptosis [2, 7, 8] .", [["cellular", "ANATOMY", 113, 121], ["cytoskeletal", "ANATOMY", 140, 152], ["cell", "ANATOMY", 178, 182], ["cell", "ANATOMY", 183, 187], ["cell", "ANATOMY", 201, 205], ["TSP-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["cellular", "CELL", 113, 121], ["cytoskeletal", "CELLULAR_COMPONENT", 140, 152], ["cell", "CELL", 178, 182], ["cell", "CELL", 183, 187], ["cell", "CELL", 201, 205], ["TSP-1", "PROTEIN", 0, 5], ["interacting domains", "PROTEIN", 16, 35], ["TSP", "TEST", 0, 3], ["a variety of proteins", "TREATMENT", 40, 61], ["cell proliferation", "PROBLEM", 201, 219], ["autophagy", "PROBLEM", 221, 230], ["apoptosis", "PROBLEM", 236, 245], ["cell proliferation", "OBSERVATION", 201, 219]]], ["Mechanisms of TSP-1-induced apoptosis, widely characterized in endothelial and cancer cells, have been reported to involve caspases, NF-\u03baB, Bax, Bcl-2, nitric oxide (NO), as well as p38 and c-Jun N-terminal kinases [9, 10] .", [["endothelial", "ANATOMY", 63, 74], ["cancer cells", "ANATOMY", 79, 91], ["cancer", "DISEASE", 79, 85], ["nitric oxide", "CHEMICAL", 152, 164], ["NO", "CHEMICAL", 166, 168], ["nitric oxide", "CHEMICAL", 152, 164], ["NO", "CHEMICAL", 166, 168], ["N", "CHEMICAL", 196, 197], ["TSP-1", "GENE_OR_GENE_PRODUCT", 14, 19], ["endothelial", "CELL", 63, 74], ["cancer cells", "CELL", 79, 91], ["caspases", "GENE_OR_GENE_PRODUCT", 123, 131], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 133, 138], ["Bax", "GENE_OR_GENE_PRODUCT", 140, 143], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 145, 150], ["nitric oxide", "SIMPLE_CHEMICAL", 152, 164], ["NO", "GENE_OR_GENE_PRODUCT", 166, 168], ["p38", "GENE_OR_GENE_PRODUCT", 182, 185], ["c-Jun N-terminal kinases", "GENE_OR_GENE_PRODUCT", 190, 214], ["TSP-1", "PROTEIN", 14, 19], ["endothelial and cancer cells", "CELL_TYPE", 63, 91], ["caspases", "PROTEIN", 123, 131], ["NF-\u03baB", "PROTEIN", 133, 138], ["Bax", "PROTEIN", 140, 143], ["Bcl-2", "PROTEIN", 145, 150], ["p38 and c-Jun N-terminal kinases", "PROTEIN", 182, 214], ["TSP", "TEST", 14, 17], ["induced apoptosis", "PROBLEM", 20, 37], ["cancer cells", "PROBLEM", 79, 91], ["caspases", "TEST", 123, 131], ["NF", "TEST", 133, 135], ["Bax", "TEST", 140, 143], ["Bcl", "TEST", 145, 148], ["nitric oxide", "TREATMENT", 152, 164], ["p38", "TEST", 182, 185], ["apoptosis", "OBSERVATION", 28, 37], ["endothelial", "ANATOMY", 63, 74], ["cancer cells", "OBSERVATION", 79, 91]]], ["TSP-1-induced apoptosis has been largely ascribed to its binding with tumor necrosis factor receptor-1, scavenger receptor CD36, and the integrin-associated protein CD47 [10] .", [["TSP-1", "CHEMICAL", 0, 5], ["tumor", "DISEASE", 70, 75], ["TSP-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["tumor necrosis factor receptor-1", "GENE_OR_GENE_PRODUCT", 70, 102], ["CD36", "GENE_OR_GENE_PRODUCT", 123, 127], ["CD47", "GENE_OR_GENE_PRODUCT", 165, 169], ["TSP-1", "PROTEIN", 0, 5], ["tumor necrosis factor receptor-1", "PROTEIN", 70, 102], ["scavenger receptor CD36", "PROTEIN", 104, 127], ["integrin-associated protein", "PROTEIN", 137, 164], ["CD47", "PROTEIN", 165, 169], ["TSP", "TEST", 0, 3], ["apoptosis", "PROBLEM", 14, 23], ["tumor necrosis factor receptor", "TEST", 70, 100], ["scavenger receptor CD36", "TEST", 104, 127], ["the integrin-associated protein CD47", "TEST", 133, 169], ["tumor", "OBSERVATION", 70, 75]]], ["CD47, a ubiquitously expressed glycosylated cell surface protein, regulates cell activation or survival, depending on the physiological context [11, 12] .", [["cell surface", "ANATOMY", 44, 56], ["cell", "ANATOMY", 76, 80], ["CD47", "GENE_OR_GENE_PRODUCT", 0, 4], ["cell surface", "CELLULAR_COMPONENT", 44, 56], ["cell", "CELL", 76, 80], ["CD47", "PROTEIN", 0, 4], ["ubiquitously expressed glycosylated cell surface protein", "PROTEIN", 8, 64], ["CD47", "TEST", 0, 4], ["glycosylated cell surface protein", "TEST", 31, 64], ["regulates cell activation", "PROBLEM", 66, 91], ["glycosylated cell", "OBSERVATION", 31, 48], ["cell activation", "OBSERVATION", 76, 91]]], ["TSP-1 signaling via its cognate receptor CD47 has further been implicated in orchestrating cytoplasmic Ca 2+ dynamics and, thus, influencing various physiological functions [12] .BackgroundIn mature red blood cells (RBCs), CD47 is associated with different membrane proteins forming linkages with both cytoskeletal and non-cytoskeletal cellular components [11] .", [["cytoplasmic", "ANATOMY", 91, 102], ["red blood cells", "ANATOMY", 199, 214], ["RBCs", "ANATOMY", 216, 220], ["membrane", "ANATOMY", 257, 265], ["cytoskeletal", "ANATOMY", 302, 314], ["cellular", "ANATOMY", 336, 344], ["Ca", "CHEMICAL", 103, 105], ["Ca 2+", "CHEMICAL", 103, 108], ["TSP-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["CD47", "GENE_OR_GENE_PRODUCT", 41, 45], ["cytoplasmic", "ORGANISM_SUBSTANCE", 91, 102], ["Ca 2+", "GENE_OR_GENE_PRODUCT", 103, 108], ["red blood cells", "CELL", 199, 214], ["RBCs", "CELL", 216, 220], ["CD47", "GENE_OR_GENE_PRODUCT", 223, 227], ["membrane", "CELLULAR_COMPONENT", 257, 265], ["cytoskeletal", "CELLULAR_COMPONENT", 302, 314], ["non-cytoskeletal cellular", "CELLULAR_COMPONENT", 319, 344], ["TSP", "PROTEIN", 0, 3], ["CD47", "PROTEIN", 41, 45], ["mature red blood cells", "CELL_TYPE", 192, 214], ["RBCs", "CELL_TYPE", 216, 220], ["CD47", "PROTEIN", 223, 227], ["membrane proteins", "PROTEIN", 257, 274], ["TSP", "TEST", 0, 3], ["red blood cells", "TEST", 199, 214], ["RBCs", "TEST", 216, 220], ["CD47", "TEST", 223, 227], ["different membrane proteins forming linkages", "PROBLEM", 247, 291], ["both cytoskeletal and non-cytoskeletal cellular components", "PROBLEM", 297, 355], ["cytoplasmic Ca", "OBSERVATION", 91, 105], ["red blood cells", "OBSERVATION", 199, 214], ["membrane proteins", "OBSERVATION", 257, 274], ["linkages", "OBSERVATION_MODIFIER", 283, 291], ["both", "OBSERVATION_MODIFIER", 297, 301], ["cytoskeletal", "OBSERVATION_MODIFIER", 302, 314], ["non-cytoskeletal cellular components", "OBSERVATION", 319, 355]]], ["CD47 is pivotal in inhibiting RBC phagocytosis via binding to signal regulatory protein \u03b1 (SIRP\u03b1) on macrophages, which counteracts phagocytosis of non-opsonized as well as IgG or complement-opsonized RBCs [13, 14] .", [["RBC", "ANATOMY", 30, 33], ["macrophages", "ANATOMY", 101, 112], ["RBCs", "ANATOMY", 201, 205], ["CD47", "GENE_OR_GENE_PRODUCT", 0, 4], ["RBC", "CELL", 30, 33], ["signal regulatory protein \u03b1", "GENE_OR_GENE_PRODUCT", 62, 89], ["SIRP\u03b1", "GENE_OR_GENE_PRODUCT", 91, 96], ["macrophages", "CELL", 101, 112], ["IgG", "GENE_OR_GENE_PRODUCT", 173, 176], ["RBCs", "CELL", 201, 205], ["CD47", "PROTEIN", 0, 4], ["RBC", "CELL_TYPE", 30, 33], ["signal regulatory protein \u03b1", "PROTEIN", 62, 89], ["SIRP\u03b1", "PROTEIN", 91, 96], ["macrophages", "CELL_TYPE", 101, 112], ["IgG", "PROTEIN", 173, 176], ["complement-opsonized RBCs", "CELL_TYPE", 180, 205], ["RBC phagocytosis", "TEST", 30, 46], ["signal regulatory protein", "TEST", 62, 87], ["macrophages", "PROBLEM", 101, 112], ["IgG", "TEST", 173, 176], ["opsonized RBCs", "TEST", 191, 205], ["RBC phagocytosis", "OBSERVATION", 30, 46]]], ["A decline of cell surface CD47 expression during RBC aging in vivo is believed to promote the clearance of senescent RBCs [15] .", [["cell surface", "ANATOMY", 13, 25], ["RBC", "ANATOMY", 49, 52], ["RBCs", "ANATOMY", 117, 121], ["cell", "CELL", 13, 17], ["CD47", "GENE_OR_GENE_PRODUCT", 26, 30], ["RBC", "CELL", 49, 52], ["RBCs", "CELL", 117, 121], ["CD47", "PROTEIN", 26, 30], ["RBC", "CELL_TYPE", 49, 52], ["senescent RBCs", "CELL_TYPE", 107, 121], ["A decline", "PROBLEM", 0, 9], ["cell surface CD47 expression", "TREATMENT", 13, 41], ["RBC aging", "TREATMENT", 49, 58], ["senescent RBCs", "PROBLEM", 107, 121]]], ["Furthermore, microparticle release during RBC storage has been reported to favor CD47 loss during storage of RBCs for transfusion [16] .", [["microparticle", "ANATOMY", 13, 26], ["RBC", "ANATOMY", 42, 45], ["RBCs", "ANATOMY", 109, 113], ["microparticle", "CELLULAR_COMPONENT", 13, 26], ["RBC", "CELL", 42, 45], ["CD47", "GENE_OR_GENE_PRODUCT", 81, 85], ["RBCs", "CELL", 109, 113], ["RBC", "CELL_TYPE", 42, 45], ["CD47", "PROTEIN", 81, 85], ["RBCs", "CELL_TYPE", 109, 113], ["RBC storage", "TEST", 42, 53], ["CD47 loss", "PROBLEM", 81, 90], ["RBCs", "TEST", 109, 113], ["transfusion", "TREATMENT", 118, 129]]], ["Beyond its significance in RBC aging, CD47 mediates the interaction of fibrinogen with the RBC membrane [17] , and may, therefore, contribute to RBC hyperaggregation and altered hemorheology in inflammatory conditions [18, 19] .BackgroundSimilar to apoptosis of nucleated cells [10] , ligation of CD47 with monoclonal antibodies, TSP-1, or its derivative peptides has been shown to trigger phosphatidylserine (PS) exposure on RBC cell surface with a concomitant loss of their viability [20] .", [["RBC", "ANATOMY", 27, 30], ["RBC membrane", "ANATOMY", 91, 103], ["RBC", "ANATOMY", 145, 148], ["nucleated cells", "ANATOMY", 262, 277], ["RBC cell surface", "ANATOMY", 426, 442], ["hemorheology", "DISEASE", 178, 190], ["phosphatidylserine", "CHEMICAL", 390, 408], ["PS", "CHEMICAL", 410, 412], ["phosphatidylserine", "CHEMICAL", 390, 408], ["RBC", "CELL", 27, 30], ["CD47", "GENE_OR_GENE_PRODUCT", 38, 42], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 71, 81], ["RBC membrane", "CELLULAR_COMPONENT", 91, 103], ["RBC", "CELL", 145, 148], ["nucleated cells", "CELL", 262, 277], ["CD47", "GENE_OR_GENE_PRODUCT", 297, 301], ["TSP-1", "GENE_OR_GENE_PRODUCT", 330, 335], ["phosphatidylserine", "SIMPLE_CHEMICAL", 390, 408], ["PS", "SIMPLE_CHEMICAL", 410, 412], ["RBC cell", "CELL", 426, 434], ["surface", "CELLULAR_COMPONENT", 435, 442], ["RBC", "CELL_TYPE", 27, 30], ["CD47", "PROTEIN", 38, 42], ["fibrinogen", "PROTEIN", 71, 81], ["RBC", "CELL_TYPE", 145, 148], ["nucleated cells", "CELL_TYPE", 262, 277], ["CD47", "PROTEIN", 297, 301], ["monoclonal antibodies", "PROTEIN", 307, 328], ["TSP-1", "PROTEIN", 330, 335], ["RBC aging", "TEST", 27, 36], ["fibrinogen", "TEST", 71, 81], ["the RBC membrane", "TEST", 87, 103], ["RBC hyperaggregation", "PROBLEM", 145, 165], ["altered hemorheology in inflammatory conditions", "PROBLEM", 170, 217], ["nucleated cells", "PROBLEM", 262, 277], ["ligation", "TREATMENT", 285, 293], ["CD47", "TEST", 297, 301], ["monoclonal antibodies", "TEST", 307, 328], ["TSP", "TEST", 330, 333], ["its derivative peptides", "PROBLEM", 340, 363], ["RBC cell surface", "TEST", 426, 442], ["a concomitant loss of their viability", "PROBLEM", 448, 485], ["RBC aging", "OBSERVATION", 27, 36], ["RBC hyperaggregation", "OBSERVATION", 145, 165], ["altered", "OBSERVATION_MODIFIER", 170, 177], ["hemorheology", "OBSERVATION", 178, 190], ["inflammatory", "OBSERVATION_MODIFIER", 194, 206], ["nucleated cells", "OBSERVATION", 262, 277], ["RBC cell", "OBSERVATION", 426, 434], ["surface", "OBSERVATION_MODIFIER", 435, 442]]], ["The mechanisms underlying this phenomenon in RBCs, however, remain elusive.", [["RBCs", "ANATOMY", 45, 49], ["RBCs", "CELL", 45, 49], ["RBCs", "CELL_TYPE", 45, 49], ["this phenomenon in RBCs", "PROBLEM", 26, 49]]], ["PS externalization, a cardinal morphologic sign of cell death (sometimes also referred to as eryptosis), is stimulated by activation of Ca 2+ -sensitive scramblases [21] [22] [23] .", [["cell", "ANATOMY", 51, 55], ["death", "DISEASE", 56, 61], ["eryptosis", "DISEASE", 93, 102], ["Ca", "CHEMICAL", 136, 138], ["Ca 2+", "CHEMICAL", 136, 141], ["cell", "CELL", 51, 55], ["Ca 2+", "SIMPLE_CHEMICAL", 136, 141], ["scramblases [21] [22] [23]", "SIMPLE_CHEMICAL", 153, 179], ["Ca 2+ -sensitive scramblases", "PROTEIN", 136, 164], ["PS externalization", "TEST", 0, 18], ["cell death", "PROBLEM", 51, 61], ["Ca", "TEST", 136, 138], ["sensitive scramblases", "PROBLEM", 143, 164], ["cell death", "OBSERVATION", 51, 61]]], ["Influx of extracellular Ca 2+ into the RBC cytoplasm is mediated by voltage-gated and voltageindependent non-selective cation channels (NSCC [24, 25] ), which are activated by pathophysiologic cell stressors such as hyperthermia, oxidative stress, extracellular hyperosmolality, and starvation [21, 26] .", [["extracellular", "ANATOMY", 10, 23], ["RBC cytoplasm", "ANATOMY", 39, 52], ["cell", "ANATOMY", 193, 197], ["extracellular", "ANATOMY", 248, 261], ["Ca", "CHEMICAL", 24, 26], ["hyperthermia", "DISEASE", 216, 228], ["Ca 2+", "CHEMICAL", 24, 29], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 10, 23], ["Ca 2+", "SIMPLE_CHEMICAL", 24, 29], ["RBC", "CELLULAR_COMPONENT", 39, 42], ["cytoplasm", "ORGANISM_SUBSTANCE", 43, 52], ["cation", "SIMPLE_CHEMICAL", 119, 125], ["cell", "CELL", 193, 197], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 248, 261], ["voltageindependent non-selective cation channels", "PROTEIN", 86, 134], ["Influx of extracellular Ca", "TEST", 0, 26], ["the RBC cytoplasm", "TEST", 35, 52], ["gated and voltageindependent non-selective cation channels", "PROBLEM", 76, 134], ["pathophysiologic cell stressors", "PROBLEM", 176, 207], ["hyperthermia", "PROBLEM", 216, 228], ["oxidative stress", "PROBLEM", 230, 246], ["extracellular hyperosmolality", "PROBLEM", 248, 277], ["Ca", "OBSERVATION", 24, 26], ["RBC cytoplasm", "OBSERVATION", 39, 52], ["pathophysiologic cell stressors", "OBSERVATION", 176, 207], ["extracellular hyperosmolality", "OBSERVATION", 248, 277]]], ["Supraphysiologic Ca 2+ overload in RBCs induces metabolic reprogramming [27] , and activation of multiple enzymes [21] , thereby eliciting cellular dysfunction and death.", [["RBCs", "ANATOMY", 35, 39], ["cellular", "ANATOMY", 139, 147], ["Ca", "CHEMICAL", 17, 19], ["cellular dysfunction", "DISEASE", 139, 159], ["death", "DISEASE", 164, 169], ["Ca 2+", "CHEMICAL", 17, 22], ["Ca 2+", "SIMPLE_CHEMICAL", 17, 22], ["RBCs", "CELL", 35, 39], ["cellular", "CELL", 139, 147], ["RBCs", "CELL_TYPE", 35, 39], ["Supraphysiologic Ca", "PROBLEM", 0, 19], ["overload in RBCs", "PROBLEM", 23, 39], ["metabolic reprogramming", "TEST", 48, 71], ["multiple enzymes", "TEST", 97, 113], ["eliciting cellular dysfunction", "PROBLEM", 129, 159], ["death", "PROBLEM", 164, 169], ["overload", "OBSERVATION", 23, 31], ["metabolic reprogramming", "OBSERVATION", 48, 71], ["cellular dysfunction", "OBSERVATION", 139, 159]]], ["PSexposing RBCs are rapidly cleared from the circulation and catabolized by macrophages of the reticuloendothelial system in the spleen and liver [21, 28] .BackgroundIn the present study, using cytofluorometric and electrophysiological approaches we examined the influence of CD47-dependent signaling, evoked by exogenous TSP-1 or antibody-mediated CD47 ligation, on Ca 2+ dynamics in human RBCs.", [["RBCs", "ANATOMY", 11, 15], ["macrophages", "ANATOMY", 76, 87], ["reticuloendothelial system", "ANATOMY", 95, 121], ["spleen", "ANATOMY", 129, 135], ["liver", "ANATOMY", 140, 145], ["RBCs", "ANATOMY", 391, 395], ["Ca", "CHEMICAL", 367, 369], ["Ca 2+", "CHEMICAL", 367, 372], ["RBCs", "CELL", 11, 15], ["macrophages", "CELL", 76, 87], ["reticuloendothelial system", "ANATOMICAL_SYSTEM", 95, 121], ["spleen", "ORGAN", 129, 135], ["liver", "ORGAN", 140, 145], ["CD47", "GENE_OR_GENE_PRODUCT", 276, 280], ["TSP-1", "GENE_OR_GENE_PRODUCT", 322, 327], ["CD47", "GENE_OR_GENE_PRODUCT", 349, 353], ["Ca 2+", "SIMPLE_CHEMICAL", 367, 372], ["human", "ORGANISM", 385, 390], ["RBCs", "CELL", 391, 395], ["PSexposing RBCs", "CELL_TYPE", 0, 15], ["macrophages", "CELL_TYPE", 76, 87], ["CD47", "PROTEIN", 276, 280], ["TSP", "PROTEIN", 322, 325], ["CD47", "PROTEIN", 349, 353], ["human RBCs", "CELL_TYPE", 385, 395], ["human", "SPECIES", 385, 390], ["human", "SPECIES", 385, 390], ["PSexposing RBCs", "PROBLEM", 0, 15], ["the present study", "TEST", 169, 186], ["exogenous TSP", "TEST", 312, 325], ["antibody", "TEST", 331, 339], ["CD47 ligation", "TREATMENT", 349, 362], ["Ca", "TEST", 367, 369], ["rapidly", "OBSERVATION_MODIFIER", 20, 27], ["cleared", "OBSERVATION", 28, 35], ["circulation", "ANATOMY_MODIFIER", 45, 56], ["macrophages", "OBSERVATION", 76, 87], ["reticuloendothelial system", "ANATOMY", 95, 121], ["spleen", "ANATOMY", 129, 135], ["liver", "ANATOMY", 140, 145], ["CD47 ligation", "OBSERVATION", 349, 362]]], ["We further studied the effect of TSP-1 exposure on multiple parameters of RBC deformability and cell death.RBCs and reagentsLeuko-depleted RBC concentrates were provided by Canadian Blood Services (CBS) Network Centre for Applied Development (netCAD, Vancouver, BC, Canada) after prior approval from the CBS Research Ethics Board (#2015.022).", [["RBC", "ANATOMY", 74, 77], ["cell", "ANATOMY", 96, 100], ["RBCs", "ANATOMY", 107, 111], ["RBC", "ANATOMY", 139, 142], ["Blood", "ANATOMY", 182, 187], ["TSP-1", "CHEMICAL", 33, 38], ["death", "DISEASE", 101, 106], ["TSP-1", "GENE_OR_GENE_PRODUCT", 33, 38], ["RBC", "CELL", 74, 77], ["cell", "CELL", 96, 100], ["RBCs", "CELL", 107, 111], ["Leuko", "SIMPLE_CHEMICAL", 124, 129], ["RBC", "CELL", 139, 142], ["TSP", "PROTEIN", 33, 36], ["RBC", "CELL_TYPE", 74, 77], ["RBCs", "CELL_TYPE", 107, 111], ["Leuko-depleted RBC", "CELL_TYPE", 124, 142], ["TSP", "TEST", 33, 36], ["RBC deformability", "PROBLEM", 74, 91], ["cell death", "PROBLEM", 96, 106], ["RBCs", "TEST", 107, 111], ["reagents", "TREATMENT", 116, 124], ["Leuko", "TEST", 124, 129], ["RBC concentrates", "TREATMENT", 139, 155], ["RBC deformability", "OBSERVATION", 74, 91], ["cell death", "OBSERVATION", 96, 106], ["depleted RBC concentrates", "OBSERVATION", 130, 155]]], ["For some experiments, these concentrates were provided by the blood bank of the University of T\u00fcbingen (#184/2003 V), Germany, or by the blood bank of Norrlands University Hospital, Ume\u00e5, Sweden.", [["blood", "ANATOMY", 62, 67], ["blood", "ANATOMY", 137, 142], ["blood", "ORGANISM_SUBSTANCE", 62, 67], ["blood", "ORGANISM_SUBSTANCE", 137, 142]]], ["Donor RBCs, drawn from refrigerated blood bags containing SAG-M additive solution, were washed twice in PBS (1000\u00d7g for 10 min) and subsequently incubated in vitro (1% hematocrit unless indicated otherwise) at 37\u00b0C in Ringer's solution (pH 7.4) containing 125 mM NaCl, 5 mM KCl, 1 mM MgSO 4 , 32 mM HEPES, 5 mM glucose, and 1 mM CaCl 2 .", [["RBCs", "ANATOMY", 6, 10], ["blood", "ANATOMY", 36, 41], ["SAG-M", "CHEMICAL", 58, 63], ["NaCl", "CHEMICAL", 263, 267], ["KCl", "CHEMICAL", 274, 277], ["glucose", "CHEMICAL", 311, 318], ["NaCl", "CHEMICAL", 263, 267], ["KCl", "CHEMICAL", 274, 277], ["MgSO 4", "CHEMICAL", 284, 290], ["HEPES", "CHEMICAL", 299, 304], ["glucose", "CHEMICAL", 311, 318], ["CaCl 2", "CHEMICAL", 329, 335], ["Donor RBCs", "CELL", 0, 10], ["blood", "ORGANISM_SUBSTANCE", 36, 41], ["glucose", "SIMPLE_CHEMICAL", 311, 318], ["Donor RBCs", "CELL_TYPE", 0, 10], ["Donor RBCs", "TEST", 0, 10], ["blood bags", "TREATMENT", 36, 46], ["SAG-M additive solution", "TREATMENT", 58, 81], ["hematocrit", "TEST", 168, 178], ["pH", "TEST", 237, 239], ["125 mM NaCl", "TREATMENT", 256, 267], ["5 mM KCl", "TREATMENT", 269, 277], ["MgSO", "TEST", 284, 288], ["32 mM HEPES", "TREATMENT", 293, 304], ["glucose", "TEST", 311, 318], ["1 mM CaCl", "TREATMENT", 324, 333]]], ["Sample sizes (number of RBC units; n) for control and treatment groups used in individual experiments are indicated in the figure legends.", [["Sample sizes", "TEST", 0, 12], ["RBC units", "TREATMENT", 24, 33], ["control and treatment groups", "TREATMENT", 42, 70], ["sizes", "OBSERVATION_MODIFIER", 7, 12]]], ["Where indicated, RBCs were incubated with recombinant human thrombospondin-1 (1-50 \u03bcg/mL; R&D Systems, Minneapolis, MN, USA) or with anti-human CD47 mAb 1F7 (mouse IgG1), which was purified from hybridoma supernatants [29] [30] [31] .", [["RBCs", "ANATOMY", 17, 21], ["supernatants", "ANATOMY", 205, 217], ["RBCs", "CELL", 17, 21], ["human", "ORGANISM", 54, 59], ["thrombospondin-1", "GENE_OR_GENE_PRODUCT", 60, 76], ["CD47", "GENE_OR_GENE_PRODUCT", 144, 148], ["mouse", "ORGANISM", 158, 163], ["IgG1", "GENE_OR_GENE_PRODUCT", 164, 168], ["RBCs", "CELL_TYPE", 17, 21], ["recombinant human thrombospondin-1", "PROTEIN", 42, 76], ["anti-human CD47 mAb 1F7", "PROTEIN", 133, 156], ["mouse IgG1", "PROTEIN", 158, 168], ["human", "SPECIES", 54, 59], ["mouse", "SPECIES", 158, 163], ["human", "SPECIES", 54, 59], ["mouse", "SPECIES", 158, 163], ["RBCs", "TEST", 17, 21], ["recombinant human thrombospondin", "TEST", 42, 74], ["anti-human CD47 mAb", "TREATMENT", 133, 152], ["hybridoma supernatants", "TEST", 195, 217]]], ["In some experiments, RBCs were treated with sodium nitroprusside (Sigma Aldrich, Taufkirchen, Germany) or amiloride (Sigma Aldrich), as described in the figure legends.Flow cytometryMultiple indices of RBC cell death were analyzed using flow cytometry.", [["RBCs", "ANATOMY", 21, 25], ["RBC cell", "ANATOMY", 202, 210], ["sodium nitroprusside", "CHEMICAL", 44, 64], ["amiloride", "CHEMICAL", 106, 115], ["sodium nitroprusside", "CHEMICAL", 44, 64], ["amiloride", "CHEMICAL", 106, 115], ["RBCs", "CELL", 21, 25], ["sodium nitroprusside", "SIMPLE_CHEMICAL", 44, 64], ["Sigma Aldrich", "SIMPLE_CHEMICAL", 66, 79], ["amiloride", "SIMPLE_CHEMICAL", 106, 115], ["Sigma Aldrich", "SIMPLE_CHEMICAL", 117, 130], ["RBC cell", "CELL", 202, 210], ["RBCs", "CELL_TYPE", 21, 25], ["RBC", "CELL_TYPE", 202, 205], ["RBCs", "TEST", 21, 25], ["sodium nitroprusside", "TREATMENT", 44, 64], ["Taufkirchen", "TREATMENT", 81, 92], ["amiloride (Sigma Aldrich)", "TREATMENT", 106, 131], ["Flow cytometry", "TEST", 168, 182], ["RBC cell death", "PROBLEM", 202, 216], ["flow cytometry", "TEST", 237, 251], ["RBC cell death", "OBSERVATION", 202, 216]]], ["After incubation under the respective experimental conditions, RBCs were washed once and phospholipid scrambling, intracellular Ca 2+ , and the generation of reactive oxygen species were examined using annexin V-FITC (1: 200 dilution; ImmunoTools, Friesoythe, Germany), Fluo-3/AM (5 \u03bcM, Biotium, Hayward, USA), and 2\u2032,7\u2032-dichlorodihydrofluorescein diacetate (10 \u03bcM, Sigma) staining, respectively [32] .", [["RBCs", "ANATOMY", 63, 67], ["intracellular", "ANATOMY", 114, 127], ["Ca", "CHEMICAL", 128, 130], ["oxygen", "CHEMICAL", 167, 173], ["annexin V", "CHEMICAL", 202, 211], ["Fluo-3", "CHEMICAL", 270, 276], ["2\u2032,7\u2032-dichlorodihydrofluorescein diacetate", "CHEMICAL", 315, 357], ["Ca 2+", "CHEMICAL", 128, 133], ["oxygen", "CHEMICAL", 167, 173], ["FITC", "CHEMICAL", 212, 216], ["2\u2032,7\u2032-dichlorodihydrofluorescein diacetate", "CHEMICAL", 315, 357], ["RBCs", "CELL", 63, 67], ["phospholipid", "SIMPLE_CHEMICAL", 89, 101], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 114, 127], ["Ca 2+", "SIMPLE_CHEMICAL", 128, 133], ["reactive oxygen species", "SIMPLE_CHEMICAL", 158, 181], ["annexin V-FITC", "GENE_OR_GENE_PRODUCT", 202, 216], ["Fluo-3", "SIMPLE_CHEMICAL", 270, 276], ["AM", "SIMPLE_CHEMICAL", 277, 279], ["2\u2032,7\u2032-dichlorodihydrofluorescein diacetate", "SIMPLE_CHEMICAL", 315, 357], ["RBCs", "CELL_TYPE", 63, 67], ["RBCs", "TREATMENT", 63, 67], ["phospholipid scrambling", "PROBLEM", 89, 112], ["intracellular Ca", "TEST", 114, 130], ["reactive oxygen species", "PROBLEM", 158, 181], ["annexin V", "TEST", 202, 211], ["ImmunoTools", "TREATMENT", 235, 246], ["Fluo", "TEST", 270, 274], ["Biotium", "TEST", 287, 294], ["Hayward", "TEST", 296, 303], ["7\u2032-dichlorodihydrofluorescein diacetate", "TREATMENT", 318, 357], ["reactive", "OBSERVATION_MODIFIER", 158, 166], ["oxygen species", "OBSERVATION", 167, 181]]], ["Ceramide abundance was determined using a previously described monoclonal antibody-based assay with a primary anticeramide antibody (1:50 dilution; clone MID15B4; Alexis, Gr\u00fcnberg, Germany) and a fluorescent secondary antibody (1:500 dilution; FITC-conjugated goat antimouse IgG/IgM; BD, San Jose, CA, USA) [32] .", [["Ceramide", "CHEMICAL", 0, 8], ["Ceramide", "CHEMICAL", 0, 8], ["FITC", "CHEMICAL", 244, 248], ["Ceramide", "SIMPLE_CHEMICAL", 0, 8], ["FITC", "SIMPLE_CHEMICAL", 244, 248], ["monoclonal antibody", "PROTEIN", 63, 82], ["primary anticeramide antibody", "PROTEIN", 102, 131], ["fluorescent secondary antibody", "PROTEIN", 196, 226], ["1:500 dilution; FITC-conjugated goat antimouse IgG", "PROTEIN", 228, 278], ["IgM", "PROTEIN", 279, 282], ["BD", "PROTEIN", 284, 286], ["goat", "SPECIES", 260, 264], ["goat", "SPECIES", 260, 264], ["Ceramide abundance", "TEST", 0, 18], ["monoclonal antibody", "TEST", 63, 82], ["a primary anticeramide antibody", "TEST", 100, 131], ["a fluorescent secondary antibody", "TEST", 194, 226], ["dilution", "TEST", 234, 242], ["FITC", "TEST", 244, 248], ["antimouse IgG", "TEST", 265, 278]]], ["Data were analyzed using FlowJo software (FlowJo LLC, Ashland, OR, USA).", [["FlowJo software", "TEST", 25, 40], ["LLC", "ANATOMY", 49, 52]]], ["Fluorescence parameters in all samples were analyzed at an excitation wavelength of 488 nm and an emission wavelength of 530 nm.Flow cytometryRBC morphology and microparticle (MP) generation were examined simultaneously using high-throughput imaging flow cytometry, which enables qualitative phenotypic screening of both parent RBCs and MPs, and thereby circumvents the limitations of conventional flow cytometry [33] .", [["samples", "ANATOMY", 31, 38], ["RBCs", "ANATOMY", 328, 332], ["MPs", "ANATOMY", 337, 340], ["microparticle", "CELLULAR_COMPONENT", 161, 174], ["RBCs", "CELL", 328, 332], ["MPs", "GENE_OR_GENE_PRODUCT", 337, 340], ["RBCs", "CELL_TYPE", 328, 332], ["MPs", "CELL_TYPE", 337, 340], ["Fluorescence parameters", "TEST", 0, 23], ["all samples", "TEST", 27, 38], ["an emission wavelength", "TEST", 95, 117], ["Flow cytometryRBC morphology", "TEST", 128, 156], ["imaging flow cytometry", "TEST", 242, 264], ["qualitative phenotypic screening", "TEST", 280, 312], ["MPs", "TEST", 337, 340], ["conventional flow cytometry", "TEST", 385, 412], ["530 nm", "OBSERVATION_MODIFIER", 121, 127]]], ["Using differences in scattering intensities, RBCs, ghosts, and MPs were characterized and their concentrations (objects) were determined by extrapolating the area of each subpopulation for a given sample [33, 34] .", [["RBCs", "ANATOMY", 45, 49], ["RBCs", "CELL", 45, 49], ["MPs", "GENE_OR_GENE_PRODUCT", 63, 66], ["RBCs", "CELL_TYPE", 45, 49], ["ghosts", "CELL_TYPE", 51, 57], ["MPs", "CELL_TYPE", 63, 66], ["scattering intensities", "TEST", 21, 43], ["RBCs", "TEST", 45, 49], ["MPs", "TEST", 63, 66]]], ["To tackle inter-sample variability in RBC and MP counts in the control and treated groups, the relative concentration of MPs in the sample, calculated as a ratio of RBC-derived (CD47 + CD235a + ) MPs to total RBC, was determined.", [["RBC", "ANATOMY", 38, 41], ["sample", "ANATOMY", 132, 138], ["RBC", "ANATOMY", 165, 168], ["CD47 + CD235a + ) MPs", "ANATOMY", 178, 199], ["RBC", "ANATOMY", 209, 212], ["RBC", "CELL", 38, 41], ["MP", "GENE_OR_GENE_PRODUCT", 46, 48], ["MPs", "GENE_OR_GENE_PRODUCT", 121, 124], ["RBC", "CELL", 165, 168], ["CD47", "GENE_OR_GENE_PRODUCT", 178, 182], ["CD235a + ) MPs", "GENE_OR_GENE_PRODUCT", 185, 199], ["RBC", "CELL", 209, 212], ["RBC", "CELL_TYPE", 38, 41], ["MPs", "PROTEIN", 121, 124], ["RBC", "CELL_TYPE", 165, 168], ["CD47", "PROTEIN", 178, 182], ["CD235a", "PROTEIN", 185, 191], ["MPs", "CELL_TYPE", 196, 199], ["RBC", "CELL_TYPE", 209, 212], ["RBC", "TEST", 38, 41], ["MP counts", "TEST", 46, 55], ["RBC", "TEST", 165, 168], ["CD47", "TEST", 178, 182], ["MPs", "PROBLEM", 196, 199], ["total RBC", "TEST", 203, 212], ["MP counts", "OBSERVATION_MODIFIER", 46, 55]]], ["For RBC morphology index (MI) assessment, a sequentially-numbered set of individually captured RBC brightfield images (170 \u00b1 7 images per sample) was manually assigned by a human operator to six morphology subclasses: smooth discs (SDCs), crenated discs (CDCs), crenated discoids (CDDs), crenated spheroids (CSDs), crenated spheres (CSEs), smooth spheres (SSEs), and multiplied by fractional weights [35] :Flow cytometryAfter a 48-h incubation with 50 \u03bcg/mL TSP-1 (at 40% hematocrit) in Ringer's solution, 75-\u03bcL of the cell suspension was washed once and adjusted to 100 \u03bcL with Ringer's solution.", [["RBC", "ANATOMY", 4, 7], ["RBC", "ANATOMY", 95, 98], ["smooth discs", "ANATOMY", 218, 230], ["SDCs", "ANATOMY", 232, 236], ["discs", "ANATOMY", 248, 253], ["CDCs", "ANATOMY", 255, 259], ["CDDs", "ANATOMY", 281, 285], ["spheroids", "ANATOMY", 297, 306], ["CSDs", "ANATOMY", 308, 312], ["CSEs", "ANATOMY", 333, 337], ["smooth spheres", "ANATOMY", 340, 354], ["SSEs", "ANATOMY", 356, 360], ["cell", "ANATOMY", 519, 523], ["RBC", "CELL", 4, 7], ["RBC", "CELL", 95, 98], ["human", "ORGANISM", 173, 178], ["smooth discs", "TISSUE", 218, 230], ["crenated discoids", "SIMPLE_CHEMICAL", 262, 279], ["CDDs", "SIMPLE_CHEMICAL", 281, 285], ["spheroids", "CELL", 297, 306], ["TSP-1", "GENE_OR_GENE_PRODUCT", 458, 463], ["cell", "CELL", 519, 523], ["CDDs", "CELL_TYPE", 281, 285], ["crenated spheroids", "CELL_LINE", 288, 306], ["human", "SPECIES", 173, 178], ["human", "SPECIES", 173, 178], ["RBC morphology index", "TEST", 4, 24], ["assessment", "TEST", 30, 40], ["RBC brightfield images", "TEST", 95, 117], ["smooth discs (SDCs)", "PROBLEM", 218, 237], ["crenated discs (CDCs)", "PROBLEM", 239, 260], ["crenated discoids (CDDs)", "PROBLEM", 262, 286], ["crenated spheroids (CSDs)", "PROBLEM", 288, 313], ["crenated spheres (CSEs)", "PROBLEM", 315, 338], ["fractional weights", "TEST", 381, 399], ["Flow cytometryAfter", "TEST", 406, 425], ["TSP", "TEST", 458, 461], ["hematocrit", "TEST", 472, 482], ["Ringer's solution", "TREATMENT", 487, 504], ["the cell suspension", "TREATMENT", 515, 534], ["Ringer's solution", "TREATMENT", 579, 596], ["smooth discs", "OBSERVATION", 218, 230], ["spheroids", "OBSERVATION_MODIFIER", 297, 306]]], ["For qualitative analyses, the control and TSP-1-treated RBC samples containing all three subpopulations were then incubated at room temperature (30 min; under protection from light) with 5 \u03bcL of CD47 PerCP-Cy\u21225.5 (BD Pharmingen\u2122, clone B6H12) and 2.5 \u03bcL of 20 \u03bcg/mL CD235a BV510 (BD Pharmingen\u2122, clone GA-R2 (HIR2)).", [["RBC samples", "ANATOMY", 56, 67], ["PerCP-Cy\u2122", "CHEMICAL", 200, 209], ["TSP-1", "GENE_OR_GENE_PRODUCT", 42, 47], ["RBC samples", "CELL", 56, 67], ["CD47", "GENE_OR_GENE_PRODUCT", 195, 199], ["CD235a BV510", "SIMPLE_CHEMICAL", 266, 278], ["TSP", "PROTEIN", 42, 45], ["CD47", "PROTEIN", 195, 199], ["clone B6H12", "CELL_LINE", 230, 241], ["qualitative analyses", "TEST", 4, 24], ["TSP", "TEST", 42, 45], ["RBC samples", "TEST", 56, 67], ["CD47 PerCP", "TREATMENT", 195, 205], ["Cy", "TEST", 206, 208]]], ["The samples were then examined on an Ima-geStreamX MkII instrument (ISX; Amnis/MilliporeSigma) equipped with 4 lasers (405 nm, 488 nm, 642 nm, 785 nm (SSC)) and 3 objectives (20\u00d7, 40\u00d7, and 60\u00d7).", [["samples", "ANATOMY", 4, 11], ["The samples", "TEST", 0, 11], ["an Ima-geStreamX MkII instrument", "TREATMENT", 34, 66], ["SSC", "TEST", 151, 154]]], ["All data was acquired at 60\u00d7 magnification, 7 \u03bcm core size and low flow rate.", [["All data", "TEST", 0, 8], ["magnification", "TEST", 29, 42], ["low flow rate", "TEST", 63, 76], ["size", "OBSERVATION_MODIFIER", 54, 58], ["low flow", "OBSERVATION", 63, 71]]], ["CD47 PerCP-Cy5.5 signals were collected in channel 5 (642-745 nm filter) and CD235a BV510 signals in channel 8 (505-570 nm filter).", [["CD47", "GENE_OR_GENE_PRODUCT", 0, 4], ["CD47", "PROTEIN", 0, 4], ["PerCP", "PROTEIN", 5, 10], ["Cy5.5", "PROTEIN", 11, 16], ["Cy5.5 signals", "TEST", 11, 24], ["nm filter", "TEST", 62, 71], ["channel", "TEST", 101, 108], ["nm filter", "TEST", 120, 129]]], ["Channels 1 (420-480 nm filter) and 9 (570-595 nm filter) were used as Bright Field channels (BF1, BF2) and channel 12 (745-800 nm filter) for SSC detection (Dark Field (DF) Scattering intensity).", [["Bright Field channels", "PROTEIN", 70, 91], ["BF1", "PROTEIN", 93, 96], ["BF2", "PROTEIN", 98, 101], ["nm filter)", "TREATMENT", 46, 56], ["Bright Field channels", "TEST", 70, 91], ["BF1", "TEST", 93, 96], ["nm filter", "TREATMENT", 127, 136], ["SSC detection", "TEST", 142, 155]]], ["Data analyses was performed using Amnis IDEAS software (version 6.2).ElectrophysiologyPatch-clamp measurements were performed with a NPC-16 Patchliner (Nanion Technologies, Munich, Germany).", [["Data analyses", "TEST", 0, 13], ["version", "TEST", 56, 63], ["clamp measurements", "TEST", 92, 110], ["a NPC", "TREATMENT", 131, 136]]], ["The internal and external solutions were as follows: KCl 70 mM, KF 70 mM, NaCl 10 mM, HEPES 10 mM, MgATP 2 mM, EGTA 3 mM, and CaCl 2 1.2 mM to give 120 nM free [Ca 2+ ] i , pH = 7.2 adjusted with KOH (internal) and NaCl 140 mM, KCl 4 mM, MgCl 2 5 mM, D-glucose 5 mM, HEPES 10 mM, CaCl 2 2 mM, pH = 7.3 adjusted with NaOH (external).", [["KCl", "CHEMICAL", 53, 56], ["KF", "CHEMICAL", 64, 66], ["NaCl", "CHEMICAL", 74, 78], ["MgATP", "CHEMICAL", 99, 104], ["EGTA", "CHEMICAL", 111, 115], ["CaCl", "CHEMICAL", 126, 130], ["Ca", "CHEMICAL", 161, 163], ["NaCl", "CHEMICAL", 215, 219], ["KCl", "CHEMICAL", 228, 231], ["MgCl", "CHEMICAL", 238, 242], ["D-glucose", "CHEMICAL", 251, 260], ["CaCl", "CHEMICAL", 280, 284], ["NaOH", "CHEMICAL", 316, 320], ["KCl", "CHEMICAL", 53, 56], ["NaCl", "CHEMICAL", 74, 78], ["HEPES", "CHEMICAL", 86, 91], ["MgATP", "CHEMICAL", 99, 104], ["EGTA", "CHEMICAL", 111, 115], ["CaCl 2", "CHEMICAL", 126, 132], ["Ca 2+ ]", "CHEMICAL", 161, 168], ["KOH", "CHEMICAL", 196, 199], ["NaCl", "CHEMICAL", 215, 219], ["KCl", "CHEMICAL", 228, 231], ["MgCl 2", "CHEMICAL", 238, 244], ["D-glucose", "CHEMICAL", 251, 260], ["HEPES", "CHEMICAL", 267, 272], ["CaCl 2", "CHEMICAL", 280, 286], ["NaOH", "CHEMICAL", 316, 320], ["KOH", "SIMPLE_CHEMICAL", 196, 199], ["D-glucose", "SIMPLE_CHEMICAL", 251, 260], ["NaOH", "SIMPLE_CHEMICAL", 316, 320], ["KCl", "TEST", 53, 56], ["KF", "TEST", 64, 66], ["NaCl", "TEST", 74, 78], ["HEPES", "TEST", 86, 91], ["MgATP", "TEST", 99, 104], ["EGTA", "TEST", 111, 115], ["CaCl", "TEST", 126, 130], ["Ca", "TEST", 161, 163], ["pH", "TEST", 173, 175], ["KOH", "TEST", 196, 199], ["NaCl", "TEST", 215, 219], ["KCl", "TEST", 228, 231], ["MgCl", "TEST", 238, 242], ["glucose", "TEST", 253, 260], ["HEPES", "TEST", 267, 272], ["CaCl", "TEST", 280, 284], ["pH", "TEST", 293, 295], ["internal", "ANATOMY_MODIFIER", 4, 12]]], ["In these solutions, the resistance of the chips was between 5 and 8 M\u03a9.", [["the chips", "TREATMENT", 38, 47], ["resistance", "OBSERVATION_MODIFIER", 24, 34]]], ["Gigaseal formation was facilitated using a seal enhancing solution as recommended by the Patchliner manufacturer and containing: NaCl 80 mM, KCl 3 mM, MgCl 2 10 mM, CaCl 2 35 mM, HEPES 10 mM, pH = 7.3 adjusted with NaOH.", [["NaCl", "CHEMICAL", 129, 133], ["KCl", "CHEMICAL", 141, 144], ["MgCl", "CHEMICAL", 151, 155], ["CaCl", "CHEMICAL", 165, 169], ["NaOH", "CHEMICAL", 215, 219], ["NaCl", "CHEMICAL", 129, 133], ["KCl", "CHEMICAL", 141, 144], ["MgCl 2", "CHEMICAL", 151, 157], ["CaCl 2", "CHEMICAL", 165, 171], ["HEPES", "CHEMICAL", 179, 184], ["NaOH", "CHEMICAL", 215, 219], ["Gigaseal", "SIMPLE_CHEMICAL", 0, 8], ["NaOH", "SIMPLE_CHEMICAL", 215, 219], ["Gigaseal formation", "PROBLEM", 0, 18], ["a seal enhancing solution", "TREATMENT", 41, 66], ["NaCl", "TREATMENT", 129, 133], ["KCl", "TREATMENT", 141, 144], ["MgCl", "TEST", 151, 155], ["CaCl", "TEST", 165, 169], ["HEPES", "TEST", 179, 184], ["pH", "TEST", 192, 194], ["NaOH", "TREATMENT", 215, 219]]], ["Whole-cell configuration was achieved by negative pressure suction pulses between \u2212 45 mbar and \u2212 150 mbar and its formation judged by the appearance of sharp capacitive transients.", [["Whole-cell", "ANATOMY", 0, 10], ["cell", "CELL", 6, 10], ["pressure suction pulses", "TEST", 50, 73], ["sharp capacitive transients", "PROBLEM", 153, 180], ["cell configuration", "OBSERVATION", 6, 24], ["sharp", "OBSERVATION_MODIFIER", 153, 158], ["capacitive transients", "OBSERVATION", 159, 180]]], ["Whole-cell patch-clamp recordings were conducted at room temperature using voltage steps from \u2212 100 mV to 80 mV for 500 ms in 20 mV increments at 5 s intervals, the holding potential being set at \u2212 30 mV.", [["cell", "ANATOMY", 6, 10], ["cell", "CELL", 6, 10], ["Whole-cell patch", "TREATMENT", 0, 16], ["clamp recordings", "TEST", 17, 33]]], ["Whole-cell currents were assessed before (control) and after adding 50 \u03bcg/mL TSP-1.", [["Whole-cell", "ANATOMY", 0, 10], ["Whole-cell", "CELL", 0, 10], ["TSP-1", "GENE_OR_GENE_PRODUCT", 77, 82], ["TSP", "PROTEIN", 77, 80], ["Whole-cell currents", "TREATMENT", 0, 19]]], ["To reduce inter-cell variability, data are expressed as normalized current, which is the ratio of the current under specified experimental conditions, i.e. before and in the presence of 50 \u03bcg/mL at the membrane potentials used in the protocol, to the current at + 80 mV determined 30-60 s before starting the control measurement.RBC deformability measurementRBCs were incubated (40% hematocrit) for 48 h at 37\u00b0C. After incubation time, 250 \u03bcL of control or TSP-1treated RBCs were washed once with Ringer's solution.", [["inter-cell", "ANATOMY", 10, 20], ["membrane", "ANATOMY", 202, 210], ["RBC", "ANATOMY", 329, 332], ["RBCs", "ANATOMY", 470, 474], ["inter-cell", "CELL", 10, 20], ["RBC", "CELL", 329, 332], ["RBCs", "CELL", 470, 474], ["RBC", "CELL_TYPE", 329, 332], ["TSP-1treated RBCs", "CELL_LINE", 457, 474], ["the control measurement", "TEST", 305, 328], ["RBC deformability measurementRBCs", "TEST", 329, 362], ["hematocrit", "TEST", 383, 393], ["TSP-1treated RBCs", "TREATMENT", 457, 474], ["Ringer's solution", "TREATMENT", 497, 514], ["inter-cell variability", "OBSERVATION", 10, 32]]], ["Ten \u03bcL of the aliquot was transferred into 1 mL viscous PVP (polyvinylpyrrolidone; RR Mechatronics, The Netherlands) for RBC deformability measurements.", [["RBC", "ANATOMY", 121, 124], ["PVP", "CHEMICAL", 56, 59], ["polyvinylpyrrolidone", "CHEMICAL", 61, 81], ["PVP", "CHEMICAL", 56, 59], ["polyvinylpyrrolidone", "CHEMICAL", 61, 81], ["PVP", "SIMPLE_CHEMICAL", 56, 59], ["polyvinylpyrrolidone", "SIMPLE_CHEMICAL", 61, 81], ["RBC", "CELL", 121, 124], ["RBC", "CELL_TYPE", 121, 124], ["the aliquot", "TREATMENT", 10, 21], ["1 mL viscous PVP (polyvinylpyrrolidone", "TREATMENT", 43, 81], ["RR Mechatronics", "TREATMENT", 83, 98], ["RBC deformability measurements", "TEST", 121, 151], ["RBC deformability", "OBSERVATION", 121, 138]]], ["RBC deformability was measured using the laser assisted optical rotational red cell analyzer (LORRCA; RR Mechatronics, The Netherlands).", [["RBC", "ANATOMY", 0, 3], ["red cell", "ANATOMY", 75, 83], ["RBC", "CELL", 0, 3], ["RBC", "CELL_TYPE", 0, 3], ["RBC deformability", "TEST", 0, 17], ["the laser assisted optical rotational red cell analyzer", "TREATMENT", 37, 92], ["LORRCA", "TEST", 94, 100], ["RR Mechatronics", "TREATMENT", 102, 117], ["deformability", "OBSERVATION", 4, 17]]], ["The two parameters used to describe RBC deformability are EI max and K EI .", [["RBC", "ANATOMY", 36, 39], ["RBC", "CELL", 36, 39], ["RBC", "CELL_TYPE", 36, 39], ["RBC deformability", "TEST", 36, 53], ["EI max", "TEST", 58, 64], ["RBC deformability", "OBSERVATION", 36, 53]]], ["The EI max is defined as the maximum elongation index predicted at an infinite shear stress.", [["the maximum elongation index", "PROBLEM", 25, 53], ["maximum", "OBSERVATION_MODIFIER", 29, 36], ["elongation", "OBSERVATION_MODIFIER", 37, 47]]], ["The K EI is the shear stress required to elongate to half the EI max .", [["K", "CHEMICAL", 4, 5], ["The K EI", "TEST", 0, 8], ["the shear stress", "PROBLEM", 12, 28]]], ["These parameters are obtained using an Eadie-Hofstee linearization, which plots the measured EI values versus the EI/respective shear stress (EI/SS) [36] .", [["an Eadie-Hofstee linearization", "TREATMENT", 36, 66]]], ["The slope of the best fit line provides the K EI and the y-intercept corresponds to the EI max .Statistical analysisData are expressed as arithmetic means \u00b1 SEM. n denotes the number of different donor RBCs studied.", [["RBCs", "ANATOMY", 202, 206], ["RBCs", "CELL", 202, 206], ["donor RBCs", "CELL_TYPE", 196, 206], ["different donor RBCs", "TREATMENT", 186, 206], ["slope", "OBSERVATION_MODIFIER", 4, 9], ["donor RBCs", "OBSERVATION", 196, 206]]], ["Statistical analysis was performed using ANOVA with Tukey's test as a post-test, t test or non-parametric Wilcoxon signed rank test by GraphPad Prism Version 8.4.3 (GraphPad Software, La Jolla, CA).", [["Statistical analysis", "TEST", 0, 20], ["Tukey's test", "TEST", 52, 64], ["a post-test", "TEST", 68, 79], ["t test", "TEST", 81, 87], ["Prism Version", "TEST", 144, 157], ["GraphPad", "TEST", 165, 173], ["Software", "TEST", 174, 182]]], ["A P-value less than 0.05 was considered statistically significant.Effect of thrombospondin-1 on Ca 2+ homeostasis in human red blood cellsThe impact of TSP-1 treatment on RBC intracellular Ca 2+ levels was examined using Fluo3 fluorescence in flow cytometry analysis.", [["red blood cells", "ANATOMY", 123, 138], ["RBC intracellular", "ANATOMY", 171, 188], ["Ca", "CHEMICAL", 96, 98], ["TSP-1", "CHEMICAL", 152, 157], ["Ca", "CHEMICAL", 189, 191], ["Ca 2+", "CHEMICAL", 96, 101], ["Ca 2+", "CHEMICAL", 189, 194], ["thrombospondin-1", "GENE_OR_GENE_PRODUCT", 76, 92], ["Ca 2+", "SIMPLE_CHEMICAL", 96, 101], ["human", "ORGANISM", 117, 122], ["red blood cells", "CELL", 123, 138], ["TSP-1", "GENE_OR_GENE_PRODUCT", 152, 157], ["RBC", "CELL", 171, 174], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 175, 188], ["Ca 2+", "SIMPLE_CHEMICAL", 189, 194], ["Fluo3", "SIMPLE_CHEMICAL", 221, 226], ["thrombospondin-1", "PROTEIN", 76, 92], ["human red blood cells", "CELL_TYPE", 117, 138], ["TSP", "PROTEIN", 152, 155], ["RBC", "CELL_TYPE", 171, 174], ["human", "SPECIES", 117, 122], ["human", "SPECIES", 117, 122], ["A P-value", "TEST", 0, 9], ["thrombospondin", "TEST", 76, 90], ["Ca", "TEST", 96, 98], ["red blood cells", "TEST", 123, 138], ["TSP-1 treatment", "TREATMENT", 152, 167], ["RBC intracellular Ca 2+ levels", "TEST", 171, 201], ["Fluo3 fluorescence", "TEST", 221, 239], ["flow cytometry analysis", "TEST", 243, 266], ["blood cells", "ANATOMY", 127, 138], ["flow cytometry", "OBSERVATION", 243, 257]]], ["As shown in Fig. 1a and b, exposure of RBCs to TSP-1 (50 \u03bcg/mL) for 48 h significantly enhanced the percentage of RBCs with increased Fluo3 fluorescence indicating increased cytoplasmic Ca 2+ concentration.", [["RBCs", "ANATOMY", 39, 43], ["RBCs", "ANATOMY", 114, 118], ["cytoplasmic", "ANATOMY", 174, 185], ["TSP-1", "CHEMICAL", 47, 52], ["Ca", "CHEMICAL", 186, 188], ["Ca 2+", "CHEMICAL", 186, 191], ["RBCs", "CELL", 39, 43], ["TSP-1", "GENE_OR_GENE_PRODUCT", 47, 52], ["RBCs", "CELL", 114, 118], ["Fluo3", "SIMPLE_CHEMICAL", 134, 139], ["cytoplasmic", "ORGANISM_SUBSTANCE", 174, 185], ["Ca 2+", "SIMPLE_CHEMICAL", 186, 191], ["RBCs", "CELL_TYPE", 39, 43], ["TSP", "PROTEIN", 47, 50], ["RBCs", "CELL_TYPE", 114, 118], ["Fluo3", "PROTEIN", 134, 139], ["RBCs", "TEST", 39, 43], ["TSP", "TEST", 47, 50], ["RBCs", "TEST", 114, 118], ["increased Fluo3 fluorescence", "PROBLEM", 124, 152], ["increased cytoplasmic Ca", "TREATMENT", 164, 188], ["Fig", "OBSERVATION", 12, 15], ["increased", "OBSERVATION_MODIFIER", 164, 173], ["cytoplasmic Ca", "OBSERVATION", 174, 188]]], ["Whole-cell patch-clamp experiments were performed to elucidate whether TSP-1 influences cation channel activity.", [["cell", "ANATOMY", 6, 10], ["cell", "CELL", 6, 10], ["TSP-1", "GENE_OR_GENE_PRODUCT", 71, 76], ["cation", "SIMPLE_CHEMICAL", 88, 94], ["TSP-1", "PROTEIN", 71, 76], ["Whole-cell patch", "TREATMENT", 0, 16], ["clamp experiments", "TEST", 17, 34], ["TSP", "TEST", 71, 74]]], ["As illustrated in Fig. 1c and d, exposure of RBCs to 50 \u03bcg/mL TSP-1 using physiological internal and external solutions induced an increase in an inward conductance, indicating a possible cation flux into the cells, that may be related to the increase in the intracellular Ca 2+ concentration.", [["RBCs", "ANATOMY", 45, 49], ["cells", "ANATOMY", 209, 214], ["intracellular", "ANATOMY", 259, 272], ["Ca", "CHEMICAL", 273, 275], ["Ca 2+", "CHEMICAL", 273, 278], ["RBCs", "CELL", 45, 49], ["TSP-1", "GENE_OR_GENE_PRODUCT", 62, 67], ["cation", "SIMPLE_CHEMICAL", 188, 194], ["cells", "CELL", 209, 214], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 259, 272], ["Ca 2+", "SIMPLE_CHEMICAL", 273, 278], ["RBCs", "CELL_TYPE", 45, 49], ["RBCs", "TEST", 45, 49], ["TSP", "TEST", 62, 65], ["physiological internal and external solutions", "TREATMENT", 74, 119], ["an inward conductance", "PROBLEM", 143, 164], ["cation flux into the cells", "PROBLEM", 188, 214], ["the intracellular Ca", "TREATMENT", 255, 275], ["Fig", "OBSERVATION_MODIFIER", 18, 21], ["increase", "OBSERVATION_MODIFIER", 131, 139], ["inward conductance", "OBSERVATION", 146, 164], ["possible", "UNCERTAINTY", 179, 187], ["cation flux", "OBSERVATION", 188, 199], ["cells", "ANATOMY", 209, 214], ["may be related to", "UNCERTAINTY", 221, 238], ["increase", "OBSERVATION_MODIFIER", 243, 251]]], ["Furthermore, treatment with 1 mM amiloride, a cation channel inhibitor [28] , abrogated the TSP-1-induced increase in the inward conductance (Fig. 1e ).", [["amiloride", "CHEMICAL", 33, 42], ["amiloride", "CHEMICAL", 33, 42], ["amiloride", "SIMPLE_CHEMICAL", 33, 42], ["cation", "SIMPLE_CHEMICAL", 46, 52], ["TSP-1", "GENE_OR_GENE_PRODUCT", 92, 97], ["TSP-1", "PROTEIN", 92, 97], ["1 mM amiloride", "TREATMENT", 28, 42], ["a cation channel inhibitor", "TREATMENT", 44, 70], ["the TSP", "TEST", 88, 95], ["the inward conductance", "PROBLEM", 118, 140], ["increase", "OBSERVATION_MODIFIER", 106, 114]]], ["In addition, amiloride also blocked an outward current that was not induced by TSP-1.Effect of thrombospondin-1 on Ca 2+ homeostasis in human red blood cellsEffect of thrombospondin-1 on phosphatidylserine externalization, sphingomyelinase activation, and the generation of reactive oxygen species in human red blood cellsEffect of thrombospondin-1 on Ca 2+ homeostasis in human red blood cellsEnhanced cytosolic Ca 2+ content is expected to activate scramblases which, in turn, elicit cell membrane PS externalization.", [["red blood cells", "ANATOMY", 142, 157], ["red blood cells", "ANATOMY", 307, 322], ["red blood cells", "ANATOMY", 379, 394], ["cytosolic", "ANATOMY", 403, 412], ["cell membrane", "ANATOMY", 486, 499], ["amiloride", "CHEMICAL", 13, 22], ["Ca", "CHEMICAL", 115, 117], ["phosphatidylserine", "CHEMICAL", 187, 205], ["oxygen", "CHEMICAL", 283, 289], ["Ca", "CHEMICAL", 352, 354], ["Ca", "CHEMICAL", 413, 415], ["amiloride", "CHEMICAL", 13, 22], ["Ca 2+", "CHEMICAL", 115, 120], ["phosphatidylserine", "CHEMICAL", 187, 205], ["oxygen", "CHEMICAL", 283, 289], ["Ca 2+", "CHEMICAL", 352, 357], ["Ca 2+", "CHEMICAL", 413, 418], ["amiloride", "SIMPLE_CHEMICAL", 13, 22], ["TSP-1", "GENE_OR_GENE_PRODUCT", 79, 84], ["thrombospondin-1", "GENE_OR_GENE_PRODUCT", 95, 111], ["Ca 2+", "SIMPLE_CHEMICAL", 115, 120], ["human", "ORGANISM", 136, 141], ["red blood cells", "CELL", 142, 157], ["thrombospondin-1", "GENE_OR_GENE_PRODUCT", 167, 183], ["phosphatidylserine", "AMINO_ACID", 187, 205], ["sphingomyelinase", "SIMPLE_CHEMICAL", 223, 239], ["reactive oxygen species", "SIMPLE_CHEMICAL", 274, 297], ["human", "ORGANISM", 301, 306], ["red blood cells", "CELL", 307, 322], ["thrombospondin-1", "GENE_OR_GENE_PRODUCT", 332, 348], ["Ca 2+", "SIMPLE_CHEMICAL", 352, 357], ["human", "ORGANISM", 373, 378], ["red blood cells", "CELL", 379, 394], ["Ca 2+", "SIMPLE_CHEMICAL", 413, 418], ["scramblases", "GENE_OR_GENE_PRODUCT", 451, 462], ["cell", "CELL", 486, 490], ["TSP", "PROTEIN", 79, 82], ["thrombospondin-1", "PROTEIN", 95, 111], ["human red blood cells", "CELL_TYPE", 136, 157], ["thrombospondin-1", "PROTEIN", 167, 183], ["sphingomyelinase", "PROTEIN", 223, 239], ["human red blood cells", "CELL_TYPE", 301, 322], ["thrombospondin-1", "PROTEIN", 332, 348], ["human red blood cells", "CELL_TYPE", 373, 394], ["scramblases", "PROTEIN", 451, 462], ["human", "SPECIES", 136, 141], ["human", "SPECIES", 301, 306], ["human", "SPECIES", 373, 378], ["human", "SPECIES", 136, 141], ["human", "SPECIES", 301, 306], ["human", "SPECIES", 373, 378], ["amiloride", "TREATMENT", 13, 22], ["thrombospondin", "TEST", 95, 109], ["Ca", "TEST", 115, 117], ["red blood cells", "TEST", 142, 157], ["thrombospondin", "TEST", 167, 181], ["phosphatidylserine externalization", "TREATMENT", 187, 221], ["sphingomyelinase activation", "PROBLEM", 223, 250], ["reactive oxygen species", "TREATMENT", 274, 297], ["red blood cells", "TEST", 307, 322], ["thrombospondin", "TEST", 332, 346], ["Ca", "TEST", 352, 354], ["red blood cells", "TEST", 379, 394], ["Enhanced cytosolic Ca", "TEST", 394, 415], ["scramblases", "PROBLEM", 451, 462], ["cell membrane PS externalization", "TREATMENT", 486, 518], ["blood cells", "ANATOMY", 146, 157], ["sphingomyelinase activation", "OBSERVATION", 223, 250], ["reactive", "OBSERVATION_MODIFIER", 274, 282], ["oxygen species", "OBSERVATION", 283, 297], ["blood cells", "ANATOMY", 383, 394], ["cytosolic", "OBSERVATION_MODIFIER", 403, 412], ["Ca", "OBSERVATION", 413, 415], ["scramblases", "OBSERVATION", 451, 462], ["cell membrane", "OBSERVATION", 486, 499], ["PS externalization", "OBSERVATION", 500, 518]]], ["We observed that a 48-h incubation of RBCs in the presence of TSP-1 (50 \u03bcg/mL) significantly increased the percentage of annexin V-positive RBCs, reflecting cell membrane PS exposure ( Fig. 2a and b) .", [["RBCs", "ANATOMY", 38, 42], ["RBCs", "ANATOMY", 140, 144], ["cell membrane", "ANATOMY", 157, 170], ["TSP-1", "CHEMICAL", 62, 67], ["RBCs", "CELL", 38, 42], ["TSP-1", "GENE_OR_GENE_PRODUCT", 62, 67], ["annexin V", "GENE_OR_GENE_PRODUCT", 121, 130], ["RBCs", "CELL", 140, 144], ["cell", "CELL", 157, 161], ["RBCs", "CELL_TYPE", 38, 42], ["TSP", "PROTEIN", 62, 65], ["annexin V-positive RBCs", "CELL_TYPE", 121, 144], ["RBCs", "TEST", 38, 42], ["TSP", "TEST", 62, 65], ["annexin V", "TEST", 121, 130], ["positive RBCs", "PROBLEM", 131, 144], ["cell membrane PS exposure", "TREATMENT", 157, 182], ["positive RBCs", "OBSERVATION", 131, 144], ["cell membrane PS", "OBSERVATION", 157, 173]]], ["We then interrogated the extent to which Ca 2+ influx contributes to PS externalization triggered by TSP-1.", [["Ca", "CHEMICAL", 41, 43], ["Ca 2+", "CHEMICAL", 41, 46], ["Ca 2+", "SIMPLE_CHEMICAL", 41, 46], ["TSP-1", "GENE_OR_GENE_PRODUCT", 101, 106], ["TSP", "PROTEIN", 101, 104], ["Ca", "TEST", 41, 43], ["influx", "PROBLEM", 47, 53], ["PS externalization", "PROBLEM", 69, 87], ["TSP", "TEST", 101, 104]]], ["Blocking Ca 2+ entry via NSCC using amiloride (1 mM [26] ; Fig. 2c ) or removal of extracellular Ca 2+ (Fig. 2d) significantly blunted, but did not abolish, TSP-1-induced PS exposure suggesting that increased Ca 2+ entry participates in, but does not completely account for, TSP-1induced cell death.", [["NSCC", "ANATOMY", 25, 29], ["extracellular", "ANATOMY", 83, 96], ["cell", "ANATOMY", 288, 292], ["Ca", "CHEMICAL", 9, 11], ["amiloride", "CHEMICAL", 36, 45], ["Ca", "CHEMICAL", 97, 99], ["PS", "CHEMICAL", 171, 173], ["Ca", "CHEMICAL", 209, 211], ["death", "DISEASE", 293, 298], ["Ca 2+", "CHEMICAL", 9, 14], ["amiloride", "CHEMICAL", 36, 45], ["Ca 2+", "CHEMICAL", 97, 102], ["Ca 2+", "CHEMICAL", 209, 214], ["Ca 2+", "SIMPLE_CHEMICAL", 9, 14], ["amiloride", "SIMPLE_CHEMICAL", 36, 45], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 83, 96], ["Ca 2+", "SIMPLE_CHEMICAL", 97, 102], ["TSP-1", "GENE_OR_GENE_PRODUCT", 157, 162], ["PS", "SIMPLE_CHEMICAL", 171, 173], ["Ca 2+", "SIMPLE_CHEMICAL", 209, 214], ["cell", "CELL", 288, 292], ["NSCC", "CELL_TYPE", 25, 29], ["TSP", "PROTEIN", 157, 160], ["TSP", "PROTEIN", 275, 278], ["amiloride", "TREATMENT", 36, 45], ["removal", "TREATMENT", 72, 79], ["extracellular Ca", "TEST", 83, 99], ["blunted", "PROBLEM", 127, 134], ["TSP", "TEST", 157, 160], ["PS exposure", "PROBLEM", 171, 182], ["increased Ca", "PROBLEM", 199, 211], ["1induced cell death", "PROBLEM", 279, 298], ["Ca", "OBSERVATION", 97, 99], ["increased", "OBSERVATION_MODIFIER", 199, 208], ["Ca", "OBSERVATION", 209, 211]]], ["As TSP-1-induced PS exposure was not abolished by extracellular Ca 2+ removal, we hypothesized that non-Ca 2+ -dependent mechanisms may contribute to the breakdown of phospholipid asymmetry.", [["extracellular", "ANATOMY", 50, 63], ["TSP-1", "CHEMICAL", 3, 8], ["Ca", "CHEMICAL", 64, 66], ["Ca 2+", "CHEMICAL", 64, 69], ["non-Ca 2+", "CHEMICAL", 100, 109], ["TSP-1", "GENE_OR_GENE_PRODUCT", 3, 8], ["PS", "SIMPLE_CHEMICAL", 17, 19], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 50, 63], ["Ca 2+", "SIMPLE_CHEMICAL", 64, 69], ["non-Ca 2+", "SIMPLE_CHEMICAL", 100, 109], ["phospholipid", "SIMPLE_CHEMICAL", 167, 179], ["TSP", "PROTEIN", 3, 6], ["TSP", "TEST", 3, 6], ["extracellular Ca", "TREATMENT", 50, 66], ["removal", "TREATMENT", 70, 77], ["dependent mechanisms", "PROBLEM", 111, 131], ["the breakdown of phospholipid asymmetry", "PROBLEM", 150, 189], ["may contribute to", "UNCERTAINTY", 132, 149], ["phospholipid asymmetry", "OBSERVATION", 167, 189]]], ["Multiple recent studies have shown the role of TSP-1 in modulating NO signaling in various cell types (reviewed in [3] ).", [["cell", "ANATOMY", 91, 95], ["NO", "CHEMICAL", 67, 69], ["NO", "CHEMICAL", 67, 69], ["TSP-1", "GENE_OR_GENE_PRODUCT", 47, 52], ["NO", "GENE_OR_GENE_PRODUCT", 67, 69], ["cell", "CELL", 91, 95], ["TSP-1", "PROTEIN", 47, 52], ["Multiple recent studies", "TEST", 0, 23], ["TSP", "TEST", 47, 50], ["NO", "UNCERTAINTY", 67, 69], ["various cell types", "OBSERVATION", 83, 101]]], ["We, thus, explored whether NO-mediated signaling similarly modulates TSP-1-induced alterations in RBCs.", [["RBCs", "ANATOMY", 98, 102], ["NO", "CHEMICAL", 27, 29], ["NO", "CHEMICAL", 27, 29], ["NO", "GENE_OR_GENE_PRODUCT", 27, 29], ["TSP-1", "GENE_OR_GENE_PRODUCT", 69, 74], ["RBCs", "CELL", 98, 102], ["TSP-1", "PROTEIN", 69, 74], ["RBCs", "CELL_TYPE", 98, 102], ["TSP", "TEST", 69, 72], ["induced alterations in RBCs", "PROBLEM", 75, 102]]], ["As shown in Fig. 2e , treatment of RBCs with the NO donor sodium nitroprusside (1 \u03bcM) significantly reduced TSP-1-induced PS externalization, suggesting the involvement of this mechanism in concert with Ca 2+dependent signaling leading to RBC cell death.", [["RBCs", "ANATOMY", 35, 39], ["RBC cell", "ANATOMY", 239, 247], ["NO", "CHEMICAL", 49, 51], ["sodium nitroprusside", "CHEMICAL", 58, 78], ["Ca", "CHEMICAL", 203, 205], ["death", "DISEASE", 248, 253], ["NO", "CHEMICAL", 49, 51], ["sodium nitroprusside", "CHEMICAL", 58, 78], ["Ca 2+", "CHEMICAL", 203, 208], ["RBCs", "CELL", 35, 39], ["NO", "SIMPLE_CHEMICAL", 49, 51], ["sodium nitroprusside", "SIMPLE_CHEMICAL", 58, 78], ["TSP-1", "GENE_OR_GENE_PRODUCT", 108, 113], ["PS", "SIMPLE_CHEMICAL", 122, 124], ["Ca 2+", "SIMPLE_CHEMICAL", 203, 208], ["RBC cell", "CELL", 239, 247], ["RBCs", "CELL_TYPE", 35, 39], ["TSP", "PROTEIN", 108, 111], ["RBC", "CELL_TYPE", 239, 242], ["RBCs", "TREATMENT", 35, 39], ["donor sodium nitroprusside", "TREATMENT", 52, 78], ["TSP", "TEST", 108, 111], ["induced PS externalization", "PROBLEM", 114, 140], ["Ca 2+dependent signaling", "PROBLEM", 203, 227], ["RBC cell death", "PROBLEM", 239, 253], ["Fig", "OBSERVATION", 12, 15], ["RBC cell death", "OBSERVATION", 239, 253]]], ["We then examined whether TSP-1 elicits oxidative stress and sphingomyelinase activation, putative RBC cell death effectors [21] .", [["RBC cell", "ANATOMY", 98, 106], ["TSP-1", "GENE_OR_GENE_PRODUCT", 25, 30], ["sphingomyelinase", "SIMPLE_CHEMICAL", 60, 76], ["RBC cell", "CELL", 98, 106], ["TSP-1", "PROTEIN", 25, 30], ["sphingomyelinase", "PROTEIN", 60, 76], ["TSP", "TEST", 25, 28], ["oxidative stress", "PROBLEM", 39, 55], ["sphingomyelinase activation", "PROBLEM", 60, 87], ["putative RBC cell death effectors", "PROBLEM", 89, 122], ["RBC cell", "OBSERVATION", 98, 106]]], ["As shown in Fig. 2f and g, a 48 -h exposure of RBCs to 50 \u03bcg/mL TSP-1 significantly enhanced DCFDA fluorescence, reflecting ROS production, but did not significantly enhance ceramide abundance suggesting that TSP-1 affects RBC redox balance favoring their suicidal death.Effect of thrombospondin-1 on Ca 2+ homeostasis in human red blood cellsSince CD47 is a receptor for TSP-1 and CD47signaling can regulate cytoplasmic Ca 2+ dynamics [12] , an anti-CD47 mAb could induce an increased RBC intracellular Ca 2+ level.", [["RBCs", "ANATOMY", 47, 51], ["RBC", "ANATOMY", 223, 226], ["red blood cells", "ANATOMY", 328, 343], ["cytoplasmic", "ANATOMY", 409, 420], ["RBC", "ANATOMY", 486, 489], ["intracellular", "ANATOMY", 490, 503], ["ROS", "CHEMICAL", 124, 127], ["ceramide", "CHEMICAL", 174, 182], ["suicidal death", "DISEASE", 256, 270], ["Ca", "CHEMICAL", 301, 303], ["Ca", "CHEMICAL", 421, 423], ["Ca", "CHEMICAL", 504, 506], ["ceramide", "CHEMICAL", 174, 182], ["Ca 2+", "CHEMICAL", 301, 306], ["Ca 2+", "CHEMICAL", 421, 426], ["Ca 2+", "CHEMICAL", 504, 509], ["RBCs", "CELL", 47, 51], ["TSP-1", "GENE_OR_GENE_PRODUCT", 64, 69], ["DCFDA", "SIMPLE_CHEMICAL", 93, 98], ["ROS", "SIMPLE_CHEMICAL", 124, 127], ["ceramide", "SIMPLE_CHEMICAL", 174, 182], ["TSP-1", "GENE_OR_GENE_PRODUCT", 209, 214], ["RBC", "CELL", 223, 226], ["thrombospondin-1", "GENE_OR_GENE_PRODUCT", 281, 297], ["Ca 2+", "SIMPLE_CHEMICAL", 301, 306], ["human", "ORGANISM", 322, 327], ["red blood cells", "CELL", 328, 343], ["CD47", "GENE_OR_GENE_PRODUCT", 349, 353], ["TSP-1", "GENE_OR_GENE_PRODUCT", 372, 377], ["CD47signaling", "GENE_OR_GENE_PRODUCT", 382, 395], ["cytoplasmic", "ORGANISM_SUBSTANCE", 409, 420], ["Ca 2+", "SIMPLE_CHEMICAL", 421, 426], ["anti-CD47 mAb", "GENE_OR_GENE_PRODUCT", 446, 459], ["RBC", "CELL", 486, 489], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 490, 503], ["RBCs", "CELL_TYPE", 47, 51], ["TSP", "PROTEIN", 209, 212], ["RBC", "CELL_TYPE", 223, 226], ["thrombospondin-1", "PROTEIN", 281, 297], ["human red blood cells", "CELL_TYPE", 322, 343], ["CD47", "PROTEIN", 349, 353], ["TSP", "PROTEIN", 372, 375], ["CD47signaling", "PROTEIN", 382, 395], ["anti-CD47 mAb", "PROTEIN", 446, 459], ["RBC", "CELL_TYPE", 486, 489], ["human", "SPECIES", 322, 327], ["human", "SPECIES", 322, 327], ["RBCs", "TEST", 47, 51], ["TSP", "TEST", 64, 67], ["significantly enhanced DCFDA fluorescence", "PROBLEM", 70, 111], ["TSP", "TEST", 209, 212], ["RBC redox balance", "PROBLEM", 223, 240], ["their suicidal death", "PROBLEM", 250, 270], ["thrombospondin", "TEST", 281, 295], ["Ca", "TEST", 301, 303], ["red blood cells", "TEST", 328, 343], ["TSP", "TEST", 372, 375], ["cytoplasmic Ca", "TEST", 409, 423], ["an anti-CD47 mAb", "TREATMENT", 443, 459], ["an increased RBC intracellular Ca", "PROBLEM", 473, 506], ["Fig", "OBSERVATION", 12, 15], ["ROS production", "OBSERVATION", 124, 138], ["blood cells", "ANATOMY", 332, 343], ["increased", "OBSERVATION", 476, 485]]], ["For this, anti-CD47 mAb 1F7 was used as it has been shown to induce apoptosis in other cell types [29, 31] .", [["cell", "ANATOMY", 87, 91], ["1F7", "CHEMICAL", 24, 27], ["anti-CD47 mAb 1F7", "SIMPLE_CHEMICAL", 10, 27], ["cell", "CELL", 87, 91], ["anti-CD47 mAb 1F7", "PROTEIN", 10, 27], ["this, anti-CD47 mAb", "TREATMENT", 4, 23], ["apoptosis", "PROBLEM", 68, 77]]], ["As illustrated in Fig. 3a and b , exposure of RBCs to mAb 1F7 (10 \u03bcg/mL) for 1-4 h significantly increased Fluo3 fluorescence.", [["RBCs", "ANATOMY", 46, 50], ["1F7", "CHEMICAL", 58, 61], ["Fluo3", "CHEMICAL", 107, 112], ["RBCs", "CELL", 46, 50], ["mAb 1F7", "SIMPLE_CHEMICAL", 54, 61], ["Fluo3", "SIMPLE_CHEMICAL", 107, 112], ["RBCs", "CELL_TYPE", 46, 50], ["mAb 1F7", "PROTEIN", 54, 61], ["Fluo3", "PROTEIN", 107, 112], ["RBCs to mAb", "TREATMENT", 46, 57], ["significantly increased Fluo3 fluorescence", "PROBLEM", 83, 125], ["Fig", "OBSERVATION_MODIFIER", 18, 21], ["increased", "OBSERVATION_MODIFIER", 97, 106], ["Fluo3 fluorescence", "OBSERVATION", 107, 125]]], ["However, such an effect of mAb 1F7 was absent after a 24-h incubation (Fig. 3b) .", [["mAb 1F7", "GENE_OR_GENE_PRODUCT", 27, 34], ["mAb 1F7", "PROTEIN", 27, 34], ["mAb", "TEST", 27, 30], ["a 24-h incubation", "TREATMENT", 52, 69]]], ["We observed that mAb 1F7 (0.1-10 \u03bcg/mL) dose-dependently increased the percentage of annexin Vpositive RBCs after a 24-h incubation (Fig. 3c ).", [["RBCs", "ANATOMY", 103, 107], ["1F7", "CHEMICAL", 21, 24], ["mAb 1F7", "SIMPLE_CHEMICAL", 17, 24], ["annexin", "GENE_OR_GENE_PRODUCT", 85, 92], ["RBCs", "CELL", 103, 107], ["mAb 1F7", "PROTEIN", 17, 24], ["annexin Vpositive RBCs", "CELL_TYPE", 85, 107], ["mAb", "TEST", 17, 20], ["annexin Vpositive RBCs", "TREATMENT", 85, 107], ["a 24-h incubation", "TREATMENT", 114, 131]]], ["In addition, there was a time-dependent increase in the percentage of annexin V-positive RBCs in response to mAb 1F7 (Fig. 3d) .", [["RBCs", "ANATOMY", 89, 93], ["annexin V", "GENE_OR_GENE_PRODUCT", 70, 79], ["RBCs", "CELL", 89, 93], ["annexin V-positive RBCs", "CELL_TYPE", 70, 93], ["mAb 1F7", "PROTEIN", 109, 116], ["annexin V", "TEST", 70, 79], ["positive RBCs", "PROBLEM", 80, 93], ["mAb", "TEST", 109, 112], ["dependent", "OBSERVATION_MODIFIER", 30, 39], ["increase", "OBSERVATION_MODIFIER", 40, 48], ["positive RBCs", "OBSERVATION", 80, 93]]], ["Interestingly, similar levels of RBC PS exposure in response to mAb 1F7 were also seen in the absence of extracellular Ca 2+ during incubation (Fig. 3e) .Effect of thrombospondin-1 on morphology and deformability of human red blood cellsThe effect of TSP-1 on RBC morphology and deformability was determined.", [["RBC", "ANATOMY", 33, 36], ["extracellular", "ANATOMY", 105, 118], ["red blood cells", "ANATOMY", 222, 237], ["RBC", "ANATOMY", 260, 263], ["PS", "CHEMICAL", 37, 39], ["Ca", "CHEMICAL", 119, 121], ["TSP-1", "CHEMICAL", 251, 256], ["Ca 2+", "CHEMICAL", 119, 124], ["RBC", "CELL", 33, 36], ["mAb 1F7", "SIMPLE_CHEMICAL", 64, 71], ["thrombospondin-1", "GENE_OR_GENE_PRODUCT", 164, 180], ["human", "ORGANISM", 216, 221], ["red blood cells", "CELL", 222, 237], ["TSP-1", "GENE_OR_GENE_PRODUCT", 251, 256], ["RBC", "CELL", 260, 263], ["RBC", "CELL_TYPE", 33, 36], ["mAb 1F7", "PROTEIN", 64, 71], ["thrombospondin-1", "PROTEIN", 164, 180], ["human red blood cells", "CELL_TYPE", 216, 237], ["TSP-1", "PROTEIN", 251, 256], ["RBC", "CELL_TYPE", 260, 263], ["human", "SPECIES", 216, 221], ["human", "SPECIES", 216, 221], ["RBC PS exposure", "PROBLEM", 33, 48], ["mAb", "TEST", 64, 67], ["extracellular Ca", "TEST", 105, 121], ["thrombospondin", "TEST", 164, 178], ["morphology", "TEST", 184, 194], ["human red blood cells", "TEST", 216, 237], ["TSP", "TEST", 251, 254], ["RBC morphology", "TEST", 260, 274], ["deformability", "TEST", 279, 292], ["similar", "OBSERVATION_MODIFIER", 15, 22], ["levels", "OBSERVATION_MODIFIER", 23, 29], ["RBC PS exposure", "OBSERVATION", 33, 48], ["extracellular", "ANATOMY_MODIFIER", 105, 118], ["Ca", "OBSERVATION", 119, 121], ["blood cells", "ANATOMY", 226, 237], ["deformability", "OBSERVATION", 279, 292]]], ["In imaging flow cytometry analyses, it was observed that the proportion of RBCs with Fig. 2 Effect of thrombospondin-1 on phosphatidylserine externalization, sphingomyelinase activation, and the generation of reactive oxygen species in human red blood cells.", [["RBCs", "ANATOMY", 75, 79], ["red blood cells", "ANATOMY", 242, 257], ["phosphatidylserine", "CHEMICAL", 122, 140], ["oxygen", "CHEMICAL", 218, 224], ["phosphatidylserine", "CHEMICAL", 122, 140], ["oxygen", "CHEMICAL", 218, 224], ["RBCs", "CELL", 75, 79], ["thrombospondin-1", "GENE_OR_GENE_PRODUCT", 102, 118], ["phosphatidylserine", "AMINO_ACID", 122, 140], ["sphingomyelinase", "SIMPLE_CHEMICAL", 158, 174], ["reactive oxygen species", "SIMPLE_CHEMICAL", 209, 232], ["human", "ORGANISM", 236, 241], ["red blood cells", "CELL", 242, 257], ["RBCs", "CELL_TYPE", 75, 79], ["thrombospondin-1", "PROTEIN", 102, 118], ["sphingomyelinase", "PROTEIN", 158, 174], ["human red blood cells", "CELL_TYPE", 236, 257], ["human", "SPECIES", 236, 241], ["human", "SPECIES", 236, 241], ["imaging flow cytometry analyses", "TEST", 3, 34], ["Fig", "TREATMENT", 85, 88], ["thrombospondin", "TEST", 102, 116], ["phosphatidylserine externalization", "TREATMENT", 122, 156], ["sphingomyelinase activation", "PROBLEM", 158, 185], ["reactive oxygen species", "PROBLEM", 209, 232], ["human red blood cells", "TREATMENT", 236, 257], ["sphingomyelinase activation", "OBSERVATION", 158, 185], ["reactive", "OBSERVATION_MODIFIER", 209, 217], ["oxygen species", "OBSERVATION", 218, 232]]], ["Representative histogram (Black line: 0 \u03bcg/mL TSP-1, orange line: 50 \u03bcg/mL TSP-1; a and means \u00b1 SEM. b of annexin V positive RBCs (n = 7) following 48-h incubation at 37\u00b0C in Ringer's solution containing 0-50 \u03bcg/mL TSP-1. *** indicate significant difference (P < 0.001) from the absence of TSP-1.", [["RBCs", "ANATOMY", 125, 129], ["annexin V", "GENE_OR_GENE_PRODUCT", 106, 115], ["TSP-1", "GENE_OR_GENE_PRODUCT", 215, 220], ["TSP-1", "GENE_OR_GENE_PRODUCT", 290, 295], ["TSP", "PROTEIN", 75, 78], ["annexin V positive RBCs", "CELL_TYPE", 106, 129], ["TSP", "PROTEIN", 290, 293], ["Representative histogram", "TEST", 0, 24], ["Black line", "TEST", 26, 36], ["TSP", "TEST", 46, 49], ["TSP", "TEST", 75, 78], ["annexin V", "TEST", 106, 115], ["RBCs", "TEST", 125, 129], ["Ringer's solution", "TREATMENT", 175, 192], ["significant difference", "PROBLEM", 235, 257], ["significant", "OBSERVATION_MODIFIER", 235, 246]]], ["Means \u00b1 SEM of annexin V positive RBCs following 48-h incubation in 50 \u03bcg/mL TSP-1 in the absence or presence of 1 mM amiloride (n = 27; c), 1 mM CaCl 2 (n = 8; d) or 1 \u03bcM sodium nitroprusside (n = 12; e). *** indicates significant difference (P < 0.001) from the absence of amiloride, CaCl 2 or sodium nitroprusside.", [["RBCs", "ANATOMY", 34, 38], ["amiloride", "CHEMICAL", 118, 127], ["sodium nitroprusside", "CHEMICAL", 172, 192], ["amiloride", "CHEMICAL", 275, 284], ["CaCl 2", "CHEMICAL", 286, 292], ["sodium nitroprusside", "CHEMICAL", 296, 316], ["amiloride", "CHEMICAL", 118, 127], ["CaCl 2", "CHEMICAL", 146, 152], ["sodium nitroprusside", "CHEMICAL", 172, 192], ["amiloride", "CHEMICAL", 275, 284], ["CaCl 2", "CHEMICAL", 286, 292], ["sodium nitroprusside", "CHEMICAL", 296, 316], ["annexin V", "GENE_OR_GENE_PRODUCT", 15, 24], ["TSP-1", "GENE_OR_GENE_PRODUCT", 77, 82], ["amiloride", "SIMPLE_CHEMICAL", 118, 127], ["sodium nitroprusside", "SIMPLE_CHEMICAL", 172, 192], ["amiloride", "SIMPLE_CHEMICAL", 275, 284], ["CaCl 2", "SIMPLE_CHEMICAL", 286, 292], ["sodium nitroprusside", "SIMPLE_CHEMICAL", 296, 316], ["annexin V positive RBCs", "CELL_TYPE", 15, 38], ["TSP", "PROTEIN", 77, 80], ["Means", "TEST", 0, 5], ["annexin V positive RBCs", "PROBLEM", 15, 38], ["TSP", "TEST", 77, 80], ["1 mM amiloride", "TREATMENT", 113, 127], ["CaCl", "TEST", 146, 150], ["1 \u03bcM sodium nitroprusside", "TREATMENT", 167, 192], ["amiloride", "TREATMENT", 275, 284], ["CaCl", "TREATMENT", 286, 290], ["sodium nitroprusside", "TREATMENT", 296, 316], ["significant", "OBSERVATION_MODIFIER", 220, 231], ["difference", "OBSERVATION_MODIFIER", 232, 242]]], ["Means \u00b1 SEM of the geometric means of DCFDA (n = 9; f) or ceramide-dependent (n = 14; g) fluorescence of RBCs following 48-h incubation without or with 50 \u03bcg/mL TSP-1. * indicates significant difference (P < 0.05) from the absence of TSP-1 smooth disc shape was significantly reduced and RBCs with crenated sphere shape were significantly increased after a 48-h incubation in the presence of TSP-1 (Fig. 4a) .", [["RBCs", "ANATOMY", 105, 109], ["RBCs", "ANATOMY", 288, 292], ["ceramide", "CHEMICAL", 58, 66], ["ceramide", "CHEMICAL", 58, 66], ["ceramide", "SIMPLE_CHEMICAL", 58, 66], ["RBCs", "CELL", 105, 109], ["TSP-1", "GENE_OR_GENE_PRODUCT", 161, 166], ["TSP-1", "GENE_OR_GENE_PRODUCT", 234, 239], ["RBCs", "CELL", 288, 292], ["TSP-1", "GENE_OR_GENE_PRODUCT", 392, 397], ["RBCs", "CELL_TYPE", 105, 109], ["TSP", "PROTEIN", 161, 164], ["TSP", "PROTEIN", 234, 237], ["RBCs", "CELL_TYPE", 288, 292], ["TSP", "PROTEIN", 392, 395], ["DCFDA", "TEST", 38, 43], ["ceramide", "TEST", 58, 66], ["fluorescence of RBCs", "PROBLEM", 89, 109], ["significant difference", "PROBLEM", 180, 202], ["TSP", "TEST", 234, 237], ["smooth disc shape", "TEST", 240, 257], ["RBCs", "TEST", 288, 292], ["crenated sphere shape", "PROBLEM", 298, 319], ["TSP", "TEST", 392, 395], ["significant", "OBSERVATION_MODIFIER", 180, 191], ["difference", "OBSERVATION_MODIFIER", 192, 202], ["reduced", "OBSERVATION_MODIFIER", 276, 283], ["sphere", "OBSERVATION_MODIFIER", 307, 313], ["shape", "OBSERVATION_MODIFIER", 314, 319], ["significantly", "OBSERVATION_MODIFIER", 325, 338], ["increased", "OBSERVATION_MODIFIER", 339, 348]]], ["Accordingly, as shown in Fig. 4b , TSP-1 treatment significantly reduced the morphology index of RBCs.", [["RBCs", "ANATOMY", 97, 101], ["TSP-1", "CHEMICAL", 35, 40], ["TSP-1", "GENE_OR_GENE_PRODUCT", 35, 40], ["RBCs", "CELL", 97, 101], ["TSP", "PROTEIN", 35, 38], ["RBCs", "CELL_TYPE", 97, 101], ["TSP", "TEST", 35, 38]]], ["Ektacytometry analyses revealed that TSP-1 treatment affected RBC deformability (Fig. 4c) .", [["RBC", "ANATOMY", 62, 65], ["TSP-1", "CHEMICAL", 37, 42], ["TSP-1", "GENE_OR_GENE_PRODUCT", 37, 42], ["RBC", "CELL", 62, 65], ["TSP", "PROTEIN", 37, 40], ["RBC", "CELL_TYPE", 62, 65], ["Ektacytometry analyses", "TEST", 0, 22], ["TSP", "TEST", 37, 40], ["RBC deformability", "TEST", 62, 79], ["RBC deformability", "OBSERVATION", 62, 79]]], ["As depicted in Fig. 4d , in comparison to untreated RBCs, TSP-1 (50 \u03bcg/mL) exposure for 48 h significantly reduced maximum elongation index (EI max ) suggesting that TSP-1 induces increased RBC stiffness.", [["RBCs", "ANATOMY", 52, 56], ["RBC", "ANATOMY", 190, 193], ["TSP-1", "CHEMICAL", 58, 63], ["RBCs", "CELL", 52, 56], ["TSP-1", "GENE_OR_GENE_PRODUCT", 58, 63], ["TSP-1", "GENE_OR_GENE_PRODUCT", 166, 171], ["RBC", "CELL", 190, 193], ["RBCs", "CELL_TYPE", 52, 56], ["TSP-1", "PROTEIN", 166, 171], ["RBC", "CELL_TYPE", 190, 193], ["RBCs", "TEST", 52, 56], ["TSP", "TEST", 58, 61], ["significantly reduced maximum elongation index", "PROBLEM", 93, 139], ["EI max", "TEST", 141, 147], ["TSP", "TEST", 166, 169], ["increased RBC stiffness", "PROBLEM", 180, 203], ["elongation", "OBSERVATION_MODIFIER", 123, 133], ["increased RBC stiffness", "OBSERVATION", 180, 203]]], ["Furthermore, TSP-1 (50 \u03bcg/mL) treatment tended to increase K EI reflecting RBC rigidity (Fig. 4e) .", [["RBC", "ANATOMY", 75, 78], ["TSP-1", "CHEMICAL", 13, 18], ["K", "CHEMICAL", 59, 60], ["rigidity", "DISEASE", 79, 87], ["TSP-1", "GENE_OR_GENE_PRODUCT", 13, 18], ["RBC", "CELL", 75, 78], ["TSP", "PROTEIN", 13, 16], ["RBC", "CELL_TYPE", 75, 78], ["Furthermore", "TEST", 0, 11], ["TSP", "TEST", 13, 16], ["treatment", "TREATMENT", 30, 39], ["K EI", "TEST", 59, 63], ["RBC rigidity", "PROBLEM", 75, 87], ["RBC rigidity", "OBSERVATION", 75, 87]]], ["Thus, the ability of RBCs to adopt a new shape in response to deforming forces, which dictate their rheological properties, is affected by TSP-1.Effect of thrombospondin-1 on microvesiculation of human red blood cellsThe impact of TSP-1-induced RBC dysfunction on microvesiculation was assessed.", [["RBCs", "ANATOMY", 21, 25], ["red blood cells", "ANATOMY", 202, 217], ["RBC", "ANATOMY", 245, 248], ["TSP-1", "CHEMICAL", 231, 236], ["RBC dysfunction", "DISEASE", 245, 260], ["RBCs", "CELL", 21, 25], ["TSP-1", "GENE_OR_GENE_PRODUCT", 139, 144], ["thrombospondin-1", "GENE_OR_GENE_PRODUCT", 155, 171], ["human", "ORGANISM", 196, 201], ["red blood cells", "CELL", 202, 217], ["TSP-1", "GENE_OR_GENE_PRODUCT", 231, 236], ["RBC", "CELL", 245, 248], ["RBCs", "CELL_TYPE", 21, 25], ["TSP", "PROTEIN", 139, 142], ["thrombospondin-1", "PROTEIN", 155, 171], ["human red blood cells", "CELL_TYPE", 196, 217], ["TSP-1", "PROTEIN", 231, 236], ["human", "SPECIES", 196, 201], ["human", "SPECIES", 196, 201], ["deforming forces", "PROBLEM", 62, 78], ["thrombospondin", "TEST", 155, 169], ["human red blood cells", "TEST", 196, 217], ["TSP", "TEST", 231, 234], ["RBC dysfunction on microvesiculation", "PROBLEM", 245, 281], ["deforming forces", "OBSERVATION", 62, 78], ["blood cells", "ANATOMY", 206, 217], ["RBC dysfunction", "OBSERVATION", 245, 260]]], ["As shown in Fig. 5b and c, incubation of RBCs with TSP-1 for 48 h significantly increased CD47 + /CD235a + MPs relative to RBC count, as compared to untreated RBCs indicating that TSP-1 promotes MP shedding.DiscussionCompelling molecular evidence points to an essential role for CD47-dependent TSP-1 signaling in the pathophysiology of a wide range of systemic diseases [3] [4] [5] [6] .", [["RBCs", "ANATOMY", 41, 45], ["CD47 + /CD235a + MPs", "ANATOMY", 90, 110], ["RBC", "ANATOMY", 123, 126], ["RBCs", "ANATOMY", 159, 163], ["systemic diseases", "DISEASE", 352, 369], ["c", "GENE_OR_GENE_PRODUCT", 24, 25], ["RBCs", "CELL", 41, 45], ["TSP-1", "GENE_OR_GENE_PRODUCT", 51, 56], ["CD47", "GENE_OR_GENE_PRODUCT", 90, 94], ["CD235a + MPs", "GENE_OR_GENE_PRODUCT", 98, 110], ["RBC", "CELL", 123, 126], ["RBCs", "CELL", 159, 163], ["TSP-1", "GENE_OR_GENE_PRODUCT", 180, 185], ["MP", "GENE_OR_GENE_PRODUCT", 195, 197], ["CD47", "GENE_OR_GENE_PRODUCT", 279, 283], ["TSP-1", "GENE_OR_GENE_PRODUCT", 294, 299], ["[3] [4] [5] [6]", "SIMPLE_CHEMICAL", 370, 385], ["RBCs", "CELL_TYPE", 41, 45], ["TSP", "PROTEIN", 51, 54], ["CD47", "PROTEIN", 90, 94], ["CD235a", "PROTEIN", 98, 104], ["RBC", "CELL_TYPE", 123, 126], ["untreated RBCs", "CELL_TYPE", 149, 163], ["TSP", "PROTEIN", 180, 183], ["CD47", "PROTEIN", 279, 283], ["TSP-1", "PROTEIN", 294, 299], ["RBCs", "TEST", 41, 45], ["TSP", "TEST", 51, 54], ["CD47", "TEST", 90, 94], ["MPs", "PROBLEM", 107, 110], ["RBC count", "TEST", 123, 132], ["untreated RBCs", "PROBLEM", 149, 163], ["TSP", "TEST", 180, 183], ["CD47", "TEST", 279, 283], ["dependent TSP", "PROBLEM", 284, 297], ["systemic diseases", "PROBLEM", 352, 369]]], ["However, little is known about this signaling mechanism in influencing anucleate RBC functions.", [["RBC", "ANATOMY", 81, 84], ["RBC", "CELL", 81, 84], ["RBC", "CELL_TYPE", 81, 84], ["this signaling mechanism", "PROBLEM", 31, 55], ["influencing anucleate RBC functions", "PROBLEM", 59, 94], ["anucleate RBC functions", "OBSERVATION", 71, 94]]], ["Increase of cytoplasmic Ca 2+ levels is a vital element in potentiating premature cell death and clearance of circulating RBCs [21, 37] .", [["cytoplasmic", "ANATOMY", 12, 23], ["cell", "ANATOMY", 82, 86], ["RBCs", "ANATOMY", 122, 126], ["Ca", "CHEMICAL", 24, 26], ["premature cell death", "DISEASE", 72, 92], ["Ca 2+", "CHEMICAL", 24, 29], ["cytoplasmic", "ORGANISM_SUBSTANCE", 12, 23], ["Ca 2+", "GENE_OR_GENE_PRODUCT", 24, 29], ["cell", "CELL", 82, 86], ["RBCs", "CELL", 122, 126], ["cytoplasmic Ca 2", "PROTEIN", 12, 28], ["circulating RBCs", "CELL_TYPE", 110, 126], ["cytoplasmic Ca", "TEST", 12, 26], ["a vital element", "PROBLEM", 40, 55], ["potentiating premature cell death", "PROBLEM", 59, 92], ["circulating RBCs", "TEST", 110, 126], ["cytoplasmic", "OBSERVATION_MODIFIER", 12, 23], ["Ca", "OBSERVATION", 24, 26]]], ["In the current study, we demonstrate, for the first time, that exogenous TSP-1 causes RBC dysfunction evoking an increase in intracellular Ca 2+ levels, triggering cell death, and altering cell morphology and rheological properties.DiscussionIncreased intracellular Ca 2+ concentration in RBCs, triggered by the opening of NSCC, stimulates phospholipid scrambling, bleb formation, and vesiculation of the cell membrane [21, 28] .", [["RBC", "ANATOMY", 86, 89], ["intracellular", "ANATOMY", 125, 138], ["cell", "ANATOMY", 164, 168], ["cell", "ANATOMY", 189, 193], ["intracellular", "ANATOMY", 252, 265], ["RBCs", "ANATOMY", 289, 293], ["NSCC", "ANATOMY", 323, 327], ["bleb", "ANATOMY", 365, 369], ["cell membrane", "ANATOMY", 405, 418], ["RBC dysfunction", "DISEASE", 86, 101], ["Ca", "CHEMICAL", 139, 141], ["death", "DISEASE", 169, 174], ["Ca", "CHEMICAL", 266, 268], ["Ca 2+", "CHEMICAL", 139, 144], ["Ca 2+", "CHEMICAL", 266, 271], ["TSP-1", "GENE_OR_GENE_PRODUCT", 73, 78], ["RBC", "CELL", 86, 89], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 125, 138], ["Ca 2+", "SIMPLE_CHEMICAL", 139, 144], ["cell", "CELL", 164, 168], ["cell", "CELL", 189, 193], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 252, 265], ["Ca 2+", "SIMPLE_CHEMICAL", 266, 271], ["RBCs", "CELL", 289, 293], ["NSCC", "GENE_OR_GENE_PRODUCT", 323, 327], ["phospholipid", "SIMPLE_CHEMICAL", 340, 352], ["bleb", "PATHOLOGICAL_FORMATION", 365, 369], ["cell membrane", "CELLULAR_COMPONENT", 405, 418], ["TSP-1", "PROTEIN", 73, 78], ["RBCs", "CELL_TYPE", 289, 293], ["the current study", "TEST", 3, 20], ["exogenous TSP", "TEST", 63, 76], ["RBC dysfunction", "PROBLEM", 86, 101], ["intracellular Ca", "TEST", 125, 141], ["triggering cell death", "PROBLEM", 153, 174], ["altering cell morphology", "PROBLEM", 180, 204], ["Increased intracellular Ca", "PROBLEM", 242, 268], ["concentration in RBCs", "PROBLEM", 272, 293], ["stimulates phospholipid scrambling", "PROBLEM", 329, 363], ["bleb formation", "PROBLEM", 365, 379], ["RBC dysfunction", "OBSERVATION", 86, 101], ["increase", "OBSERVATION_MODIFIER", 113, 121], ["intracellular Ca", "OBSERVATION", 125, 141], ["cell death", "OBSERVATION", 164, 174], ["altering cell morphology", "OBSERVATION", 180, 204], ["rheological properties", "OBSERVATION", 209, 231], ["phospholipid scrambling", "OBSERVATION", 340, 363], ["bleb formation", "OBSERVATION", 365, 379], ["vesiculation", "OBSERVATION_MODIFIER", 385, 397], ["cell membrane", "OBSERVATION", 405, 418]]], ["Enhanced cytosolic Ca 2+ is further involved in the activation of multiple Ca 2+ -sensitive enzymes such as transglutaminases, phospholipases, calpains, protein kinases and phosphatases [21] .", [["cytosolic", "ANATOMY", 9, 18], ["Ca", "CHEMICAL", 19, 21], ["Ca", "CHEMICAL", 75, 77], ["Ca 2+", "CHEMICAL", 19, 24], ["Ca 2+", "CHEMICAL", 75, 80], ["Ca 2+", "SIMPLE_CHEMICAL", 19, 24], ["transglutaminases", "GENE_OR_GENE_PRODUCT", 108, 125], ["phospholipases", "GENE_OR_GENE_PRODUCT", 127, 141], ["calpains", "GENE_OR_GENE_PRODUCT", 143, 151], ["protein kinases", "GENE_OR_GENE_PRODUCT", 153, 168], ["Ca 2+ -sensitive enzymes", "PROTEIN", 75, 99], ["transglutaminases", "PROTEIN", 108, 125], ["phospholipases", "PROTEIN", 127, 141], ["calpains", "PROTEIN", 143, 151], ["protein kinases", "PROTEIN", 153, 168], ["phosphatases [21]", "PROTEIN", 173, 190], ["Enhanced cytosolic Ca", "TEST", 0, 21], ["multiple Ca", "TEST", 66, 77], ["sensitive enzymes", "TEST", 82, 99], ["transglutaminases", "TEST", 108, 125], ["phospholipases", "TEST", 127, 141], ["calpains", "TEST", 143, 151], ["protein kinases", "TEST", 153, 168], ["phosphatases", "TEST", 173, 185], ["cytosolic", "OBSERVATION_MODIFIER", 9, 18], ["Ca", "OBSERVATION", 19, 21]]], ["While the molecular identity of the cation channels remains incompletely characterized, it is believed to involve the TRPC6 channel [21, 28] .", [["cation", "SIMPLE_CHEMICAL", 36, 42], ["TRPC6", "GENE_OR_GENE_PRODUCT", 118, 123], ["cation channels", "PROTEIN", 36, 51], ["TRPC6", "PROTEIN", 118, 123], ["cation channels", "OBSERVATION", 36, 51], ["incompletely characterized", "OBSERVATION_MODIFIER", 60, 86]]], ["According to our data, the TSP-1-elicited increase in the cytosolic Ca 2+ concentration could be corroborated using whole-cell patch-clamp recordings which showed the presence of a TSP-1induced inward current, alluding to a possible Ca 2+ Fig. 3 Effects of the anti-CD47 mAb 1F7 on cytosolic Ca 2+ levels and phosphatidylserine exposure in human red blood cells.", [["cytosolic", "ANATOMY", 58, 67], ["cell", "ANATOMY", 122, 126], ["cytosolic", "ANATOMY", 282, 291], ["red blood cells", "ANATOMY", 346, 361], ["Ca", "CHEMICAL", 68, 70], ["Ca", "CHEMICAL", 233, 235], ["Ca", "CHEMICAL", 292, 294], ["phosphatidylserine", "CHEMICAL", 309, 327], ["Ca 2+", "CHEMICAL", 68, 73], ["Ca 2+", "CHEMICAL", 233, 238], ["Ca 2+", "CHEMICAL", 292, 297], ["phosphatidylserine", "CHEMICAL", 309, 327], ["TSP-1", "GENE_OR_GENE_PRODUCT", 27, 32], ["Ca 2+", "SIMPLE_CHEMICAL", 68, 73], ["anti-CD47 mAb 1F7", "SIMPLE_CHEMICAL", 261, 278], ["Ca 2+", "SIMPLE_CHEMICAL", 292, 297], ["phosphatidylserine", "SIMPLE_CHEMICAL", 309, 327], ["human", "ORGANISM", 340, 345], ["red blood cells", "CELL", 346, 361], ["TSP-1", "PROTEIN", 27, 32], ["TSP", "PROTEIN", 181, 184], ["anti-CD47 mAb 1F7", "PROTEIN", 261, 278], ["human red blood cells", "CELL_TYPE", 340, 361], ["human", "SPECIES", 340, 345], ["human", "SPECIES", 340, 345], ["the TSP", "TEST", 23, 30], ["the cytosolic Ca", "TEST", 54, 70], ["whole-cell patch", "TREATMENT", 116, 132], ["clamp recordings", "TEST", 133, 149], ["a TSP", "PROBLEM", 179, 184], ["Ca", "TEST", 233, 235], ["the anti-CD47 mAb", "TREATMENT", 257, 274], ["cytosolic Ca", "TEST", 282, 294], ["phosphatidylserine exposure", "TEST", 309, 336], ["human red blood cells", "TEST", 340, 361], ["increase", "OBSERVATION_MODIFIER", 42, 50], ["phosphatidylserine exposure", "OBSERVATION", 309, 336]]], ["Representative histogram (Black line: 0 \u03bcg/mL mAb 1F7, orange line: 10 \u03bcg/mL mAb 1F7, following a 4-h incubation; a) and means \u00b1 SEM. b of Fluo3-positive RBCs (%) (n = 6; b) following incubation for 0-24 h at 37\u00b0C in the presence of 10 \u03bcg/mL mAb 1F7. ** indicate significant difference (P < 0.01) from the zero time-point. c Means \u00b1 SEM of annexin V positive RBCs (n = 3) following 24-h incubation with 0-10 \u03bcg/mL mAb 1F7. * indicates significant difference (P < 0.05) from the absence of mAb 1F7. d Means \u00b1 SEM of annexin V positive RBCs (n = 5) following incubation with 10 \u03bcg/ mL mAb 1F7 for 0-24 h. * and ** indicate significant difference (P < 0.05 and P < 0.01, respectively) from the zero time-point. e Means \u00b1 SEM of annexin V positive RBCs (n = 7) following 24-h incubation with 10 \u03bcg/mL mAb 1F7 in the absence or presence of 1 mM CaCl 2 influx.", [["RBCs", "ANATOMY", 154, 158], ["RBCs", "ANATOMY", 359, 363], ["RBCs", "ANATOMY", 534, 538], ["RBCs", "ANATOMY", 744, 748], ["1F7", "CHEMICAL", 801, 804], ["CaCl", "CHEMICAL", 840, 844], ["CaCl 2", "CHEMICAL", 840, 846], ["Fluo3", "GENE_OR_GENE_PRODUCT", 139, 144], ["RBCs", "CELL", 154, 158], ["annexin V", "GENE_OR_GENE_PRODUCT", 340, 349], ["annexin V", "GENE_OR_GENE_PRODUCT", 515, 524], ["annexin V", "GENE_OR_GENE_PRODUCT", 725, 734], ["CaCl 2", "SIMPLE_CHEMICAL", 840, 846], ["mAb 1F7", "PROTEIN", 46, 53], ["mAb 1F7", "PROTEIN", 77, 84], ["Fluo3", "PROTEIN", 139, 144], ["positive RBCs", "CELL_TYPE", 145, 158], ["mAb 1F7", "PROTEIN", 242, 249], ["annexin V positive RBCs", "CELL_TYPE", 340, 363], ["mAb 1F7", "PROTEIN", 414, 421], ["mAb 1F7", "PROTEIN", 489, 496], ["annexin V positive RBCs", "CELL_TYPE", 515, 538], ["mAb 1F7", "PROTEIN", 583, 590], ["annexin V positive RBCs", "CELL_TYPE", 725, 748], ["mAb 1F7", "PROTEIN", 797, 804], ["Representative histogram", "TEST", 0, 24], ["Black line", "TREATMENT", 26, 36], ["a 4-h incubation", "TREATMENT", 96, 112], ["Fluo3", "TEST", 139, 144], ["RBCs", "TEST", 154, 158], ["annexin V", "TEST", 340, 349], ["RBCs", "TEST", 359, 363], ["significant difference", "PROBLEM", 435, 457], ["annexin V positive RBCs", "PROBLEM", 515, 538], ["P", "TEST", 645, 646], ["annexin V positive RBCs", "PROBLEM", 725, 748], ["1 mM CaCl 2 influx", "PROBLEM", 835, 853], ["positive RBCs", "OBSERVATION_MODIFIER", 145, 158], ["significant", "OBSERVATION_MODIFIER", 263, 274], ["difference", "OBSERVATION_MODIFIER", 275, 285], ["significant", "OBSERVATION_MODIFIER", 435, 446], ["difference", "OBSERVATION_MODIFIER", 447, 457], ["significant", "OBSERVATION_MODIFIER", 621, 632]]], ["In addition, we also observed that ligation of the anti-CD47 mAb 1F7 induced an increase in RBC cytosolic Ca 2+ levels.", [["RBC cytosolic", "ANATOMY", 92, 105], ["1F7", "CHEMICAL", 65, 68], ["Ca", "CHEMICAL", 106, 108], ["Ca 2+", "CHEMICAL", 106, 111], ["anti-CD47", "GENE_OR_GENE_PRODUCT", 51, 60], ["RBC", "CELL", 92, 95], ["Ca 2+", "SIMPLE_CHEMICAL", 106, 111], ["anti-CD47 mAb 1F7", "PROTEIN", 51, 68], ["RBC", "CELL_TYPE", 92, 95], ["ligation", "TREATMENT", 35, 43], ["the anti-CD47 mAb", "TREATMENT", 47, 64], ["an increase", "PROBLEM", 77, 88], ["RBC cytosolic Ca", "TEST", 92, 108], ["increase", "OBSERVATION_MODIFIER", 80, 88], ["RBC cytosolic Ca", "OBSERVATION", 92, 108]]], ["These findings are consistent with previous studies in nucleated cells, which suggest that CD47/TSP-1 signal transduction impacts cellular Ca 2+ homeostasis [38] [39] [40] .", [["cells", "ANATOMY", 65, 70], ["cellular", "ANATOMY", 130, 138], ["Ca", "CHEMICAL", 139, 141], ["Ca 2+", "CHEMICAL", 139, 144], ["nucleated cells", "CELL", 55, 70], ["CD47", "GENE_OR_GENE_PRODUCT", 91, 95], ["TSP-1", "GENE_OR_GENE_PRODUCT", 96, 101], ["cellular", "CELL", 130, 138], ["Ca 2+", "SIMPLE_CHEMICAL", 139, 144], ["nucleated cells", "CELL_TYPE", 55, 70], ["CD47", "PROTEIN", 91, 95], ["TSP", "PROTEIN", 96, 99], ["previous studies in nucleated cells", "TEST", 35, 70], ["CD47", "TEST", 91, 95], ["TSP", "TEST", 96, 99], ["signal transduction", "TEST", 102, 121], ["cellular Ca", "TEST", 130, 141], ["consistent with", "UNCERTAINTY", 19, 34], ["nucleated cells", "OBSERVATION", 55, 70]]], ["Notably, intact TSP-1 was previously demonstrated to upregulate intracellular Ca 2+ levels in fibroblasts; this effect was recapitulated by the TSP-1derived peptide RFYVVMWK underlining the primordial role of TSP-1/CD47 signaling in regulating cytoplasmic Ca 2+ levels [38] .", [["intracellular", "ANATOMY", 64, 77], ["fibroblasts", "ANATOMY", 94, 105], ["cytoplasmic", "ANATOMY", 244, 255], ["Ca", "CHEMICAL", 78, 80], ["Ca", "CHEMICAL", 256, 258], ["Ca 2+", "CHEMICAL", 78, 83], ["Ca 2+", "CHEMICAL", 256, 261], ["TSP-1", "GENE_OR_GENE_PRODUCT", 16, 21], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 64, 77], ["Ca 2+", "SIMPLE_CHEMICAL", 78, 83], ["fibroblasts", "CELL", 94, 105], ["TSP-1derived", "GENE_OR_GENE_PRODUCT", 144, 156], ["RFYVVMWK", "GENE_OR_GENE_PRODUCT", 165, 173], ["TSP-1", "GENE_OR_GENE_PRODUCT", 209, 214], ["CD47", "GENE_OR_GENE_PRODUCT", 215, 219], ["cytoplasmic", "ORGANISM_SUBSTANCE", 244, 255], ["Ca 2+", "SIMPLE_CHEMICAL", 256, 261], ["TSP-1", "PROTEIN", 16, 21], ["fibroblasts", "CELL_TYPE", 94, 105], ["TSP", "PROTEIN", 144, 147], ["TSP-1", "PROTEIN", 209, 214], ["CD47", "PROTEIN", 215, 219], ["intracellular Ca", "TEST", 64, 80], ["levels in fibroblasts", "PROBLEM", 84, 105], ["the TSP", "TEST", 140, 147], ["TSP", "TEST", 209, 212], ["cytoplasmic Ca", "TEST", 244, 258], ["Ca", "OBSERVATION", 78, 80], ["fibroblasts", "OBSERVATION", 94, 105]]], ["Furthermore, cardiac myocytes treated with 7 N3, a peptide derived from the C-terminal of TSP-1, displayed acutely elevated intracellular Ca 2+ levels through the release of Ca 2+ from the sarcoplasmic reticulum [39] .DiscussionAmple evidence underscores the role of oxidative stress in modulating RBC Ca 2+ homeostasis and survival by stimulating NSCC conductance [41] .", [["cardiac myocytes", "ANATOMY", 13, 29], ["intracellular", "ANATOMY", 124, 137], ["sarcoplasmic reticulum", "ANATOMY", 189, 211], ["RBC", "ANATOMY", 298, 301], ["NSCC", "ANATOMY", 348, 352], ["Ca", "CHEMICAL", 138, 140], ["Ca", "CHEMICAL", 174, 176], ["Ca", "CHEMICAL", 302, 304], ["C", "CHEMICAL", 76, 77], ["Ca 2+", "CHEMICAL", 138, 143], ["Ca 2+", "CHEMICAL", 174, 179], ["Ca 2+", "CHEMICAL", 302, 307], ["cardiac myocytes", "CELL", 13, 29], ["7 N3", "SIMPLE_CHEMICAL", 43, 47], ["TSP-1", "GENE_OR_GENE_PRODUCT", 90, 95], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 124, 137], ["Ca 2+", "SIMPLE_CHEMICAL", 138, 143], ["Ca 2+", "GENE_OR_GENE_PRODUCT", 174, 179], ["sarcoplasmic reticulum", "CELLULAR_COMPONENT", 189, 211], ["RBC", "CELL", 298, 301], ["NSCC", "GENE_OR_GENE_PRODUCT", 348, 352], ["cardiac myocytes", "CELL_TYPE", 13, 29], ["TSP-1", "PROTEIN", 90, 95], ["a peptide", "TREATMENT", 49, 58], ["TSP", "TEST", 90, 93], ["acutely elevated intracellular Ca", "PROBLEM", 107, 140], ["Ca", "TEST", 174, 176], ["oxidative stress", "PROBLEM", 267, 283], ["modulating RBC Ca", "TREATMENT", 287, 304], ["cardiac myocytes", "ANATOMY", 13, 29], ["elevated", "OBSERVATION", 115, 123], ["sarcoplasmic reticulum", "ANATOMY", 189, 211]]], ["In accordance, our data reveal that TSP-1 treatment stimulated a subtle increase in RBC ROS production, which, in turn, may favor Ca 2+ entry and promote cell death.", [["RBC", "ANATOMY", 84, 87], ["cell", "ANATOMY", 154, 158], ["TSP-1", "CHEMICAL", 36, 41], ["ROS", "CHEMICAL", 88, 91], ["Ca", "CHEMICAL", 130, 132], ["death", "DISEASE", 159, 164], ["Ca 2+", "CHEMICAL", 130, 135], ["TSP-1", "GENE_OR_GENE_PRODUCT", 36, 41], ["RBC", "CELL", 84, 87], ["ROS", "SIMPLE_CHEMICAL", 88, 91], ["Ca 2+", "SIMPLE_CHEMICAL", 130, 135], ["cell", "CELL", 154, 158], ["TSP", "PROTEIN", 36, 39], ["RBC", "CELL_TYPE", 84, 87], ["our data", "TEST", 15, 23], ["TSP-1 treatment", "TREATMENT", 36, 51], ["a subtle increase in RBC ROS production", "PROBLEM", 63, 102], ["promote cell death", "PROBLEM", 146, 164], ["subtle", "OBSERVATION_MODIFIER", 65, 71], ["increase", "OBSERVATION_MODIFIER", 72, 80], ["RBC ROS production", "OBSERVATION", 84, 102], ["cell death", "OBSERVATION", 154, 164]]], ["TSP-1 has previously been shown to potentiate ROS generation in vascular smooth muscle cells via CD47-dependent activation of NADPH oxidase 1 [42] .", [["vascular smooth muscle cells", "ANATOMY", 64, 92], ["ROS", "CHEMICAL", 46, 49], ["NADPH", "CHEMICAL", 126, 131], ["NADPH", "CHEMICAL", 126, 131], ["TSP-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["ROS", "SIMPLE_CHEMICAL", 46, 49], ["vascular smooth muscle cells", "CELL", 64, 92], ["CD47", "GENE_OR_GENE_PRODUCT", 97, 101], ["NADPH oxidase 1", "GENE_OR_GENE_PRODUCT", 126, 141], ["TSP-1", "PROTEIN", 0, 5], ["vascular smooth muscle cells", "CELL_TYPE", 64, 92], ["CD47", "PROTEIN", 97, 101], ["NADPH oxidase 1", "PROTEIN", 126, 141], ["TSP", "TEST", 0, 3], ["ROS generation in vascular smooth muscle cells", "PROBLEM", 46, 92], ["CD47", "TEST", 97, 101], ["NADPH oxidase", "TEST", 126, 139], ["vascular", "ANATOMY", 64, 72], ["smooth muscle", "ANATOMY", 73, 86]]], ["TSP-1 has further been implicated in oxidative stress-mediated renal ischemia-reperfusion injury by stimulating ROS production in renal tubular endothelial cells [43] .", [["renal", "ANATOMY", 63, 68], ["renal tubular endothelial cells", "ANATOMY", 130, 161], ["ROS", "CHEMICAL", 112, 115], ["TSP-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["renal", "ORGAN", 63, 68], ["ROS", "SIMPLE_CHEMICAL", 112, 115], ["renal tubular endothelial cells", "CELL", 130, 161], ["TSP-1", "PROTEIN", 0, 5], ["renal tubular endothelial cells", "CELL_TYPE", 130, 161], ["TSP", "TEST", 0, 3], ["oxidative stress", "PROBLEM", 37, 53], ["renal ischemia-reperfusion injury", "PROBLEM", 63, 96], ["stimulating ROS production in renal tubular endothelial cells", "PROBLEM", 100, 161], ["oxidative stress", "OBSERVATION", 37, 53], ["renal", "ANATOMY", 63, 68], ["ischemia-reperfusion injury", "OBSERVATION", 69, 96], ["renal", "ANATOMY", 130, 135], ["tubular", "ANATOMY_MODIFIER", 136, 143], ["endothelial cells", "OBSERVATION", 144, 161]]], ["In addition, the present study also revealed that pharmacological NO supplementation significantly blunted TSP-1-induced PS externalization in RBCs.", [["RBCs", "ANATOMY", 143, 147], ["NO", "CHEMICAL", 66, 68], ["NO", "CHEMICAL", 66, 68], ["NO", "SIMPLE_CHEMICAL", 66, 68], ["TSP-1", "GENE_OR_GENE_PRODUCT", 107, 112], ["PS", "SIMPLE_CHEMICAL", 121, 123], ["RBCs", "CELL", 143, 147], ["TSP", "PROTEIN", 107, 110], ["RBCs", "CELL_TYPE", 143, 147], ["the present study", "TEST", 13, 30], ["significantly blunted TSP", "PROBLEM", 85, 110], ["induced PS externalization in RBCs", "PROBLEM", 113, 147]]], ["NO was previously shown to influence RBC survival by modulating cell death pathways downstream of intracellular Ca 2+ increase, but not by directly influencing Ca 2+ entry per se [44] .", [["RBC", "ANATOMY", 37, 40], ["cell", "ANATOMY", 64, 68], ["intracellular", "ANATOMY", 98, 111], ["NO", "CHEMICAL", 0, 2], ["Ca", "CHEMICAL", 112, 114], ["Ca", "CHEMICAL", 160, 162], ["NO", "CHEMICAL", 0, 2], ["Ca 2+", "CHEMICAL", 112, 117], ["Ca 2+", "CHEMICAL", 160, 165], ["NO", "SIMPLE_CHEMICAL", 0, 2], ["RBC", "CELL", 37, 40], ["cell", "CELL", 64, 68], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 98, 111], ["Ca 2+", "SIMPLE_CHEMICAL", 112, 117], ["Ca 2+", "SIMPLE_CHEMICAL", 160, 165], ["RBC", "CELL_TYPE", 37, 40], ["RBC survival", "TREATMENT", 37, 49], ["modulating cell death pathways", "PROBLEM", 53, 83], ["intracellular Ca", "TEST", 98, 114], ["increase", "OBSERVATION_MODIFIER", 118, 126]]], ["In purview of these findings, NO has previously been documented to be an essential effector of TSP-1 signaling in a wide range of cell types, and is associated with various clinical conditions [3, 45] .DiscussionRBC CD47 serves as a putative molecular switch in erythrophagocytosis [46] .", [["cell", "ANATOMY", 130, 134], ["NO", "CHEMICAL", 30, 32], ["erythrophagocytosis", "DISEASE", 262, 281], ["NO", "CHEMICAL", 30, 32], ["NO", "GENE_OR_GENE_PRODUCT", 30, 32], ["TSP-1", "GENE_OR_GENE_PRODUCT", 95, 100], ["cell", "CELL", 130, 134], ["CD47", "GENE_OR_GENE_PRODUCT", 216, 220], ["TSP", "PROTEIN", 95, 98], ["DiscussionRBC", "PROTEIN", 202, 215], ["CD47", "PROTEIN", 216, 220], ["TSP", "TEST", 95, 98], ["essential", "OBSERVATION_MODIFIER", 73, 82], ["effector", "OBSERVATION", 83, 91], ["wide", "OBSERVATION_MODIFIER", 116, 120], ["cell types", "OBSERVATION", 130, 140]]], ["Through activation of signaling mediated by tyrosine phosphatases, downstream of its interaction with SIRP\u03b1, CD47 inhibits phagocytosis, and thereby functions as a \"do not eat me\" signal [11] .", [["tyrosine", "CHEMICAL", 44, 52], ["tyrosine", "CHEMICAL", 44, 52], ["SIRP\u03b1", "GENE_OR_GENE_PRODUCT", 102, 107], ["CD47", "GENE_OR_GENE_PRODUCT", 109, 113], ["tyrosine phosphatases", "PROTEIN", 44, 65], ["SIRP\u03b1", "PROTEIN", 102, 107], ["CD47", "PROTEIN", 109, 113], ["tyrosine phosphatases", "TEST", 44, 65], ["SIRP\u03b1", "TREATMENT", 102, 107]]], ["Paradoxically, however, CD47 in experimentally aged RBCs was shown to undergo a conformational change and increased binding to TSP-1, which, in turn, promoted phagocytosis [46] .", [["RBCs", "ANATOMY", 52, 56], ["CD47", "GENE_OR_GENE_PRODUCT", 24, 28], ["RBCs", "CELL", 52, 56], ["TSP-1", "GENE_OR_GENE_PRODUCT", 127, 132], ["CD47", "PROTEIN", 24, 28], ["RBCs", "CELL_TYPE", 52, 56], ["TSP", "PROTEIN", 127, 130], ["CD47", "TEST", 24, 28], ["a conformational change", "PROBLEM", 78, 101], ["increased binding", "PROBLEM", 106, 123], ["TSP", "TEST", 127, 130]]], ["It is, therefore, possible that PS externalization during RBC cell death induced by TSP-1/CD47 signaling contributes, at least in part, to this \"eat me\" response.DiscussionRBCs exhibit an extraordinary ability to deform which facilitates their smooth passage in the microcirculation and, thus, aids in maintaining optimal rheology [47] .", [["RBC cell", "ANATOMY", 58, 66], ["death", "DISEASE", 67, 72], ["RBC cell", "CELL", 58, 66], ["TSP-1", "GENE_OR_GENE_PRODUCT", 84, 89], ["CD47", "GENE_OR_GENE_PRODUCT", 90, 94], ["RBC", "CELL_TYPE", 58, 61], ["TSP", "PROTEIN", 84, 87], ["CD47", "PROTEIN", 90, 94], ["PS externalization", "PROBLEM", 32, 50], ["RBC cell death", "PROBLEM", 58, 72], ["TSP", "TEST", 84, 87], ["RBC cell death", "OBSERVATION", 58, 72], ["smooth", "OBSERVATION_MODIFIER", 244, 250], ["passage", "OBSERVATION_MODIFIER", 251, 258], ["microcirculation", "ANATOMY", 266, 282]]], ["Increased RBC stiffness facilitates the elimination of senescent and Fig. 4 Effect of thrombospondin-1 on morphology and deformability of human red blood cells.", [["RBC", "ANATOMY", 10, 13], ["red blood cells", "ANATOMY", 144, 159], ["RBC", "CELL", 10, 13], ["thrombospondin-1", "GENE_OR_GENE_PRODUCT", 86, 102], ["human", "ORGANISM", 138, 143], ["red blood cells", "CELL", 144, 159], ["RBC", "CELL_TYPE", 10, 13], ["thrombospondin-1", "PROTEIN", 86, 102], ["human red blood cells", "CELL_TYPE", 138, 159], ["human", "SPECIES", 138, 143], ["human", "SPECIES", 138, 143], ["Increased RBC stiffness", "PROBLEM", 0, 23], ["senescent and Fig", "PROBLEM", 55, 72], ["thrombospondin", "TEST", 86, 100], ["human red blood cells", "TEST", 138, 159], ["RBC stiffness", "OBSERVATION", 10, 23], ["blood cells", "OBSERVATION", 148, 159]]], ["Means \u00b1 SEM showing distribution of RBC morphology (n = 6; a) following a 48-h incubation at 37\u00b0C in Ringer's solution in the absence (Control) or presence of TSP-1 (50 \u03bcg/mL).", [["RBC", "ANATOMY", 36, 39], ["RBC", "CELL", 36, 39], ["TSP-1", "GENE_OR_GENE_PRODUCT", 159, 164], ["RBC", "CELL_TYPE", 36, 39], ["TSP", "PROTEIN", 159, 162], ["RBC morphology", "TEST", 36, 50], ["a 48-h incubation", "TREATMENT", 72, 89], ["Ringer's solution", "TREATMENT", 101, 118], ["TSP", "TEST", 159, 162], ["distribution", "OBSERVATION_MODIFIER", 20, 32], ["RBC morphology", "OBSERVATION", 36, 50]]], ["RBC morphology was assessed using Bright Field images from ImageStream X MkII (60x magnification).", [["RBC", "ANATOMY", 0, 3], ["RBC", "CELL", 0, 3], ["RBC", "CELL_TYPE", 0, 3], ["RBC morphology", "TEST", 0, 14], ["Bright Field images", "TEST", 34, 53], ["ImageStream X MkII", "TREATMENT", 59, 77]]], ["Morphology index (n = 6; b) following a 48-h incubation of RBCs at 37\u00b0C in the absence (Control) or presence of TSP-1 (50 \u03bcg/mL). c Representative deformability curve (for RBCs from a single donor) of untreated (Control; black line) and TSP-1-treated (red line) RBCs obtained from LORRCA prior to Eadie-Hofstee linearization.", [["RBCs", "ANATOMY", 59, 63], ["RBCs", "ANATOMY", 172, 176], ["RBCs", "ANATOMY", 262, 266], ["RBCs", "CELL", 59, 63], ["TSP-1", "GENE_OR_GENE_PRODUCT", 112, 117], ["RBCs", "CELL", 172, 176], ["TSP-1", "GENE_OR_GENE_PRODUCT", 237, 242], ["RBCs", "CELL", 262, 266], ["RBCs", "CELL_TYPE", 59, 63], ["TSP", "PROTEIN", 112, 115], ["RBCs", "CELL_TYPE", 172, 176], ["TSP-1-treated (red line) RBCs", "CELL_LINE", 237, 266], ["Morphology index", "TEST", 0, 16], ["RBCs", "TREATMENT", 59, 63], ["TSP", "TEST", 112, 115], ["Representative deformability curve", "TEST", 132, 166], ["RBCs", "PROBLEM", 172, 176], ["a single donor) of untreated (Control; black line", "TREATMENT", 182, 231], ["TSP", "TEST", 237, 240], ["red line) RBCs", "TEST", 252, 266], ["Eadie-Hofstee linearization", "TREATMENT", 297, 324], ["deformability curve", "OBSERVATION", 147, 166]]], ["Maximum elongation index (EI max ; n = 6; d) and rigidity (K EI ; n = 6; e) following a 48-h incubation of RBCs in the absence (Control) or presence of TSP-1 (50 \u03bcg/mL). * and ** indicate significant difference (P < 0.05 and P < 0.01, respectively) from the absence of TSP-1.", [["RBCs", "ANATOMY", 107, 111], ["rigidity", "DISEASE", 49, 57], ["RBCs", "CELL", 107, 111], ["TSP-1", "GENE_OR_GENE_PRODUCT", 152, 157], ["TSP-1", "GENE_OR_GENE_PRODUCT", 269, 274], ["RBCs", "CELL_TYPE", 107, 111], ["TSP", "PROTEIN", 152, 155], ["TSP", "PROTEIN", 269, 272], ["Maximum elongation index", "TEST", 0, 24], ["EI max", "TEST", 26, 32], ["rigidity", "TEST", 49, 57], ["K EI", "TEST", 59, 63], ["RBCs", "TREATMENT", 107, 111], ["TSP", "TEST", 152, 155], ["significant difference", "PROBLEM", 188, 210], ["P", "TEST", 212, 213], ["elongation", "OBSERVATION_MODIFIER", 8, 18], ["index", "OBSERVATION_MODIFIER", 19, 24], ["significant", "OBSERVATION_MODIFIER", 188, 199]]], ["Gray lines indicate means injured RBCs from the circulation in the spleen [48] .", [["Gray lines", "ANATOMY", 0, 10], ["RBCs", "ANATOMY", 34, 38], ["spleen", "ANATOMY", 67, 73], ["Gray lines", "CELL", 0, 10], ["RBCs", "CELL", 34, 38], ["spleen", "ORGAN", 67, 73], ["Gray lines", "CELL_LINE", 0, 10], ["injured RBCs", "CELL_TYPE", 26, 38], ["Gray lines", "TEST", 0, 10], ["means injured RBCs", "PROBLEM", 20, 38], ["injured RBCs", "OBSERVATION", 26, 38], ["circulation", "OBSERVATION_MODIFIER", 48, 59], ["spleen", "ANATOMY", 67, 73]]], ["Previous studies have elucidated the pivotal role of RBC NO synthase-derived NO in the regulation of RBC deformability [49, 50] .", [["RBC", "ANATOMY", 101, 104], ["NO", "CHEMICAL", 57, 59], ["NO", "CHEMICAL", 77, 79], ["NO", "CHEMICAL", 57, 59], ["NO", "CHEMICAL", 77, 79], ["RBC NO synthase", "GENE_OR_GENE_PRODUCT", 53, 68], ["NO", "SIMPLE_CHEMICAL", 77, 79], ["RBC", "CELL", 101, 104], ["RBC NO synthase", "PROTEIN", 53, 68], ["RBC", "CELL_TYPE", 101, 104], ["Previous studies", "TEST", 0, 16], ["RBC deformability", "TEST", 101, 118], ["RBC deformability", "OBSERVATION", 101, 118]]], ["On the other hand, elevated cytoplasmic Ca 2+ levels in RBCs are associated with reduced deformability [51] .", [["cytoplasmic", "ANATOMY", 28, 39], ["RBCs", "ANATOMY", 56, 60], ["Ca", "CHEMICAL", 40, 42], ["Ca 2+", "CHEMICAL", 40, 45], ["cytoplasmic", "ORGANISM_SUBSTANCE", 28, 39], ["Ca 2+", "SIMPLE_CHEMICAL", 40, 45], ["RBCs", "CELL", 56, 60], ["RBCs", "CELL_TYPE", 56, 60], ["elevated cytoplasmic Ca", "PROBLEM", 19, 42], ["levels in RBCs", "PROBLEM", 46, 60], ["reduced deformability", "PROBLEM", 81, 102], ["reduced", "OBSERVATION_MODIFIER", 81, 88], ["deformability", "OBSERVATION_MODIFIER", 89, 102]]], ["Along these lines, we observed that TSP-1 treatment altered the indices of RBC deformability at exposure durations, which also elicited both enhanced cellular Ca 2+ concentration and cell death.", [["RBC", "ANATOMY", 75, 78], ["cellular", "ANATOMY", 150, 158], ["cell", "ANATOMY", 183, 187], ["Ca", "CHEMICAL", 159, 161], ["death", "DISEASE", 188, 193], ["Ca 2+", "CHEMICAL", 159, 164], ["lines", "CELL", 12, 17], ["TSP-1", "GENE_OR_GENE_PRODUCT", 36, 41], ["RBC", "CELL", 75, 78], ["cellular", "CELL", 150, 158], ["Ca 2+", "SIMPLE_CHEMICAL", 159, 164], ["cell", "CELL", 183, 187], ["TSP", "PROTEIN", 36, 39], ["RBC", "CELL_TYPE", 75, 78], ["TSP", "TEST", 36, 39], ["RBC deformability at exposure durations", "PROBLEM", 75, 114], ["cell death", "PROBLEM", 183, 193], ["lines", "OBSERVATION", 12, 17], ["RBC deformability", "OBSERVATION", 75, 92], ["both", "OBSERVATION_MODIFIER", 136, 140], ["enhanced", "OBSERVATION_MODIFIER", 141, 149], ["cellular Ca", "OBSERVATION", 150, 161], ["cell death", "OBSERVATION", 183, 193]]], ["As RBC rigidity is an important hemorheological parameter leading to reduced blood viscosity, our findings may explain the occurrence of vaso-occlusive events associated with enhanced TSP-1 plasma levels [52] .DiscussionTSP-1 has previously been implicated in the pathophysiology of vascular occlusion and pulmonary hypertension associated with sickle cell disease (SCD) [53, 54] .", [["RBC", "ANATOMY", 3, 6], ["blood", "ANATOMY", 77, 82], ["plasma", "ANATOMY", 190, 196], ["vascular", "ANATOMY", 283, 291], ["pulmonary", "ANATOMY", 306, 315], ["sickle cell", "ANATOMY", 345, 356], ["rigidity", "DISEASE", 7, 15], ["vascular occlusion", "DISEASE", 283, 301], ["pulmonary hypertension", "DISEASE", 306, 328], ["sickle cell disease", "DISEASE", 345, 364], ["SCD", "DISEASE", 366, 369], ["RBC", "CELL", 3, 6], ["blood", "ORGANISM_SUBSTANCE", 77, 82], ["TSP-1", "GENE_OR_GENE_PRODUCT", 184, 189], ["plasma", "ORGANISM_SUBSTANCE", 190, 196], ["DiscussionTSP-1", "GENE_OR_GENE_PRODUCT", 210, 225], ["vascular", "MULTI-TISSUE_STRUCTURE", 283, 291], ["pulmonary", "ORGAN", 306, 315], ["RBC", "CELL_TYPE", 3, 6], ["TSP", "PROTEIN", 184, 187], ["DiscussionTSP-1", "PROTEIN", 210, 225], ["RBC rigidity", "PROBLEM", 3, 15], ["an important hemorheological parameter", "PROBLEM", 19, 57], ["reduced blood viscosity", "PROBLEM", 69, 92], ["vaso-occlusive events", "PROBLEM", 137, 158], ["enhanced TSP", "TEST", 175, 187], ["plasma levels", "TEST", 190, 203], ["vascular occlusion", "PROBLEM", 283, 301], ["pulmonary hypertension", "PROBLEM", 306, 328], ["sickle cell disease", "PROBLEM", 345, 364], ["RBC rigidity", "OBSERVATION", 3, 15], ["vaso-occlusive", "OBSERVATION", 137, 151], ["vascular", "ANATOMY", 283, 291], ["occlusion", "OBSERVATION", 292, 301], ["pulmonary", "ANATOMY", 306, 315], ["hypertension", "OBSERVATION", 316, 328], ["sickle cell disease", "OBSERVATION", 345, 364]]], ["Increased prothrombotic risk in SCD is linked to elevated TSP-1 levels, which not only inhibit ADAMTS13 proteolysis of von Willebrand Factor [55] , but also provoke RBC MP shedding; this process, in turn, favors RBC adhesion to endothelial cells as well as stimulation of endothelial cell apoptosis [56] .", [["RBC", "ANATOMY", 165, 168], ["RBC", "ANATOMY", 212, 215], ["endothelial cells", "ANATOMY", 228, 245], ["endothelial cell", "ANATOMY", 272, 288], ["SCD", "DISEASE", 32, 35], ["TSP-1", "GENE_OR_GENE_PRODUCT", 58, 63], ["ADAMTS13", "GENE_OR_GENE_PRODUCT", 95, 103], ["von Willebrand Factor [55", "GENE_OR_GENE_PRODUCT", 119, 144], ["RBC MP", "GENE_OR_GENE_PRODUCT", 165, 171], ["RBC", "CELL", 212, 215], ["endothelial cells", "CELL", 228, 245], ["endothelial cell", "CELL", 272, 288], ["TSP", "PROTEIN", 58, 61], ["ADAMTS13", "PROTEIN", 95, 103], ["RBC", "CELL_TYPE", 165, 168], ["RBC", "CELL_TYPE", 212, 215], ["endothelial cells", "CELL_TYPE", 228, 245], ["Increased prothrombotic risk in SCD", "PROBLEM", 0, 35], ["elevated TSP", "PROBLEM", 49, 61], ["von Willebrand Factor", "TEST", 119, 140], ["RBC MP shedding", "PROBLEM", 165, 180], ["RBC adhesion to endothelial cells", "PROBLEM", 212, 245], ["endothelial cell apoptosis", "PROBLEM", 272, 298], ["prothrombotic", "OBSERVATION", 10, 23], ["RBC adhesion", "OBSERVATION", 212, 224], ["endothelial cells", "OBSERVATION", 228, 245], ["endothelial cell apoptosis", "OBSERVATION", 272, 298]]], ["Our data confirm MP shedding from RBCs following exposure to TSP-1 in vitro.", [["RBCs", "ANATOMY", 34, 38], ["MP", "GENE_OR_GENE_PRODUCT", 17, 19], ["RBCs", "CELL", 34, 38], ["TSP-1", "GENE_OR_GENE_PRODUCT", 61, 66], ["RBCs", "CELL_TYPE", 34, 38], ["TSP", "PROTEIN", 61, 64], ["Our data", "TEST", 0, 8], ["MP shedding", "PROBLEM", 17, 28], ["TSP", "TEST", 61, 64]]], ["Mechanistically, MP shedding by RBCs, as elucidated during their storage under blood banking conditions, may be a consequence of ATP depletion, K + leakage, and elevation of intracellular Ca 2+ [16] It may, therefore, be inferred that TSP-1-induced increase of intracellular Ca 2+ concentration leads to activation of Ca 2+ -dependent proteases leading to cytoskeletal damage and MP shedding [16] .", [["RBCs", "ANATOMY", 32, 36], ["blood", "ANATOMY", 79, 84], ["intracellular", "ANATOMY", 174, 187], ["intracellular", "ANATOMY", 261, 274], ["cytoskeletal", "ANATOMY", 356, 368], ["ATP", "CHEMICAL", 129, 132], ["K", "CHEMICAL", 144, 145], ["Ca", "CHEMICAL", 188, 190], ["Ca", "CHEMICAL", 275, 277], ["Ca", "CHEMICAL", 318, 320], ["MP", "DISEASE", 380, 382], ["ATP", "CHEMICAL", 129, 132], ["K +", "CHEMICAL", 144, 147], ["Ca 2+", "CHEMICAL", 188, 193], ["Ca 2+", "CHEMICAL", 275, 280], ["Ca 2+", "CHEMICAL", 318, 323], ["MP", "GENE_OR_GENE_PRODUCT", 17, 19], ["RBCs", "CELL", 32, 36], ["blood", "ORGANISM_SUBSTANCE", 79, 84], ["ATP", "SIMPLE_CHEMICAL", 129, 132], ["K +", "SIMPLE_CHEMICAL", 144, 147], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 174, 187], ["TSP-1", "GENE_OR_GENE_PRODUCT", 235, 240], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 261, 274], ["Ca 2+", "SIMPLE_CHEMICAL", 275, 280], ["Ca 2+", "SIMPLE_CHEMICAL", 318, 323], ["cytoskeletal", "CELLULAR_COMPONENT", 356, 368], ["MP", "GENE_OR_GENE_PRODUCT", 380, 382], ["RBCs", "CELL_TYPE", 32, 36], ["TSP-1", "PROTEIN", 235, 240], ["Ca 2+ -dependent proteases", "PROTEIN", 318, 344], ["blood banking conditions", "TREATMENT", 79, 103], ["ATP depletion", "PROBLEM", 129, 142], ["K", "TEST", 144, 145], ["leakage", "PROBLEM", 148, 155], ["elevation of intracellular Ca", "PROBLEM", 161, 190], ["TSP", "TEST", 235, 238], ["intracellular Ca", "PROBLEM", 261, 277], ["Ca", "TEST", 318, 320], ["dependent proteases", "PROBLEM", 325, 344], ["cytoskeletal damage", "PROBLEM", 356, 375], ["MP shedding", "PROBLEM", 380, 391], ["ATP depletion", "OBSERVATION", 129, 142], ["elevation", "OBSERVATION_MODIFIER", 161, 170], ["cytoskeletal damage", "OBSERVATION", 356, 375]]], ["Intriguingly, both TSP-1 and the CD47 agonist 4 N1-1 have been shown to potentiate the transformation of cell shape in SCD from discocytes to echinocytes [56] .", [["cell", "ANATOMY", 105, 109], ["discocytes", "ANATOMY", 128, 138], ["echinocytes", "ANATOMY", 142, 153], ["SCD", "DISEASE", 119, 122], ["TSP-1", "GENE_OR_GENE_PRODUCT", 19, 24], ["CD47", "GENE_OR_GENE_PRODUCT", 33, 37], ["N1-1", "GENE_OR_GENE_PRODUCT", 48, 52], ["cell", "CELL", 105, 109], ["TSP", "PROTEIN", 19, 22], ["CD47", "PROTEIN", 33, 37], ["TSP", "TEST", 19, 22], ["the CD47 agonist", "TEST", 29, 45], ["cell shape in SCD", "PROBLEM", 105, 122], ["echinocytes", "TEST", 142, 153], ["cell shape", "OBSERVATION", 105, 115]]], ["It is well established that an increased proportion of RBCs in SCD patients expose procoagulant PS on their surface, which may lead to thrombosis [57] .", [["RBCs", "ANATOMY", 55, 59], ["surface", "ANATOMY", 108, 115], ["SCD", "DISEASE", 63, 66], ["thrombosis", "DISEASE", 135, 145], ["RBCs", "CELL", 55, 59], ["patients", "ORGANISM", 67, 75], ["procoagulant PS", "GENE_OR_GENE_PRODUCT", 83, 98], ["surface", "CELLULAR_COMPONENT", 108, 115], ["RBCs", "CELL_TYPE", 55, 59], ["patients", "SPECIES", 67, 75], ["an increased proportion of RBCs", "PROBLEM", 28, 59], ["procoagulant PS", "TREATMENT", 83, 98], ["thrombosis", "PROBLEM", 135, 145], ["increased", "OBSERVATION_MODIFIER", 31, 40], ["may lead to", "UNCERTAINTY", 123, 134], ["thrombosis", "OBSERVATION", 135, 145]]], ["It is, therefore, reasonable to conjecture that hyperactive cation currents in RBCs are an important underlying mechanism of RBC dysfunction and thrombosis in SCD patients.", [["RBCs", "ANATOMY", 79, 83], ["RBC", "ANATOMY", 125, 128], ["RBC dysfunction", "DISEASE", 125, 140], ["thrombosis", "DISEASE", 145, 155], ["SCD", "DISEASE", 159, 162], ["cation", "SIMPLE_CHEMICAL", 60, 66], ["RBCs", "CELL", 79, 83], ["RBC", "CELL", 125, 128], ["patients", "ORGANISM", 163, 171], ["RBCs", "CELL_TYPE", 79, 83], ["patients", "SPECIES", 163, 171], ["hyperactive cation currents in RBCs", "PROBLEM", 48, 83], ["RBC dysfunction", "PROBLEM", 125, 140], ["thrombosis in SCD patients", "PROBLEM", 145, 171], ["hyperactive", "OBSERVATION", 48, 59], ["RBC dysfunction", "OBSERVATION", 125, 140], ["thrombosis", "OBSERVATION", 145, 155]]], ["TSP-1 may contribute to this channel activation.DiscussionAccelerated cell death of RBCs has been shown to occur in a variety of systemic conditions and may contribute to anemia, thrombosis, and impaired microcirculation in these disorders [21] .", [["cell", "ANATOMY", 70, 74], ["RBCs", "ANATOMY", 84, 88], ["death", "DISEASE", 75, 80], ["anemia", "DISEASE", 171, 177], ["thrombosis", "DISEASE", 179, 189], ["impaired microcirculation", "DISEASE", 195, 220], ["TSP-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["cell", "CELL", 70, 74], ["RBCs", "CELL", 84, 88], ["TSP-1", "PROTEIN", 0, 5], ["RBCs", "CELL_TYPE", 84, 88], ["TSP", "TEST", 0, 3], ["this channel activation", "PROBLEM", 24, 47], ["Accelerated cell death of RBCs", "PROBLEM", 58, 88], ["anemia", "PROBLEM", 171, 177], ["thrombosis", "PROBLEM", 179, 189], ["impaired microcirculation in these disorders", "PROBLEM", 195, 239], ["anemia", "OBSERVATION", 171, 177], ["thrombosis", "OBSERVATION", 179, 189], ["impaired", "OBSERVATION_MODIFIER", 195, 203], ["microcirculation", "OBSERVATION_MODIFIER", 204, 220]]], ["At least in theory, increased TSP-1 levels, encountered in these conditions, may aggravate RBC Ca 2+ entry leading to RBC cell death [21] .", [["RBC", "ANATOMY", 91, 94], ["RBC cell", "ANATOMY", 118, 126], ["Ca", "CHEMICAL", 95, 97], ["death", "DISEASE", 127, 132], ["Ca 2+", "CHEMICAL", 95, 100], ["TSP-1", "GENE_OR_GENE_PRODUCT", 30, 35], ["RBC", "CELL", 91, 94], ["Ca 2+", "SIMPLE_CHEMICAL", 95, 100], ["RBC cell", "CELL", 118, 126], ["TSP", "PROTEIN", 30, 33], ["RBC", "CELL_TYPE", 118, 121], ["increased TSP", "PROBLEM", 20, 33], ["RBC Ca", "TEST", 91, 97], ["RBC cell death", "PROBLEM", 118, 132], ["increased", "OBSERVATION_MODIFIER", 20, 29], ["RBC cell death", "OBSERVATION", 118, 132]]], ["Remarkably, TSP-1 serum concentrations were documented to be 100-fold higher than plasma concentrations indicating TSP-1 release by platelets [58] .", [["serum", "ANATOMY", 18, 23], ["plasma", "ANATOMY", 82, 88], ["platelets", "ANATOMY", 132, 141], ["TSP-1", "GENE_OR_GENE_PRODUCT", 12, 17], ["serum", "ORGANISM_SUBSTANCE", 18, 23], ["plasma", "ORGANISM_SUBSTANCE", 82, 88], ["TSP-1", "GENE_OR_GENE_PRODUCT", 115, 120], ["platelets", "CELL", 132, 141], ["TSP", "PROTEIN", 12, 15], ["TSP", "PROTEIN", 115, 118], ["platelets", "CELL_TYPE", 132, 141], ["TSP", "TEST", 12, 15], ["serum concentrations", "TEST", 18, 38], ["plasma concentrations", "TEST", 82, 103], ["TSP", "TEST", 115, 118], ["platelets", "TEST", 132, 141]]], ["TSP-1 concentrations used in this study (1-50 \u03bcg/mL) are well in the range of plasma and serum levels achieved in conditions such as SCD [53] , and interstitial pneumonia [59] , respectively.", [["plasma", "ANATOMY", 78, 84], ["serum", "ANATOMY", 89, 94], ["SCD", "DISEASE", 133, 136], ["interstitial pneumonia", "DISEASE", 148, 170], ["TSP-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["plasma", "ORGANISM_SUBSTANCE", 78, 84], ["serum", "ORGANISM_SUBSTANCE", 89, 94], ["TSP", "PROTEIN", 0, 3], ["TSP", "TEST", 0, 3], ["this study", "TEST", 29, 39], ["plasma and serum levels", "TEST", 78, 101], ["interstitial pneumonia", "PROBLEM", 148, 170], ["interstitial", "ANATOMY_MODIFIER", 148, 160], ["pneumonia", "OBSERVATION", 161, 170]]], ["Furthermore, 100 \u03bcg/mL of TSP-1 was previously used to demonstrate the impact of CD47 ligation on RBC viability in vitro [20] .ConclusionsTaken together, our data unravel that TSP-1/CD47 signaling mediates enhanced RBC Ca 2+ concentration contributing to cell death.", [["RBC", "ANATOMY", 98, 101], ["RBC", "ANATOMY", 215, 218], ["cell", "ANATOMY", 255, 259], ["Ca", "CHEMICAL", 219, 221], ["death", "DISEASE", 260, 265], ["Ca 2+", "CHEMICAL", 219, 224], ["TSP-1", "GENE_OR_GENE_PRODUCT", 26, 31], ["CD47", "GENE_OR_GENE_PRODUCT", 81, 85], ["RBC", "CELL", 98, 101], ["TSP-1", "GENE_OR_GENE_PRODUCT", 176, 181], ["CD47", "GENE_OR_GENE_PRODUCT", 182, 186], ["RBC", "CELL", 215, 218], ["Ca 2+", "SIMPLE_CHEMICAL", 219, 224], ["cell", "CELL", 255, 259], ["TSP", "PROTEIN", 26, 29], ["CD47", "PROTEIN", 81, 85], ["RBC", "CELL_TYPE", 98, 101], ["TSP", "PROTEIN", 176, 179], ["CD47", "PROTEIN", 182, 186], ["TSP", "TEST", 26, 29], ["CD47 ligation", "TREATMENT", 81, 94], ["RBC viability", "TEST", 98, 111], ["our data", "TEST", 154, 162], ["TSP", "TEST", 176, 179], ["RBC Ca", "TEST", 215, 221], ["cell death", "PROBLEM", 255, 265], ["CD47 ligation", "OBSERVATION", 81, 94], ["cell death", "OBSERVATION", 255, 265]]], ["Targeting this signaling pathway may represent a possible therapeutic option in mitigating RBC-related pathophysiology in different clinical conditions associated with elevated TSP-1 levels.", [["RBC", "ANATOMY", 91, 94], ["RBC", "CELL", 91, 94], ["TSP-1", "GENE_OR_GENE_PRODUCT", 177, 182], ["RBC", "CELL_TYPE", 91, 94], ["TSP", "PROTEIN", 177, 180], ["this signaling pathway", "PROBLEM", 10, 32], ["mitigating RBC", "PROBLEM", 80, 94], ["elevated TSP", "PROBLEM", 168, 180], ["may represent", "UNCERTAINTY", 33, 46], ["possible", "UNCERTAINTY", 49, 57], ["therapeutic", "OBSERVATION_MODIFIER", 58, 69]]]], "PMC7502678": [["Medical trainees constituted 7% of the respondents, while 5% were advanced practice providers, and 3% were electroencephalography (EEG) technologists.", [["electroencephalography", "TEST", 107, 129], ["EEG", "TEST", 131, 134]]], ["Respondents were asked how they would describe the degree of community spread of COVID-19 cases in their region using subjective terms (no reported cases, mild, moderate, severe).", [["mild, moderate, severe)", "PROBLEM", 155, 178], ["mild", "OBSERVATION_MODIFIER", 155, 159], ["moderate", "OBSERVATION_MODIFIER", 161, 169]]], ["At the time the survey was conducted, one-half (50%) described their geographic region (American state or country) as \u201cmoderately\u201d affected by the COVID-19 pandemic, while a quarter each described their region as \u201cseverely\u201d or \u201cmildly\u201d affected.", [["the survey", "TEST", 12, 22], ["the COVID", "TEST", 143, 152], ["pandemic", "PROBLEM", 156, 164], ["mildly\u201d affected", "PROBLEM", 228, 244], ["mildly", "OBSERVATION_MODIFIER", 228, 234]]], ["Only one respondent was not aware of COVID-19 cases in their area (Figure 1).Seizures and COVID-19 ::: Impact on Patient CareAbout a third (30%) of the survey respondents reported a suspected cause for new onset seizures in COVID-19 patients.", [["Seizures", "DISEASE", 77, 85], ["seizures", "DISEASE", 212, 220], ["patients", "ORGANISM", 233, 241], ["Patient", "SPECIES", 113, 120], ["patients", "SPECIES", 233, 241], ["COVID", "TEST", 37, 42], ["Seizures", "PROBLEM", 77, 85], ["COVID", "TEST", 90, 95], ["new onset seizures", "PROBLEM", 202, 220]]], ["Most often the mechanism thought to be responsible for the seizures was lowered seizure threshold with preexisting risk factors.", [["seizures", "DISEASE", 59, 67], ["seizure", "DISEASE", 80, 87], ["the seizures", "PROBLEM", 55, 67], ["lowered seizure threshold", "PROBLEM", 72, 97], ["preexisting risk factors", "PROBLEM", 103, 127]]], ["Some respondents suspected viral invasion of the central nervous system (CNS) and injury from SARS-CoV-2.", [["central nervous system", "ANATOMY", 49, 71], ["CNS", "ANATOMY", 73, 76], ["viral invasion of the central nervous system", "DISEASE", 27, 71], ["SARS", "DISEASE", 94, 98], ["central nervous system", "ANATOMICAL_SYSTEM", 49, 71], ["CNS", "ANATOMICAL_SYSTEM", 73, 76], ["SARS-CoV", "SPECIES", 94, 102], ["viral invasion of the central nervous system", "PROBLEM", 27, 71], ["injury", "PROBLEM", 82, 88], ["SARS", "PROBLEM", 94, 98], ["CoV", "TEST", 99, 102], ["viral invasion", "OBSERVATION", 27, 41], ["central", "ANATOMY_MODIFIER", 49, 56], ["nervous system", "ANATOMY", 57, 71], ["CNS", "ANATOMY", 73, 76], ["injury", "OBSERVATION", 82, 88]]], ["Rarely, seizures were attributed to cardiac arrest or stroke that occurred during the illness.", [["cardiac", "ANATOMY", 36, 43], ["seizures", "DISEASE", 8, 16], ["cardiac arrest", "DISEASE", 36, 50], ["stroke", "DISEASE", 54, 60], ["cardiac", "ORGAN", 36, 43], ["seizures", "PROBLEM", 8, 16], ["cardiac arrest", "PROBLEM", 36, 50], ["stroke", "PROBLEM", 54, 60], ["the illness", "PROBLEM", 82, 93], ["cardiac", "ANATOMY", 36, 43], ["arrest", "OBSERVATION", 44, 50], ["stroke", "OBSERVATION", 54, 60]]], ["Most survey respondents (63%) indicated that the new-onset seizures were mostly focal-onset with or without evolution to bilateral tonic\u2013clonic seizures.", [["seizures", "DISEASE", 59, 67], ["seizures", "DISEASE", 144, 152], ["the new-onset seizures", "PROBLEM", 45, 67], ["bilateral tonic\u2013clonic seizures", "PROBLEM", 121, 152], ["focal", "OBSERVATION_MODIFIER", 80, 85], ["bilateral", "ANATOMY_MODIFIER", 121, 130], ["tonic\u2013clonic", "ANATOMY", 131, 143], ["seizures", "OBSERVATION", 144, 152]]], ["Other respondents identified seizures as generalized, electrographic only or unclassifiable almost equally.Seizures and COVID-19 ::: Impact on Patient CareOne-third of respondents reported that they had PWE in their practice that had been diagnosed with COVID-19.", [["seizures", "DISEASE", 29, 37], ["Seizures", "DISEASE", 107, 115], ["COVID-19", "CHEMICAL", 254, 262], ["Patient", "SPECIES", 143, 150], ["seizures", "PROBLEM", 29, 37], ["Seizures", "PROBLEM", 107, 115], ["COVID", "TEST", 254, 259], ["seizures", "OBSERVATION", 29, 37]]], ["A majority of these PWE had no change in seizure frequency.", [["seizure", "DISEASE", 41, 48], ["change in seizure frequency", "PROBLEM", 31, 58], ["no", "UNCERTAINTY", 28, 30], ["change", "OBSERVATION_MODIFIER", 31, 37]]], ["About 17% of the respondents noted worsening, while none noted an improvement in seizures in PWE with COVID-19.Seizures and COVID-19 ::: Impact on Patient CareIn PWE who had not been infected with SARS-CoV-2, most respondents did not see a change in seizure frequency in their patients.", [["seizures", "DISEASE", 81, 89], ["Seizures", "DISEASE", 111, 119], ["SARS", "DISEASE", 197, 201], ["seizure", "DISEASE", 250, 257], ["COVID-19", "CHEMICAL", 124, 132], ["SARS-CoV-2", "ORGANISM", 197, 207], ["patients", "ORGANISM", 277, 285], ["Patient", "SPECIES", 147, 154], ["patients", "SPECIES", 277, 285], ["seizures", "PROBLEM", 81, 89], ["COVID", "TEST", 102, 107], ["Seizures", "PROBLEM", 111, 119], ["a change in seizure frequency", "PROBLEM", 238, 267], ["worsening", "OBSERVATION_MODIFIER", 35, 44], ["seizures", "OBSERVATION", 81, 89]]], ["However, 10% of respondents noted a worsening in seizure frequency, while 5% noted an improvement (Figure 2).", [["seizure", "DISEASE", 49, 56], ["a worsening in seizure frequency", "PROBLEM", 34, 66], ["worsening", "OBSERVATION_MODIFIER", 36, 45]]], ["Worsening of seizure frequency was attributed to increased stress, sleep deprivation, and reduced access to pharmacies and medications.", [["seizure", "DISEASE", 13, 20], ["Worsening of seizure frequency", "PROBLEM", 0, 30], ["increased stress", "PROBLEM", 49, 65], ["sleep deprivation", "PROBLEM", 67, 84], ["medications", "TREATMENT", 123, 134], ["seizure", "OBSERVATION", 13, 20], ["increased", "OBSERVATION_MODIFIER", 49, 58], ["stress", "OBSERVATION", 59, 65]]], ["However, when survey participants were specifically asked if PWE were reporting increased seizures as a result of emotional stress, more than 80% of respondents either disagreed or were neutral or unsure.", [["seizures", "DISEASE", 90, 98], ["participants", "SPECIES", 21, 33], ["increased seizures", "PROBLEM", 80, 98], ["emotional stress", "PROBLEM", 114, 130]]], ["Conversely, improved seizure control was attributed to better sleep and medication adherence.Epilepsy Clinical Care ::: Impact on Patient CareConcerns have been raised about the quality of care provided to PWE during the COVID-19 pandemic.", [["seizure", "DISEASE", 21, 28], ["Epilepsy", "DISEASE", 93, 101], ["Patient", "SPECIES", 130, 137], ["improved seizure control", "PROBLEM", 12, 36], ["medication adherence", "TREATMENT", 72, 92], ["Patient CareConcerns", "TREATMENT", 130, 150], ["the COVID", "TEST", 217, 226], ["pandemic", "PROBLEM", 230, 238]]], ["The remaining 17% were either neutral or unsure.Epilepsy Clinical Care ::: Impact on Patient CareThe majority of respondents felt that there were at least some barriers for PWE in getting appropriate clinical care, testing (including EEG and video EEG monitoring) and elective surgery.", [["Epilepsy", "DISEASE", 48, 56], ["Patient", "SPECIES", 85, 92], ["testing", "TEST", 215, 222], ["EEG", "TEST", 234, 237], ["video EEG monitoring", "TEST", 242, 262], ["elective surgery", "TREATMENT", 268, 284]]], ["The reasons for these barriers were thought to include loss of employment and financial stress, lack of access to health care service due to closure, transportation issues, lack of access to technology for telehealth, and reluctance to seek care due to fear of viral outbreak (Figure 3).", [["financial stress", "PROBLEM", 78, 94], ["closure", "TREATMENT", 141, 148], ["viral outbreak", "PROBLEM", 261, 275], ["closure", "OBSERVATION", 141, 148]]], ["Other barriers identified by some respondents were reduced access to specialty pharmacy services for patients with severe epilepsies, loss of insurance leading to lack of medication coverage, loss of behavioral health services, and increase in stress, anxiety, and depression due to the pandemic.", [["epilepsies", "DISEASE", 122, 132], ["loss of insurance", "DISEASE", 134, 151], ["anxiety", "DISEASE", 252, 259], ["depression", "DISEASE", 265, 275], ["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["severe epilepsies", "PROBLEM", 115, 132], ["loss of insurance", "PROBLEM", 134, 151], ["medication coverage", "TREATMENT", 171, 190], ["stress", "PROBLEM", 244, 250], ["anxiety", "PROBLEM", 252, 259], ["depression", "PROBLEM", 265, 275], ["the pandemic", "PROBLEM", 283, 295], ["severe", "OBSERVATION_MODIFIER", 115, 121], ["epilepsies", "OBSERVATION", 122, 132]]], ["Respondents noted that overall, the COVID-19 pandemic has not resulted in a significant change in phone calls from patients to clinics, although both increased and decreased calls were reported in some instances.Barriers to Providing Care ::: Impact on Clinical PracticeA range of barriers were reported in providing care during the pandemic.", [["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123], ["significant", "OBSERVATION_MODIFIER", 76, 87], ["change", "OBSERVATION_MODIFIER", 88, 94], ["increased", "OBSERVATION_MODIFIER", 150, 159]]], ["Most frequently noted were limited access to in-person visits and nonemergency testing reported by 74% and 66% of respondents, respectively.", [["nonemergency testing", "TEST", 66, 86]]], ["Only 7% of respondents experienced no barriers in providing patient care during the pandemic.", [["patient", "ORGANISM", 60, 67], ["patient", "SPECIES", 60, 67]]], ["One respondent noted that between the pandemic and Centers for Medicare and Medicaid Services (CMS) cutbacks on EEG reimbursement, continuing practice appeared difficult.Barriers to Providing Care ::: Impact on Clinical PracticeRespondents also cited the following additional practice-related barriers to providing care: prioritization of COVID over nonurgent care; suspensions of epilepsy monitoring units (EMUs), vagus nerve stimulator implantations, and presurgical evaluation and surgery; reopening logistics; staff cuts; and clinic staffing (eg, childcare challenges and fear of exposure to COVID).", [["vagus nerve", "ANATOMY", 415, 426], ["pandemic", "DISEASE", 38, 46], ["epilepsy", "DISEASE", 381, 389], ["vagus nerve", "MULTI-TISSUE_STRUCTURE", 415, 426], ["EEG reimbursement", "TREATMENT", 112, 129], ["nonurgent care", "TREATMENT", 350, 364], ["epilepsy monitoring units", "TREATMENT", 381, 406], ["EMUs)", "TREATMENT", 408, 413], ["vagus nerve stimulator implantations", "TREATMENT", 415, 451], ["presurgical evaluation", "TEST", 457, 479], ["surgery", "TREATMENT", 484, 491], ["vagus nerve", "ANATOMY", 415, 426]]], ["Regarding when respondents expected to return services to pre-COVID-19 levels, the answers formed a normally distributed Bell-shaped curve between now and never, centered at approximately 6 months.", [["pre-COVID", "TEST", 58, 67]]], ["Approximately 5% did not feel their practice would ever return to normal.Neurophysiologic Evaluations ::: Impact on Clinical PracticeAbout half of respondents (47%) reported that EEGs were discouraged for patients admitted to the hospital with COVID-19 or those suspected of having the infection.", [["infection", "DISEASE", 286, 295], ["patients", "ORGANISM", 205, 213], ["patients", "SPECIES", 205, 213], ["Neurophysiologic Evaluations", "TEST", 73, 101], ["EEGs", "TEST", 179, 183], ["COVID", "TREATMENT", 244, 249], ["the infection", "PROBLEM", 282, 295], ["normal", "OBSERVATION", 66, 72], ["infection", "OBSERVATION", 286, 295]]], ["Even without restrictions, nearly a quarter (22%) reported they were doing fewer studies than usual (Figure 4).", [["without", "UNCERTAINTY", 5, 12]]], ["About 9% responded they were no longer doing continuous video-EEG monitoring.", [["continuous video", "TEST", 45, 61], ["EEG monitoring", "TEST", 62, 76]]], ["In the write in comments, many respondents noted that their EMUs had closed.", [["EMUs", "CANCER", 60, 64]]], ["Very few respondents (2%) reported that they were doing more EEGs than usual; of this group, 5 were from institutions where there were no restrictions for performing EEGs during the COVID-19 pandemic.Medication Interactions or Shortages ::: Impact on Clinical PracticeAlmost no respondents had seen unusual interactions between anti-seizure medications (ASM) and medications used to treat COVID-19.", [["COVID-19", "CHEMICAL", 389, 397], ["EEGs", "TEST", 166, 170], ["the COVID", "TEST", 178, 187], ["pandemic", "PROBLEM", 191, 199], ["anti-seizure medications", "TREATMENT", 328, 352], ["medications", "TREATMENT", 363, 374], ["COVID", "TEST", 389, 394], ["few", "OBSERVATION_MODIFIER", 5, 8]]], ["Medications shortages were noted by approximately 44% of respondents (Figure 5).", [["Medications shortages", "TREATMENT", 0, 21]]], ["In write-in comments, the most frequently noted shortages were of extended release levetiracetam and midazolam, and other shortages of several IV benzodiazepines were noted by some respondents.", [["levetiracetam", "CHEMICAL", 83, 96], ["midazolam", "CHEMICAL", 101, 110], ["benzodiazepines", "CHEMICAL", 146, 161], ["levetiracetam", "CHEMICAL", 83, 96], ["midazolam", "CHEMICAL", 101, 110], ["benzodiazepines", "CHEMICAL", 146, 161], ["levetiracetam", "SIMPLE_CHEMICAL", 83, 96], ["midazolam", "SIMPLE_CHEMICAL", 101, 110], ["extended release levetiracetam", "TREATMENT", 66, 96], ["midazolam", "TREATMENT", 101, 110], ["several IV benzodiazepines", "TREATMENT", 135, 161]]], ["However, it appears some of these shortages existed from prior to the pandemic.", [["the pandemic", "PROBLEM", 66, 78]]], ["By and large, there appeared to be no consistent pattern of shortages of conventional ASMs directly attributable to the pandemic.", [["ASMs", "DISEASE", 86, 90], ["conventional ASMs", "PROBLEM", 73, 90], ["the pandemic", "PROBLEM", 116, 128], ["large", "OBSERVATION_MODIFIER", 7, 12], ["no consistent", "UNCERTAINTY", 35, 48], ["pattern", "OBSERVATION_MODIFIER", 49, 56], ["pandemic", "OBSERVATION", 120, 128]]], ["The majority of shortage reports originated from patients; IV anesthetic shortages were reported by inpatient pharmacies.Impact on Trainees ::: Impact on Clinical PracticeTrainees (residents and fellows) responded in low numbers and noted that the pandemic has harmed their educational experience.", [["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["IV anesthetic shortages", "TREATMENT", 59, 82]]], ["They cited reduced patient volumes and canceled clinics as responsible factors.", [["patient", "ORGANISM", 19, 26], ["patient", "SPECIES", 19, 26]]], ["The benefits included improved access, decreased no-show rates, observations of the home environment, participation of families/caregivers, general efficiency of the visits, flexibility for patients and providers, enhanced integration with multidisciplinary teams, and increased access to psychosocial care providers.", [["patients", "ORGANISM", 190, 198], ["patients", "SPECIES", 190, 198], ["psychosocial care providers", "TREATMENT", 289, 316]]], ["Respondents also reported that their recent telemedicine experience demonstrates that much of pertinent examinations for epilepsy care, especially for follow-up visits, can be done with telehealth (eg, mental status, gait, coordination, cranial nerves, nystagmus, and ataxia evaluation).", [["cranial nerves", "ANATOMY", 237, 251], ["epilepsy", "DISEASE", 121, 129], ["nystagmus", "DISEASE", 253, 262], ["ataxia", "DISEASE", 268, 274], ["cranial nerves", "MULTI-TISSUE_STRUCTURE", 237, 251], ["pertinent examinations", "TEST", 94, 116], ["epilepsy care", "TREATMENT", 121, 134], ["nystagmus", "PROBLEM", 253, 262], ["ataxia evaluation", "TEST", 268, 285], ["cranial nerves", "ANATOMY", 237, 251]]], ["Problems identified by respondents included technical difficulties, lack of physical contact, and inability to perform diagnostic monitoring and laboratory tests.TelehealthCertain patient populations emerged as likely to particularly benefit from telehealth.", [["patient", "ORGANISM", 180, 187], ["patient", "SPECIES", 180, 187], ["technical difficulties", "PROBLEM", 44, 66], ["diagnostic monitoring", "TEST", 119, 140], ["laboratory tests", "TEST", 145, 161]]], ["This included patients living far away from clinics, needing to take extended time off from work to attend clinic visits, with disabilities and requiring transportation, or living in extended care facilities.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22]]], ["This survey also suggested that the most vulnerable patients are negatively affected by the use of telehealth services, in that the lack of internet access and/or video-capable device has resulted in suboptimal interaction or necessitated an in-person visits to the clinic.TelehealthThe Veterans Administration\u2019s Epilepsy Centers of Excellence longstanding experience with telehealth was cited as a model for utilization of telemedicine for providing direct patient care, reading EEG studies remotely or reviewing them for quality assurance, and provider-to-provider consultation in treating epilepsy patients.TelehealthThe survey respondents emphasized concerns regarding continued reimbursement for telehealth visits.", [["Epilepsy", "DISEASE", 313, 321], ["epilepsy", "DISEASE", 592, 600], ["patients", "ORGANISM", 52, 60], ["patient", "ORGANISM", 458, 465], ["patients", "ORGANISM", 601, 609], ["patients", "SPECIES", 52, 60], ["patient", "SPECIES", 458, 465], ["patients", "SPECIES", 601, 609], ["telehealth services", "TREATMENT", 99, 118], ["video-capable device", "TREATMENT", 163, 183], ["direct patient care", "TREATMENT", 451, 470], ["reading EEG studies", "TEST", 472, 491], ["epilepsy", "PROBLEM", 592, 600]]], ["Many respondents wanted advocacy for continued reimbursement parity for telemedicine visits compared to in-person visits.Seizures and COVID-19 ::: DiscussionInitially thought to be mainly a respiratory infection, it is now clear that COVID-19 is associated with neurological involvement in more than 30% of patients, with approximately 25% having symptoms indicating CNS dysfunction.", [["respiratory", "ANATOMY", 190, 201], ["neurological", "ANATOMY", 262, 274], ["CNS", "ANATOMY", 367, 370], ["Seizures", "DISEASE", 121, 129], ["respiratory infection", "DISEASE", 190, 211], ["CNS dysfunction", "DISEASE", 367, 382], ["COVID-19", "CHEMICAL", 134, 142], ["patients", "ORGANISM", 307, 315], ["CNS", "ANATOMICAL_SYSTEM", 367, 370], ["patients", "SPECIES", 307, 315], ["Seizures", "PROBLEM", 121, 129], ["a respiratory infection", "PROBLEM", 188, 211], ["COVID", "TEST", 234, 239], ["neurological involvement", "PROBLEM", 262, 286], ["symptoms", "PROBLEM", 347, 355], ["CNS dysfunction", "PROBLEM", 367, 382], ["thought to be", "UNCERTAINTY", 167, 180], ["respiratory", "ANATOMY", 190, 201], ["infection", "OBSERVATION", 202, 211], ["CNS", "ANATOMY", 367, 370], ["dysfunction", "OBSERVATION", 371, 382]]], ["Fortunately, the incidence of seizures appears to be low (0.5%).3 Although there are case reports of seizures at onset in both adults and children, new-onset seizures and status epilepticus (SE) are rarely described.", [["seizures", "DISEASE", 30, 38], ["seizures", "DISEASE", 101, 109], ["seizures", "DISEASE", 158, 166], ["status epilepticus", "DISEASE", 171, 189], ["SE", "DISEASE", 191, 193], ["children", "ORGANISM", 138, 146], ["children", "SPECIES", 138, 146], ["seizures", "PROBLEM", 30, 38], ["seizures", "PROBLEM", 101, 109], ["new-onset seizures", "PROBLEM", 148, 166], ["status epilepticus", "PROBLEM", 171, 189], ["seizures", "OBSERVATION", 30, 38], ["low", "OBSERVATION_MODIFIER", 53, 56], ["seizures", "OBSERVATION", 101, 109], ["seizures", "OBSERVATION", 158, 166]]], ["In a recent multicenter, retrospective study of 304 people with no known history of epilepsy in China, neither acute symptomatic seizures nor SE was observed.4 Two people had seizure-like symptoms during hospitalization that were thought to be related to acute stress reaction and hypocalcemia.", [["epilepsy", "DISEASE", 84, 92], ["seizures", "DISEASE", 129, 137], ["SE", "DISEASE", 142, 144], ["seizure", "DISEASE", 175, 182], ["acute stress reaction", "DISEASE", 255, 276], ["hypocalcemia", "DISEASE", 281, 293], ["people", "ORGANISM", 52, 58], ["people", "ORGANISM", 164, 170], ["people", "SPECIES", 52, 58], ["people", "SPECIES", 164, 170], ["retrospective study", "TEST", 25, 44], ["epilepsy", "PROBLEM", 84, 92], ["neither acute symptomatic seizures", "PROBLEM", 103, 137], ["seizure-like symptoms", "PROBLEM", 175, 196], ["acute stress reaction", "PROBLEM", 255, 276], ["hypocalcemia", "PROBLEM", 281, 293], ["epilepsy", "OBSERVATION", 84, 92], ["acute", "OBSERVATION_MODIFIER", 111, 116], ["symptomatic", "OBSERVATION_MODIFIER", 117, 128], ["seizures", "OBSERVATION", 129, 137], ["thought to be related to", "UNCERTAINTY", 230, 254], ["acute", "OBSERVATION_MODIFIER", 255, 260], ["stress", "OBSERVATION", 261, 267], ["hypocalcemia", "OBSERVATION", 281, 293]]], ["There was no evidence suggesting an additional risk of acute symptomatic seizures in people with COVID-19.", [["seizures", "DISEASE", 73, 81], ["COVID-19", "CHEMICAL", 97, 105], ["people", "ORGANISM", 85, 91], ["people", "SPECIES", 85, 91], ["acute symptomatic seizures", "PROBLEM", 55, 81], ["COVID", "TEST", 97, 102], ["no evidence suggesting", "UNCERTAINTY", 10, 32], ["acute", "OBSERVATION_MODIFIER", 55, 60], ["symptomatic", "OBSERVATION_MODIFIER", 61, 72], ["seizures", "OBSERVATION", 73, 81]]], ["About a third (30%) of respondents in the current survey reported seeing COVID-19 patients with new-onset seizures.", [["seizures", "DISEASE", 106, 114], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["new-onset seizures", "PROBLEM", 96, 114], ["seizures", "OBSERVATION", 106, 114]]], ["This high rate, which is much higher than we might expect given the reported rate of new-onset seizures in the literature (0.5%), is likely reflective of the population surveyed, namely epilepsy specialists.3", [["seizures", "DISEASE", 95, 103], ["epilepsy", "DISEASE", 186, 194], ["new-onset seizures", "PROBLEM", 85, 103], ["new", "OBSERVATION_MODIFIER", 85, 88], ["onset", "OBSERVATION_MODIFIER", 89, 94], ["seizures", "OBSERVATION", 95, 103], ["likely reflective", "UNCERTAINTY", 133, 150]]]], "PMC7150004": [["PathogenesisViruses can be released by infected humans or animals in saliva, respiratory droplets, breast milk, feces, urine, semen, vaginal secretions, blood, or tissue.", [["saliva", "ANATOMY", 69, 75], ["respiratory droplets", "ANATOMY", 77, 97], ["breast milk", "ANATOMY", 99, 110], ["feces", "ANATOMY", 112, 117], ["urine", "ANATOMY", 119, 124], ["semen", "ANATOMY", 126, 131], ["vaginal secretions", "ANATOMY", 133, 151], ["blood", "ANATOMY", 153, 158], ["tissue", "ANATOMY", 163, 169], ["humans", "ORGANISM", 48, 54], ["saliva", "ORGANISM_SUBSTANCE", 69, 75], ["breast milk", "ORGANISM_SUBSTANCE", 99, 110], ["feces", "ORGANISM_SUBSTANCE", 112, 117], ["urine", "ORGANISM_SUBSTANCE", 119, 124], ["semen", "ORGANISM_SUBSTANCE", 126, 131], ["vaginal secretions", "ORGANISM_SUBSTANCE", 133, 151], ["blood", "ORGANISM_SUBSTANCE", 153, 158], ["tissue", "TISSUE", 163, 169], ["humans", "SPECIES", 48, 54], ["milk", "SPECIES", 106, 110], ["humans", "SPECIES", 48, 54], ["PathogenesisViruses", "PROBLEM", 0, 19], ["respiratory droplets", "TEST", 77, 97], ["breast milk, feces, urine", "TEST", 99, 124], ["vaginal secretions", "PROBLEM", 133, 151], ["blood", "PROBLEM", 153, 158], ["infected", "OBSERVATION", 39, 47], ["breast", "ANATOMY", 99, 105], ["vaginal", "ANATOMY", 133, 140], ["secretions", "OBSERVATION", 141, 151]]], ["Viruses have no mobility but must penetrate formidable barriers to enter the body of a susceptible human host.", [["body", "ANATOMY", 77, 81], ["body", "ORGANISM_SUBDIVISION", 77, 81], ["human", "ORGANISM", 99, 104], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 99, 104], ["Viruses", "PROBLEM", 0, 7], ["no", "UNCERTAINTY", 13, 15], ["mobility", "OBSERVATION_MODIFIER", 16, 24]]], ["The skin is covered by a layer of keratinized cells that will not sustain virus replication, but arthropods and animal bites, needles, and tissue transplantation can breach this barrier directly (Table 1).", [["skin", "ANATOMY", 4, 8], ["keratinized cells", "ANATOMY", 34, 51], ["tissue", "ANATOMY", 139, 145], ["skin", "ORGAN", 4, 8], ["keratinized cells", "CELL", 34, 51], ["tissue", "TISSUE", 139, 145], ["keratinized cells", "CELL_TYPE", 34, 51], ["a layer of keratinized cells", "TREATMENT", 23, 51], ["virus replication", "TREATMENT", 74, 91], ["arthropods", "TREATMENT", 97, 107], ["needles", "TREATMENT", 126, 133], ["tissue transplantation", "TREATMENT", 139, 161], ["skin", "ANATOMY", 4, 8], ["keratinized cells", "OBSERVATION", 34, 51]]], ["The mucous membranes of the respiratory, gastrointestinal, and genitourinary tract are protected by secretory immunoglobulins, and all are monitored by macrophages that phagocytize viruses and other particles.", [["mucous membranes", "ANATOMY", 4, 20], ["respiratory", "ANATOMY", 28, 39], ["gastrointestinal", "ANATOMY", 41, 57], ["genitourinary tract", "ANATOMY", 63, 82], ["macrophages", "ANATOMY", 152, 163], ["respiratory, gastrointestinal, and genitourinary tract", "DISEASE", 28, 82], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 4, 20], ["gastrointestinal", "ORGAN", 41, 57], ["genitourinary tract", "ORGAN", 63, 82], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 110, 125], ["macrophages", "CELL", 152, 163], ["secretory immunoglobulins", "PROTEIN", 100, 125], ["macrophages", "CELL_TYPE", 152, 163], ["secretory immunoglobulins", "TEST", 100, 125], ["mucous membranes", "OBSERVATION", 4, 20], ["respiratory", "ANATOMY", 28, 39], ["gastrointestinal", "ANATOMY", 41, 57], ["genitourinary tract", "ANATOMY", 63, 82], ["phagocytize viruses", "OBSERVATION", 169, 188]]], ["In addition, the respiratory tract has a mucous coating and cilia that beat the film containing inhaled particles outward and away from the epithelial cells of the lower respiratory tract, and the gastrointestinal and genitourinary tracts have extremes of acidity.", [["respiratory tract", "ANATOMY", 17, 34], ["mucous", "ANATOMY", 41, 47], ["cilia", "ANATOMY", 60, 65], ["epithelial cells", "ANATOMY", 140, 156], ["lower respiratory tract", "ANATOMY", 164, 187], ["gastrointestinal", "ANATOMY", 197, 213], ["genitourinary tracts", "ANATOMY", 218, 238], ["gastrointestinal and genitourinary tracts", "DISEASE", 197, 238], ["respiratory tract", "ORGANISM_SUBDIVISION", 17, 34], ["cilia", "CELLULAR_COMPONENT", 60, 65], ["epithelial cells", "CELL", 140, 156], ["lower respiratory", "ORGANISM_SUBDIVISION", 164, 181], ["tract", "ORGANISM_SUBDIVISION", 182, 187], ["gastrointestinal", "ORGAN", 197, 213], ["genitourinary tracts", "PATHOLOGICAL_FORMATION", 218, 238], ["epithelial cells", "CELL_TYPE", 140, 156], ["the respiratory tract", "PROBLEM", 13, 34], ["a mucous coating and cilia", "PROBLEM", 39, 65], ["the film", "TEST", 76, 84], ["extremes of acidity", "PROBLEM", 244, 263], ["respiratory tract", "ANATOMY", 17, 34], ["mucous coating", "OBSERVATION", 41, 55], ["cilia", "ANATOMY_MODIFIER", 60, 65], ["inhaled particles", "OBSERVATION", 96, 113], ["epithelial cells", "OBSERVATION", 140, 156], ["lower", "ANATOMY_MODIFIER", 164, 169], ["respiratory tract", "ANATOMY", 170, 187], ["gastrointestinal", "ANATOMY", 197, 213], ["genitourinary tracts", "ANATOMY", 218, 238], ["acidity", "OBSERVATION", 256, 263]]], ["A few nonenveloped, acid-resistant viruses (adenoviruses, enteroviruses, parvoviruses, and reoviruses) can survive passage through the acidity and solvents of the gastrointestinal tract.PathogenesisOnce permissive host cells are infected in the subcutaneous tissue, the mucous membranes, or the hematopoietic system (particularly macrophages), cycles of replication usually occur locally before there is invasion of the central nervous system (CNS).", [["gastrointestinal tract", "ANATOMY", 163, 185], ["cells", "ANATOMY", 219, 224], ["subcutaneous tissue", "ANATOMY", 245, 264], ["mucous membranes", "ANATOMY", 270, 286], ["hematopoietic system", "ANATOMY", 295, 315], ["macrophages", "ANATOMY", 330, 341], ["central nervous system", "ANATOMY", 420, 442], ["CNS", "ANATOMY", 444, 447], ["enteroviruses", "DISEASE", 58, 71], ["adenoviruses", "ORGANISM", 44, 56], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 163, 185], ["host cells", "CELL", 214, 224], ["subcutaneous tissue", "TISSUE", 245, 264], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 270, 286], ["macrophages", "CELL", 330, 341], ["central nervous system", "ANATOMICAL_SYSTEM", 420, 442], ["CNS", "ANATOMICAL_SYSTEM", 444, 447], ["host cells", "CELL_TYPE", 214, 224], ["macrophages", "CELL_TYPE", 330, 341], ["A few nonenveloped, acid-resistant viruses", "PROBLEM", 0, 42], ["adenoviruses", "PROBLEM", 44, 56], ["enteroviruses", "PROBLEM", 58, 71], ["parvoviruses", "TREATMENT", 73, 85], ["reoviruses", "TREATMENT", 91, 101], ["permissive host cells", "PROBLEM", 203, 224], ["the hematopoietic system", "PROBLEM", 291, 315], ["invasion of the central nervous system", "PROBLEM", 404, 442], ["few", "OBSERVATION_MODIFIER", 2, 5], ["nonenveloped", "OBSERVATION_MODIFIER", 6, 18], ["acid-resistant viruses", "OBSERVATION", 20, 42], ["gastrointestinal tract", "ANATOMY", 163, 185], ["permissive", "OBSERVATION_MODIFIER", 203, 213], ["host cells", "OBSERVATION", 214, 224], ["infected", "OBSERVATION_MODIFIER", 229, 237], ["subcutaneous tissue", "ANATOMY", 245, 264], ["mucous membranes", "ANATOMY", 270, 286], ["hematopoietic system", "ANATOMY", 295, 315], ["invasion", "OBSERVATION", 404, 412], ["central", "ANATOMY_MODIFIER", 420, 427], ["nervous system", "ANATOMY", 428, 442], ["CNS", "ANATOMY", 444, 447]]], ["Pathways of spread into the CNS are along nerves or via the blood (Table 2).", [["CNS", "ANATOMY", 28, 31], ["nerves", "ANATOMY", 42, 48], ["blood", "ANATOMY", 60, 65], ["CNS", "ANATOMICAL_SYSTEM", 28, 31], ["nerves", "MULTI-TISSUE_STRUCTURE", 42, 48], ["blood", "ORGANISM_SUBSTANCE", 60, 65], ["CNS", "ANATOMY", 28, 31], ["nerves", "ANATOMY", 42, 48]]], ["For many years, the nerves, both peripheral and olfactory, were regarded as the sole portals into the CNS, and early experimental studies documented the neural transmission of rabies virus, herpes simplex virus, and polioviruses.", [["nerves", "ANATOMY", 20, 26], ["olfactory", "ANATOMY", 48, 57], ["CNS", "ANATOMY", 102, 105], ["neural", "ANATOMY", 153, 159], ["rabies virus", "DISEASE", 176, 188], ["herpes simplex virus", "DISEASE", 190, 210], ["nerves", "MULTI-TISSUE_STRUCTURE", 20, 26], ["peripheral", "TISSUE", 33, 43], ["olfactory", "ORGAN", 48, 57], ["CNS", "ANATOMICAL_SYSTEM", 102, 105], ["rabies virus", "ORGANISM", 176, 188], ["herpes simplex virus", "ORGANISM", 190, 210], ["rabies virus", "SPECIES", 176, 188], ["herpes simplex virus", "SPECIES", 190, 210], ["rabies virus", "SPECIES", 176, 188], ["herpes simplex virus", "SPECIES", 190, 210], ["early experimental studies", "TEST", 111, 137], ["rabies virus", "PROBLEM", 176, 188], ["herpes simplex virus", "PROBLEM", 190, 210], ["polioviruses", "PROBLEM", 216, 228], ["nerves", "ANATOMY", 20, 26], ["peripheral", "ANATOMY_MODIFIER", 33, 43], ["CNS", "ANATOMY", 102, 105], ["rabies virus", "OBSERVATION", 176, 188]]], ["Nerve endings have receptors for some viruses, and the viruses are transported by the retrograde axon transport system to the cell bodies, where replication is possible.", [["Nerve endings", "ANATOMY", 0, 13], ["axon", "ANATOMY", 97, 101], ["cell bodies", "ANATOMY", 126, 137], ["Nerve endings", "MULTI-TISSUE_STRUCTURE", 0, 13], ["cell bodies", "CELLULAR_COMPONENT", 126, 137], ["some viruses", "PROBLEM", 33, 45], ["the viruses", "PROBLEM", 51, 62], ["viruses", "OBSERVATION", 38, 45], ["viruses", "OBSERVATION", 55, 62], ["cell", "ANATOMY", 126, 130], ["bodies", "ANATOMY_MODIFIER", 131, 137]]], ["This transport occurs in the peripheral nervous system along motor and sensory fibers and also within the CNS, exemplified by the movement of polioviruses between spinal cord motor neurons and corresponding cortical neurons.", [["peripheral nervous system", "ANATOMY", 29, 54], ["sensory fibers", "ANATOMY", 71, 85], ["CNS", "ANATOMY", 106, 109], ["spinal cord motor neurons", "ANATOMY", 163, 188], ["cortical neurons", "ANATOMY", 207, 223], ["peripheral nervous system", "ANATOMICAL_SYSTEM", 29, 54], ["sensory fibers", "CELLULAR_COMPONENT", 71, 85], ["CNS", "ANATOMICAL_SYSTEM", 106, 109], ["spinal cord motor neurons", "CELL", 163, 188], ["cortical neurons", "CELL", 207, 223], ["spinal cord motor neurons", "CELL_TYPE", 163, 188], ["cortical neurons", "CELL_TYPE", 207, 223], ["polioviruses between spinal cord motor neurons", "PROBLEM", 142, 188], ["peripheral", "ANATOMY_MODIFIER", 29, 39], ["nervous system", "ANATOMY", 40, 54], ["sensory fibers", "OBSERVATION", 71, 85], ["CNS", "ANATOMY", 106, 109], ["polioviruses", "OBSERVATION", 142, 154], ["spinal cord", "ANATOMY", 163, 174], ["cortical neurons", "OBSERVATION", 207, 223]]], ["The olfactory pathway is a unique venue for neural spread since the olfactory rods extend out from the olfactory mucosa and the central processes of the olfactory neurons synapse within the CNS.", [["neural", "ANATOMY", 44, 50], ["olfactory rods", "ANATOMY", 68, 82], ["olfactory mucosa", "ANATOMY", 103, 119], ["olfactory neurons synapse", "ANATOMY", 153, 178], ["CNS", "ANATOMY", 190, 193], ["olfactory", "ORGAN", 4, 13], ["olfactory rods", "MULTI-TISSUE_STRUCTURE", 68, 82], ["olfactory mucosa", "MULTI-TISSUE_STRUCTURE", 103, 119], ["olfactory neurons synapse", "CELLULAR_COMPONENT", 153, 178], ["CNS", "ANATOMICAL_SYSTEM", 190, 193], ["neural spread", "PROBLEM", 44, 57], ["the olfactory rods", "TEST", 64, 82], ["olfactory rods", "OBSERVATION", 68, 82], ["olfactory mucosa", "ANATOMY", 103, 119], ["central", "ANATOMY_MODIFIER", 128, 135], ["olfactory neurons", "ANATOMY", 153, 170], ["CNS", "ANATOMY", 190, 193]]], ["Thus, a single neuron can provide transport from the ambient environment to the CNS.", [["neuron", "ANATOMY", 15, 21], ["CNS", "ANATOMY", 80, 83], ["CNS", "ANATOMICAL_SYSTEM", 80, 83], ["CNS", "ANATOMY", 80, 83]]], ["Despite this direct connection, few aerosol or respiratory infections have been found to invade through the olfactory route.PathogenesisAlthough early studies concluded that the blood\u2013brain barrier was impenetrable by viruses, most viruses do invade the CNS from the blood.", [["respiratory", "ANATOMY", 47, 58], ["olfactory", "ANATOMY", 108, 117], ["blood\u2013brain barrier", "ANATOMY", 178, 197], ["CNS", "ANATOMY", 254, 257], ["blood", "ANATOMY", 267, 272], ["respiratory infections", "DISEASE", 47, 69], ["olfactory route", "MULTI-TISSUE_STRUCTURE", 108, 123], ["blood\u2013brain barrier", "TISSUE", 178, 197], ["CNS", "ANATOMICAL_SYSTEM", 254, 257], ["blood", "ORGANISM_SUBSTANCE", 267, 272], ["respiratory infections", "PROBLEM", 47, 69], ["early studies", "TEST", 145, 158], ["the blood\u2013brain barrier", "PROBLEM", 174, 197], ["viruses", "PROBLEM", 218, 225], ["most viruses", "PROBLEM", 227, 239], ["few", "OBSERVATION_MODIFIER", 32, 35], ["aerosol", "OBSERVATION", 36, 43], ["respiratory", "ANATOMY", 47, 58], ["infections", "OBSERVATION", 59, 69], ["viruses", "OBSERVATION", 218, 225]]], ["Some viruses infect cerebral endothelial cells or choroid plexus epithelial cells and \u201cgrow\u201d into the CNS.", [["cerebral endothelial cells", "ANATOMY", 20, 46], ["choroid plexus epithelial cells", "ANATOMY", 50, 81], ["CNS", "ANATOMY", 102, 105], ["cerebral endothelial cells", "CELL", 20, 46], ["choroid plexus epithelial cells", "CELL", 50, 81], ["CNS", "ANATOMICAL_SYSTEM", 102, 105], ["cerebral endothelial cells", "CELL_TYPE", 20, 46], ["choroid plexus epithelial cells", "CELL_TYPE", 50, 81], ["Some viruses infect cerebral endothelial cells", "PROBLEM", 0, 46], ["choroid plexus epithelial cells", "PROBLEM", 50, 81], ["viruses", "OBSERVATION", 5, 12], ["cerebral endothelial cells", "OBSERVATION", 20, 46], ["choroid plexus", "ANATOMY", 50, 64], ["epithelial cells", "OBSERVATION", 65, 81], ["CNS", "ANATOMY", 102, 105]]], ["Others cross uninfected vascular endothelial cells into the brain in endocytotic vesicles or within infected mononuclear cells.", [["vascular endothelial cells", "ANATOMY", 24, 50], ["brain", "ANATOMY", 60, 65], ["endocytotic vesicles", "ANATOMY", 69, 89], ["mononuclear cells", "ANATOMY", 109, 126], ["vascular endothelial cells", "CELL", 24, 50], ["brain", "ORGAN", 60, 65], ["endocytotic vesicles", "CELLULAR_COMPONENT", 69, 89], ["mononuclear cells", "CELL", 109, 126], ["uninfected vascular endothelial cells", "CELL_TYPE", 13, 50], ["infected mononuclear cells", "CELL_TYPE", 100, 126], ["infected mononuclear cells", "PROBLEM", 100, 126], ["uninfected", "OBSERVATION", 13, 23], ["vascular endothelial cells", "OBSERVATION", 24, 50], ["brain", "ANATOMY", 60, 65], ["endocytotic vesicles", "OBSERVATION", 69, 89], ["infected mononuclear cells", "OBSERVATION", 100, 126]]], ["Invasion from blood depends on the magnitude and duration of the viremia.", [["blood", "ANATOMY", 14, 19], ["viremia", "DISEASE", 65, 72], ["blood", "ORGANISM_SUBSTANCE", 14, 19], ["Invasion", "PROBLEM", 0, 8], ["the viremia", "PROBLEM", 61, 72], ["viremia", "OBSERVATION", 65, 72]]], ["Viruses in the blood are promptly removed by the reticuloendothelial system and, like other particles, speed of clearance is size dependent.", [["blood", "ANATOMY", 15, 20], ["reticuloendothelial system", "ANATOMY", 49, 75], ["blood", "ORGANISM_SUBSTANCE", 15, 20], ["reticuloendothelial system", "ANATOMICAL_SYSTEM", 49, 75], ["Viruses in the blood", "PROBLEM", 0, 20], ["size dependent", "PROBLEM", 125, 139], ["blood", "ANATOMY", 15, 20], ["reticuloendothelial system", "ANATOMY", 49, 75], ["particles", "OBSERVATION_MODIFIER", 92, 101], ["size", "OBSERVATION_MODIFIER", 125, 129], ["dependent", "OBSERVATION_MODIFIER", 130, 139]]], ["Small viruses are removed more slowly, and many larger viruses avoid clearance by growth in leukocytes or adhesion to red cells.PathogenesisWithin the CNS, specific cell populations may be vulnerable to specific viruses.", [["leukocytes", "ANATOMY", 92, 102], ["red cells", "ANATOMY", 118, 127], ["CNS", "ANATOMY", 151, 154], ["cell", "ANATOMY", 165, 169], ["leukocytes", "CELL", 92, 102], ["red cells", "CELL", 118, 127], ["CNS", "ANATOMICAL_SYSTEM", 151, 154], ["cell populations", "CELL", 165, 181], ["leukocytes", "CELL_TYPE", 92, 102], ["red cells", "CELL_TYPE", 118, 127], ["Small viruses", "PROBLEM", 0, 13], ["leukocytes", "PROBLEM", 92, 102], ["adhesion to red cells", "PROBLEM", 106, 127], ["PathogenesisWithin the CNS", "PROBLEM", 128, 154], ["specific cell populations", "PROBLEM", 156, 181], ["viruses", "OBSERVATION", 6, 13], ["slowly", "OBSERVATION_MODIFIER", 31, 37], ["larger", "OBSERVATION_MODIFIER", 48, 54], ["viruses", "OBSERVATION", 55, 62], ["growth", "OBSERVATION_MODIFIER", 82, 88], ["red cells", "OBSERVATION", 118, 127], ["CNS", "ANATOMY", 151, 154], ["specific cell populations", "OBSERVATION", 156, 181], ["viruses", "OBSERVATION", 212, 219]]], ["For example, rabies virus infects only neurons, and early in infection neurons that modify behavior are selectively affected.", [["neurons", "ANATOMY", 39, 46], ["neurons", "ANATOMY", 71, 78], ["infection", "DISEASE", 61, 70], ["rabies virus", "ORGANISM", 13, 25], ["neurons", "CELL", 39, 46], ["neurons", "CELL", 71, 78], ["rabies virus", "SPECIES", 13, 25], ["rabies virus", "SPECIES", 13, 25], ["rabies virus infects only neurons", "PROBLEM", 13, 46], ["early in infection neurons", "PROBLEM", 52, 78], ["infection", "OBSERVATION", 61, 70]]], ["This explains the unique clinical syndrome of vigilance and agitation.", [["agitation", "DISEASE", 60, 69], ["the unique clinical syndrome of vigilance", "PROBLEM", 14, 55], ["agitation", "PROBLEM", 60, 69]]], ["Similarly, polioviruses selectively infect and destroy motor neurons causing the syndrome of flaccid paralysis.", [["motor neurons", "ANATOMY", 55, 68], ["flaccid", "ANATOMY", 93, 100], ["flaccid paralysis", "DISEASE", 93, 110], ["motor neurons", "CELL", 55, 68], ["motor neurons", "CELL_TYPE", 55, 68], ["polioviruses", "PROBLEM", 11, 23], ["the syndrome", "PROBLEM", 77, 89], ["flaccid paralysis", "PROBLEM", 93, 110], ["polioviruses", "OBSERVATION", 11, 23], ["flaccid", "OBSERVATION_MODIFIER", 93, 100], ["paralysis", "OBSERVATION", 101, 110]]], ["Arboviruses infect primarily neurons, and herpes simplex virus infects neurons, glia, and endothelial cells.", [["neurons", "ANATOMY", 29, 36], ["neurons", "ANATOMY", 71, 78], ["glia", "ANATOMY", 80, 84], ["endothelial cells", "ANATOMY", 90, 107], ["herpes simplex", "DISEASE", 42, 56], ["Arboviruses", "GENE_OR_GENE_PRODUCT", 0, 11], ["neurons", "CELL", 29, 36], ["herpes simplex virus", "ORGANISM", 42, 62], ["neurons", "CELL", 71, 78], ["glia", "CELL", 80, 84], ["endothelial cells", "CELL", 90, 107], ["glia", "CELL_TYPE", 80, 84], ["endothelial cells", "CELL_TYPE", 90, 107], ["herpes simplex virus", "SPECIES", 42, 62], ["herpes simplex virus", "SPECIES", 42, 62], ["Arboviruses infect primarily neurons", "PROBLEM", 0, 36], ["herpes simplex virus infects neurons", "PROBLEM", 42, 78], ["herpes simplex virus", "OBSERVATION", 42, 62], ["glia", "ANATOMY", 80, 84], ["endothelial cells", "OBSERVATION", 90, 107]]], ["JC virus selectively lyses oligodendrocytes causing demyelinating disease.", [["oligodendrocytes", "ANATOMY", 27, 43], ["demyelinating disease", "DISEASE", 52, 73], ["JC virus", "ORGANISM", 0, 8], ["oligodendrocytes", "CELL", 27, 43], ["oligodendrocytes", "CELL_TYPE", 27, 43], ["JC virus", "SPECIES", 0, 8], ["JC virus selectively lyses oligodendrocytes", "PROBLEM", 0, 43], ["demyelinating disease", "PROBLEM", 52, 73], ["virus selectively", "OBSERVATION", 3, 20], ["lyses oligodendrocytes", "OBSERVATION", 21, 43], ["demyelinating disease", "OBSERVATION", 52, 73]]], ["Enteroviruses and mumps virus infect primarily meningeal and ependymal cells; therefore, they usually cause benign meningitis and only rarely are associated with encephalitis.PathogenesisNeuroinvasiveness, neurotropism, and neurovirulence are features of viruses that need to be differentiated.", [["meningeal", "ANATOMY", 47, 56], ["ependymal cells", "ANATOMY", 61, 76], ["meningitis", "DISEASE", 115, 125], ["encephalitis", "DISEASE", 162, 174], ["Neuroinvasiveness", "DISEASE", 187, 204], ["neurotropism", "DISEASE", 206, 218], ["Enteroviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["mumps virus", "ORGANISM", 18, 29], ["meningeal", "CELL", 47, 56], ["ependymal cells", "CELL", 61, 76], ["meningeal and ependymal cells", "CELL_TYPE", 47, 76], ["mumps virus", "SPECIES", 18, 29], ["mumps virus", "SPECIES", 18, 29], ["Enteroviruses", "PROBLEM", 0, 13], ["mumps virus infect primarily meningeal and ependymal cells", "PROBLEM", 18, 76], ["benign meningitis", "PROBLEM", 108, 125], ["encephalitis", "PROBLEM", 162, 174], ["neurotropism", "PROBLEM", 206, 218], ["neurovirulence", "PROBLEM", 224, 238], ["viruses", "PROBLEM", 255, 262], ["mumps virus", "OBSERVATION", 18, 29], ["meningeal", "ANATOMY", 47, 56], ["ependymal cells", "OBSERVATION", 61, 76], ["benign", "OBSERVATION_MODIFIER", 108, 114], ["meningitis", "OBSERVATION", 115, 125], ["encephalitis", "OBSERVATION", 162, 174], ["viruses", "OBSERVATION", 255, 262]]], ["Neuroinvasiveness is the ability to penetrate the CNS.", [["CNS", "ANATOMY", 50, 53], ["Neuroinvasiveness", "DISEASE", 0, 17], ["CNS", "ANATOMICAL_SYSTEM", 50, 53], ["CNS", "ANATOMY", 50, 53]]], ["Neurotropism is the ability to infect neural cells other than neurons and is distinct from neuronotropism, which indicates the ability to infect neurons.", [["neural cells", "ANATOMY", 38, 50], ["neurons", "ANATOMY", 62, 69], ["neurons", "ANATOMY", 145, 152], ["neural cells", "CELL", 38, 50], ["neurons", "CELL", 62, 69], ["neurons", "CELL", 145, 152], ["neural cells", "CELL_TYPE", 38, 50], ["neuronotropism", "PROBLEM", 91, 105]]], ["Neurovirulence relates to the ability to cause disease.", [["Neurovirulence", "DISEASE", 0, 14], ["Neurovirulence", "PROBLEM", 0, 14], ["disease", "PROBLEM", 47, 54]]], ["Thus, mumps virus that can often be recovered from spinal fluid during uncomplicated parotitis is highly neuroinvasive, is neurotropic in ependymal cells but not neuronotropic, and has a low level of neurovirulence.", [["spinal fluid", "ANATOMY", 51, 63], ["ependymal cells", "ANATOMY", 138, 153], ["parotitis", "DISEASE", 85, 94], ["mumps virus", "ORGANISM", 6, 17], ["spinal fluid", "MULTI-TISSUE_STRUCTURE", 51, 63], ["ependymal cells", "CELL", 138, 153], ["ependymal cells", "CELL_TYPE", 138, 153], ["mumps virus", "SPECIES", 6, 17], ["mumps virus", "PROBLEM", 6, 17], ["spinal fluid", "PROBLEM", 51, 63], ["uncomplicated parotitis", "PROBLEM", 71, 94], ["neurotropic in ependymal cells", "PROBLEM", 123, 153], ["neurovirulence", "PROBLEM", 200, 214], ["spinal", "ANATOMY", 51, 57], ["fluid", "OBSERVATION", 58, 63], ["parotitis", "OBSERVATION", 85, 94], ["neurovirulence", "OBSERVATION", 200, 214]]], ["In contrast, most arbovirus infections are asymptomatic or cause only fever, malaise, and minor systemic symptoms.", [["arbovirus infections", "DISEASE", 18, 38], ["fever", "DISEASE", 70, 75], ["arbovirus", "ORGANISM", 18, 27], ["most arbovirus infections", "PROBLEM", 13, 38], ["asymptomatic", "PROBLEM", 43, 55], ["fever", "PROBLEM", 70, 75], ["malaise", "PROBLEM", 77, 84], ["minor systemic symptoms", "PROBLEM", 90, 113], ["arbovirus infections", "OBSERVATION", 18, 38], ["minor", "OBSERVATION_MODIFIER", 90, 95], ["systemic", "OBSERVATION_MODIFIER", 96, 104], ["symptoms", "OBSERVATION", 105, 113]]], ["On rare occasions when arboviruses infect the brain, they usually cause encephalitis with a significant death rate; thus, these viruses are not highly neuroinvasive but are highly neurotropic (and neuronotropic) and neurovirulent.", [["brain", "ANATOMY", 46, 51], ["arboviruses infect the brain", "DISEASE", 23, 51], ["encephalitis", "DISEASE", 72, 84], ["death", "DISEASE", 104, 109], ["arboviruses", "ORGANISM", 23, 34], ["brain", "ORGAN", 46, 51], ["neuronotropic", "CANCER", 197, 210], ["arboviruses infect the brain", "PROBLEM", 23, 51], ["encephalitis", "PROBLEM", 72, 84], ["a significant death rate", "PROBLEM", 90, 114], ["these viruses", "PROBLEM", 122, 135], ["neurovirulent", "PROBLEM", 216, 229], ["brain", "ANATOMY", 46, 51], ["encephalitis", "OBSERVATION", 72, 84], ["significant", "OBSERVATION_MODIFIER", 92, 103], ["death", "OBSERVATION", 104, 109]]], ["It must be noted that neuroinvasiveness and neurovirulence are also dependent on a myriad of host factors, such as age, immune responses, and genetic constitution.Epidemiology ::: Acute Viral EncephalitisThe incidence of acute encephalitis is estimated between 3.5 and 7.4 per 100,000 persons per year (which is approximately one-third the incidence of viral meningitis).", [["neuroinvasiveness", "DISEASE", 22, 39], ["neurovirulence", "DISEASE", 44, 58], ["Viral Encephalitis", "DISEASE", 186, 204], ["encephalitis", "DISEASE", 227, 239], ["meningitis", "DISEASE", 359, 369], ["neuroinvasiveness", "PROBLEM", 22, 39], ["neurovirulence", "PROBLEM", 44, 58], ["Acute Viral Encephalitis", "PROBLEM", 180, 204], ["acute encephalitis", "PROBLEM", 221, 239], ["viral meningitis", "PROBLEM", 353, 369], ["Viral Encephalitis", "OBSERVATION", 186, 204], ["acute", "OBSERVATION_MODIFIER", 221, 226], ["encephalitis", "OBSERVATION", 227, 239], ["viral", "OBSERVATION_MODIFIER", 353, 358], ["meningitis", "OBSERVATION", 359, 369]]], ["Encephalitis has been associated with approximately 100 different viruses that cause disease of variable severity (Table 3).", [["Encephalitis", "DISEASE", 0, 12], ["Encephalitis", "PROBLEM", 0, 12], ["disease of variable severity", "PROBLEM", 85, 113], ["100 different", "OBSERVATION_MODIFIER", 52, 65], ["viruses", "OBSERVATION", 66, 73], ["variable", "OBSERVATION_MODIFIER", 96, 104], ["severity", "OBSERVATION_MODIFIER", 105, 113]]], ["Encephalitis is more common in children than in adults and varies by gender, season, and geographic location.", [["Encephalitis", "DISEASE", 0, 12], ["children", "ORGANISM", 31, 39], ["children", "SPECIES", 31, 39], ["Encephalitis", "PROBLEM", 0, 12]]], ["For example, CNS complications of mumps virus infections are three times more common in males than females.", [["CNS", "ANATOMY", 13, 16], ["mumps virus infections", "DISEASE", 34, 56], ["CNS", "ANATOMICAL_SYSTEM", 13, 16], ["mumps virus", "ORGANISM", 34, 45], ["mumps virus", "SPECIES", 34, 45], ["CNS complications", "PROBLEM", 13, 30], ["mumps virus infections", "PROBLEM", 34, 56], ["CNS", "ANATOMY", 13, 16], ["complications", "OBSERVATION", 17, 30], ["mumps virus", "OBSERVATION", 34, 45]]], ["Seasonally, enterovirus infections are more common in summer and early fall, lymphocytic choriomeningitis virus infections are more common in winter, and arbovirus infections are more common during the feeding season of the transmitting arthropod.", [["enterovirus infections", "DISEASE", 12, 34], ["lymphocytic choriomeningitis virus infections", "DISEASE", 77, 122], ["arbovirus infections", "DISEASE", 154, 174], ["enterovirus", "ORGANISM", 12, 23], ["lymphocytic choriomeningitis virus", "ORGANISM", 77, 111], ["choriomeningitis virus", "SPECIES", 89, 111], ["lymphocytic choriomeningitis virus", "SPECIES", 77, 111], ["enterovirus infections", "PROBLEM", 12, 34], ["early fall", "PROBLEM", 65, 75], ["lymphocytic choriomeningitis virus infections", "PROBLEM", 77, 122], ["arbovirus infections", "PROBLEM", 154, 174], ["enterovirus infections", "OBSERVATION", 12, 34], ["lymphocytic choriomeningitis", "OBSERVATION", 77, 105]]], ["Regionally, rabies causes more than 25,000 deaths per year in India but only 1\u20135 deaths in the United States.", [["rabies", "DISEASE", 12, 18], ["deaths", "DISEASE", 43, 49], ["deaths", "DISEASE", 81, 87]]], ["Each year a variety of arboviruses cause 200\u20132000 cases of encephalitis in the United States, tick-borne encephalitis virus causes several thousand cases in Europe, and Japanese encephalitis virus causes approximately 30,000 cases in Asia.Clinical Findings ::: Acute Viral EncephalitisClues to the causative agent may be found in a history of travel, family illnesses, recreational activities, animal exposures, and past immunization.", [["arboviruses", "DISEASE", 23, 34], ["encephalitis", "DISEASE", 59, 71], ["tick-borne encephalitis", "DISEASE", 94, 117], ["Japanese encephalitis virus", "DISEASE", 169, 196], ["Viral EncephalitisClues", "DISEASE", 267, 290], ["tick-borne encephalitis virus", "ORGANISM", 94, 123], ["Japanese encephalitis virus", "ORGANISM", 169, 196], ["tick-borne encephalitis virus", "SPECIES", 94, 123], ["Japanese encephalitis virus", "SPECIES", 169, 196], ["tick-borne encephalitis virus", "SPECIES", 94, 123], ["Japanese encephalitis virus", "SPECIES", 169, 196], ["encephalitis", "PROBLEM", 59, 71], ["tick-borne encephalitis virus", "PROBLEM", 94, 123], ["Japanese encephalitis virus", "PROBLEM", 169, 196], ["Acute Viral EncephalitisClues", "PROBLEM", 261, 290], ["encephalitis", "OBSERVATION", 59, 71], ["Viral EncephalitisClues", "OBSERVATION", 267, 290]]], ["General examination may show a rash in enterovirus, herpesvirus 6 and 7, and West Nile virus infections; herpangina in coxsackievirus infections; adenopathy in HIV, Epstein\u2013Barr virus, and cytomegalovirus infections; parotitis in mumps or lymphocytic choriomeningitis virus infections; or pneumonitis in adenovirus, lymphocytic choriomeningitis, or Nipah virus infections.Clinical Findings ::: Acute Viral EncephalitisThe classic clinical symptoms and signs of encephalitis are fever, headache, nuchal rigidity, depression of consciousness, focal neurological signs, and often seizures.", [["nuchal", "ANATOMY", 495, 501], ["neurological", "ANATOMY", 547, 559], ["rash", "DISEASE", 31, 35], ["enterovirus", "DISEASE", 39, 50], ["West Nile virus infections", "DISEASE", 77, 103], ["herpangina", "DISEASE", 105, 115], ["coxsackievirus infections", "DISEASE", 119, 144], ["adenopathy", "DISEASE", 146, 156], ["Epstein\u2013Barr virus", "DISEASE", 165, 183], ["cytomegalovirus infections", "DISEASE", 189, 215], ["parotitis", "DISEASE", 217, 226], ["mumps", "DISEASE", 230, 235], ["lymphocytic choriomeningitis virus infections", "DISEASE", 239, 284], ["pneumonitis", "DISEASE", 289, 300], ["lymphocytic choriomeningitis", "DISEASE", 316, 344], ["Nipah virus infections", "DISEASE", 349, 371], ["Viral Encephalitis", "DISEASE", 400, 418], ["encephalitis", "DISEASE", 461, 473], ["fever", "DISEASE", 478, 483], ["headache", "DISEASE", 485, 493], ["nuchal rigidity", "DISEASE", 495, 510], ["depression of consciousness", "DISEASE", 512, 539], ["neurological signs", "DISEASE", 547, 565], ["seizures", "DISEASE", 577, 585], ["herpesvirus 6", "ORGANISM", 52, 65], ["West Nile virus", "ORGANISM", 77, 92], ["coxsackievirus", "ORGANISM", 119, 133], ["Epstein\u2013Barr virus", "ORGANISM", 165, 183], ["cytomegalovirus", "ORGANISM", 189, 204], ["lymphocytic choriomeningitis virus", "ORGANISM", 239, 273], ["adenovirus", "ORGANISM", 304, 314], ["lymphocytic choriomeningitis", "ORGANISM", 316, 344], ["Nipah virus", "ORGANISM", 349, 360], ["nuchal", "ORGANISM_SUBDIVISION", 495, 501], ["Nile virus", "SPECIES", 82, 92], ["HIV", "SPECIES", 160, 163], ["lymphocytic choriomeningitis virus", "SPECIES", 239, 273], ["Nipah virus", "SPECIES", 349, 360], ["West Nile virus", "SPECIES", 77, 92], ["HIV", "SPECIES", 160, 163], ["Epstein\u2013Barr virus", "SPECIES", 165, 183], ["lymphocytic choriomeningitis virus", "SPECIES", 239, 273], ["Nipah virus", "SPECIES", 349, 360], ["General examination", "TEST", 0, 19], ["a rash in enterovirus", "PROBLEM", 29, 50], ["herpesvirus", "PROBLEM", 52, 63], ["West Nile virus infections", "PROBLEM", 77, 103], ["herpangina", "PROBLEM", 105, 115], ["coxsackievirus infections", "PROBLEM", 119, 144], ["adenopathy", "PROBLEM", 146, 156], ["HIV", "PROBLEM", 160, 163], ["Epstein\u2013Barr virus", "PROBLEM", 165, 183], ["cytomegalovirus infections", "PROBLEM", 189, 215], ["parotitis", "PROBLEM", 217, 226], ["mumps", "PROBLEM", 230, 235], ["lymphocytic choriomeningitis virus infections", "PROBLEM", 239, 284], ["pneumonitis", "PROBLEM", 289, 300], ["adenovirus", "PROBLEM", 304, 314], ["lymphocytic choriomeningitis", "PROBLEM", 316, 344], ["Nipah virus infections", "PROBLEM", 349, 371], ["Acute Viral Encephalitis", "PROBLEM", 394, 418], ["The classic clinical symptoms", "PROBLEM", 418, 447], ["encephalitis", "PROBLEM", 461, 473], ["fever", "PROBLEM", 478, 483], ["headache", "PROBLEM", 485, 493], ["nuchal rigidity", "PROBLEM", 495, 510], ["depression of consciousness", "PROBLEM", 512, 539], ["focal neurological signs", "PROBLEM", 541, 565], ["often seizures", "PROBLEM", 571, 585], ["rash", "OBSERVATION", 31, 35], ["coxsackievirus infections", "OBSERVATION", 119, 144], ["adenopathy", "OBSERVATION", 146, 156], ["Barr virus", "OBSERVATION", 173, 183], ["cytomegalovirus infections", "OBSERVATION", 189, 215], ["parotitis", "OBSERVATION", 217, 226], ["lymphocytic choriomeningitis", "OBSERVATION", 239, 267], ["pneumonitis", "OBSERVATION", 289, 300], ["lymphocytic choriomeningitis", "OBSERVATION", 316, 344], ["Nipah virus infections", "OBSERVATION", 349, 371], ["Viral Encephalitis", "OBSERVATION", 400, 418], ["encephalitis", "OBSERVATION", 461, 473], ["nuchal rigidity", "ANATOMY", 495, 510], ["focal", "OBSERVATION_MODIFIER", 541, 546]]], ["Occasionally, fever is not present at the time of presentation, stupor may obscure a complaint of headache, or nuchal rigidity may be absent; thus, no finding is absolute.", [["nuchal", "ANATOMY", 111, 117], ["fever", "DISEASE", 14, 19], ["stupor", "DISEASE", 64, 70], ["headache", "DISEASE", 98, 106], ["nuchal rigidity", "DISEASE", 111, 126], ["nuchal", "ORGANISM_SUBDIVISION", 111, 117], ["fever", "PROBLEM", 14, 19], ["stupor", "PROBLEM", 64, 70], ["headache", "PROBLEM", 98, 106], ["nuchal rigidity", "PROBLEM", 111, 126], ["fever", "OBSERVATION", 14, 19], ["nuchal rigidity", "ANATOMY", 111, 126]]], ["Spinal fluid examination is critical for diagnosis.", [["Spinal fluid", "ANATOMY", 0, 12], ["Spinal fluid examination", "TEST", 0, 24], ["fluid", "OBSERVATION", 7, 12]]], ["Typically, a mononuclear cell pleocytosis, modest elevation of protein, normal sugar content, and often increased pressure are found.", [["mononuclear cell", "ANATOMY", 13, 29], ["pleocytosis", "DISEASE", 30, 41], ["sugar", "CHEMICAL", 79, 84], ["mononuclear cell", "CELL", 13, 29], ["sugar", "SIMPLE_CHEMICAL", 79, 84], ["a mononuclear cell pleocytosis", "PROBLEM", 11, 41], ["modest elevation of protein", "PROBLEM", 43, 70], ["often increased pressure", "PROBLEM", 98, 122], ["mononuclear cell pleocytosis", "OBSERVATION", 13, 41], ["modest", "OBSERVATION_MODIFIER", 43, 49], ["elevation", "OBSERVATION_MODIFIER", 50, 59], ["sugar content", "OBSERVATION_MODIFIER", 79, 92], ["increased", "OBSERVATION_MODIFIER", 104, 113], ["pressure", "OBSERVATION_MODIFIER", 114, 122]]], ["Early in disease, polymorphonuclear cells may predominate or fluid may be acellular, but within 24 hr a mononuclear cell response usually evolves.", [["polymorphonuclear cells", "ANATOMY", 18, 41], ["mononuclear cell", "ANATOMY", 104, 120], ["polymorphonuclear cells", "CELL", 18, 41], ["mononuclear cell", "CELL", 104, 120], ["polymorphonuclear cells", "CELL_TYPE", 18, 41], ["Early in disease", "PROBLEM", 0, 16], ["polymorphonuclear cells", "PROBLEM", 18, 41], ["fluid", "PROBLEM", 61, 66], ["acellular", "PROBLEM", 74, 83], ["disease", "OBSERVATION", 9, 16], ["polymorphonuclear cells", "OBSERVATION", 18, 41], ["fluid", "OBSERVATION", 61, 66], ["may be", "UNCERTAINTY", 67, 73], ["acellular", "OBSERVATION_MODIFIER", 74, 83], ["mononuclear cell response", "OBSERVATION", 104, 129]]], ["In some infections mild depressions of sugar content are present.", [["infections", "DISEASE", 8, 18], ["depressions", "DISEASE", 24, 35], ["sugar", "CHEMICAL", 39, 44], ["sugar", "SIMPLE_CHEMICAL", 39, 44], ["some infections mild depressions of sugar content", "PROBLEM", 3, 52], ["some", "OBSERVATION_MODIFIER", 3, 7], ["infections", "OBSERVATION", 8, 18], ["mild", "OBSERVATION_MODIFIER", 19, 23], ["depressions", "OBSERVATION", 24, 35], ["sugar content", "OBSERVATION", 39, 52]]], ["The presence of red cells may suggest herpetic encephalitis, but the finding is neither consistent nor specific.Clinical Findings ::: Acute Viral EncephalitisRabies and herpes simplex virus encephalitis usually present with characteristic syndromes.", [["red cells", "ANATOMY", 16, 25], ["herpetic encephalitis", "DISEASE", 38, 59], ["Viral EncephalitisRabies", "DISEASE", 140, 164], ["herpes simplex virus encephalitis", "DISEASE", 169, 202], ["red cells", "CELL", 16, 25], ["Viral EncephalitisRabies", "ORGANISM", 140, 164], ["herpes simplex virus encephalitis", "ORGANISM", 169, 202], ["red cells", "CELL_TYPE", 16, 25], ["herpes simplex virus encephalitis", "SPECIES", 169, 202], ["herpes simplex virus", "SPECIES", 169, 189], ["red cells", "PROBLEM", 16, 25], ["herpetic encephalitis", "PROBLEM", 38, 59], ["Acute Viral EncephalitisRabies", "PROBLEM", 134, 164], ["herpes simplex virus encephalitis", "PROBLEM", 169, 202], ["characteristic syndromes", "PROBLEM", 224, 248], ["red cells", "OBSERVATION", 16, 25], ["may", "UNCERTAINTY", 26, 29], ["suggest", "UNCERTAINTY", 30, 37], ["herpetic", "OBSERVATION_MODIFIER", 38, 46], ["encephalitis", "OBSERVATION", 47, 59], ["neither consistent nor", "UNCERTAINTY", 80, 102], ["Viral EncephalitisRabies", "OBSERVATION", 140, 164], ["herpes simplex virus encephalitis", "OBSERVATION", 169, 202]]], ["Rabies may present as either an ascending paralysis simulating the Guillian\u2013Barr\u00e9 syndrome or an altered mental status with periods of confusion with bizarre behavior and autonomic signs progressing to intense agitation with aerophobia and hydrophobia.", [["Rabies", "DISEASE", 0, 6], ["paralysis", "DISEASE", 42, 51], ["Guillian\u2013Barr\u00e9 syndrome", "DISEASE", 67, 90], ["confusion", "DISEASE", 135, 144], ["bizarre behavior", "DISEASE", 150, 166], ["agitation", "DISEASE", 210, 219], ["aerophobia", "DISEASE", 225, 235], ["hydrophobia", "DISEASE", 240, 251], ["Rabies", "ORGANISM", 0, 6], ["an ascending paralysis", "PROBLEM", 29, 51], ["the Guillian\u2013Barr\u00e9 syndrome", "PROBLEM", 63, 90], ["an altered mental status", "PROBLEM", 94, 118], ["confusion", "PROBLEM", 135, 144], ["bizarre behavior", "PROBLEM", 150, 166], ["autonomic signs", "PROBLEM", 171, 186], ["intense agitation", "PROBLEM", 202, 219], ["aerophobia", "PROBLEM", 225, 235], ["hydrophobia", "PROBLEM", 240, 251], ["ascending", "OBSERVATION_MODIFIER", 32, 41], ["paralysis", "OBSERVATION", 42, 51], ["Barr\u00e9 syndrome", "OBSERVATION", 76, 90], ["intense", "OBSERVATION_MODIFIER", 202, 209], ["agitation", "OBSERVATION", 210, 219]]], ["Herpes simplex virus encephalitis usually localizes to one or both temporal lobes, which may cause bizarre behavior, hallucinations, aphasia, and quadratic visual field defects.", [["temporal lobes", "ANATOMY", 67, 81], ["Herpes simplex virus encephalitis", "DISEASE", 0, 33], ["hallucinations", "DISEASE", 117, 131], ["aphasia", "DISEASE", 133, 140], ["visual field defects", "DISEASE", 156, 176], ["Herpes simplex virus encephalitis", "ORGANISM", 0, 33], ["temporal lobes", "MULTI-TISSUE_STRUCTURE", 67, 81], ["Herpes simplex virus", "SPECIES", 0, 20], ["Herpes simplex virus", "SPECIES", 0, 20], ["Herpes simplex virus encephalitis", "PROBLEM", 0, 33], ["bizarre behavior", "PROBLEM", 99, 115], ["hallucinations", "PROBLEM", 117, 131], ["aphasia", "PROBLEM", 133, 140], ["quadratic visual field defects", "PROBLEM", 146, 176], ["simplex virus encephalitis", "OBSERVATION", 7, 33], ["both temporal lobes", "ANATOMY", 62, 81], ["may cause", "UNCERTAINTY", 89, 98], ["bizarre", "OBSERVATION_MODIFIER", 99, 106], ["aphasia", "OBSERVATION", 133, 140], ["quadratic", "OBSERVATION_MODIFIER", 146, 155], ["visual field defects", "OBSERVATION", 156, 176]]], ["Imaging studies typically show low-density lesions in one or both temporal lobes with enhancement and mass effect.", [["lesions", "ANATOMY", 43, 50], ["temporal lobes", "ANATOMY", 66, 80], ["lesions", "PATHOLOGICAL_FORMATION", 43, 50], ["temporal lobes", "MULTI-TISSUE_STRUCTURE", 66, 80], ["Imaging studies", "TEST", 0, 15], ["low-density lesions in one or both temporal lobes", "PROBLEM", 31, 80], ["mass effect", "PROBLEM", 102, 113], ["low-density", "OBSERVATION_MODIFIER", 31, 42], ["lesions", "OBSERVATION", 43, 50], ["one", "ANATOMY_MODIFIER", 54, 57], ["both temporal lobes", "ANATOMY", 61, 80], ["enhancement", "OBSERVATION_MODIFIER", 86, 97], ["mass effect", "OBSERVATION", 102, 113]]], ["Only approximately one-half of patients with encephalitis with temporal lobe signs prove to have herpes simplex virus encephalitis.", [["temporal lobe", "ANATOMY", 63, 76], ["encephalitis", "DISEASE", 45, 57], ["temporal lobe signs", "DISEASE", 63, 82], ["herpes simplex virus encephalitis", "DISEASE", 97, 130], ["patients", "ORGANISM", 31, 39], ["herpes simplex virus encephalitis", "ORGANISM", 97, 130], ["patients", "SPECIES", 31, 39], ["herpes simplex virus", "SPECIES", 97, 117], ["encephalitis", "PROBLEM", 45, 57], ["temporal lobe signs", "PROBLEM", 63, 82], ["herpes simplex virus encephalitis", "PROBLEM", 97, 130], ["encephalitis", "OBSERVATION", 45, 57], ["temporal lobe", "ANATOMY", 63, 76], ["herpes simplex virus encephalitis", "OBSERVATION", 97, 130]]], ["More than 90% of patients with herpetic encephalitis have these findings, but herpes simplex virus causes only 10% of cases of encephalitis and other agents may occasionally mimic these symptoms and signs.Diagnosis ::: Acute Viral EncephalitisDiagnosis of herpes simplex virus encephalitis is important since it is the most common cause of fatal nonepidemic encephalitis worldwide, and there is specific treatment that can reduce the fatality rate from approximately 70 to 20%.", [["herpetic encephalitis", "DISEASE", 31, 52], ["herpes simplex virus", "DISEASE", 78, 98], ["encephalitis", "DISEASE", 127, 139], ["herpes simplex virus encephalitis", "DISEASE", 256, 289], ["encephalitis", "DISEASE", 358, 370], ["patients", "ORGANISM", 17, 25], ["herpes simplex virus", "ORGANISM", 78, 98], ["herpes simplex virus", "ORGANISM", 256, 276], ["patients", "SPECIES", 17, 25], ["herpes simplex virus", "SPECIES", 78, 98], ["herpes simplex virus encephalitis", "SPECIES", 256, 289], ["herpes simplex virus", "SPECIES", 78, 98], ["herpes simplex virus", "SPECIES", 256, 276], ["herpetic encephalitis", "PROBLEM", 31, 52], ["herpes simplex virus", "PROBLEM", 78, 98], ["encephalitis", "PROBLEM", 127, 139], ["other agents", "TREATMENT", 144, 156], ["these symptoms", "PROBLEM", 180, 194], ["Acute Viral EncephalitisDiagnosis", "PROBLEM", 219, 252], ["herpes simplex virus encephalitis", "PROBLEM", 256, 289], ["fatal nonepidemic encephalitis", "PROBLEM", 340, 370], ["the fatality rate", "TEST", 430, 447], ["herpetic", "OBSERVATION_MODIFIER", 31, 39], ["encephalitis", "OBSERVATION", 40, 52], ["encephalitis", "OBSERVATION", 127, 139], ["Viral EncephalitisDiagnosis", "OBSERVATION", 225, 252], ["herpes simplex virus encephalitis", "OBSERVATION", 256, 289], ["most common", "OBSERVATION_MODIFIER", 319, 330], ["fatal", "OBSERVATION_MODIFIER", 340, 345], ["nonepidemic", "OBSERVATION_MODIFIER", 346, 357], ["encephalitis", "OBSERVATION", 358, 370]]], ["The second diagnostic imperative is to rule out nonviral disease that can masquerade as viral encephalitis and that requires specific therapies (Table 4).Diagnosis ::: Acute Viral EncephalitisDiagnosis is dependent on identifying virus in spinal fluid or brain tissue or on serological tests that often require a convalescent serum too late to aid in acute management.", [["spinal fluid", "ANATOMY", 239, 251], ["brain tissue", "ANATOMY", 255, 267], ["serum", "ANATOMY", 326, 331], ["viral encephalitis", "DISEASE", 88, 106], ["Viral EncephalitisDiagnosis", "DISEASE", 174, 201], ["spinal fluid", "ORGANISM_SUBSTANCE", 239, 251], ["brain tissue", "TISSUE", 255, 267], ["serum", "ORGANISM_SUBSTANCE", 326, 331], ["nonviral disease", "PROBLEM", 48, 64], ["viral encephalitis", "PROBLEM", 88, 106], ["specific therapies", "TREATMENT", 125, 143], ["Acute Viral EncephalitisDiagnosis", "PROBLEM", 168, 201], ["virus in spinal fluid", "PROBLEM", 230, 251], ["brain tissue", "PROBLEM", 255, 267], ["serological tests", "TEST", 274, 291], ["a convalescent serum", "TEST", 311, 331], ["acute management", "TREATMENT", 351, 367], ["viral encephalitis", "OBSERVATION", 88, 106], ["Viral EncephalitisDiagnosis", "OBSERVATION", 174, 201], ["virus", "OBSERVATION", 230, 235], ["spinal", "ANATOMY", 239, 245], ["fluid", "OBSERVATION", 246, 251], ["brain tissue", "ANATOMY", 255, 267], ["acute", "OBSERVATION_MODIFIER", 351, 356]]], ["In herpes simplex and other herpesvirus infections, polymerase chain reactions can identify specific viral DNA in spinal fluid.", [["spinal fluid", "ANATOMY", 114, 126], ["herpes simplex", "DISEASE", 3, 17], ["herpesvirus infections", "DISEASE", 28, 50], ["herpes simplex", "ORGANISM", 3, 17], ["herpesvirus", "ORGANISM", 28, 39], ["DNA", "CELLULAR_COMPONENT", 107, 110], ["spinal fluid", "ORGANISM_SUBSTANCE", 114, 126], ["viral DNA", "DNA", 101, 110], ["herpes simplex", "SPECIES", 3, 17], ["herpes simplex", "PROBLEM", 3, 17], ["other herpesvirus infections", "PROBLEM", 22, 50], ["polymerase chain reactions", "PROBLEM", 52, 78], ["specific viral DNA in spinal fluid", "PROBLEM", 92, 126], ["herpes simplex", "OBSERVATION", 3, 17], ["herpesvirus infections", "OBSERVATION", 28, 50], ["viral DNA", "OBSERVATION", 101, 110], ["spinal", "ANATOMY", 114, 120], ["fluid", "OBSERVATION", 121, 126]]], ["In many arbovirus infections, IgM capture enzyme-linked immunoassays on spinal fluid can quickly identify specific viral infections.Epidemiology ::: Acute Disseminated EncephalomyelitisHistorically, ADEM accounted for one-third of cases of acute encephalitis.", [["spinal fluid", "ANATOMY", 72, 84], ["arbovirus infections", "DISEASE", 8, 28], ["viral infections", "DISEASE", 115, 131], ["ADEM", "DISEASE", 199, 203], ["encephalitis", "DISEASE", 246, 258], ["IgM", "GENE_OR_GENE_PRODUCT", 30, 33], ["IgM", "PROTEIN", 30, 33], ["many arbovirus infections", "PROBLEM", 3, 28], ["IgM capture enzyme", "TEST", 30, 48], ["linked immunoassays on spinal fluid", "PROBLEM", 49, 84], ["specific viral infections", "PROBLEM", 106, 131], ["Acute Disseminated EncephalomyelitisHistorically", "PROBLEM", 149, 197], ["ADEM", "PROBLEM", 199, 203], ["acute encephalitis", "PROBLEM", 240, 258], ["many", "OBSERVATION_MODIFIER", 3, 7], ["arbovirus infections", "OBSERVATION", 8, 28], ["spinal", "ANATOMY", 72, 78], ["viral infections", "OBSERVATION", 115, 131], ["Disseminated", "OBSERVATION_MODIFIER", 155, 167], ["EncephalomyelitisHistorically", "OBSERVATION", 168, 197], ["acute", "OBSERVATION_MODIFIER", 240, 245], ["encephalitis", "OBSERVATION", 246, 258]]], ["Vaccine practices have reduced or eliminated the major causes (Table 5).", [["Vaccine practices", "TREATMENT", 0, 17]]], ["Cessation of vaccinia infections to prevent smallpox and institution of immunizations for measles, mumps, rubella, and varicella viruses have eliminated the majority of cases of ADEM.", [["vaccinia infections", "DISEASE", 13, 32], ["smallpox", "DISEASE", 44, 52], ["measles", "DISEASE", 90, 97], ["mumps, rubella", "DISEASE", 99, 113], ["varicella viruses", "DISEASE", 119, 136], ["ADEM", "DISEASE", 178, 182], ["vaccinia", "ORGANISM", 13, 21], ["varicella viruses", "ORGANISM", 119, 136], ["vaccinia", "SPECIES", 13, 21], ["vaccinia infections", "PROBLEM", 13, 32], ["smallpox", "TREATMENT", 44, 52], ["immunizations", "TREATMENT", 72, 85], ["measles", "PROBLEM", 90, 97], ["mumps", "PROBLEM", 99, 104], ["rubella", "PROBLEM", 106, 113], ["varicella viruses", "PROBLEM", 119, 136], ["ADEM", "PROBLEM", 178, 182], ["vaccinia infections", "OBSERVATION", 13, 32], ["ADEM", "OBSERVATION", 178, 182]]], ["Indeed, in nations with successful immunization policies, the majority of cases are now related to nonspecific upper respiratory infections.Clinical Findings ::: Acute Disseminated EncephalomyelitisA history is often obtained that an exanthem or a nonspecific respiratory or gastrointestinal illness preceded the encephalitis symptoms by 5 days to 3 weeks.", [["respiratory", "ANATOMY", 117, 128], ["respiratory", "ANATOMY", 260, 271], ["gastrointestinal", "ANATOMY", 275, 291], ["upper respiratory infections", "DISEASE", 111, 139], ["exanthem", "DISEASE", 234, 242], ["respiratory or gastrointestinal illness", "DISEASE", 260, 299], ["encephalitis", "DISEASE", 313, 325], ["exanthem", "CANCER", 234, 242], ["gastrointestinal", "ORGAN", 275, 291], ["successful immunization policies", "TREATMENT", 24, 56], ["nonspecific upper respiratory infections", "PROBLEM", 99, 139], ["Acute Disseminated EncephalomyelitisA", "PROBLEM", 162, 199], ["an exanthem", "PROBLEM", 231, 242], ["a nonspecific respiratory or gastrointestinal illness", "PROBLEM", 246, 299], ["the encephalitis symptoms", "PROBLEM", 309, 334], ["nonspecific", "OBSERVATION_MODIFIER", 99, 110], ["upper", "ANATOMY_MODIFIER", 111, 116], ["respiratory", "ANATOMY", 117, 128], ["infections", "OBSERVATION", 129, 139], ["Disseminated", "OBSERVATION_MODIFIER", 168, 180], ["EncephalomyelitisA", "OBSERVATION", 181, 199], ["gastrointestinal", "ANATOMY", 275, 291], ["encephalitis", "OBSERVATION", 313, 325]]], ["For example, postmeasles encephalomyelitis typically begins 4\u20138 days after the rash when the child has defervesced and is returning to normal activities.", [["encephalomyelitis", "DISEASE", 25, 42], ["rash", "DISEASE", 79, 83], ["child", "ORGANISM", 93, 98], ["postmeasles encephalomyelitis", "SPECIES", 13, 42], ["postmeasles encephalomyelitis", "PROBLEM", 13, 42], ["the rash", "PROBLEM", 75, 83], ["encephalomyelitis", "OBSERVATION", 25, 42]]], ["Headache, fever, and depressed consciousness develop abruptly, often with focal neurological signs and seizures.", [["neurological", "ANATOMY", 80, 92], ["Headache", "DISEASE", 0, 8], ["fever", "DISEASE", 10, 15], ["depressed consciousness", "DISEASE", 21, 44], ["seizures", "DISEASE", 103, 111], ["Headache", "PROBLEM", 0, 8], ["fever", "PROBLEM", 10, 15], ["depressed consciousness", "PROBLEM", 21, 44], ["focal neurological signs", "PROBLEM", 74, 98], ["seizures", "PROBLEM", 103, 111], ["fever", "OBSERVATION", 10, 15], ["focal", "OBSERVATION_MODIFIER", 74, 79]]], ["Postvaricella encephalitis is commonly limited to acute cerebellar ataxia.Clinical Findings ::: Acute Disseminated EncephalomyelitisThe spinal fluid may show a mild pleocytosis and protein elevation, but in one-third of patients these analyses remain normal.", [["cerebellar", "ANATOMY", 56, 66], ["spinal fluid", "ANATOMY", 136, 148], ["Postvaricella encephalitis", "DISEASE", 0, 26], ["cerebellar ataxia", "DISEASE", 56, 73], ["Disseminated Encephalomyelitis", "DISEASE", 102, 132], ["pleocytosis", "DISEASE", 165, 176], ["spinal fluid", "ORGANISM_SUBSTANCE", 136, 148], ["patients", "ORGANISM", 220, 228], ["patients", "SPECIES", 220, 228], ["Postvaricella encephalitis", "PROBLEM", 0, 26], ["acute cerebellar ataxia", "PROBLEM", 50, 73], ["Acute Disseminated Encephalomyelitis", "PROBLEM", 96, 132], ["The spinal fluid", "TEST", 132, 148], ["a mild pleocytosis", "PROBLEM", 158, 176], ["protein elevation", "PROBLEM", 181, 198], ["encephalitis", "OBSERVATION", 14, 26], ["acute", "OBSERVATION_MODIFIER", 50, 55], ["cerebellar", "ANATOMY", 56, 66], ["ataxia", "OBSERVATION", 67, 73], ["Disseminated", "OBSERVATION_MODIFIER", 102, 114], ["Encephalomyelitis", "OBSERVATION", 115, 132], ["spinal", "ANATOMY", 136, 142], ["fluid", "OBSERVATION", 143, 148], ["mild", "OBSERVATION_MODIFIER", 160, 164], ["pleocytosis", "OBSERVATION", 165, 176], ["protein elevation", "OBSERVATION", 181, 198], ["normal", "OBSERVATION", 251, 257]]], ["Assays for myelin basic protein are often positive, consistent with the demyelinating nature of the disease.", [["myelin basic protein", "GENE_OR_GENE_PRODUCT", 11, 31], ["myelin basic protein", "PROTEIN", 11, 31], ["Assays", "TEST", 0, 6], ["myelin basic protein", "TEST", 11, 31], ["the disease", "PROBLEM", 96, 107], ["consistent with", "UNCERTAINTY", 52, 67], ["demyelinating", "OBSERVATION_MODIFIER", 72, 85], ["disease", "OBSERVATION", 100, 107]]], ["Magnetic resonance imaging is the more definitive test, often showing multifocal white matter lesions with enhancement suggesting inflammatory lesions of similar age.Diagnosis ::: Acute Disseminated EncephalomyelitisIn ADEM, virus isolation or serological studies are of little aid in diagnosis.", [["white matter lesions", "ANATOMY", 81, 101], ["inflammatory lesions", "ANATOMY", 130, 150], ["white matter lesions", "DISEASE", 81, 101], ["Disseminated EncephalomyelitisIn ADEM", "DISEASE", 186, 223], ["white matter lesions", "PATHOLOGICAL_FORMATION", 81, 101], ["inflammatory lesions", "CANCER", 130, 150], ["Magnetic resonance imaging", "TEST", 0, 26], ["multifocal white matter lesions", "PROBLEM", 70, 101], ["inflammatory lesions", "PROBLEM", 130, 150], ["Acute Disseminated EncephalomyelitisIn ADEM", "PROBLEM", 180, 223], ["virus isolation", "TREATMENT", 225, 240], ["serological studies", "TEST", 244, 263], ["multifocal", "OBSERVATION_MODIFIER", 70, 80], ["white matter", "OBSERVATION_MODIFIER", 81, 93], ["lesions", "OBSERVATION", 94, 101], ["enhancement", "OBSERVATION_MODIFIER", 107, 118], ["suggesting", "UNCERTAINTY", 119, 129], ["inflammatory", "OBSERVATION_MODIFIER", 130, 142], ["lesions", "OBSERVATION", 143, 150], ["Disseminated", "OBSERVATION_MODIFIER", 186, 198]]], ["A similar clinical\u2013pathological syndrome follows immunization with rabies and Japanese encephalitis vaccines prepared in neural tissues and, in the case of rabies vaccines, has been shown to be associated with an immune response to myelin basic protein.", [["neural tissues", "ANATOMY", 121, 135], ["rabies and Japanese encephalitis", "DISEASE", 67, 99], ["rabies", "ORGANISM", 67, 73], ["neural tissues", "TISSUE", 121, 135], ["rabies", "ORGANISM", 156, 162], ["myelin basic protein", "GENE_OR_GENE_PRODUCT", 232, 252], ["myelin basic protein", "PROTEIN", 232, 252], ["rabies", "SPECIES", 67, 73], ["rabies", "SPECIES", 156, 162], ["A similar clinical\u2013pathological syndrome", "PROBLEM", 0, 40], ["immunization", "TREATMENT", 49, 61], ["rabies", "TREATMENT", 67, 73], ["Japanese encephalitis vaccines", "TREATMENT", 78, 108], ["rabies vaccines", "TREATMENT", 156, 171], ["myelin basic protein", "PROBLEM", 232, 252], ["clinical\u2013pathological syndrome", "OBSERVATION", 10, 40], ["neural tissues", "ANATOMY", 121, 135]]], ["Similar lymphoproliferative responses to myelin basic protein have been shown in postmeasles encephalomyelitis and in postvaricella cerebellar ataxia, indicating an analogous autoimmune mechanism.", [["cerebellar", "ANATOMY", 132, 142], ["encephalomyelitis", "DISEASE", 93, 110], ["cerebellar ataxia", "DISEASE", 132, 149], ["myelin basic protein", "GENE_OR_GENE_PRODUCT", 41, 61], ["myelin basic protein", "PROTEIN", 41, 61], ["postmeasles encephalomyelitis", "SPECIES", 81, 110], ["Similar lymphoproliferative responses", "PROBLEM", 0, 37], ["myelin basic protein", "TEST", 41, 61], ["encephalomyelitis", "PROBLEM", 93, 110], ["postvaricella cerebellar ataxia", "PROBLEM", 118, 149], ["an analogous autoimmune mechanism", "PROBLEM", 162, 195], ["lymphoproliferative", "OBSERVATION", 8, 27], ["encephalomyelitis", "OBSERVATION", 93, 110], ["postvaricella cerebellar", "ANATOMY", 118, 142], ["ataxia", "OBSERVATION", 143, 149], ["analogous autoimmune", "OBSERVATION", 165, 185]]], ["Indeed, in ADEM, after measles the virus cannot be found in the brain by virus isolation, immunocytochemical staining, or in situ hybridization; in this disease encephalitis occurs without evidence of neuroinvasion.Slow Infections of the CNSChronic inflammatory diseases of the CNS include subacute sclerosing panencephalitis with measles virus, progressive multifocal leukoencephalopathy with JC virus, HIV-associated encephalitis, and myelopathy with HTLV-1 virus.", [["brain", "ANATOMY", 64, 69], ["CNS", "ANATOMY", 278, 281], ["ADEM", "DISEASE", 11, 15], ["encephalitis", "DISEASE", 161, 173], ["neuroinvasion", "DISEASE", 201, 214], ["sclerosing panencephalitis", "DISEASE", 299, 325], ["measles virus", "DISEASE", 331, 344], ["leukoencephalopathy", "DISEASE", 369, 388], ["JC virus", "DISEASE", 394, 402], ["HIV-associated encephalitis", "DISEASE", 404, 431], ["myelopathy", "DISEASE", 437, 447], ["HTLV-1 virus", "DISEASE", 453, 465], ["brain", "ORGAN", 64, 69], ["CNS", "ANATOMICAL_SYSTEM", 278, 281], ["JC virus", "ORGANISM", 394, 402], ["HIV", "ORGANISM", 404, 407], ["HTLV-1 virus", "ORGANISM", 453, 465], ["measles virus", "SPECIES", 331, 344], ["HIV-", "SPECIES", 404, 408], ["HTLV-1 virus", "SPECIES", 453, 465], ["measles virus", "SPECIES", 331, 344], ["JC virus", "SPECIES", 394, 402], ["HTLV-1 virus", "SPECIES", 453, 465], ["ADEM", "PROBLEM", 11, 15], ["measles the virus", "PROBLEM", 23, 40], ["immunocytochemical staining", "TEST", 90, 117], ["this disease encephalitis", "PROBLEM", 148, 173], ["neuroinvasion", "PROBLEM", 201, 214], ["Slow Infections", "PROBLEM", 215, 230], ["the CNSChronic inflammatory diseases", "PROBLEM", 234, 270], ["the CNS", "PROBLEM", 274, 281], ["subacute sclerosing panencephalitis", "PROBLEM", 290, 325], ["measles virus", "PROBLEM", 331, 344], ["progressive multifocal leukoencephalopathy", "PROBLEM", 346, 388], ["JC virus", "PROBLEM", 394, 402], ["HIV-associated encephalitis", "PROBLEM", 404, 431], ["myelopathy", "PROBLEM", 437, 447], ["HTLV-1 virus", "PROBLEM", 453, 465], ["brain", "ANATOMY", 64, 69], ["without evidence of", "UNCERTAINTY", 181, 200], ["neuroinvasion", "OBSERVATION", 201, 214], ["Infections", "OBSERVATION", 220, 230], ["CNSChronic", "OBSERVATION_MODIFIER", 238, 248], ["inflammatory", "OBSERVATION_MODIFIER", 249, 261], ["CNS", "ANATOMY", 278, 281], ["subacute", "OBSERVATION_MODIFIER", 290, 298], ["sclerosing", "OBSERVATION_MODIFIER", 299, 309], ["panencephalitis", "OBSERVATION", 310, 325], ["progressive", "OBSERVATION_MODIFIER", 346, 357], ["multifocal", "OBSERVATION_MODIFIER", 358, 368], ["leukoencephalopathy", "OBSERVATION", 369, 388], ["JC virus", "OBSERVATION", 394, 402], ["encephalitis", "OBSERVATION", 419, 431], ["myelopathy", "OBSERVATION", 437, 447]]], ["These diseases represent distinct syndromes with unique mechanisms of pathogenesis.Treatment and PreventionSpecific drug treatments are available only for herpesvirus infections.", [["herpesvirus infections", "DISEASE", 155, 177], ["herpesvirus", "ORGANISM", 155, 166], ["These diseases", "PROBLEM", 0, 14], ["distinct syndromes", "PROBLEM", 25, 43], ["pathogenesis", "PROBLEM", 70, 82], ["Treatment", "TREATMENT", 83, 92], ["PreventionSpecific drug treatments", "TREATMENT", 97, 131], ["herpesvirus infections", "PROBLEM", 155, 177], ["diseases", "OBSERVATION", 6, 14], ["distinct", "OBSERVATION_MODIFIER", 25, 33], ["syndromes", "OBSERVATION", 34, 43]]], ["The incidence of HIV-associated encephalitis has been reduced by antiviral therapy, but whether this represents only a postponement of CNS disease is yet to be determined.", [["CNS", "ANATOMY", 135, 138], ["HIV-associated encephalitis", "DISEASE", 17, 44], ["HIV", "ORGANISM", 17, 20], ["CNS", "ANATOMICAL_SYSTEM", 135, 138], ["HIV-", "SPECIES", 17, 21], ["HIV", "SPECIES", 17, 20], ["HIV-associated encephalitis", "PROBLEM", 17, 44], ["antiviral therapy", "TREATMENT", 65, 82], ["CNS disease", "PROBLEM", 135, 146], ["HIV", "OBSERVATION", 17, 20], ["encephalitis", "OBSERVATION", 32, 44], ["reduced", "OBSERVATION_MODIFIER", 54, 61], ["antiviral therapy", "OBSERVATION", 65, 82], ["CNS", "ANATOMY", 135, 138], ["disease", "OBSERVATION", 139, 146]]], ["Rabies is unique in that postexposure treatment with vaccine and immune globulin can reduce the hazard of disease, but once clinical symptoms have developed no treatment is effective.Treatment and PreventionVaccines can prevent measles, mumps, rubella, chickenpox, Japanese encephalitis, and tick-borne virus infections.", [["Rabies", "DISEASE", 0, 6], ["measles, mumps, rubella", "DISEASE", 228, 251], ["chickenpox", "DISEASE", 253, 263], ["Japanese encephalitis", "DISEASE", 265, 286], ["tick-borne virus infections", "DISEASE", 292, 319], ["Rabies", "ORGANISM", 0, 6], ["immune globulin", "GENE_OR_GENE_PRODUCT", 65, 80], ["tick-borne virus", "ORGANISM", 292, 308], ["tick-borne virus", "SPECIES", 292, 308], ["Japanese encephalitis", "SPECIES", 265, 286], ["tick-borne virus", "SPECIES", 292, 308], ["postexposure treatment", "TREATMENT", 25, 47], ["vaccine", "TREATMENT", 53, 60], ["immune globulin", "TREATMENT", 65, 80], ["disease", "PROBLEM", 106, 113], ["clinical symptoms", "PROBLEM", 124, 141], ["treatment", "TREATMENT", 160, 169], ["Treatment", "TREATMENT", 183, 192], ["PreventionVaccines", "TREATMENT", 197, 215], ["measles", "PROBLEM", 228, 235], ["mumps", "PROBLEM", 237, 242], ["rubella", "PROBLEM", 244, 251], ["chickenpox", "PROBLEM", 253, 263], ["Japanese encephalitis", "PROBLEM", 265, 286], ["tick-borne virus infections", "PROBLEM", 292, 319], ["disease", "OBSERVATION", 106, 113]]], ["An unanticipated bonus of measles immunization has been the virtual elimination of subacute sclerosing panencephalitis.See also\u2013", [["measles", "DISEASE", 26, 33], ["panencephalitis", "DISEASE", 103, 118], ["measles immunization", "TREATMENT", 26, 46], ["subacute sclerosing panencephalitis", "PROBLEM", 83, 118], ["subacute", "OBSERVATION_MODIFIER", 83, 91], ["sclerosing panencephalitis", "OBSERVATION", 92, 118]]]], "PMC7117111": [["IntroductionThe spike protein S of the porcine coronavirus transmissible gastroenteritis virus (TGEV) binds to porcine aminopeptidase N to enter the cell (Delmas et al., 1992).", [["cell", "ANATOMY", 149, 153], ["transmissible gastroenteritis", "DISEASE", 59, 88], ["porcine", "ORGANISM", 39, 46], ["coronavirus transmissible gastroenteritis virus", "ORGANISM", 47, 94], ["TGEV", "ORGANISM", 96, 100], ["porcine aminopeptidase N", "GENE_OR_GENE_PRODUCT", 111, 135], ["cell", "CELL", 149, 153], ["spike protein S", "PROTEIN", 16, 31], ["porcine aminopeptidase N", "PROTEIN", 111, 135], ["porcine coronavirus transmissible gastroenteritis virus", "SPECIES", 39, 94], ["porcine coronavirus transmissible gastroenteritis virus", "SPECIES", 39, 94], ["TGEV", "SPECIES", 96, 100], ["The spike protein S", "PROBLEM", 12, 31], ["the porcine coronavirus transmissible gastroenteritis virus", "PROBLEM", 35, 94], ["porcine aminopeptidase N", "TREATMENT", 111, 135]]], ["Additionally, sialic acids are used in facilitating virus entry (Schwegmann-Wessels et al., 2011, Schwegmann-Wessels et al., 2003).IntroductionTransmissible gastroenteritis in swine is characterized by vomiting and severe diarrhea causing death in piglets within the first weeks of age (Laude et al., 1993, Wesley et al., 1991).", [["sialic acids", "CHEMICAL", 14, 26], ["gastroenteritis", "DISEASE", 157, 172], ["vomiting", "DISEASE", 202, 210], ["diarrhea", "DISEASE", 222, 230], ["death", "DISEASE", 239, 244], ["sialic acids", "CHEMICAL", 14, 26], ["sialic acids", "SIMPLE_CHEMICAL", 14, 26], ["swine", "ORGANISM", 176, 181], ["piglets", "ORGANISM", 248, 255], ["swine", "SPECIES", 176, 181], ["piglets", "SPECIES", 248, 255], ["swine", "SPECIES", 176, 181], ["sialic acids", "TREATMENT", 14, 26], ["Transmissible gastroenteritis in swine", "PROBLEM", 143, 181], ["vomiting", "PROBLEM", 202, 210], ["severe diarrhea", "PROBLEM", 215, 230], ["death", "PROBLEM", 239, 244], ["sialic acids", "OBSERVATION", 14, 26], ["gastroenteritis", "OBSERVATION", 157, 172], ["severe", "OBSERVATION_MODIFIER", 215, 221], ["diarrhea", "OBSERVATION", 222, 230]]], ["Virus infection leads to destruction of the epithelial cell layer at the tips of the jejunal villi of newborn piglets (Thake, 1968).", [["epithelial cell layer", "ANATOMY", 44, 65], ["jejunal villi", "ANATOMY", 85, 98], ["Virus infection", "DISEASE", 0, 15], ["Virus", "ORGANISM", 0, 5], ["epithelial cell layer", "TISSUE", 44, 65], ["jejunal villi", "MULTI-TISSUE_STRUCTURE", 85, 98], ["piglets", "ORGANISM", 110, 117], ["piglets", "SPECIES", 110, 117], ["Virus infection", "PROBLEM", 0, 15], ["destruction of the epithelial cell layer", "PROBLEM", 25, 65], ["infection", "OBSERVATION", 6, 15], ["destruction", "OBSERVATION_MODIFIER", 25, 36], ["epithelial cell", "OBSERVATION", 44, 59], ["layer", "OBSERVATION_MODIFIER", 60, 65], ["tips", "ANATOMY_MODIFIER", 73, 77], ["jejunal villi", "ANATOMY", 85, 98], ["newborn piglets", "OBSERVATION", 102, 117]]], ["Most studies on TGEV infection are based on permanent cell lines (Rudiger et al., 2016, Tuboly et al., 2000) or are dependent on swine in vivo models (Chai et al., 2014, Chen et al., 2016, Woods and Wesley, 1986).", [["cell lines", "ANATOMY", 54, 64], ["TGEV infection", "DISEASE", 16, 30], ["TGEV", "ORGANISM", 16, 20], ["cell lines", "CELL", 54, 64], ["permanent cell lines", "CELL_LINE", 44, 64], ["TGEV", "SPECIES", 16, 20], ["TGEV", "SPECIES", 16, 20], ["swine", "SPECIES", 129, 134], ["TGEV infection", "PROBLEM", 16, 30], ["permanent cell lines", "TREATMENT", 44, 64], ["infection", "OBSERVATION", 21, 30], ["cell lines", "OBSERVATION", 54, 64]]], ["In general, primary intestinal cell culture systems to study pathogenesis are still very limiting in the way that isolated cells are low in recovery and difficult to culture (de Graaf et al., 2010, Sirinarumitr et al., 1996).", [["intestinal cell", "ANATOMY", 20, 35], ["cells", "ANATOMY", 123, 128], ["intestinal cell", "CELL", 20, 35], ["cells", "CELL", 123, 128], ["primary intestinal cell culture systems", "CELL_LINE", 12, 51], ["isolated cells", "CELL_TYPE", 114, 128], ["primary intestinal cell culture systems", "TEST", 12, 51], ["study pathogenesis", "TEST", 55, 73], ["isolated cells", "PROBLEM", 114, 128], ["culture", "TEST", 166, 173], ["intestinal", "ANATOMY", 20, 30], ["cell", "OBSERVATION", 31, 35], ["low", "OBSERVATION_MODIFIER", 133, 136]]], ["A relatively new method is the production of precision cut intestinal slices (PCIS) that are used in the field of toxicology (de Graaf et al., 2010).", [["intestinal slices", "ANATOMY", 59, 76], ["intestinal slices", "MULTI-TISSUE_STRUCTURE", 59, 76], ["relatively", "OBSERVATION_MODIFIER", 2, 12], ["new", "OBSERVATION_MODIFIER", 13, 16], ["method", "OBSERVATION", 17, 23], ["intestinal slices", "ANATOMY", 59, 76]]], ["PCIS are explants of tissue, cultured ex vivo, that allow an intercellular and cell-matrix interaction of all cells in the tissue (de Graaf et al., 2010).", [["explants", "ANATOMY", 9, 17], ["tissue", "ANATOMY", 21, 27], ["intercellular", "ANATOMY", 61, 74], ["cell", "ANATOMY", 79, 83], ["matrix", "ANATOMY", 84, 90], ["cells", "ANATOMY", 110, 115], ["tissue", "ANATOMY", 123, 129], ["tissue", "TISSUE", 21, 27], ["intercellular", "CELL", 61, 74], ["cell", "CELL", 79, 83], ["matrix", "CELLULAR_COMPONENT", 84, 90], ["cells", "CELL", 110, 115], ["tissue", "TISSUE", 123, 129], ["PCIS", "TREATMENT", 0, 4], ["an intercellular and cell-matrix interaction", "TREATMENT", 58, 102], ["tissue", "ANATOMY", 21, 27], ["all cells", "OBSERVATION", 106, 115], ["tissue", "ANATOMY", 123, 129]]], ["These slices are produced to stay vital in culture and have been already used to study the intestinal tissue in smaller species like rodents (Niu et al., 2014).", [["slices", "ANATOMY", 6, 12], ["intestinal tissue", "ANATOMY", 91, 108], ["slices", "MULTI-TISSUE_STRUCTURE", 6, 12], ["intestinal tissue", "TISSUE", 91, 108], ["vital in culture", "TEST", 34, 50], ["intestinal tissue", "ANATOMY", 91, 108], ["smaller", "OBSERVATION_MODIFIER", 112, 119]]], ["So far they have been established in rat, mouse, and human jejunum (Pham et al., 2015).", [["jejunum", "ANATOMY", 59, 66], ["rat", "ORGANISM", 37, 40], ["mouse", "ORGANISM", 42, 47], ["human", "ORGANISM", 53, 58], ["jejunum", "ORGAN", 59, 66], ["rat", "SPECIES", 37, 40], ["mouse", "SPECIES", 42, 47], ["human", "SPECIES", 53, 58], ["rat", "SPECIES", 37, 40], ["mouse", "SPECIES", 42, 47], ["human", "SPECIES", 53, 58], ["jejunum", "ANATOMY", 59, 66]]], ["Here for the first time, we established porcine jejunum PCIS and demonstrate that they can be infected by different TGEV strains.", [["jejunum PCIS", "ANATOMY", 48, 60], ["porcine", "ORGANISM", 40, 47], ["jejunum PCIS", "CANCER", 48, 60], ["TGEV", "ORGANISM", 116, 120], ["porcine", "SPECIES", 40, 47], ["porcine jejunum PCIS", "SPECIES", 40, 60], ["TGEV", "SPECIES", 116, 120], ["porcine jejunum PCIS", "TREATMENT", 40, 60], ["different TGEV strains", "PROBLEM", 106, 128], ["jejunum", "ANATOMY", 48, 55]]], ["The TGEV strain PUR46-MAD is known to be attenuated by cell passaging over the years, but is still widely used in cell culture infection systems (Sanchez et al., 1999).", [["cell", "ANATOMY", 55, 59], ["cell culture", "ANATOMY", 114, 126], ["PUR46", "CHEMICAL", 16, 21], ["infection", "DISEASE", 127, 136], ["TGEV strain", "ORGANISM", 4, 15], ["PUR46-MAD", "GENE_OR_GENE_PRODUCT", 16, 25], ["cell", "CELL", 55, 59], ["cell", "CELL", 114, 118], ["MAD", "PROTEIN", 22, 25], ["TGEV", "SPECIES", 4, 8], ["The TGEV strain PUR46", "TEST", 0, 21], ["cell passaging", "PROBLEM", 55, 69], ["known to be", "UNCERTAINTY", 29, 40], ["attenuated", "OBSERVATION_MODIFIER", 41, 51], ["cell passaging", "OBSERVATION", 55, 69]]], ["TGEV Miller (MIL65), the second strain, is a virulent cell-passaged strain (Bohl et al., 1972).", [["cell", "ANATOMY", 54, 58], ["strain", "ANATOMY", 68, 74], ["TGEV Miller", "ORGANISM", 0, 11], ["MIL65", "GENE_OR_GENE_PRODUCT", 13, 18], ["cell", "CELL", 54, 58], ["TGEV", "SPECIES", 0, 4], ["TGEV", "SPECIES", 0, 4], ["the second strain", "PROBLEM", 21, 38], ["a virulent cell", "PROBLEM", 43, 58], ["virulent cell", "OBSERVATION", 45, 58]]], ["The third strain used in our study is TGEV GFP, a recombinant TGEV strain that includes the green fluorescent protein (Almazan et al., 2000).", [["TGEV", "ORGANISM", 38, 42], ["GFP", "GENE_OR_GENE_PRODUCT", 43, 46], ["TGEV", "ORGANISM", 62, 66], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 92, 117], ["green fluorescent protein", "PROTEIN", 92, 117], ["TGEV", "SPECIES", 38, 42], ["TGEV", "SPECIES", 62, 66], ["The third strain", "PROBLEM", 0, 16], ["our study", "TEST", 25, 34], ["TGEV GFP", "PROBLEM", 38, 46], ["a recombinant TGEV strain", "PROBLEM", 48, 73]]], ["Our study showed that porcine PCIS can be used for TGEV infection.", [["PCIS", "CHEMICAL", 30, 34], ["TGEV infection", "DISEASE", 51, 65], ["porcine", "ORGANISM", 22, 29], ["PCIS", "SIMPLE_CHEMICAL", 30, 34], ["TGEV", "ORGANISM", 51, 55], ["porcine", "SPECIES", 22, 29], ["porcine", "SPECIES", 22, 29], ["TGEV", "SPECIES", 51, 55], ["Our study", "TEST", 0, 9], ["porcine PCIS", "TREATMENT", 22, 34], ["TGEV infection", "PROBLEM", 51, 65], ["infection", "OBSERVATION", 56, 65]]], ["PCIS are a valuable tool to analyze the enterotropism of TGEV and can be potentially used for the study of other pathogens that cause gastrointestinal diseases.Buffer and medium ::: MethodsFor the preparation of the intestine Krebs-Henseleit Buffer (KHB) was produced as described before (de Graaf et al., 2010).", [["gastrointestinal", "ANATOMY", 134, 150], ["intestine", "ANATOMY", 216, 225], ["gastrointestinal diseases", "DISEASE", 134, 159], ["TGEV", "ORGANISM", 57, 61], ["gastrointestinal", "ORGAN", 134, 150], ["intestine", "ORGAN", 216, 225], ["TGEV", "SPECIES", 57, 61], ["PCIS", "TREATMENT", 0, 4], ["TGEV", "PROBLEM", 57, 61], ["the study", "TEST", 94, 103], ["other pathogens", "PROBLEM", 107, 122], ["gastrointestinal diseases", "PROBLEM", 134, 159], ["Methods", "TREATMENT", 182, 189], ["the intestine Krebs", "TREATMENT", 212, 231], ["Henseleit Buffer (KHB)", "TREATMENT", 232, 254], ["gastrointestinal", "ANATOMY", 134, 150], ["diseases", "OBSERVATION", 151, 159], ["intestine", "ANATOMY", 216, 225]]], ["The solution was oxygenated with carbogen (Carbogen Lab, Linde) for 30 min.", [["carbogen", "CHEMICAL", 33, 41], ["carbogen", "CHEMICAL", 33, 41], ["carbogen", "SIMPLE_CHEMICAL", 33, 41], ["Carbogen", "SIMPLE_CHEMICAL", 43, 51], ["The solution", "TREATMENT", 0, 12], ["carbogen (Carbogen Lab", "TREATMENT", 33, 55]]], ["Afterwards the pH was adjusted to 7.42.", [["the pH", "TEST", 11, 17]]], ["For the PCIS incubation medium 14.0 mM D-Glucose, 50 \u03bcg/ml Gentamicin, and 2.5 \u03bcg/ml Amphotericin B were added to Williams medium E (containing L-glutamine; Invitrogen).", [["D-Glucose", "CHEMICAL", 39, 48], ["Gentamicin", "CHEMICAL", 59, 69], ["Amphotericin B", "CHEMICAL", 85, 99], ["L-glutamine", "CHEMICAL", 144, 155], ["D-Glucose", "CHEMICAL", 39, 48], ["Gentamicin", "CHEMICAL", 59, 69], ["Amphotericin B", "CHEMICAL", 85, 99], ["L-glutamine", "CHEMICAL", 144, 155], ["D-Glucose", "SIMPLE_CHEMICAL", 39, 48], ["Gentamicin", "SIMPLE_CHEMICAL", 59, 69], ["Amphotericin B", "SIMPLE_CHEMICAL", 85, 99], ["L-glutamine", "SIMPLE_CHEMICAL", 144, 155], ["the PCIS incubation medium", "TREATMENT", 4, 30], ["mM D-Glucose", "TREATMENT", 36, 48], ["Gentamicin", "TREATMENT", 59, 69], ["Amphotericin B", "TREATMENT", 85, 99], ["Williams medium E (containing L-glutamine", "TREATMENT", 114, 155], ["Invitrogen", "TREATMENT", 157, 167]]], ["The medium was oxygenated for at least 30 min with carbogen.Precision cut intestinal slices ::: MethodsSwine were housed conventionally and obtained from the Clinic for Swine, Small Ruminants and Forensic Medicine and the Institute for Physiology at the University of Veterinary Medicine, Hannover.", [["intestinal slices", "ANATOMY", 74, 91], ["carbogen", "CHEMICAL", 51, 59], ["carbogen", "CHEMICAL", 51, 59], ["carbogen", "SIMPLE_CHEMICAL", 51, 59], ["intestinal slices", "MULTI-TISSUE_STRUCTURE", 74, 91], ["Swine", "SPECIES", 103, 108], ["carbogen", "TREATMENT", 51, 59], ["Methods", "TREATMENT", 96, 103], ["medium", "OBSERVATION_MODIFIER", 4, 10], ["oxygenated", "OBSERVATION_MODIFIER", 15, 25], ["intestinal", "ANATOMY", 74, 84]]], ["Jejunum from ca.", [["ca", "OBSERVATION", 13, 15]]], ["25 kg German landrace piglets was used (n = 11).", [["piglets", "ORGANISM", 22, 29], ["piglets", "SPECIES", 22, 29], ["German landrace piglets", "TREATMENT", 6, 29]]], ["Tissue was collected directly after euthanasia of swine.", [["Tissue", "ANATOMY", 0, 6], ["Tissue", "TISSUE", 0, 6], ["swine", "ORGANISM", 50, 55], ["swine", "SPECIES", 50, 55], ["swine", "SPECIES", 50, 55]]], ["KHB Buffer and WME medium were prepared and oxygenated in advance.", [["KHB Buffer and WME medium", "TREATMENT", 0, 25]]], ["Swine intestine was transported in freshly oxygenated KHB buffer on ice.", [["intestine", "ANATOMY", 6, 15], ["KHB", "CHEMICAL", 54, 57], ["Swine", "ORGANISM", 0, 5], ["intestine", "ORGAN", 6, 15], ["KHB", "SIMPLE_CHEMICAL", 54, 57], ["Swine", "SPECIES", 0, 5], ["intestine", "ANATOMY", 6, 15]]], ["After transport intestinal tissue was flushed with ice-cold PBS to remove fecal residuals and transferred into freshly oxygenated KHB buffer on ice.", [["intestinal tissue", "ANATOMY", 16, 33], ["KHB", "CHEMICAL", 130, 133], ["intestinal tissue", "TISSUE", 16, 33], ["KHB", "SIMPLE_CHEMICAL", 130, 133], ["ice-cold PBS", "TREATMENT", 51, 63], ["fecal residuals", "PROBLEM", 74, 89], ["ice", "TREATMENT", 144, 147], ["intestinal tissue", "ANATOMY", 16, 33], ["fecal", "ANATOMY", 74, 79], ["residuals", "OBSERVATION", 80, 89]]], ["Preparation of cores of porcine intestine was done as described for human intestine (de Graaf et al., 2010).", [["intestine", "ANATOMY", 32, 41], ["intestine", "ANATOMY", 74, 83], ["porcine", "ORGANISM", 24, 31], ["intestine", "ORGAN", 32, 41], ["human", "ORGANISM", 68, 73], ["intestine", "ORGAN", 74, 83], ["porcine", "SPECIES", 24, 31], ["human", "SPECIES", 68, 73], ["porcine", "SPECIES", 24, 31], ["human", "SPECIES", 68, 73], ["cores", "ANATOMY_MODIFIER", 15, 20], ["porcine", "ANATOMY_MODIFIER", 24, 31], ["intestine", "ANATOMY", 32, 41], ["intestine", "ANATOMY", 74, 83]]], ["The intestine pieces were then embedded into 6% low melting agarose with RPMI (AGAROSE LM; GERBU, Gaiberg, Germany) and put on ice for 20 min (Fig. 1A).", [["intestine", "ANATOMY", 4, 13], ["intestine", "ORGAN", 4, 13], ["The intestine pieces", "TREATMENT", 0, 20], ["6% low melting agarose", "TREATMENT", 45, 67], ["RPMI (AGAROSE LM", "TREATMENT", 73, 89], ["ice", "TREATMENT", 127, 130], ["intestine", "ANATOMY", 4, 13]]], ["During this time, the Krumdiek tissue slicer (TSE systems, model MD4000-01) was prepared and flushed twice with cold KHB.", [["tissue", "ANATOMY", 31, 37], ["KHB", "CHEMICAL", 117, 120], ["Krumdiek tissue slicer", "TISSUE", 22, 44], ["the Krumdiek tissue slicer (TSE systems", "TREATMENT", 18, 57], ["model MD4000", "TREATMENT", 59, 71]]], ["Subsequently, the agarose cylinders containing the tissue were removed from the syringe tubes (Fig. 1B).", [["tissue", "ANATOMY", 51, 57], ["tissue", "TISSUE", 51, 57], ["the agarose cylinders", "TREATMENT", 14, 35], ["the syringe tubes", "TREATMENT", 76, 93], ["tissue", "ANATOMY", 51, 57], ["syringe tubes", "OBSERVATION", 80, 93]]], ["Suited pieces were stamped out to the fitting diameter of the Krumdiek tissue slicer (Fig. 1C).", [["tissue", "ANATOMY", 71, 77], ["Krumdiek tissue", "TISSUE", 62, 77], ["Suited pieces", "TREATMENT", 0, 13], ["Krumdiek tissue", "ANATOMY", 62, 77]]], ["Slices were cut with a cycle speed of 60 slices/min and were apparently 250 \u03bcm thick (Fig. 1D).", [["Slices", "ANATOMY", 0, 6], ["Slices", "MULTI-TISSUE_STRUCTURE", 0, 6], ["a cycle speed", "TEST", 21, 34]]], ["PCIS were collected in a 24 well plate filled with 1 ml WME medium per well with 2\u20133 PCIS.", [["PCIS", "CANCER", 0, 4], ["PCIS", "TREATMENT", 0, 4], ["2\u20133 PCIS", "TREATMENT", 81, 89]]], ["Slices rested for 30 min in an incubator flushed with carbogen.", [["Slices", "ANATOMY", 0, 6], ["carbogen", "CHEMICAL", 54, 62], ["carbogen", "CHEMICAL", 54, 62], ["carbogen", "SIMPLE_CHEMICAL", 54, 62], ["an incubator flushed with carbogen", "TREATMENT", 28, 62]]], ["Afterwards, PCIS were used for infection experiments.", [["PCIS", "CHEMICAL", 12, 16], ["infection", "DISEASE", 31, 40], ["PCIS", "TREATMENT", 12, 16], ["infection experiments", "PROBLEM", 31, 52]]], ["Table 1summarizes the number of swines per time point used for PCIS preparation and the different experimental setups.Virus infection ::: MethodsPCIS were infected by three different TGEV strains: TGEV PUR46-MAD and TGEV Miller MIL65 (Sanchez et al., 1990), as well as TGEV GFP rPUR46-C11 (Almazan et al., 2000).", [["Virus infection", "DISEASE", 118, 133], ["Virus", "ORGANISM", 118, 123], ["MethodsPCIS", "GENE_OR_GENE_PRODUCT", 138, 149], ["TGEV", "ORGANISM", 183, 187], ["TGEV", "ORGANISM", 197, 201], ["TGEV", "ORGANISM", 216, 220], ["TGEV", "ORGANISM", 269, 273], ["TGEV", "SPECIES", 197, 201], ["TGEV", "SPECIES", 216, 220], ["TGEV", "SPECIES", 183, 187], ["TGEV", "SPECIES", 197, 201], ["TGEV", "SPECIES", 216, 220], ["TGEV", "SPECIES", 269, 273], ["PCIS preparation", "TREATMENT", 63, 79], ["Virus infection", "PROBLEM", 118, 133], ["MethodsPCIS", "TREATMENT", 138, 149], ["infection", "OBSERVATION", 124, 133]]], ["TGEV PUR46 has been isolated initially in 1946 at the Purdue University Indiana, USA (Doyle and Hutchings, 1946).", [["PUR46", "CHEMICAL", 5, 10], ["TGEV", "ORGANISM", 0, 4], ["PUR46", "GENE_OR_GENE_PRODUCT", 5, 10], ["TGEV PUR46", "PROTEIN", 0, 10], ["TGEV", "SPECIES", 0, 4], ["TGEV", "SPECIES", 0, 4]]], ["The TGEV PUR46-MAD strain used in this study was passaged 128 times in porcine cell cultures (after around 11 times in swine) and is known to be attenuated (Bohl et al., 1972, Sanchez et al., 1990, Sanchez et al., 1999).", [["cell cultures", "ANATOMY", 79, 92], ["TGEV", "ORGANISM", 4, 8], ["PUR46", "GENE_OR_GENE_PRODUCT", 9, 14], ["porcine", "ORGANISM", 71, 78], ["cell cultures", "CELL", 79, 92], ["swine", "ORGANISM", 119, 124], ["TGEV PUR46-MAD strain", "DNA", 4, 25], ["porcine cell cultures", "CELL_LINE", 71, 92], ["swine", "SPECIES", 119, 124], ["TGEV", "SPECIES", 4, 8], ["swine", "SPECIES", 119, 124], ["The TGEV PUR46", "TEST", 0, 14], ["MAD strain", "PROBLEM", 15, 25], ["this study", "TEST", 34, 44], ["porcine cell cultures", "TEST", 71, 92]]], ["TGEV GFP rPUR46-C11 (TGEV GFP) is a recombinant TGEV PUR46-MAD where the S gene is replaced by the TGEV virulent strain PUR46-SW11-ST2-C11 (Almazan et al., 2000, Sanchez et al., 1999).", [["TGEV GFP", "ORGANISM", 0, 8], ["rPUR46-C11", "GENE_OR_GENE_PRODUCT", 9, 19], ["TGEV", "ORGANISM", 21, 25], ["GFP", "GENE_OR_GENE_PRODUCT", 26, 29], ["TGEV", "ORGANISM", 48, 52], ["PUR46-MAD", "GENE_OR_GENE_PRODUCT", 53, 62], ["TGEV", "ORGANISM", 99, 103], ["TGEV GFP rPUR46-C11 (TGEV GFP", "DNA", 0, 29], ["recombinant TGEV PUR46-MAD", "DNA", 36, 62], ["S gene", "DNA", 73, 79], ["SW11", "DNA", 126, 130], ["ST2", "PROTEIN", 131, 134], ["TGEV", "SPECIES", 99, 103], ["TGEV", "SPECIES", 0, 4], ["TGEV", "SPECIES", 21, 25], ["TGEV", "SPECIES", 48, 52], ["TGEV GFP rPUR46", "TEST", 0, 15], ["TGEV GFP", "TEST", 21, 29]]], ["This virulent TGEV PUR46 had the same origin than PUR46-MAD from Purdue University and was passaged 11 times in swine and two times in porcine cell culture.", [["cell culture", "ANATOMY", 143, 155], ["TGEV", "ORGANISM", 14, 18], ["PUR46", "ORGANISM", 19, 24], ["porcine", "ORGANISM", 135, 142], ["cell culture", "CELL", 143, 155], ["PUR46", "DNA", 50, 55], ["MAD", "DNA", 56, 59], ["porcine cell culture", "CELL_LINE", 135, 155], ["TGEV", "SPECIES", 14, 18], ["swine", "SPECIES", 112, 117], ["porcine", "SPECIES", 135, 142], ["TGEV", "SPECIES", 14, 18], ["swine", "SPECIES", 112, 117], ["porcine", "SPECIES", 135, 142], ["porcine cell culture", "TEST", 135, 155]]], ["The virulent C11 was obtained after plaque purification and highly replicates in the porcine enteric tract (Sanchez et al., 1999).", [["plaque", "ANATOMY", 36, 42], ["enteric tract", "ANATOMY", 93, 106], ["porcine", "ORGANISM", 85, 92], ["enteric tract", "ORGANISM_SUBDIVISION", 93, 106], ["porcine", "SPECIES", 85, 92], ["plaque purification", "TREATMENT", 36, 55], ["virulent", "OBSERVATION_MODIFIER", 4, 12], ["C11", "OBSERVATION_MODIFIER", 13, 16], ["porcine", "ANATOMY_MODIFIER", 85, 92], ["enteric tract", "ANATOMY", 93, 106]]], ["For the described study the TGEV GFP was passaged two times in ST cells.", [["ST cells", "ANATOMY", 63, 71], ["TGEV", "ORGANISM", 28, 32], ["GFP", "GENE_OR_GENE_PRODUCT", 33, 36], ["ST cells", "CELL", 63, 71], ["TGEV GFP", "DNA", 28, 36], ["ST cells", "CELL_TYPE", 63, 71], ["TGEV", "SPECIES", 28, 32], ["the described study", "TEST", 4, 23], ["the TGEV GFP", "TEST", 24, 36]]], ["TGEV Miller is a virulent cell-passaged strain of TGEV, isolated from young pig small intestine (Bohl et al., 1972, Sanchez et al., 1990).", [["cell", "ANATOMY", 26, 30], ["strain", "ANATOMY", 40, 46], ["intestine", "ANATOMY", 86, 95], ["TGEV", "ORGANISM", 0, 4], ["cell", "CELL", 26, 30], ["TGEV", "ORGANISM", 50, 54], ["pig", "ORGANISM", 76, 79], ["intestine", "ORGAN", 86, 95], ["TGEV", "SPECIES", 0, 4], ["TGEV", "SPECIES", 50, 54], ["pig", "SPECIES", 76, 79], ["TGEV", "SPECIES", 0, 4], ["TGEV", "SPECIES", 50, 54], ["pig", "SPECIES", 76, 79], ["a virulent cell", "PROBLEM", 15, 30], ["TGEV", "PROBLEM", 50, 54], ["virulent cell", "OBSERVATION_MODIFIER", 17, 30], ["small intestine", "ANATOMY", 80, 95]]], ["This virulent MIL65 strain was isolated in 1965 in the USA, passaged 13 times in porcine cell culture, 5 times in gnotobiotic pigs, and 6 times on ST cells prior to be used for this study.", [["cell culture", "ANATOMY", 89, 101], ["ST cells", "ANATOMY", 147, 155], ["MIL65 strain", "ORGANISM", 14, 26], ["porcine", "ORGANISM", 81, 88], ["cell culture", "CELL", 89, 101], ["pigs", "ORGANISM", 126, 130], ["ST cells", "CELL", 147, 155], ["ST cells", "CELL_TYPE", 147, 155], ["porcine", "SPECIES", 81, 88], ["gnotobiotic pigs", "SPECIES", 114, 130], ["porcine", "SPECIES", 81, 88], ["This virulent MIL65 strain", "PROBLEM", 0, 26], ["porcine cell culture", "TEST", 81, 101], ["gnotobiotic pigs", "TREATMENT", 114, 130], ["ST cells", "TREATMENT", 147, 155], ["this study", "TEST", 177, 187]]], ["All virus strains were provided by Luis Enjuanes.", [["All virus strains", "PROBLEM", 0, 17], ["virus strains", "OBSERVATION", 4, 17]]], ["A volume of 300 \u03bcl of the different TGEV strains was used for the inoculation of one well containing two PCIS.", [["TGEV", "ORGANISM", 36, 40], ["TGEV", "SPECIES", 36, 40], ["A volume", "TEST", 0, 8], ["the different TGEV strains", "TREATMENT", 22, 48], ["the inoculation", "TREATMENT", 62, 77], ["volume", "OBSERVATION_MODIFIER", 2, 8]]], ["For TGEV GFP 2.16 \u00d7 105 PFU/ml, for TGEV Miller 1.9 \u00d7 106 PFU/ml and for TGEV PUR46-MAD 4.11 \u00d7 107 PFU/ml were added.", [["TGEV", "ORGANISM", 4, 8], ["GFP", "GENE_OR_GENE_PRODUCT", 9, 12], ["TGEV", "ORGANISM", 36, 40], ["TGEV", "ORGANISM", 73, 77], ["TGEV", "SPECIES", 4, 8], ["TGEV", "SPECIES", 36, 40], ["TGEV", "SPECIES", 73, 77], ["TGEV GFP", "TEST", 4, 12], ["TGEV Miller", "TEST", 36, 47], ["TGEV PUR46", "TEST", 73, 83], ["MAD", "TEST", 84, 87]]], ["After 1 h of infection, virus suspension was removed and 1 ml WME per well was added.", [["infection", "DISEASE", 13, 22], ["WME", "CHEMICAL", 62, 65], ["infection", "PROBLEM", 13, 22], ["virus suspension", "TREATMENT", 24, 40], ["infection", "OBSERVATION", 13, 22]]], ["Infected PCIS as well as uninfected controls were incubated in a carbogen gassed incubator for 9 h, 12 h, 16 h and 24 h.ATP determination ::: MethodsATP sonification solution was produced as described before (de Graaf et al., 2010).", [["PCIS", "ANATOMY", 9, 13], ["carbogen", "CHEMICAL", 65, 73], ["carbogen", "CHEMICAL", 65, 73], ["PCIS", "CANCER", 9, 13], ["controls", "ORGANISM", 36, 44], ["carbogen", "SIMPLE_CHEMICAL", 65, 73], ["MethodsATP", "SIMPLE_CHEMICAL", 142, 152], ["Infected PCIS", "TREATMENT", 0, 13], ["a carbogen gassed incubator", "TREATMENT", 63, 90], ["MethodsATP sonification solution", "TREATMENT", 142, 174], ["PCIS", "OBSERVATION", 9, 13]]], ["Uninfected slices for ATP determination were collected at 0 h, 3 h, 9 h, 12 h, 16 h and 24 h post infection.", [["slices", "ANATOMY", 11, 17], ["ATP", "CHEMICAL", 22, 25], ["infection", "DISEASE", 98, 107], ["ATP", "CHEMICAL", 22, 25], ["slices", "MULTI-TISSUE_STRUCTURE", 11, 17], ["ATP", "SIMPLE_CHEMICAL", 22, 25], ["ATP determination", "TEST", 22, 39], ["infection", "PROBLEM", 98, 107], ["infection", "OBSERVATION", 98, 107]]], ["Samples in the sonification solution were immediately frosted in liquid nitrogen and stored at \u221280 \u00b0C for later analysis.", [["Samples", "ANATOMY", 0, 7], ["nitrogen", "CHEMICAL", 72, 80], ["the sonification solution", "TREATMENT", 11, 36], ["liquid nitrogen", "TREATMENT", 65, 80], ["later analysis", "TEST", 106, 120]]], ["For evaluation of ATP, an ATP Bioluminescence Assay Kit CLS II (Roche) was used.", [["ATP", "CHEMICAL", 18, 21], ["ATP", "CHEMICAL", 26, 29], ["ATP", "CHEMICAL", 18, 21], ["ATP", "CHEMICAL", 26, 29], ["ATP", "SIMPLE_CHEMICAL", 18, 21], ["ATP", "SIMPLE_CHEMICAL", 26, 29], ["evaluation", "TEST", 4, 14], ["ATP", "PROBLEM", 18, 21], ["an ATP Bioluminescence", "TEST", 23, 45]]], ["Samples were thawed slowly on ice and homogenized by a Polytron\u00ae PT 1200C sonifier (Kinematica AG).", [["Samples", "ANATOMY", 0, 7], ["Polytron\u00ae PT 1200C sonifier", "SPECIES", 55, 82], ["Samples", "TEST", 0, 7]]], ["After full homogenization of the PCIS, samples were centrifuged (Eppendorf) for 2 min at 13,000 rpm.", [["samples", "ANATOMY", 39, 46], ["the PCIS", "TREATMENT", 29, 37]]], ["Further analysis was done according to the manufacturer\u2018s instruction for ATP determination from biological material.Histology and immunohistochemistry ::: MethodsHistology and immunohistochemistry were performed as described previously (Horst et al., 2015).", [["ATP", "CHEMICAL", 74, 77], ["ATP", "CHEMICAL", 74, 77], ["ATP", "SIMPLE_CHEMICAL", 74, 77], ["Further analysis", "TEST", 0, 16], ["ATP determination", "TEST", 74, 91], ["immunohistochemistry", "TEST", 177, 197]]], ["A monoclonal mouse anti-coronavirus-antibody (FIPV3-70; Invitrogen, Thermo Fischer Scientific) was used for the detection of the nucleocapsid protein (N protein).", [["mouse", "ORGANISM", 13, 18], ["Invitrogen", "ORGANISM", 56, 66], ["nucleocapsid protein", "GENE_OR_GENE_PRODUCT", 129, 149], ["monoclonal mouse anti-coronavirus-antibody", "PROTEIN", 2, 44], ["FIPV3", "PROTEIN", 46, 51], ["nucleocapsid protein", "PROTEIN", 129, 149], ["N protein", "PROTEIN", 151, 160], ["mouse", "SPECIES", 13, 18], ["mouse", "SPECIES", 13, 18], ["A monoclonal mouse anti-coronavirus", "TEST", 0, 35], ["FIPV3", "TEST", 46, 51], ["the nucleocapsid protein", "TEST", 125, 149]]], ["In an immunofluorescence assay on infected ST cells the FIPV3-70 antibody cross-reacted with the N protein of the three TGEV strains used in this study (data not shown).", [["ST cells", "ANATOMY", 43, 51], ["ST cells", "CELL", 43, 51], ["FIPV3-70", "GENE_OR_GENE_PRODUCT", 56, 64], ["TGEV", "ORGANISM", 120, 124], ["infected ST cells", "CELL_TYPE", 34, 51], ["FIPV3-70 antibody", "PROTEIN", 56, 73], ["N protein", "PROTEIN", 97, 106], ["TGEV", "SPECIES", 120, 124], ["an immunofluorescence assay", "TEST", 3, 30], ["infected ST cells", "TEST", 34, 51], ["the FIPV3", "TEST", 52, 61], ["the N protein", "TEST", 93, 106], ["the three TGEV strains", "PROBLEM", 110, 132], ["this study", "TEST", 141, 151]]], ["Biotinylated goat\u2010anti-mouse IgG diluted 1:200 (Vector Laboratories, Burlingame, CA, USA) was used as a secondary antibody.", [["Biotinylated goat\u2010anti-mouse IgG", "PROTEIN", 0, 32], ["secondary antibody", "PROTEIN", 104, 122], ["Biotinylated goat\u2010anti-mouse IgG", "TEST", 0, 32], ["a secondary antibody", "PROBLEM", 102, 122]]], ["Slides were subsequently incubated with the peroxidase-conjugated avidin-biotin complex (ABC method, Vector Laboratories, Burlingame, CA, USA) for 30 min at RT.", [["biotin", "CHEMICAL", 73, 79], ["peroxidase", "GENE_OR_GENE_PRODUCT", 44, 54], ["avidin", "SIMPLE_CHEMICAL", 66, 72], ["biotin", "SIMPLE_CHEMICAL", 73, 79], ["peroxidase", "PROTEIN", 44, 54], ["biotin complex", "PROTEIN", 73, 87], ["the peroxidase", "TEST", 40, 54]]], ["After the positive antigen-antibody reaction visualization by incubation with 3.3-diaminobenzidine-tetrachloride (DAB) in 0.1 M imidazole, sections were counterstained with Mayer\u2019s hematoxylin.ResultsPorcine PCIS were successfully established and TGEV infection was visible in two of the three tested virus strains.", [["sections", "ANATOMY", 139, 147], ["3.3-diaminobenzidine-tetrachloride", "CHEMICAL", 78, 112], ["DAB", "CHEMICAL", 114, 117], ["imidazole", "CHEMICAL", 128, 137], ["TGEV infection", "DISEASE", 247, 261], ["3.3-diaminobenzidine-tetrachloride", "CHEMICAL", 78, 112], ["DAB", "CHEMICAL", 114, 117], ["imidazole", "CHEMICAL", 128, 137], ["hematoxylin", "CHEMICAL", 181, 192], ["3.3-diaminobenzidine-tetrachloride", "SIMPLE_CHEMICAL", 78, 112], ["DAB", "SIMPLE_CHEMICAL", 114, 117], ["0.1 M imidazole", "SIMPLE_CHEMICAL", 122, 137], ["sections", "MULTI-TISSUE_STRUCTURE", 139, 147], ["hematoxylin", "SIMPLE_CHEMICAL", 181, 192], ["TGEV", "ORGANISM", 247, 251], ["TGEV", "SPECIES", 247, 251], ["the positive antigen", "TEST", 6, 26], ["incubation", "TEST", 62, 72], ["diaminobenzidine-tetrachloride (DAB)", "TREATMENT", 82, 118], ["imidazole", "TREATMENT", 128, 137], ["ResultsPorcine PCIS", "TREATMENT", 193, 212], ["TGEV infection", "PROBLEM", 247, 261], ["TGEV", "OBSERVATION_MODIFIER", 247, 251], ["infection", "OBSERVATION", 252, 261]]], ["First, PCIS were tested for their integrity for up to 6 h, but no TGEV infected cells were visible (data not shown).", [["cells", "ANATOMY", 80, 85], ["PCIS", "CANCER", 7, 11], ["TGEV", "ORGANISM", 66, 70], ["cells", "CELL", 80, 85], ["TGEV infected cells", "CELL_TYPE", 66, 85], ["TGEV", "SPECIES", 66, 70], ["PCIS", "TREATMENT", 7, 11], ["TGEV infected cells", "PROBLEM", 66, 85], ["no", "UNCERTAINTY", 63, 65], ["infected cells", "OBSERVATION", 71, 85]]], ["To further check for complete epithelial layers of the jejunum conventional HE staining was performed (Fig. 2A, B).", [["epithelial layers", "ANATOMY", 30, 47], ["jejunum", "ANATOMY", 55, 62], ["epithelial layers", "TISSUE", 30, 47], ["jejunum", "MULTI-TISSUE_STRUCTURE", 55, 62], ["B", "GENE_OR_GENE_PRODUCT", 112, 113], ["epithelial", "ANATOMY_MODIFIER", 30, 40], ["layers", "ANATOMY_MODIFIER", 41, 47], ["jejunum", "ANATOMY", 55, 62]]], ["The epithelial cell layer was complete up to 24 h.", [["epithelial cell layer", "ANATOMY", 4, 25], ["epithelial cell layer", "TISSUE", 4, 25], ["epithelial cell", "OBSERVATION", 4, 19], ["layer", "OBSERVATION_MODIFIER", 20, 25]]], ["PCIS have an ellipse shape where the villi always pull over to the outside because of the muscularis mucosae.", [["villi", "ANATOMY", 37, 42], ["muscularis mucosae", "ANATOMY", 90, 108], ["villi", "MULTI-TISSUE_STRUCTURE", 37, 42], ["muscularis mucosae", "MULTI-TISSUE_STRUCTURE", 90, 108], ["PCIS", "TREATMENT", 0, 4], ["ellipse", "OBSERVATION_MODIFIER", 13, 20], ["shape", "OBSERVATION_MODIFIER", 21, 26], ["villi", "ANATOMY", 37, 42], ["muscularis mucosae", "ANATOMY", 90, 108]]], ["For vitality ATP concentration of the slices was measured by relative luminescence units (RLU).", [["slices", "ANATOMY", 38, 44], ["ATP", "CHEMICAL", 13, 16], ["ATP", "CHEMICAL", 13, 16], ["ATP", "SIMPLE_CHEMICAL", 13, 16], ["vitality ATP concentration", "TEST", 4, 30], ["the slices", "TEST", 34, 44]]], ["To compare the values we used ATP tenfold dilutions starting at 16500 \u03bcM.", [["ATP", "CHEMICAL", 30, 33], ["ATP", "CHEMICAL", 30, 33], ["ATP", "SIMPLE_CHEMICAL", 30, 33], ["ATP tenfold dilutions", "TREATMENT", 30, 51]]], ["Directly after PCIS production the highest value of ca 0.63 \u03bcM ATP was measured.", [["ATP", "CHEMICAL", 63, 66], ["ATP", "CHEMICAL", 63, 66], ["ATP", "SIMPLE_CHEMICAL", 63, 66], ["PCIS production", "TEST", 15, 30], ["ca", "TEST", 52, 54], ["ATP", "TEST", 63, 66]]], ["Further time points at 3, 9, 12, 16, and 24 h showed lower ATP values (Fig. 3).", [["ATP", "CHEMICAL", 59, 62], ["ATP", "CHEMICAL", 59, 62], ["ATP", "SIMPLE_CHEMICAL", 59, 62], ["lower ATP values", "TEST", 53, 69]]], ["However, statistical analysis showed no significant differences in ATP of 3 h and 9 h slices compared to the first time point.", [["ATP", "CHEMICAL", 67, 70], ["ATP", "CHEMICAL", 67, 70], ["ATP", "SIMPLE_CHEMICAL", 67, 70], ["statistical analysis", "TEST", 9, 29], ["ATP", "TEST", 67, 70], ["no", "UNCERTAINTY", 37, 39], ["significant", "OBSERVATION_MODIFIER", 40, 51]]], ["After 12 h and 16 h the ATP measurement showed significant differences compared to the start of PCIS incubation (Fig. 3).", [["ATP", "CHEMICAL", 24, 27], ["PCIS", "CHEMICAL", 96, 100], ["ATP", "CHEMICAL", 24, 27], ["ATP", "SIMPLE_CHEMICAL", 24, 27], ["the ATP measurement", "TEST", 20, 39], ["significant differences", "PROBLEM", 47, 70], ["PCIS incubation", "TREATMENT", 96, 111], ["significant", "OBSERVATION_MODIFIER", 47, 58]]], ["The 16 h and 24 h ATP, was the lowest measured with 0.018 \u03bcM and 0.013 \u03bcM.", [["ATP", "CHEMICAL", 18, 21], ["ATP", "CHEMICAL", 18, 21], ["ATP", "SIMPLE_CHEMICAL", 18, 21], ["ATP", "TEST", 18, 21]]], ["ATP concentration of the PCIS after several hours in culture is reduced slightly, and showed low levels after more than 16 h.ResultsThe three tested strains of TGEV showed differences in their ability to infect the PCIS.", [["ATP", "CHEMICAL", 0, 3], ["PCIS", "CHEMICAL", 25, 29], ["PCIS", "DISEASE", 215, 219], ["ATP", "CHEMICAL", 0, 3], ["ATP", "SIMPLE_CHEMICAL", 0, 3], ["TGEV", "ORGANISM", 160, 164], ["PCIS", "CANCER", 215, 219], ["TGEV", "SPECIES", 160, 164], ["the PCIS", "TREATMENT", 21, 29], ["culture", "TEST", 53, 60], ["low levels", "PROBLEM", 93, 103], ["TGEV", "PROBLEM", 160, 164], ["low levels", "OBSERVATION_MODIFIER", 93, 103], ["PCIS", "OBSERVATION", 215, 219]]], ["Generally, HE staining could not show any differences in the structure of the PCIS or their villi post infection compared to uninfected controls.", [["PCIS", "ANATOMY", 78, 82], ["villi", "ANATOMY", 92, 97], ["infection", "DISEASE", 103, 112], ["PCIS", "GENE_OR_GENE_PRODUCT", 78, 82], ["villi", "MULTI-TISSUE_STRUCTURE", 92, 97], ["their villi post infection", "PROBLEM", 86, 112], ["PCIS", "ANATOMY", 78, 82], ["villi", "ANATOMY", 92, 97], ["infection", "OBSERVATION", 103, 112]]], ["The different time points and TGEV strains were further analyzed by antibody staining for their N protein in the epithelial cell layer of jejunal villi.", [["epithelial cell layer", "ANATOMY", 113, 134], ["jejunal villi", "ANATOMY", 138, 151], ["TGEV", "ORGANISM", 30, 34], ["epithelial cell layer", "TISSUE", 113, 134], ["jejunal villi", "TISSUE", 138, 151], ["N protein", "PROTEIN", 96, 105], ["TGEV", "SPECIES", 30, 34], ["TGEV strains", "PROBLEM", 30, 42], ["antibody staining", "TEST", 68, 85], ["their N protein", "TEST", 90, 105], ["epithelial cell", "OBSERVATION", 113, 128], ["layer", "ANATOMY_MODIFIER", 129, 134], ["jejunal villi", "ANATOMY", 138, 151]]], ["The infection with TGEV GFP, the recombinant TGEV strain, was tested for 6, 9, 12, 16, and 24 h post infection (Table 1).", [["infection", "DISEASE", 4, 13], ["infection", "DISEASE", 101, 110], ["TGEV", "ORGANISM", 19, 23], ["GFP", "GENE_OR_GENE_PRODUCT", 24, 27], ["TGEV", "ORGANISM", 45, 49], ["TGEV GFP", "PROTEIN", 19, 27], ["TGEV", "SPECIES", 19, 23], ["TGEV", "SPECIES", 45, 49], ["The infection", "PROBLEM", 0, 13], ["TGEV GFP", "PROBLEM", 19, 27], ["the recombinant TGEV strain", "PROBLEM", 29, 56], ["infection", "PROBLEM", 101, 110], ["infection", "OBSERVATION", 4, 13], ["TGEV GFP", "OBSERVATION", 19, 27], ["infection", "OBSERVATION", 101, 110]]], ["Except of the first timepoint, immunohistochemistry of PCIS showed viral N protein at all time points tested; in contrast to non-infected control slices (Fig. 2G\u2013J, Table 1).", [["slices", "ANATOMY", 146, 152], ["PCIS", "CANCER", 55, 59], ["PCIS", "PROTEIN", 55, 59], ["viral N protein", "PROTEIN", 67, 82], ["PCIS", "TEST", 55, 59], ["viral N protein", "PROBLEM", 67, 82]]], ["Viral antigen of TGEV MIL65 was also detectable in PCIS at 12, 16 and 24 h p.i., but not after 9 h of infection (Fig. 2 O-R, Table 1).", [["infection", "DISEASE", 102, 111], ["TGEV", "ORGANISM", 17, 21], ["MIL65", "GENE_OR_GENE_PRODUCT", 22, 27], ["PCIS", "PATHOLOGICAL_FORMATION", 51, 55], ["Viral antigen", "PROTEIN", 0, 13], ["TGEV MIL65", "PROTEIN", 17, 27], ["TGEV", "SPECIES", 17, 21], ["TGEV", "SPECIES", 17, 21], ["Viral antigen", "TEST", 0, 13], ["TGEV MIL65", "TEST", 17, 27], ["PCIS", "TEST", 51, 55], ["infection", "PROBLEM", 102, 111], ["infection", "OBSERVATION", 102, 111]]], ["Finally, TGEV PUR46-MAD was not able to infect PCIS at any time point analyzed (Fig. 2C, D, Table 1).", [["PCIS", "ANATOMY", 47, 51], ["PCIS", "DISEASE", 47, 51], ["TGEV", "ORGANISM", 9, 13], ["PUR46", "GENE_OR_GENE_PRODUCT", 14, 19], ["PCIS", "CANCER", 47, 51], ["PUR46", "PROTEIN", 14, 19], ["MAD", "PROTEIN", 20, 23], ["TGEV", "SPECIES", 9, 13], ["TGEV PUR46-MAD", "TREATMENT", 9, 23], ["PCIS", "TREATMENT", 47, 51]]], ["This demonstrates a high strain dependency of intestinal infection that can be visualized in porcine jejunal PCIS.DiscussionIntestinal slices have been established for rodents like rat and mouse as well as for human intestine (de Graaf et al., 2010).", [["intestinal", "ANATOMY", 46, 56], ["jejunal PCIS", "ANATOMY", 101, 113], ["Intestinal slices", "ANATOMY", 124, 141], ["intestine", "ANATOMY", 216, 225], ["intestinal infection", "DISEASE", 46, 66], ["intestinal", "ORGAN", 46, 56], ["porcine", "ORGANISM", 93, 100], ["jejunal PCIS", "CANCER", 101, 113], ["Intestinal slices", "MULTI-TISSUE_STRUCTURE", 124, 141], ["rat", "ORGANISM", 181, 184], ["mouse", "ORGANISM", 189, 194], ["human", "ORGANISM", 210, 215], ["intestine", "ORGAN", 216, 225], ["rat", "SPECIES", 181, 184], ["mouse", "SPECIES", 189, 194], ["human", "SPECIES", 210, 215], ["porcine", "SPECIES", 93, 100], ["rat", "SPECIES", 181, 184], ["mouse", "SPECIES", 189, 194], ["human", "SPECIES", 210, 215], ["a high strain dependency", "PROBLEM", 18, 42], ["intestinal infection", "PROBLEM", 46, 66], ["porcine jejunal PCIS", "TREATMENT", 93, 113], ["Intestinal slices", "TREATMENT", 124, 141], ["high strain", "OBSERVATION_MODIFIER", 20, 31], ["dependency", "OBSERVATION_MODIFIER", 32, 42], ["intestinal", "ANATOMY", 46, 56], ["infection", "OBSERVATION", 57, 66], ["jejunal PCIS", "OBSERVATION", 101, 113], ["intestine", "ANATOMY", 216, 225]]], ["We were able to produce intestinal tissue slices that are from porcine origin by following the protocol for human PCIS described by de Graaf et al. This method gives new impact on studying not only viral infections in porcine intestine but also other research fields like pharmacological or toxicological matters.", [["intestinal tissue slices", "ANATOMY", 24, 48], ["intestine", "ANATOMY", 226, 235], ["infections", "DISEASE", 204, 214], ["intestinal tissue slices", "TISSUE", 24, 48], ["porcine", "ORGANISM", 63, 70], ["human", "ORGANISM", 108, 113], ["PCIS", "CANCER", 114, 118], ["porcine", "ORGANISM", 218, 225], ["intestine", "ORGAN", 226, 235], ["human", "SPECIES", 108, 113], ["human", "SPECIES", 108, 113], ["porcine", "SPECIES", 218, 225], ["intestinal tissue slices", "TREATMENT", 24, 48], ["human PCIS", "TREATMENT", 108, 118], ["viral infections in porcine intestine", "PROBLEM", 198, 235], ["intestinal tissue", "ANATOMY", 24, 41], ["infections", "OBSERVATION", 204, 214], ["intestine", "ANATOMY", 226, 235]]], ["As de Graaf et al. described, it is the best way to use non-solid organs like the intestine by embedding them in agarose to form solid-like structures (de Graaf et al., 2010).", [["non-solid organs", "ANATOMY", 56, 72], ["intestine", "ANATOMY", 82, 91], ["organs", "ORGAN", 66, 72], ["intestine", "ORGAN", 82, 91], ["agarose", "SIMPLE_CHEMICAL", 113, 120], ["intestine", "ANATOMY", 82, 91]]], ["The surrounding agarose protects the PCIS from handling and cutting procedures and allows a reproducible cutting process with consistent thickness of the PCIS.", [["agarose", "SIMPLE_CHEMICAL", 16, 23], ["the PCIS", "TREATMENT", 33, 41], ["cutting procedures", "TREATMENT", 60, 78], ["a reproducible cutting process", "PROBLEM", 90, 120], ["the PCIS", "TREATMENT", 150, 158], ["agarose", "OBSERVATION_MODIFIER", 16, 23], ["PCIS", "OBSERVATION", 37, 41], ["PCIS", "OBSERVATION", 154, 158]]], ["Adjusting the level of agarose from 3% to 6% showed to be the best concentration for the production of porcine PCIS.", [["agarose", "SIMPLE_CHEMICAL", 23, 30], ["porcine", "ORGANISM", 103, 110], ["PCIS", "CANCER", 111, 115], ["porcine", "SPECIES", 103, 110], ["porcine", "SPECIES", 103, 110], ["agarose", "TEST", 23, 30], ["porcine PCIS", "TREATMENT", 103, 115], ["porcine PCIS", "OBSERVATION", 103, 115]]], ["Manipulation of the incubator by inserting a flexible tube to adjust the carbogen level inside the chamber revealed the best possible condition for the slices.", [["slices", "ANATOMY", 152, 158], ["carbogen", "CHEMICAL", 73, 81], ["carbogen", "CHEMICAL", 73, 81], ["tube", "TISSUE", 54, 58], ["carbogen", "SIMPLE_CHEMICAL", 73, 81], ["the incubator", "TREATMENT", 16, 29], ["a flexible tube", "TREATMENT", 43, 58], ["the carbogen level", "TEST", 69, 87], ["the slices", "TEST", 148, 158]]], ["However, the gas influx also caused temperature issues for the PCIS.", [["the gas influx", "PROBLEM", 9, 23], ["temperature issues", "PROBLEM", 36, 54], ["the PCIS", "TREATMENT", 59, 67], ["gas influx", "OBSERVATION", 13, 23]]], ["This can be prevented by storing gassed medium in an incubator one hour before usage or generally light gas influx in big chambers that do not cause any temperature change.", [["any temperature change", "PROBLEM", 149, 171]]], ["Gas washing bottles filled with 37 \u00b0C distilled water do also prevent cooling down of samples as well as a dry atmosphere for the samples (de Graaf et al., 2010).", [["samples", "ANATOMY", 86, 93], ["Gas washing bottles", "TREATMENT", 0, 19], ["37 \u00b0C distilled water", "TREATMENT", 32, 53]]], ["Best results were obtained by reducing the carbogen influx to a minimum level, while starting it before samples were set in the incubator.", [["samples", "ANATOMY", 104, 111], ["carbogen", "CHEMICAL", 43, 51], ["carbogen", "CHEMICAL", 43, 51], ["carbogen", "SIMPLE_CHEMICAL", 43, 51], ["the carbogen influx", "TREATMENT", 39, 58]]], ["The survival time of porcine PCIS may be improved by the use of incubators with automated oxygenation.", [["porcine", "ORGANISM", 21, 28], ["porcine", "SPECIES", 21, 28], ["porcine PCIS", "TREATMENT", 21, 33], ["automated oxygenation", "TEST", 80, 101]]], ["Additionally the culture medium might be optimized by supplemental compounds leading to longer vitality of PCIS.DiscussionATP concentration showed a reduction of ATP level throughout time.", [["PCIS", "DISEASE", 107, 111], ["DiscussionATP", "CHEMICAL", 112, 125], ["ATP", "CHEMICAL", 162, 165], ["ATP", "CHEMICAL", 162, 165], ["DiscussionATP", "SIMPLE_CHEMICAL", 112, 125], ["ATP", "SIMPLE_CHEMICAL", 162, 165], ["the culture medium", "TEST", 13, 31], ["PCIS", "TREATMENT", 107, 111], ["a reduction of ATP level", "TREATMENT", 147, 171], ["reduction", "OBSERVATION_MODIFIER", 149, 158], ["ATP level", "OBSERVATION", 162, 171]]], ["However, the level also revealed a high concentration of ATP compared to their thickness of ca 250 \u03bcm and weight lower than 0.01 mg.", [["ATP", "CHEMICAL", 57, 60], ["ATP", "CHEMICAL", 57, 60], ["ATP", "SIMPLE_CHEMICAL", 57, 60], ["a high concentration of ATP", "PROBLEM", 33, 60], ["ca", "TEST", 92, 94], ["weight", "TEST", 106, 112], ["high", "OBSERVATION_MODIFIER", 35, 39], ["concentration", "OBSERVATION_MODIFIER", 40, 53]]], ["Irrespective of the fact that the weight of individual PCIS could not be measured, the ATP level showed that PCIS are vital tissue samples.", [["tissue samples", "ANATOMY", 124, 138], ["ATP", "CHEMICAL", 87, 90], ["ATP", "CHEMICAL", 87, 90], ["PCIS", "CANCER", 55, 59], ["ATP", "SIMPLE_CHEMICAL", 87, 90], ["tissue samples", "TISSUE", 124, 138], ["individual PCIS", "PROBLEM", 44, 59], ["the ATP level", "TEST", 83, 96], ["PCIS", "TREATMENT", 109, 113], ["vital tissue samples", "TEST", 118, 138]]], ["This is also in conformance to studies measuring ATP level from human intestinal slices of 2 nmol mg\u22121 after 24 h incubation (de Graaf et al., 2010).", [["intestinal slices", "ANATOMY", 70, 87], ["ATP", "CHEMICAL", 49, 52], ["ATP", "CHEMICAL", 49, 52], ["ATP", "SIMPLE_CHEMICAL", 49, 52], ["human", "ORGANISM", 64, 69], ["intestinal slices", "MULTI-TISSUE_STRUCTURE", 70, 87], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 64, 69], ["studies", "TEST", 31, 38], ["ATP level", "TEST", 49, 58], ["human intestinal slices", "TEST", 64, 87], ["intestinal", "ANATOMY", 70, 80]]], ["Furthermore, ATP levels seem to stagnate after more than 16 h.", [["ATP", "CHEMICAL", 13, 16], ["ATP", "CHEMICAL", 13, 16], ["ATP", "SIMPLE_CHEMICAL", 13, 16], ["ATP levels", "TEST", 13, 23]]], ["Supported are these findings by the HE staining showing intact epithelial layers of the PCIS after 24 h in culture, but also after virus infection.", [["epithelial layers", "ANATOMY", 63, 80], ["PCIS", "ANATOMY", 88, 92], ["infection", "DISEASE", 137, 146], ["epithelial layers", "TISSUE", 63, 80], ["the HE staining", "TEST", 32, 47], ["the PCIS", "TREATMENT", 84, 92], ["culture", "TEST", 107, 114], ["virus infection", "PROBLEM", 131, 146], ["epithelial layers", "OBSERVATION_MODIFIER", 63, 80], ["PCIS", "ANATOMY", 88, 92], ["infection", "OBSERVATION", 137, 146]]], ["Ultimately, 16 h and 24 h showed a high level of infected cells by antibody staining, which proved again that PCIS contained viable cells.DiscussionViruses need time to be able to replicate in the cell.", [["cells", "ANATOMY", 58, 63], ["cells", "ANATOMY", 132, 137], ["cell", "ANATOMY", 197, 201], ["cells", "CELL", 58, 63], ["PCIS", "SIMPLE_CHEMICAL", 110, 114], ["cells", "CELL", 132, 137], ["cell", "CELL", 197, 201], ["infected cells", "CELL_TYPE", 49, 63], ["PCIS", "PROTEIN", 110, 114], ["a high level of infected cells", "PROBLEM", 33, 63], ["antibody staining", "TEST", 67, 84], ["PCIS", "TREATMENT", 110, 114], ["infected cells", "OBSERVATION", 49, 63], ["antibody staining", "OBSERVATION", 67, 84], ["viable cells", "OBSERVATION", 125, 137]]], ["In the case of TGEV more than 6 h are necessary to synthesize new viral proteins inside the cells.", [["cells", "ANATOMY", 92, 97], ["TGEV", "ORGANISM", 15, 19], ["cells", "CELL", 92, 97], ["viral proteins", "PROTEIN", 66, 80], ["TGEV", "SPECIES", 15, 19], ["TGEV", "PROBLEM", 15, 19], ["new viral proteins inside the cells", "PROBLEM", 62, 97], ["cells", "ANATOMY", 92, 97]]], ["This demonstrates that a long life span of the PCIS is crucial for infection studies.", [["infection", "DISEASE", 67, 76], ["the PCIS", "TREATMENT", 43, 51], ["infection studies", "PROBLEM", 67, 84], ["PCIS", "OBSERVATION", 47, 51], ["crucial for", "UNCERTAINTY", 55, 66], ["infection", "OBSERVATION", 67, 76]]], ["The precision cut intestinal slices showed an intact epithelial cell layer of the jejunum up to 24 h in our experiments and are therefore suitable for infection studies with TGEV.DiscussionThere were obvious differences between the TGEV strains tested in our study.", [["intestinal slices", "ANATOMY", 18, 35], ["epithelial cell layer", "ANATOMY", 53, 74], ["jejunum", "ANATOMY", 82, 89], ["infection", "DISEASE", 151, 160], ["intestinal slices", "MULTI-TISSUE_STRUCTURE", 18, 35], ["epithelial cell layer", "TISSUE", 53, 74], ["jejunum", "ORGAN", 82, 89], ["TGEV", "ORGANISM", 174, 178], ["TGEV", "ORGANISM", 232, 236], ["TGEV", "SPECIES", 174, 178], ["TGEV", "SPECIES", 232, 236], ["The precision cut intestinal slices", "TEST", 0, 35], ["infection studies", "TEST", 151, 168], ["TGEV", "PROBLEM", 174, 178], ["the TGEV strains", "PROBLEM", 228, 244], ["our study", "TEST", 255, 264], ["intestinal", "ANATOMY", 18, 28], ["intact", "OBSERVATION", 46, 52], ["epithelial cell layer", "OBSERVATION", 53, 74], ["jejunum", "ANATOMY", 82, 89], ["24 h", "OBSERVATION_MODIFIER", 96, 100], ["infection", "OBSERVATION", 151, 160]]], ["TGEV PUR46-MAD was not able to infect the PCIS, which can be explained either by the loss of enterotropism due to cell culture adaptation of this strain or by the possibility that this virus needs a longer time for PCIS infection.", [["PCIS", "ANATOMY", 42, 46], ["cell", "ANATOMY", 114, 118], ["PCIS", "DISEASE", 42, 46], ["enterotropism", "DISEASE", 93, 106], ["infection", "DISEASE", 220, 229], ["TGEV", "ORGANISM", 0, 4], ["PUR46", "GENE_OR_GENE_PRODUCT", 5, 10], ["PCIS", "CANCER", 42, 46], ["cell", "CELL", 114, 118], ["PUR46", "PROTEIN", 5, 10], ["MAD", "PROTEIN", 11, 14], ["TGEV", "SPECIES", 0, 4], ["the loss of enterotropism", "PROBLEM", 81, 106], ["cell culture adaptation", "TREATMENT", 114, 137], ["this strain", "PROBLEM", 141, 152], ["this virus", "PROBLEM", 180, 190], ["PCIS infection", "PROBLEM", 215, 229], ["infection", "OBSERVATION", 220, 229]]], ["In the end the S protein seems to be the determinant not only for cell fusion and plaque morphology (Almazan et al., 2000), but also for jejunal tissue infection.", [["cell", "ANATOMY", 66, 70], ["plaque", "ANATOMY", 82, 88], ["jejunal tissue", "ANATOMY", 137, 151], ["jejunal tissue infection", "DISEASE", 137, 161], ["cell", "CELL", 66, 70], ["plaque", "PATHOLOGICAL_FORMATION", 82, 88], ["jejunal tissue", "TISSUE", 137, 151], ["S protein", "PROTEIN", 15, 24], ["cell fusion", "TREATMENT", 66, 77], ["jejunal tissue infection", "PROBLEM", 137, 161], ["plaque", "OBSERVATION", 82, 88], ["jejunal tissue", "ANATOMY", 137, 151], ["infection", "OBSERVATION", 152, 161]]], ["The TGEV PUR-MAD provided the genome for TGEV-GFP except the gene encoding for the S protein, and did not show any clinical signs by porcine infection (Almazan et al., 2000).", [["porcine infection", "DISEASE", 133, 150], ["TGEV", "ORGANISM", 4, 8], ["PUR", "GENE_OR_GENE_PRODUCT", 9, 12], ["TGEV", "ORGANISM", 41, 45], ["GFP", "GENE_OR_GENE_PRODUCT", 46, 49], ["porcine", "ORGANISM", 133, 140], ["TGEV PUR", "DNA", 4, 12], ["MAD", "DNA", 13, 16], ["TGEV-GFP", "DNA", 41, 49], ["S protein", "PROTEIN", 83, 92], ["TGEV", "SPECIES", 4, 8], ["TGEV", "SPECIES", 41, 45], ["The TGEV PUR", "TEST", 0, 12], ["TGEV", "PROBLEM", 41, 45], ["the S protein", "TEST", 79, 92], ["porcine infection", "PROBLEM", 133, 150]]], ["Almazan et al. compared viral replication of PUR46-MAD with PUR46-C11 and the recombinant TGEV strain rPUR46-MAD-SC11.", [["PUR46-MAD", "GENE_OR_GENE_PRODUCT", 45, 54], ["PUR46-C11", "GENE_OR_GENE_PRODUCT", 60, 69], ["TGEV", "ORGANISM", 90, 94], ["PUR46", "PROTEIN", 45, 50], ["MAD", "PROTEIN", 51, 54], ["PUR46", "PROTEIN", 60, 65], ["recombinant TGEV strain rPUR46-MAD-SC11", "DNA", 78, 117], ["TGEV", "SPECIES", 90, 94], ["TGEV", "SPECIES", 90, 94], ["PUR46", "TEST", 45, 50], ["PUR46", "TEST", 60, 65]]], ["TGEV PUR46-MAD replicated to a low extent in the jejunum of infected piglets (<103 PFU/g jejunum) compared to PUR46-C11 and the recombinant TGEV (>106 PFU/g jejunum).", [["jejunum", "ANATOMY", 49, 56], ["piglets", "ANATOMY", 69, 76], ["jejunum", "ANATOMY", 89, 96], ["jejunum", "ANATOMY", 157, 164], ["PUR46-C11", "CHEMICAL", 110, 119], ["TGEV", "ORGANISM", 0, 4], ["PUR46", "GENE_OR_GENE_PRODUCT", 5, 10], ["jejunum", "ORGAN", 49, 56], ["piglets", "ORGANISM", 69, 76], ["jejunum", "ORGAN", 89, 96], ["PUR46-C11", "CELL", 110, 119], ["TGEV", "ORGANISM", 140, 144], ["jejunum", "MULTI-TISSUE_STRUCTURE", 157, 164], ["TGEV PUR46", "PROTEIN", 0, 10], ["MAD", "PROTEIN", 11, 14], ["TGEV", "SPECIES", 0, 4], ["piglets", "SPECIES", 69, 76], ["TGEV", "SPECIES", 0, 4], ["TGEV", "SPECIES", 140, 144], ["TGEV PUR46-MAD", "TREATMENT", 0, 14], ["PUR46", "TEST", 110, 115], ["the recombinant TGEV", "TREATMENT", 124, 144], ["low extent", "OBSERVATION_MODIFIER", 31, 41], ["jejunum", "ANATOMY", 49, 56], ["infected piglets", "OBSERVATION", 60, 76], ["jejunum", "ANATOMY", 89, 96], ["jejunum", "ANATOMY", 157, 164]]], ["Furthermore, the recombinant TGEV PUR46-MAD-SC11 led to 100% mortality in infected piglets 3 days after inoculation whereas TGEV PUR46-MAD caused no mortality in piglets.", [["PUR46-MAD-SC11", "CHEMICAL", 34, 48], ["TGEV PUR46-MAD", "CHEMICAL", 124, 138], ["TGEV", "ORGANISM", 29, 33], ["PUR46", "GENE_OR_GENE_PRODUCT", 34, 39], ["piglets", "ORGANISM", 83, 90], ["TGEV", "ORGANISM", 124, 128], ["piglets", "ORGANISM", 162, 169], ["recombinant TGEV PUR46-MAD-SC11", "DNA", 17, 48], ["piglets", "SPECIES", 83, 90], ["piglets", "SPECIES", 162, 169], ["TGEV", "SPECIES", 29, 33], ["TGEV", "SPECIES", 124, 128], ["the recombinant TGEV", "TREATMENT", 13, 33], ["inoculation", "PROBLEM", 104, 115], ["mortality in piglets", "PROBLEM", 149, 169]]], ["The recombinant TGEV GFP strain used in our study showed the most revealing infection of the PCIS, which is in correlation of the designed strain that was described as being suitable for tissue specific expression systems (Almazan et al., 2000).", [["tissue", "ANATOMY", 187, 193], ["infection", "DISEASE", 76, 85], ["TGEV", "ORGANISM", 16, 20], ["GFP", "GENE_OR_GENE_PRODUCT", 21, 24], ["PCIS", "PATHOLOGICAL_FORMATION", 93, 97], ["tissue", "TISSUE", 187, 193], ["TGEV", "SPECIES", 16, 20], ["TGEV", "SPECIES", 16, 20], ["The recombinant TGEV GFP strain", "PROBLEM", 0, 31], ["our study", "TEST", 40, 49], ["infection of the PCIS", "PROBLEM", 76, 97], ["the designed strain", "PROBLEM", 126, 145], ["infection", "OBSERVATION", 76, 85], ["PCIS", "OBSERVATION", 93, 97]]], ["The dependence of infection on the S protein has already been proven (Almazan et al., 2000).", [["infection", "DISEASE", 18, 27], ["S protein", "PROTEIN", 35, 44], ["infection", "PROBLEM", 18, 27], ["the S protein", "TEST", 31, 44], ["dependence", "OBSERVATION_MODIFIER", 4, 14], ["infection", "OBSERVATION", 18, 27]]], ["This is in accordance with our studies showing a high infection rate of the PCIS by TGEV GFP compared to TGEV PUR-MAD.", [["infection", "DISEASE", 54, 63], ["PCIS", "DISEASE", 76, 80], ["PCIS", "CANCER", 76, 80], ["TGEV", "ORGANISM", 84, 88], ["GFP", "GENE_OR_GENE_PRODUCT", 89, 92], ["TGEV", "ORGANISM", 105, 109], ["PUR-MAD", "GENE_OR_GENE_PRODUCT", 110, 117], ["TGEV GFP", "PROTEIN", 84, 92], ["TGEV", "SPECIES", 84, 88], ["TGEV", "SPECIES", 105, 109], ["our studies", "TEST", 27, 38], ["a high infection rate", "PROBLEM", 47, 68], ["the PCIS", "TREATMENT", 72, 80], ["TGEV GFP", "TEST", 84, 92], ["high", "OBSERVATION_MODIFIER", 49, 53], ["infection", "OBSERVATION", 54, 63]]], ["The TGEV Miller strain (MIL65) is a virulent strain passaged in piglets (see Materials and Methods).", [["TGEV Miller strain", "ORGANISM", 4, 22], ["MIL65", "ORGANISM", 24, 29], ["piglets", "ORGANISM", 64, 71], ["piglets", "SPECIES", 64, 71], ["TGEV Miller strain", "SPECIES", 4, 22], ["The TGEV Miller strain", "PROBLEM", 0, 22], ["a virulent strain", "PROBLEM", 34, 51], ["Miller strain", "OBSERVATION", 9, 22]]], ["Animals infected with this virus showed inappetence, depression, and diarrhea (Bohl et al., 1972).", [["inappetence", "DISEASE", 40, 51], ["depression", "DISEASE", 53, 63], ["diarrhea", "DISEASE", 69, 77], ["Animals", "ORGANISM", 0, 7], ["this virus", "PROBLEM", 22, 32], ["inappetence", "PROBLEM", 40, 51], ["depression", "PROBLEM", 53, 63], ["diarrhea", "PROBLEM", 69, 77], ["infected", "OBSERVATION", 8, 16], ["inappetence", "OBSERVATION", 40, 51], ["depression", "OBSERVATION", 53, 63]]], ["The Miller strain mildly infected the PCIS.", [["PCIS", "DISEASE", 38, 42], ["PCIS", "CANCER", 38, 42], ["The Miller strain mildly infected the PCIS", "PROBLEM", 0, 42], ["Miller", "OBSERVATION_MODIFIER", 4, 10], ["strain", "OBSERVATION_MODIFIER", 11, 17], ["mildly", "OBSERVATION_MODIFIER", 18, 24], ["infected", "OBSERVATION", 25, 33], ["PCIS", "OBSERVATION", 38, 42]]], ["This reduced infection can be explained by a reduction of enteropathogenicity due to the last 6 cell culture passages that were performed in our lab.", [["cell", "ANATOMY", 96, 100], ["infection", "DISEASE", 13, 22], ["cell", "CELL", 96, 100], ["This reduced infection", "PROBLEM", 0, 22], ["a reduction of enteropathogenicity", "PROBLEM", 43, 77], ["the last 6 cell culture passages", "PROBLEM", 85, 117], ["reduced", "OBSERVATION_MODIFIER", 5, 12], ["infection", "OBSERVATION", 13, 22], ["reduction", "OBSERVATION_MODIFIER", 45, 54]]], ["Nevertheless MIL65 can still replicate in the intestine (see Fig. 2).", [["intestine", "ANATOMY", 46, 55], ["MIL65", "GENE_OR_GENE_PRODUCT", 13, 18], ["intestine", "ORGAN", 46, 55], ["MIL65", "PROTEIN", 13, 18], ["intestine", "ANATOMY", 46, 55]]], ["In conclusion, by infection of PCIS it is possible to mimic jejunum infection with enteropathogenic coronaviruses.DiscussionIn general, TGEV may lose its enteropathogenicity depending on the number of cell culture passages irrespective of the strain origin (Bohl et al., 1972).", [["jejunum", "ANATOMY", 60, 67], ["cell", "ANATOMY", 201, 205], ["infection", "DISEASE", 18, 27], ["PCIS", "DISEASE", 31, 35], ["jejunum infection", "DISEASE", 60, 77], ["enteropathogenic coronaviruses", "DISEASE", 83, 113], ["PCIS", "CANCER", 31, 35], ["jejunum", "ORGAN", 60, 67], ["enteropathogenic coronaviruses", "ORGANISM", 83, 113], ["TGEV", "ORGANISM", 136, 140], ["cell", "CELL", 201, 205], ["TGEV", "SPECIES", 136, 140], ["PCIS", "TREATMENT", 31, 35], ["jejunum infection", "PROBLEM", 60, 77], ["enteropathogenic coronaviruses", "PROBLEM", 83, 113], ["its enteropathogenicity", "PROBLEM", 150, 173], ["cell culture", "TEST", 201, 213], ["infection", "OBSERVATION", 18, 27], ["PCIS", "OBSERVATION", 31, 35], ["possible to", "UNCERTAINTY", 42, 53], ["jejunum", "ANATOMY", 60, 67], ["infection", "OBSERVATION", 68, 77], ["enteropathogenic coronaviruses", "OBSERVATION", 83, 113]]], ["For the tested TGEV strains it was possible to reflect the enteropathogenicity of these strains in the PCIS system.ConclusionThe relatively long life-time of the jejunal slices makes them a good model and tool to analyze a variety of enteropathogens also in PCIS of other species and may help to reduce animal experiments.", [["jejunal slices", "ANATOMY", 162, 176], ["TGEV", "ORGANISM", 15, 19], ["jejunal slices", "MULTI-TISSUE_STRUCTURE", 162, 176], ["TGEV", "SPECIES", 15, 19], ["the tested TGEV strains", "PROBLEM", 4, 27], ["these strains in the PCIS system", "PROBLEM", 82, 114], ["the jejunal slices", "TREATMENT", 158, 176], ["enteropathogens", "PROBLEM", 234, 249], ["strains", "OBSERVATION", 88, 95], ["PCIS", "ANATOMY", 103, 107], ["jejunal", "ANATOMY", 162, 169]]], ["Moreover, the important role of the S protein for enterotropism was confirmed with this helpful ex vivo infection model.", [["infection", "DISEASE", 104, 113], ["S protein", "PROTEIN", 36, 45], ["the S protein", "TREATMENT", 32, 45], ["enterotropism", "TREATMENT", 50, 63], ["this helpful ex vivo infection model", "TREATMENT", 83, 119], ["infection", "OBSERVATION", 104, 113]]], ["Therefore, the PCIS system can be a useful tool not only to analyze virus entry and enterotropism but also to monitor new isolated viruses for their enteropathogenicity without the need of an in vivo study.", [["the PCIS system", "TREATMENT", 11, 26], ["enterotropism", "PROBLEM", 84, 97], ["new isolated viruses", "PROBLEM", 118, 138], ["their enteropathogenicity", "PROBLEM", 143, 168], ["an in vivo study", "TEST", 189, 205], ["viruses", "OBSERVATION", 131, 138]]]], "PMC7107195": [["INTRODUCTIONIn recent years, increasing requirements regarding animal welfare (AW) in broiler production have led to the development of production systems that comply with above-legal AW standards (Blokhuis et al., 2003; Fraser, 2006).", [["production systems", "PROBLEM", 136, 154]]], ["Furthermore, productivity and profitability might be negatively affected if higher production costs do not increase economic returns (McInerney, 2004).INTRODUCTIONAlthough livestock diseases occur in broiler farms regardless of which production system is used, the likelihood and the effect of livestock diseases can differ depending on the production system.", [["livestock diseases", "DISEASE", 172, 190], ["livestock diseases", "DISEASE", 294, 312], ["livestock diseases", "PROBLEM", 172, 190], ["livestock diseases", "PROBLEM", 294, 312]]], ["However, the possible effect of AW-friendly production systems on animal health is not clear.", [["AW", "CHEMICAL", 32, 34], ["AW", "SIMPLE_CHEMICAL", 32, 34], ["possible", "UNCERTAINTY", 13, 21], ["clear", "OBSERVATION", 87, 92]]], ["Lister and Van Nijhuis (2012) suggested that the prevalence of coccidiosis or other parasitic infections was higher in systems in which chickens had access to an outdoor area, such as free-range or organic systems.", [["coccidiosis", "DISEASE", 63, 74], ["parasitic infections", "DISEASE", 84, 104], ["chickens", "ORGANISM", 136, 144], ["chickens", "SPECIES", 136, 144], ["chickens", "SPECIES", 136, 144], ["coccidiosis", "PROBLEM", 63, 74], ["other parasitic infections", "PROBLEM", 78, 104], ["coccidiosis", "OBSERVATION", 63, 74], ["parasitic", "OBSERVATION_MODIFIER", 84, 93], ["infections", "OBSERVATION", 94, 104]]], ["Also, broiler chickens in organic systems showed an increased prevalence of Campylobacter compared with chickens in conventional systems.", [["Campylobacter", "CHEMICAL", 76, 89], ["chickens", "ORGANISM", 14, 22], ["chickens", "ORGANISM", 104, 112], ["chickens", "SPECIES", 14, 22], ["chickens", "SPECIES", 104, 112], ["chickens", "SPECIES", 14, 22], ["chickens", "SPECIES", 104, 112], ["broiler chickens in organic systems", "PROBLEM", 6, 41], ["Campylobacter", "PROBLEM", 76, 89], ["broiler chickens", "OBSERVATION", 6, 22], ["increased", "OBSERVATION_MODIFIER", 52, 61], ["Campylobacter", "OBSERVATION", 76, 89]]], ["Cui et al. (2005) found that organic chickens were more frequently contaminated with Campylobacter and Salmonella.", [["chickens", "ORGANISM", 37, 45], ["chickens", "SPECIES", 37, 45], ["chickens", "SPECIES", 37, 45], ["organic chickens", "PROBLEM", 29, 45], ["Campylobacter", "PROBLEM", 85, 98], ["Salmonella", "PROBLEM", 103, 113], ["organic chickens", "OBSERVATION", 29, 45], ["Campylobacter", "OBSERVATION", 85, 98], ["Salmonella", "OBSERVATION", 103, 113]]], ["In contrast, Van Overbeke et al. (2006) found no significant difference in the prevalence of Salmonella between broiler chickens kept in organic and those kept in conventional systems.INTRODUCTIONWith respect to the possible effect of AW-friendly production systems on animal health, a distinction must be made between prevalence (that is, the likelihood of introduction) and effect.", [["AW", "CHEMICAL", 235, 237], ["chickens", "ORGANISM", 120, 128], ["chickens", "SPECIES", 120, 128], ["Salmonella", "SPECIES", 93, 103], ["chickens", "SPECIES", 120, 128], ["Salmonella", "PROBLEM", 93, 103], ["broiler chickens", "TREATMENT", 112, 128], ["no", "UNCERTAINTY", 46, 48], ["significant", "OBSERVATION_MODIFIER", 49, 60], ["difference", "OBSERVATION_MODIFIER", 61, 71], ["Salmonella", "OBSERVATION", 93, 103]]], ["Increased disease prevalence and a greater effect of a disease both result in increased health care costs.", [["Increased disease prevalence", "PROBLEM", 0, 28], ["a disease", "PROBLEM", 53, 62], ["disease", "OBSERVATION", 10, 17], ["greater effect", "OBSERVATION_MODIFIER", 35, 49], ["disease", "OBSERVATION", 55, 62], ["increased", "OBSERVATION_MODIFIER", 78, 87]]], ["Health care costs include all economic effects of a disease and are the sum of 2 components: losses and expenditures (McInerney, 1996).", [["a disease", "PROBLEM", 50, 59], ["disease", "OBSERVATION", 52, 59]]], ["Losses can be caused, for example, by mortality, morbidity, reduced production efficiency, and lower meat yield and quality, which results in reduced returns.", [["meat", "ANATOMY", 101, 105], ["Losses", "DISEASE", 0, 6], ["meat", "ORGANISM_SUBDIVISION", 101, 105], ["morbidity", "PROBLEM", 49, 58], ["reduced production efficiency", "PROBLEM", 60, 89], ["reduced", "OBSERVATION_MODIFIER", 142, 149]]], ["Extra expenditures are mainly the costs of veterinary prophylactic and therapeutic treatments to prevent or treat a disease (McInerney et al., 1992; Bennett, 2003; Houe, 2003; Bennett and Ijpelaar, 2005).INTRODUCTIONThe aim of this study was to analyze the effects of different production systems on health care costs.", [["Extra expenditures", "PROBLEM", 0, 18], ["veterinary prophylactic", "TREATMENT", 43, 66], ["therapeutic treatments", "TREATMENT", 71, 93], ["a disease", "PROBLEM", 114, 123], ["this study", "TEST", 227, 237]]], ["First, we investigated whether higher AW standards increased health care costs in both absolute and relative terms.", [["increased", "OBSERVATION_MODIFIER", 51, 60]]], ["This study was restricted to the most important endemic diseases.", [["This study", "TEST", 0, 10], ["endemic", "OBSERVATION_MODIFIER", 48, 55], ["diseases", "OBSERVATION", 56, 64]]], ["Epidemic diseases, such as avian influenza, were not included because they occur only rarely and the differentiation between conventional, free-range, and organic was less relevant.Broiler Production in the Netherlands ::: MATERIALS AND METHODSDutch legislation defining standards of broiler production is based on the European Union guidelines (EC, 2007a,b, 2008).", [["Epidemic diseases", "DISEASE", 0, 17], ["avian influenza", "DISEASE", 27, 42], ["avian influenza", "SPECIES", 27, 42], ["Epidemic diseases", "PROBLEM", 0, 17], ["avian influenza", "PROBLEM", 27, 42], ["METHODSDutch legislation", "TREATMENT", 237, 261]]], ["In the Netherlands, several so-called AW concepts, such as private labels, have been developed in recent years setting higher requirements for production in terms of AW compared with the minimum standards of conventional broiler production.", [["broiler", "ORGANISM_SUBDIVISION", 221, 228], ["conventional broiler production", "TREATMENT", 208, 239]]], ["The Better Life hallmark initiated by the Dutch Society for the Protection of Animals (Dierenbescherming) enables a transparent differentiation among animal products in terms of AW.", [["Animals (Dierenbescherming)", "TREATMENT", 78, 105], ["a transparent differentiation", "TREATMENT", 114, 143]]], ["Products that can be produced under different concepts are labeled with a distinctive Better Life logo if they comply with the requirements of this hallmark.", [["Products", "TREATMENT", 0, 8]]], ["This concept has the same requirements as in the Volwaard concept, except that a lower stocking density is required (25 kg per m2).", [["a lower stocking density", "PROBLEM", 79, 103], ["lower stocking", "OBSERVATION_MODIFIER", 81, 95], ["density", "OBSERVATION", 96, 103]]], ["The organic standards of SKAL are different from the European Union standards for organic production, but the European Union standards should eventually be implemented in all European Union countries, which means that the European Union standards for organic production are included in the study as well.Endemic Diseases Included in the Study ::: MATERIALS AND METHODSThe study was limited to the most important endemic diseases because it was not possible to include all poultry diseases that can occur on a broiler farm.", [["poultry diseases", "DISEASE", 472, 488], ["SKAL", "SIMPLE_CHEMICAL", 25, 29], ["organic production", "PROBLEM", 82, 100], ["organic production", "PROBLEM", 251, 269], ["the study", "TEST", 286, 295], ["Endemic Diseases", "PROBLEM", 304, 320], ["the Study", "TEST", 333, 342], ["METHODSThe study", "TEST", 361, 377], ["endemic diseases", "PROBLEM", 412, 428], ["all poultry diseases", "PROBLEM", 468, 488], ["Diseases", "OBSERVATION", 312, 320]]], ["The selection of diseases was mainly based on Bergevoet et al. (2010), who identified the most important diseases and disorders in a broiler farm in the Netherlands by scoring them on several aspects, such as epidemiology and business economics.", [["diseases", "PROBLEM", 17, 25], ["disorders", "PROBLEM", 118, 127], ["diseases", "OBSERVATION", 17, 25]]], ["In this way, infectious bronchitis (IB), coccidiosis, Escherichia coli, and necrotic enteritis (NE) were included in this study, along with infectious bursal disease (IBD), sudden death syndrome (SDS), ascites, and leg problems (European Commission, 2000; De Jong et al., 2012).", [["bursal", "ANATOMY", 151, 157], ["ascites", "ANATOMY", 202, 209], ["leg", "ANATOMY", 215, 218], ["infectious bronchitis (IB)", "DISEASE", 13, 39], ["coccidiosis", "DISEASE", 41, 52], ["Escherichia coli", "DISEASE", 54, 70], ["necrotic enteritis", "DISEASE", 76, 94], ["NE", "CHEMICAL", 96, 98], ["infectious bursal disease", "DISEASE", 140, 165], ["IBD", "DISEASE", 167, 170], ["sudden death", "DISEASE", 173, 185], ["SDS", "DISEASE", 196, 199], ["ascites", "DISEASE", 202, 209], ["Escherichia coli", "ORGANISM", 54, 70], ["bursal", "ORGAN", 151, 157], ["leg", "ORGANISM_SUBDIVISION", 215, 218], ["Escherichia coli", "SPECIES", 54, 70], ["Escherichia coli", "SPECIES", 54, 70], ["infectious bronchitis (IB)", "PROBLEM", 13, 39], ["coccidiosis", "PROBLEM", 41, 52], ["Escherichia coli", "PROBLEM", 54, 70], ["necrotic enteritis", "PROBLEM", 76, 94], ["this study", "TEST", 117, 127], ["infectious bursal disease", "PROBLEM", 140, 165], ["IBD)", "PROBLEM", 167, 171], ["sudden death syndrome", "PROBLEM", 173, 194], ["SDS)", "PROBLEM", 196, 200], ["ascites", "PROBLEM", 202, 209], ["leg problems", "PROBLEM", 215, 227], ["infectious", "OBSERVATION_MODIFIER", 13, 23], ["bronchitis", "OBSERVATION", 24, 34], ["coccidiosis", "OBSERVATION", 41, 52], ["Escherichia coli", "OBSERVATION", 54, 70], ["necrotic", "OBSERVATION_MODIFIER", 76, 84], ["enteritis", "OBSERVATION", 85, 94], ["infectious", "OBSERVATION_MODIFIER", 140, 150], ["sudden", "OBSERVATION_MODIFIER", 173, 179], ["death syndrome", "OBSERVATION", 180, 194], ["ascites", "OBSERVATION", 202, 209], ["leg", "ANATOMY", 215, 218]]], ["Enterococcus, which had a relatively high score in terms of epidemiological and business economics aspects, had to be excluded because little is known about its spread and pathogens (Bergevoet et al., 2010).", [["Enterococcus", "CHEMICAL", 0, 12], ["Enterococcus", "PROBLEM", 0, 12], ["relatively", "OBSERVATION_MODIFIER", 26, 36], ["high score", "OBSERVATION_MODIFIER", 37, 47]]], ["Diseases for which vaccinations are obligatory in the Netherlands, such as Newcastle disease, were excluded from the study (GD, 2012).", [["Newcastle disease", "DISEASE", 75, 92], ["Diseases", "PROBLEM", 0, 8], ["vaccinations", "TREATMENT", 19, 31], ["Newcastle disease", "PROBLEM", 75, 92], ["the study", "TEST", 113, 122]]], ["The selected diseases were considered to be the most prevalent diseases in the broiler farms; they were economically relevant and could be distinguished between systems (Ruff, 1999; European Commission, 2000; Bennett and Ijpelaar, 2005; Rushton, 2009; Bergevoet et al., 2010; De Jong et al., 2012).", [["The selected diseases", "PROBLEM", 0, 21], ["diseases", "OBSERVATION", 13, 21]]], ["Because the prevalence and severity of diseases of a particular organ system can differ depending on housing conditions, the 8 selected diseases were categorized into 5 groups according to organ system: diseases concerning the respiratory system (IB), the organs of immune system (IBD), the gastrointestinal tract (coccidiosis, E. coli, and NE), the locomotion system (leg problems), and the heart and vascular system (ascites and SDS; Table 2).", [["organ system", "ANATOMY", 64, 76], ["organ system", "ANATOMY", 189, 201], ["respiratory system", "ANATOMY", 227, 245], ["organs", "ANATOMY", 256, 262], ["immune system", "ANATOMY", 266, 279], ["gastrointestinal tract", "ANATOMY", 291, 313], ["leg", "ANATOMY", 369, 372], ["heart", "ANATOMY", 392, 397], ["vascular system", "ANATOMY", 402, 417], ["ascites", "ANATOMY", 419, 426], ["gastrointestinal tract", "DISEASE", 291, 313], ["coccidiosis", "DISEASE", 315, 326], ["ascites", "DISEASE", 419, 426], ["organ", "ORGAN", 64, 69], ["organ", "ORGAN", 189, 194], ["organs", "ORGAN", 256, 262], ["immune system", "ANATOMICAL_SYSTEM", 266, 279], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 291, 313], ["E. coli", "ORGANISM", 328, 335], ["leg", "ORGANISM_SUBDIVISION", 369, 372], ["heart", "ORGAN", 392, 397], ["vascular system", "MULTI-TISSUE_STRUCTURE", 402, 417], ["E. coli", "SPECIES", 328, 335], ["E. coli", "SPECIES", 328, 335], ["diseases", "PROBLEM", 39, 47], ["a particular organ system", "PROBLEM", 51, 76], ["the 8 selected diseases", "PROBLEM", 121, 144], ["diseases", "PROBLEM", 203, 211], ["the respiratory system", "PROBLEM", 223, 245], ["immune system", "PROBLEM", 266, 279], ["IBD", "PROBLEM", 281, 284], ["the gastrointestinal tract", "PROBLEM", 287, 313], ["coccidiosis", "PROBLEM", 315, 326], ["E. coli", "PROBLEM", 328, 335], ["the locomotion system (leg problems), and the heart and vascular system", "PROBLEM", 346, 417], ["ascites", "PROBLEM", 419, 426], ["diseases", "OBSERVATION", 39, 47], ["diseases", "OBSERVATION", 203, 211], ["respiratory system", "ANATOMY", 227, 245], ["gastrointestinal tract", "ANATOMY", 291, 313], ["coccidiosis", "OBSERVATION", 315, 326], ["leg", "ANATOMY", 369, 372], ["heart", "ANATOMY", 392, 397], ["vascular system", "ANATOMY", 402, 417], ["ascites", "OBSERVATION", 419, 426]]], ["The final selection was discussed with an expert from the Dutch Animal Health Service who specializes in poultry diseases (J. J. de Wit, Dutch Animal Health Service, Deventer, the Netherlands, personal communication).Definition of Health Care Costs ::: MATERIALS AND METHODS", [["poultry diseases", "DISEASE", 105, 121]]]], "0b752e988093bde18dd6217a515c67b099f01f45": [["IntroductionWe studied diarrhoea in newborn calves (the major cause of neonatal mortality) (Sivula et al., 1996a; Wells et al., 1996; Bendali et al., 1999b) .", [["diarrhoea", "DISEASE", 23, 32], ["calves", "ORGANISM", 44, 50], ["calves", "SPECIES", 44, 50], ["diarrhoea in newborn calves", "PROBLEM", 23, 50], ["diarrhoea", "OBSERVATION", 23, 32]]], ["Calves are at the greatest risk of diarrhoea during the first week of life, and this risk decreases with age (Vallet et al., 1985; www.elsevier.com/locate/prevetmed Preventive Veterinary Medicine 68 (2005) 91-102 Waltner-Toews et al., 1986) .", [["diarrhoea", "DISEASE", 35, 44], ["Calves", "ORGANISM", 0, 6], ["Calves", "SPECIES", 0, 6], ["diarrhoea", "PROBLEM", 35, 44], ["greatest", "OBSERVATION_MODIFIER", 18, 26], ["diarrhoea", "OBSERVATION", 35, 44]]], ["The incidence risks of diarrhoea in calves <30 days old reported by several studies varies between 15 and 20%.", [["diarrhoea", "DISEASE", 23, 32], ["calves", "ORGANISM", 36, 42], ["calves", "SPECIES", 36, 42], ["diarrhoea in calves", "PROBLEM", 23, 42], ["several studies", "TEST", 68, 83], ["diarrhoea", "OBSERVATION", 23, 32]]], ["The mortality risk is 1.5-8% (Clement et al., 1995; Quigley et al., 1995) .IntroductionIn the Midi-Pyr\u00e9n\u00e9es region (France), 80% of herds and 20% of neonatal calves are affected by diarrhoea; the case-fatality risk is 50% (Bichet, 1995) .IntroductionBecause of the large number of etiological agents (Escherichia coli, rotavirus, coronavirus and cryptosporidium), the prevention of neonatal diarrhoea in beef calves is difficult-but should be centred around management factors.IntroductionTwo groups of factors involved in gastrointestinal disease are included in the statistical analysis: factors at the herd level (e.g. herd size, calf housing) and factors at the calf level (e.g. calving conditions, colostrum-feeding management, navel treatment).", [["gastrointestinal", "ANATOMY", 523, 539], ["diarrhoea", "DISEASE", 181, 190], ["Escherichia coli, rotavirus, coronavirus and cryptosporidium", "DISEASE", 301, 361], ["diarrhoea", "DISEASE", 391, 400], ["gastrointestinal disease", "DISEASE", 523, 547], ["calves", "ORGANISM", 158, 164], ["Escherichia coli", "ORGANISM", 301, 317], ["rotavirus", "ORGANISM", 319, 328], ["coronavirus", "ORGANISM", 330, 341], ["calves", "ORGANISM_SUBDIVISION", 409, 415], ["gastrointestinal", "ORGAN", 523, 539], ["herd", "ORGANISM_SUBDIVISION", 622, 626], ["calf", "ORGANISM_SUBDIVISION", 633, 637], ["calf", "ORGANISM_SUBDIVISION", 666, 670], ["colostrum", "ORGANISM_SUBDIVISION", 703, 712], ["navel", "ORGANISM_SUBDIVISION", 733, 738], ["calves", "SPECIES", 158, 164], ["Escherichia coli", "SPECIES", 301, 317], ["coronavirus", "SPECIES", 330, 341], ["beef", "SPECIES", 404, 408], ["calves", "SPECIES", 409, 415], ["calf", "SPECIES", 633, 637], ["calf", "SPECIES", 666, 670], ["Escherichia coli", "SPECIES", 301, 317], ["beef", "SPECIES", 404, 408], ["The mortality risk", "TEST", 0, 18], ["herds", "TEST", 132, 137], ["diarrhoea", "PROBLEM", 181, 190], ["etiological agents", "TREATMENT", 281, 299], ["Escherichia coli", "PROBLEM", 301, 317], ["rotavirus", "PROBLEM", 319, 328], ["coronavirus", "PROBLEM", 330, 341], ["cryptosporidium", "PROBLEM", 346, 361], ["neonatal diarrhoea in beef calves", "PROBLEM", 382, 415], ["gastrointestinal disease", "PROBLEM", 523, 547], ["colostrum", "TREATMENT", 703, 712], ["feeding management", "TREATMENT", 713, 731], ["navel treatment", "TREATMENT", 733, 748], ["neonatal calves", "ANATOMY", 149, 164], ["diarrhoea", "OBSERVATION", 181, 190], ["large", "OBSERVATION_MODIFIER", 265, 270], ["neonatal", "OBSERVATION_MODIFIER", 382, 390], ["diarrhoea", "OBSERVATION", 391, 400], ["gastrointestinal", "ANATOMY", 523, 539], ["disease", "OBSERVATION", 540, 547], ["calf", "ANATOMY", 633, 637], ["calf", "ANATOMY", 666, 670]]], ["Our study is a continuation of a previous investigation conducted by Bendali et al. (1999b) on a large randomly selected sample of beef calves.IntroductionThere has been considerable recent interest in the regression modelling of survival data, which has led to two broad classes of models: marginal and frailty models.", [["calves", "ORGANISM", 136, 142], ["beef", "SPECIES", 131, 135], ["calves", "SPECIES", 136, 142], ["beef", "SPECIES", 131, 135], ["Our study", "TEST", 0, 9], ["a previous investigation", "TEST", 31, 55], ["a large randomly selected sample of beef calves", "TREATMENT", 95, 142], ["survival data", "TEST", 230, 243], ["marginal and frailty models", "PROBLEM", 291, 318], ["large", "OBSERVATION_MODIFIER", 97, 102], ["beef calves", "OBSERVATION", 131, 142], ["considerable", "OBSERVATION_MODIFIER", 170, 182], ["marginal", "OBSERVATION_MODIFIER", 291, 299], ["frailty models", "OBSERVATION", 304, 318]]], ["With the marginal approach (Wei et al., 1989 ), a survival model is specified for each subject of the cluster along with assumptions about the dependence of survival times within clusters.", [["a survival model", "TREATMENT", 48, 64], ["marginal", "OBSERVATION_MODIFIER", 9, 17]]], ["The frailty commonly is used to indicate unobserved (i.e. ''latent'') cluster-specific variables.", [["unobserved (i.e. ''latent'') cluster-specific variables", "PROBLEM", 41, 96]]], ["Furthermore, independence among observed data items is assumed conditional on the frailty.IntroductionIn interpretation of the results, the main difference between these two approaches is the meaning of the regression coefficients.", [["frailty", "DISEASE", 82, 89], ["main", "OBSERVATION_MODIFIER", 140, 144]]], ["In the marginal approach, the regression coefficients have a population-averaged interpretation-whereas in the frailty model, a cluster-specific response is modeled.IntroductionIn addition to the previous study, based on a marginal approach, we used a frailty Cox model to determine factors associated with time to neonatal diarrhoea in French beef calves.The Cox model for survival dataDescriptive and analytical statistics were performed using S-PLUS # (MathSoft et al., 1999) .", [["diarrhoea", "DISEASE", 324, 333], ["calves", "ORGANISM", 349, 355], ["beef", "SPECIES", 344, 348], ["calves", "SPECIES", 349, 355], ["beef", "SPECIES", 344, 348], ["the previous study", "TEST", 192, 210], ["a frailty Cox model", "TREATMENT", 250, 269], ["neonatal diarrhoea", "PROBLEM", 315, 333], ["analytical statistics", "TEST", 403, 424], ["marginal", "OBSERVATION_MODIFIER", 7, 15], ["population", "OBSERVATION_MODIFIER", 61, 71], ["diarrhoea", "OBSERVATION", 324, 333]]], ["The analysis was based on Cox's proportional-hazards model (Cox, 1972) .The Cox model for survival dataIn the semi-parametric Cox's regression model, the hazard function related to the j th subject (j \u00bc 1; . . . ; m) of the i th herd (i \u00bc 1; . . . ; n) was:The Cox model for survival data(1)The Cox model for survival datawhere t is the observed age (days) when diarrhoea occurred (or censoring time), h 0 \u00f0t\u00de an unknown non-parametric baseline hazard function (which acts like a mean hazard for the whole population), Z ij the vector of observed covariates and b the corresponding transposed vector of the regression coefficients.", [["diarrhoea", "DISEASE", 362, 371], ["The analysis", "TEST", 0, 12], ["Cox's proportional", "TEST", 26, 44], ["the hazard function", "PROBLEM", 150, 169], ["The Cox model", "TEST", 257, 270], ["survival data", "TEST", 275, 288], ["diarrhoea", "PROBLEM", 362, 371], ["Z ij the vector", "TREATMENT", 519, 534]]], ["Then, exp \u00f0b\u00de was the estimated vector of relative risks (RRs), sometimes called ''hazard risks' ' (HRs) .", [["exp \u00f0b\u00de", "GENE_OR_GENE_PRODUCT", 6, 13], ["exp \u00f0b\u00de", "DNA", 6, 13]]], ["The estimation is done by maximizing the Cox's partial likelihood.", [["The estimation", "TEST", 0, 14]]], ["Although observations generally are correlated within the same unit, the estimatorb is consistent for b (Wei et al., 1989) .", [["consistent for", "UNCERTAINTY", 87, 101]]], ["Unfortunately, the usual variance-covariance estimator is not valid.The Cox model for survival dataWe paid attention to the two types of Cox's models, which were able to take into account a possible dependence among the components.The Cox model for survival dataFirst, we used a marginal Cox's model (MCM).", [["The Cox model", "TREATMENT", 68, 81], ["survival dataWe", "TREATMENT", 86, 101], ["Cox's models", "TREATMENT", 137, 149], ["a marginal Cox's model (MCM", "TREATMENT", 277, 304]]], ["To take correlation into account, it is possible to correct the variance estimate through the estimation function (Wei et al., 1989) , as in the case of generalized estimating equations (Liang et al., 1992) .", [["generalized estimating equations", "PROBLEM", 153, 185]]], ["The new variance estimator is similar to the sandwich estimator (Binder, 1983) .", [["new", "OBSERVATION_MODIFIER", 4, 7]]], ["The regression coefficient, which remains the same as in the naive (i.e. without correlation taken into account) model, is interpreted as a ''population-average'' coefficient.", [["regression", "OBSERVATION_MODIFIER", 4, 14], ["coefficient", "OBSERVATION_MODIFIER", 15, 26]]], ["However, we may not extend the conclusions from this analysis to another herd.The Cox model for survival dataSecondly, we used a frailty Cox's model (FCM) to formulate the instantaneous risk as (Vaupel et al., 1979) :The Cox model for survival datawhere Q i is a random variable corresponding to the i th herd effect, which increases failure risk (and is consequently named ''frailty''). b is said to be ''cluster-specific'', i.e. its interpretation is conditional on the fact that a subject belongs to a particular herd.", [["this analysis", "TEST", 48, 61], ["a frailty Cox's model", "TREATMENT", 127, 148], ["failure risk", "PROBLEM", 334, 346]]], ["The distribution of Q i usually is chosen to be either gamma, normal or positive stable distributions (Hougaard, 1986 (Hougaard, , 1995 , because of the positivity of these distributions.", [["distribution", "OBSERVATION_MODIFIER", 4, 16], ["normal", "OBSERVATION", 62, 68], ["positive", "OBSERVATION_MODIFIER", 72, 80], ["stable", "OBSERVATION_MODIFIER", 81, 87], ["distributions", "OBSERVATION_MODIFIER", 88, 101]]], ["The frailty term allows both modelling of the intra-cluster correlation and generalization of the results from the sampled beef herds to the population of beef herds.ComputationAll the fits were performed with the S-PLUS coxph procedure: the MCM required the cluster option, whereas for the FCM, we specified the frailty option.", [["beef", "SPECIES", 155, 159], ["beef", "SPECIES", 123, 127], ["beef", "SPECIES", 155, 159], ["the S-PLUS coxph procedure", "TREATMENT", 210, 236], ["the cluster option", "TREATMENT", 255, 273], ["the FCM", "TEST", 287, 294], ["the frailty option", "TREATMENT", 309, 327]]], ["The risk-factor analysis was done using a backward-elimination method in four steps.", [["The risk-factor analysis", "TEST", 0, 24], ["a backward-elimination method", "TREATMENT", 40, 69]]], ["Initially, all variables taken individually with the incidence of diarrhoea were offered in a naive univariable Cox's regression model.", [["diarrhoea", "DISEASE", 66, 75], ["diarrhoea", "PROBLEM", 66, 75]]], ["Then, any variable with P 0:2 was eligible for the next step in a multivariable model.", [["P 0:2", "DNA", 24, 29]]], ["This grouping procedure took into account potential confounding factors and the inter-relationships between variables of the same class.", [["This grouping procedure", "TREATMENT", 0, 23], ["potential confounding factors", "PROBLEM", 42, 71]]], ["In the third step, two final multivariable models were fitted with all the variables that had remained significant during the two previous steps: the first one was a MCM and the second one was a gamma FCM.", [["a gamma FCM", "TEST", 193, 204], ["significant", "OBSERVATION", 103, 114], ["gamma FCM", "OBSERVATION", 195, 204]]], ["The fourth step consisted into a backward-elimination method for each of these two models.Data collection and target populationA prospective study on a random sample of 92 herds in the Midi-Pyr\u00e9n\u00e9es region was conducted in 8 departments of the southwest of France (Bendali et al., 1999a) .", [["a backward-elimination method", "TREATMENT", 31, 60], ["Data collection", "TEST", 90, 105], ["target populationA prospective study", "TEST", 110, 146], ["a random sample", "TEST", 150, 165]]], ["A simple random stratified sampling design was used to select herds for the study.", [["A simple random stratified sampling design", "TREATMENT", 0, 42], ["the study", "TEST", 72, 81], ["simple", "OBSERVATION_MODIFIER", 2, 8]]], ["The stratification was based on the department and adjusted for the number of farms in each department using a proportional sampling method.", [["a proportional sampling method", "TREATMENT", 109, 139]]], ["A random-number sampling algorithm was used to identify the herd to be enrolled in the study.", [["A random-number sampling algorithm", "TEST", 0, 34], ["the study", "TEST", 83, 92]]], ["The enumeration rule was that if a farm was selected, then all the farm's calves were enrolled in the study.Data collection and target populationThe sampling frame was the exhaustive listing of farms in that region.", [["calves", "ORGANISM", 74, 80], ["calves", "SPECIES", 74, 80], ["The enumeration rule", "TEST", 0, 20], ["the study", "TEST", 98, 107], ["Data collection", "TEST", 108, 123], ["The sampling frame", "TREATMENT", 145, 163]]], ["The inclusion criteria consisted of herds with >20 adult beef cows, at least three-quarters of calvings during the survey and the five most-important breeds of the region (Charolaise, Limousine, Gasconne, Aubrac, Blonde d'Aquitaine).", [["beef", "SPECIES", 57, 61], ["cows", "SPECIES", 62, 66], ["beef", "SPECIES", 57, 61], ["calvings", "TREATMENT", 95, 103], ["the survey", "TEST", 111, 121], ["Charolaise", "TREATMENT", 172, 182], ["Limousine", "TREATMENT", 184, 193], ["Gasconne", "TREATMENT", 195, 203], ["Aubrac", "TREATMENT", 205, 211]]], ["A total of 7000 herds was eligible and represented 30% of the total herds of that region.Data collection and target populationFrom 95 randomly selected beef herds in the Midi-Pyr\u00e9n\u00e9es, 92 were involved in this study and followed from December 1995 to April 1996.", [["Data collection", "TEST", 89, 104], ["target population", "TEST", 109, 126], ["this study", "TEST", 205, 215]]], ["During this period, 3157 calves were born in the 92 selected herds.", [["calves", "ORGANISM", 25, 31], ["calves", "SPECIES", 25, 31]]], ["Complete data were obtained from 96.5% (3047) of the calves in the study.", [["calves", "ORGANISM", 53, 59], ["calves", "SPECIES", 53, 59], ["Complete data", "TEST", 0, 13], ["the study", "TEST", 63, 72]]], ["The global incidence of diarrhoea was 14.4% and the mortality was 4.2%, but these incidences included marked variations between the herds, age of calves and month of birth (Bendali et al., 1999a) .Data managementThe cows were grouped according to their primiparous or multiparous status.", [["diarrhoea", "DISEASE", 24, 33], ["calves", "ORGANISM", 146, 152], ["cows", "ORGANISM", 216, 220], ["calves", "SPECIES", 146, 152], ["cows", "SPECIES", 216, 220], ["diarrhoea", "PROBLEM", 24, 33], ["the mortality", "TEST", 48, 61], ["marked variations", "PROBLEM", 102, 119], ["Data management", "TREATMENT", 197, 212], ["global", "OBSERVATION_MODIFIER", 4, 10], ["diarrhoea", "OBSERVATION", 24, 33], ["marked", "OBSERVATION_MODIFIER", 102, 108], ["variations", "OBSERVATION_MODIFIER", 109, 119]]], ["Some initially continuous variables were transformed into categorical data, in accordance with a supposed cut-off point or minimum level of information given in the literature.", [["categorical data", "TEST", 58, 74]]], ["The time of first colostrum (recorded in hours after birth) was grouped together for calves fed within the first 6 h of life and calves fed after 6 h (Fourichon et al., 1996; Hall et al., 1992) .", [["colostrum", "ANATOMY", 18, 27], ["colostrum", "ORGANISM_SUBSTANCE", 18, 27], ["calves", "ORGANISM", 85, 91], ["calves", "ORGANISM", 129, 135], ["calves", "SPECIES", 85, 91], ["calves", "SPECIES", 129, 135]]], ["Calf stocking density (the number of calves per available area) was considered sufficient when a calf had at least 1.6 or 1 m 2 in the tie stall or free stall, respectively (Vallet et al., 1985) .Data managementTo assess passive immunity and the effectiveness of colostrum feeding, calves were sampled for total protein in the serum.", [["Calf", "ANATOMY", 0, 4], ["colostrum", "ANATOMY", 263, 272], ["serum", "ANATOMY", 327, 332], ["Calf", "TISSUE", 0, 4], ["calves", "ORGANISM", 37, 43], ["calf", "ORGANISM_SUBDIVISION", 97, 101], ["colostrum", "ORGANISM", 263, 272], ["calves", "ORGANISM", 282, 288], ["serum", "ORGANISM_SUBSTANCE", 327, 332], ["calves", "SPECIES", 37, 43], ["calf", "SPECIES", 97, 101], ["calves", "SPECIES", 282, 288], ["calves", "SPECIES", 282, 288], ["Calf stocking density", "PROBLEM", 0, 21], ["Data management", "TREATMENT", 196, 211], ["passive immunity", "TREATMENT", 221, 237], ["colostrum feeding", "TREATMENT", 263, 280], ["total protein in the serum", "TEST", 306, 332], ["stocking", "OBSERVATION_MODIFIER", 5, 13], ["density", "OBSERVATION", 14, 21], ["calf", "ANATOMY", 97, 101]]], ["The minimum ''satisfactory'' level of this total protein concentration was 50 g/L (Perino et al., 1993; Rea et al., 1996) .Data managementThe ambient-weather variables (temperature, dampness) were recorded at the visit closest to the date of birth of each calf.", [["calf", "ORGANISM_SUBDIVISION", 256, 260], ["calf", "SPECIES", 256, 260], ["this total protein concentration", "TREATMENT", 38, 70], ["Data management", "TREATMENT", 123, 138], ["dampness", "PROBLEM", 182, 190], ["calf", "ANATOMY", 256, 260]]], ["We calculated a parameter which took into account external and internal temperatures and dampness simultaneously (Andrieu et al., 1985) ; this method allows a single efficient measurement of atmospheric conditions to be used for each calf in accordance with birth.Marginal versus frailty fits for the hazard risksCharacteristics of the study population and management practices are shown in Tables 1-3.", [["frailty fits", "DISEASE", 280, 292], ["calf", "ORGANISM_SUBDIVISION", 234, 238], ["calf", "SPECIES", 234, 238], ["external and internal temperatures", "PROBLEM", 50, 84], ["dampness", "PROBLEM", 89, 97], ["atmospheric conditions", "TREATMENT", 191, 213], ["Marginal versus frailty fits", "PROBLEM", 264, 292], ["the hazard risks", "PROBLEM", 297, 313], ["the study population", "TEST", 332, 352], ["management practices", "TREATMENT", 357, 377], ["dampness", "OBSERVATION", 89, 97], ["calf", "ANATOMY", 234, 238]]], ["No significant difference was observed between the parameters (HR and P value) estimated at the first and second steps of the analysis.", [["the parameters", "TEST", 47, 61], ["HR", "TEST", 63, 65], ["P value", "TEST", 70, 77], ["the analysis", "TEST", 122, 134], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["difference", "OBSERVATION", 15, 25]]], ["The univariable screening procedure identified more than 20 variables associated with diarrhoea (P < 0:2) in the neonatal period.", [["diarrhoea", "DISEASE", 86, 95], ["The univariable screening procedure", "TEST", 0, 35], ["diarrhoea", "PROBLEM", 86, 95]]], ["Among the variables the most positively associated with hazard of diarrhoea (Table 4) , were the dam vaccination against other agents, the presence of ammonia and the cleaning after calving season (1.54 and 1.45).Marginal versus frailty fits for the hazard risksThe variables associated with the lowest hazard in our study were the cleaning after each diarrhoea episode in calf barn and the feeding corn silage.Marginal versus frailty fits for the hazard risksThe ratio of the robust (marginal or frailty model) to the naive variances varied from 1.14 to 6.25.Marginal versus frailty fits for the hazard risksAmong the 11 variables which were significantly associated with time to diarrhoea in the MCM, only 1 became nonsignificant in the FCM: the presence of ammonia (P \u00bc 0:001 updated to 0.09).Marginal versus frailty fits for the hazard risksThe hazard of diarrhoea was higher in calves born in March than those born in December.", [["diarrhoea", "DISEASE", 66, 75], ["ammonia", "CHEMICAL", 151, 158], ["frailty fits", "DISEASE", 229, 241], ["diarrhoea", "DISEASE", 352, 361], ["frailty fits", "DISEASE", 427, 439], ["frailty fits", "DISEASE", 576, 588], ["diarrhoea", "DISEASE", 681, 690], ["ammonia", "CHEMICAL", 760, 767], ["frailty fits", "DISEASE", 812, 824], ["diarrhoea", "DISEASE", 859, 868], ["ammonia", "CHEMICAL", 151, 158], ["ammonia", "CHEMICAL", 760, 767], ["ammonia", "SIMPLE_CHEMICAL", 151, 158], ["calf", "ORGANISM_SUBDIVISION", 373, 377], ["barn", "ORGANISM_SUBDIVISION", 378, 382], ["ammonia", "SIMPLE_CHEMICAL", 760, 767], ["calves", "ORGANISM", 883, 889], ["calf", "SPECIES", 373, 377], ["corn", "SPECIES", 399, 403], ["calves", "SPECIES", 883, 889], ["calf barn", "SPECIES", 373, 382], ["corn", "SPECIES", 399, 403], ["diarrhoea", "PROBLEM", 66, 75], ["the dam vaccination", "TREATMENT", 93, 112], ["other agents", "TREATMENT", 121, 133], ["ammonia", "PROBLEM", 151, 158], ["Marginal versus frailty fits", "PROBLEM", 213, 241], ["the hazard risks", "PROBLEM", 246, 262], ["our study", "TEST", 313, 322], ["each diarrhoea episode in calf barn", "PROBLEM", 347, 382], ["Marginal versus frailty fits", "PROBLEM", 411, 439], ["the hazard risks", "PROBLEM", 444, 460], ["The ratio", "TEST", 460, 469], ["the naive variances", "TEST", 515, 534], ["Marginal versus frailty fits", "PROBLEM", 560, 588], ["the hazard risks", "PROBLEM", 593, 609], ["diarrhoea in the MCM", "PROBLEM", 681, 701], ["Marginal versus frailty fits", "PROBLEM", 796, 824], ["the hazard risks", "PROBLEM", 829, 845], ["diarrhoea", "PROBLEM", 859, 868], ["calf barn", "ANATOMY", 373, 382], ["robust", "OBSERVATION_MODIFIER", 477, 483], ["marginal", "OBSERVATION_MODIFIER", 485, 493], ["naive variances", "OBSERVATION", 519, 534], ["nonsignificant", "OBSERVATION_MODIFIER", 717, 731], ["diarrhoea", "OBSERVATION", 859, 868], ["higher", "OBSERVATION_MODIFIER", 873, 879]]], ["Moreover, a high incidence of diarrhoea in the previous season (1994) (1995) and dystocia increased the hazard.Marginal versus frailty fits for the hazard risksWe noted that hygiene and cleanliness seemed to have an impact on the time to diarrhoea.", [["diarrhoea", "DISEASE", 30, 39], ["dystocia", "DISEASE", 81, 89], ["frailty fits", "DISEASE", 127, 139], ["diarrhoea", "DISEASE", 238, 247], ["diarrhoea", "PROBLEM", 30, 39], ["dystocia", "PROBLEM", 81, 89], ["Marginal versus frailty fits", "PROBLEM", 111, 139], ["the hazard risks", "PROBLEM", 144, 160], ["diarrhoea", "PROBLEM", 238, 247], ["high", "OBSERVATION_MODIFIER", 12, 16], ["diarrhoea", "OBSERVATION", 30, 39]]], ["Newborn calves had a higher hazard of diarrhoea when stalls were not cleaned after the calving season, and when dams were not clean (as was observed in 43.5% of the farms).Marginal versus frailty fits for the hazard risksThe stocking of calves was considered insufficient in 33.7% of the herds and was associated with an increased hazard of diarrhoea-as was dam vaccination against other agents than pathogens associated with diarrhoea.Frailty as herd effectStandard S-PLUS output provides a significance test for the frailty: its effect was very significant (P < 0:001).", [["diarrhoea", "DISEASE", 38, 47], ["frailty fits", "DISEASE", 188, 200], ["diarrhoea", "DISEASE", 341, 350], ["diarrhoea", "DISEASE", 426, 435], ["Frailty", "DISEASE", 436, 443], ["frailty", "DISEASE", 518, 525], ["calves", "ORGANISM", 8, 14], ["calves", "ORGANISM", 237, 243], ["calves", "SPECIES", 8, 14], ["calves", "SPECIES", 237, 243], ["diarrhoea", "PROBLEM", 38, 47], ["Marginal versus frailty fits", "PROBLEM", 172, 200], ["the hazard risks", "PROBLEM", 205, 221], ["The stocking of calves", "TREATMENT", 221, 243], ["an increased hazard of diarrhoea", "PROBLEM", 318, 350], ["dam vaccination", "TREATMENT", 358, 373], ["pathogens", "PROBLEM", 400, 409], ["diarrhoea", "PROBLEM", 426, 435], ["PLUS output", "TEST", 469, 480], ["a significance test", "TEST", 490, 509], ["diarrhoea", "OBSERVATION", 38, 47], ["stocking", "OBSERVATION_MODIFIER", 225, 233], ["calves", "ANATOMY", 237, 243], ["increased", "OBSERVATION_MODIFIER", 321, 330], ["diarrhoea", "OBSERVATION", 341, 350], ["diarrhoea", "OBSERVATION", 426, 435]]], ["We also studied prediction of the frailty (Fig. 1) .", [["frailty", "DISEASE", 34, 41]]], ["As expected, we noted that among herds with the lowest predicted frailties, number of diarrhoea cases and number of censorings were deeply unbalanced: the censoring rate was always >90%.Factors related to birthSeveral factors were associated with diarrhoea hazard (including practices related to calving and the care of the calf).", [["diarrhoea", "DISEASE", 86, 95], ["diarrhoea", "DISEASE", 247, 256], ["calf", "ORGANISM_SUBDIVISION", 324, 328], ["birthSeveral factors", "PROTEIN", 205, 225], ["calf", "SPECIES", 324, 328], ["diarrhoea cases", "PROBLEM", 86, 101], ["the censoring rate", "TEST", 151, 169], ["birthSeveral factors", "PROBLEM", 205, 225], ["diarrhoea hazard", "PROBLEM", 247, 263], ["calf", "ANATOMY", 324, 328]]], ["Difficult calving causes stress for the newborn calf, which decreases resistance to pathogens owing to a combination of reduced calf vigour and delayed ingestion of colostrum.", [["colostrum", "ANATOMY", 165, 174], ["calf", "ORGANISM_SUBDIVISION", 48, 52], ["calf", "ORGANISM_SUBDIVISION", 128, 132], ["colostrum", "ORGANISM_SUBSTANCE", 165, 174], ["calf", "SPECIES", 48, 52], ["calf", "SPECIES", 128, 132], ["stress", "PROBLEM", 25, 31], ["the newborn calf", "PROBLEM", 36, 52], ["pathogens", "PROBLEM", 84, 93], ["reduced calf vigour", "PROBLEM", 120, 139], ["delayed ingestion of colostrum", "PROBLEM", 144, 174], ["newborn calf", "ANATOMY", 40, 52], ["calf", "ANATOMY", 128, 132]]], ["In addition, newborn calves which require assistance during parturition can be weakened for long periods after birth, and thus become exposed to more faecal pathogens than calves which stand up shortly after birth.Factors related to birthIn contrast to previous studies (Roy, 1990; Schumman et al., 1990; Sivula et al., 1996b) , dyspnea was not associated with the hazard of diarrhoea.", [["dyspnea", "DISEASE", 329, 336], ["diarrhoea", "DISEASE", 375, 384], ["calves", "ORGANISM", 21, 27], ["calves", "ORGANISM", 172, 178], ["calves", "SPECIES", 21, 27], ["calves", "SPECIES", 172, 178], ["newborn calves", "TREATMENT", 13, 27], ["dyspnea", "PROBLEM", 329, 336], ["diarrhoea", "PROBLEM", 375, 384], ["diarrhoea", "OBSERVATION", 375, 384]]], ["One explanation might be that the most calves (92.9%) had adequate respiration at birth.Factors related to birthColostrum factors were not associated with the hazard of gastroenteritis.", [["gastroenteritis", "DISEASE", 169, 184], ["calves", "ORGANISM", 39, 45], ["birthColostrum factors", "PROTEIN", 107, 129], ["calves", "SPECIES", 39, 45], ["birthColostrum factors", "PROBLEM", 107, 129], ["gastroenteritis", "PROBLEM", 169, 184], ["gastroenteritis", "OBSERVATION", 169, 184]]], ["One explanation may be that the most calves (76%) has a sufficient level of total serum protein (>50 g/L).Factors related to birthNo effect of the navel treatment on the days to diarrhoea was established-in agreement with Waltner-Toews et al. (1986) .Factors related to birthBecause testing the effect of birth season needs a follow-up longer than 1 or 2 years and more calendar months, we estimated the effect of the month rather than the season.", [["serum", "ANATOMY", 82, 87], ["navel", "ANATOMY", 147, 152], ["diarrhoea", "DISEASE", 178, 187], ["calves", "ORGANISM", 37, 43], ["serum", "ORGANISM_SUBSTANCE", 82, 87], ["navel", "ORGANISM_SUBDIVISION", 147, 152], ["serum protein", "PROTEIN", 82, 95], ["calves", "SPECIES", 37, 43], ["total serum protein", "TEST", 76, 95], ["the navel treatment", "TREATMENT", 143, 162], ["diarrhoea", "PROBLEM", 178, 187], ["may be", "UNCERTAINTY", 16, 22]]], ["The higher hazard was observed in March (as in the initial study; Bendali et al. 1999b ).", [["The higher hazard", "PROBLEM", 0, 17], ["the initial study", "TEST", 47, 64], ["higher", "OBSERVATION_MODIFIER", 4, 10], ["hazard", "OBSERVATION", 11, 17]]], ["This could be explained by calf overcrowding in addition to climate and weather conditions, and to a high burden of infection in the late calving season, which could be the result of the accumulation of manure and contaminated bedding.Management and ambient conditionsHerd size or type of housing did not have a significant influence on time to morbidity in our study.Management and ambient conditionsThe ammonia concentration was associated with the hazard of gastroenteritis.", [["infection", "DISEASE", 116, 125], ["ammonia", "CHEMICAL", 405, 412], ["gastroenteritis", "DISEASE", 461, 476], ["ammonia", "CHEMICAL", 405, 412], ["calf", "ORGANISM_SUBDIVISION", 27, 31], ["ammonia", "SIMPLE_CHEMICAL", 405, 412], ["calf", "SPECIES", 27, 31], ["calf overcrowding", "PROBLEM", 27, 44], ["a high burden of infection", "PROBLEM", 99, 125], ["the accumulation of manure", "PROBLEM", 183, 209], ["Management", "TREATMENT", 235, 245], ["ambient conditions", "TREATMENT", 250, 268], ["our study", "TEST", 358, 367], ["Management", "TREATMENT", 368, 378], ["ambient conditions", "TREATMENT", 383, 401], ["The ammonia concentration", "PROBLEM", 401, 426], ["gastroenteritis", "PROBLEM", 461, 476], ["could be explained", "UNCERTAINTY", 5, 23], ["calf", "ANATOMY", 27, 31], ["overcrowding", "OBSERVATION", 32, 44], ["high", "OBSERVATION_MODIFIER", 101, 105], ["burden", "OBSERVATION_MODIFIER", 106, 112], ["infection", "OBSERVATION", 116, 125], ["accumulation", "OBSERVATION_MODIFIER", 187, 199], ["manure", "OBSERVATION_MODIFIER", 203, 209], ["contaminated bedding", "OBSERVATION", 214, 234], ["size", "OBSERVATION_MODIFIER", 273, 277], ["ammonia concentration", "OBSERVATION", 405, 426], ["gastroenteritis", "OBSERVATION", 461, 476]]], ["This result might be a consequence of bad ventilation or an insufficient quantity of straw.", [["bad ventilation", "TREATMENT", 38, 53]]], ["The same value was reported by Schumman et al. (1990) when inadequate draining was observed.Management and ambient conditionsCleaning after each calving season probably leads to a reduction in the spread of the micro-organisms which are the origin of bovine diarrhoea.", [["diarrhoea", "DISEASE", 258, 267], ["bovine", "ORGANISM", 251, 257], ["diarrhoea", "ORGANISM_SUBDIVISION", 258, 267], ["bovine", "SPECIES", 251, 257], ["bovine", "SPECIES", 251, 257], ["inadequate draining", "PROBLEM", 59, 78], ["Management", "TREATMENT", 92, 102], ["ambient conditions", "TREATMENT", 107, 125], ["Cleaning", "TREATMENT", 125, 133], ["a reduction", "TREATMENT", 178, 189], ["the micro-organisms", "PROBLEM", 207, 226], ["bovine diarrhoea", "PROBLEM", 251, 267], ["draining", "OBSERVATION", 70, 78], ["reduction", "OBSERVATION_MODIFIER", 180, 189], ["bovine diarrhoea", "OBSERVATION", 251, 267]]], ["Two unexpected negative associations were found with the cleaning after each diarrhoea episode and the cleaning before each calving season.", [["diarrhoea", "DISEASE", 77, 86], ["each diarrhoea episode", "PROBLEM", 72, 94], ["the cleaning", "TREATMENT", 99, 111], ["negative", "OBSERVATION", 15, 23]]], ["One possible explanation is that farmers with herds with a history of disease would be more likely to clean and disinfect locations.", [["disease", "PROBLEM", 70, 77], ["possible explanation", "UNCERTAINTY", 4, 24]]], ["The second possible explanation is that the cleaning might have no substantial effect because the calf housing was already empty just before calving and therefore the number of pathogens already reduced.ProphylaxisHaving dams vaccinated against agents such as bovine viral diarrhoea and Clostridium perfringens-but not against E. coli-rotavirus and coronavirus, seems to decrease the hazard of diarrhoea.", [["viral diarrhoea", "DISEASE", 267, 282], ["Clostridium perfringens", "DISEASE", 287, 310], ["diarrhoea", "DISEASE", 394, 403], ["calf", "ORGANISM_SUBDIVISION", 98, 102], ["dams", "ORGANISM", 221, 225], ["bovine viral diarrhoea", "ORGANISM", 260, 282], ["Clostridium perfringens", "ORGANISM", 287, 310], ["E. coli-rotavirus", "ORGANISM", 327, 344], ["coronavirus", "ORGANISM", 349, 360], ["calf", "SPECIES", 98, 102], ["bovine", "SPECIES", 260, 266], ["Clostridium perfringens", "SPECIES", 287, 310], ["E. coli-rotavirus", "SPECIES", 327, 344], ["Clostridium perfringens", "SPECIES", 287, 310], ["E. coli-rotavirus", "SPECIES", 327, 344], ["the cleaning", "TREATMENT", 40, 52], ["pathogens", "PROBLEM", 177, 186], ["ProphylaxisHaving dams", "TREATMENT", 203, 225], ["agents", "TREATMENT", 245, 251], ["bovine viral diarrhoea", "PROBLEM", 260, 282], ["Clostridium perfringens", "PROBLEM", 287, 310], ["E. coli-rotavirus", "PROBLEM", 327, 344], ["coronavirus", "PROBLEM", 349, 360], ["diarrhoea", "PROBLEM", 394, 403], ["calf", "ANATOMY", 98, 102], ["empty", "OBSERVATION", 123, 128], ["pathogens", "OBSERVATION", 177, 186], ["diarrhoea", "OBSERVATION", 394, 403]]], ["This result could be explained by a general good management of the herd.ProphylaxisThe initial study (Bendali et al., 1999b) found an unexpected negative association between dam vaccination with E. coli and calf diarrhoea.", [["diarrhoea", "DISEASE", 212, 221], ["herd", "ORGANISM_SUBDIVISION", 67, 71], ["dam", "ORGANISM_SUBDIVISION", 174, 177], ["E. coli", "ORGANISM", 195, 202], ["calf diarrhoea", "ORGANISM", 207, 221], ["E. coli", "SPECIES", 195, 202], ["calf", "SPECIES", 207, 211], ["E. coli", "SPECIES", 195, 202], ["The initial study", "TEST", 83, 100], ["dam vaccination", "TREATMENT", 174, 189], ["E. coli", "PROBLEM", 195, 202], ["calf diarrhoea", "PROBLEM", 207, 221], ["negative", "OBSERVATION", 145, 153], ["E. coli", "OBSERVATION", 195, 202], ["calf", "ANATOMY", 207, 211], ["diarrhoea", "OBSERVATION", 212, 221]]], ["Although the hazard risk remained <1 in our study, the effect was no longer significant in these robust approaches.ProphylaxisMinerals and vitamins offered to cows during the dry period were associated with increased diarrhoea hazard.Feed factorsSeveral feed factors were tested.", [["ProphylaxisMinerals", "CHEMICAL", 115, 134], ["vitamins", "CHEMICAL", 139, 147], ["diarrhoea", "DISEASE", 217, 226], ["vitamins", "CHEMICAL", 139, 147], ["ProphylaxisMinerals", "SIMPLE_CHEMICAL", 115, 134], ["vitamins", "SIMPLE_CHEMICAL", 139, 147], ["cows", "ORGANISM", 159, 163], ["Feed factors", "PROTEIN", 234, 246], ["feed factors", "PROTEIN", 254, 266], ["cows", "SPECIES", 159, 163], ["our study", "TEST", 40, 49], ["ProphylaxisMinerals", "TREATMENT", 115, 134], ["vitamins", "TREATMENT", 139, 147], ["increased diarrhoea hazard", "PROBLEM", 207, 233], ["Several feed factors", "TREATMENT", 246, 266], ["no longer", "UNCERTAINTY", 66, 75], ["increased", "OBSERVATION_MODIFIER", 207, 216], ["diarrhoea", "OBSERVATION", 217, 226]]], ["Calves from herds with no concentrate feeding were at higher hazard of diarrhoea (HR \u00bc 1:43 in the FCM).Feed factorsFeeding corn silage has been associated with an increased hazard of diarrhoea.", [["diarrhoea", "DISEASE", 71, 80], ["diarrhoea", "DISEASE", 184, 193], ["Calves", "ORGANISM", 0, 6], ["Feed factors", "PROTEIN", 104, 116], ["Calves", "SPECIES", 0, 6], ["corn", "SPECIES", 124, 128], ["corn", "SPECIES", 124, 128], ["diarrhoea", "PROBLEM", 71, 80], ["HR", "TEST", 82, 84], ["diarrhoea", "PROBLEM", 184, 193], ["diarrhoea", "OBSERVATION", 71, 80], ["increased", "OBSERVATION_MODIFIER", 164, 173], ["diarrhoea", "OBSERVATION", 184, 193]]], ["One explanation might be that feeding additional corn silage could induce a transient increase in blood triglyceride and blood urea nitrogen, which may contribute to the hazard of diarrhoea.Feed factorsHerds with high incidences of diarrhoea in the previous calving season were more likely to show this high rate (HR \u00bc 1:45 in the FCM).", [["blood", "ANATOMY", 98, 103], ["blood", "ANATOMY", 121, 126], ["triglyceride", "CHEMICAL", 104, 116], ["blood urea nitrogen", "CHEMICAL", 121, 140], ["diarrhoea", "DISEASE", 180, 189], ["diarrhoea", "DISEASE", 232, 241], ["triglyceride", "CHEMICAL", 104, 116], ["urea", "CHEMICAL", 127, 131], ["nitrogen", "CHEMICAL", 132, 140], ["blood", "ORGANISM_SUBSTANCE", 98, 103], ["triglyceride", "SIMPLE_CHEMICAL", 104, 116], ["blood", "ORGANISM_SUBSTANCE", 121, 126], ["urea", "SIMPLE_CHEMICAL", 127, 131], ["nitrogen", "SIMPLE_CHEMICAL", 132, 140], ["Feed factors", "PROTEIN", 190, 202], ["corn", "SPECIES", 49, 53], ["corn", "SPECIES", 49, 53], ["feeding additional corn silage", "TREATMENT", 30, 60], ["a transient increase", "PROBLEM", 74, 94], ["blood triglyceride", "TEST", 98, 116], ["blood urea nitrogen", "TEST", 121, 140], ["diarrhoea", "PROBLEM", 180, 189], ["diarrhoea", "PROBLEM", 232, 241], ["HR", "TEST", 314, 316], ["transient", "OBSERVATION_MODIFIER", 76, 85], ["increase", "OBSERVATION_MODIFIER", 86, 94], ["diarrhoea", "OBSERVATION", 180, 189], ["diarrhoea", "OBSERVATION", 232, 241]]], ["This result may be explained by the fact that herd management did not change markedly from one season to the next and the concentration of pathogens remained roughly constant.", [["herd management", "TREATMENT", 46, 61], ["pathogens", "PROBLEM", 139, 148], ["pathogens", "OBSERVATION", 139, 148]]], ["Another explanation may be the possibility of transmission from older to younger animals.Feed factorsOur results showed that it is not easy to identify separately individual effects of several management practices, and very often, many factors are associated.", [["Feed factors", "PROTEIN", 89, 101], ["several management practices", "TREATMENT", 185, 213], ["may be the possibility", "UNCERTAINTY", 20, 42]]], ["The consequence is that providing advises to farmers should simultaneously takes several parameters into account.ConclusionConclusions regarding factors influencing the hazard of diarrhoea in neonatal calves from the two different models (with correlation taken into account) were similar.", [["diarrhoea", "DISEASE", 179, 188], ["calves", "ORGANISM", 201, 207], ["calves", "SPECIES", 201, 207], ["diarrhoea in neonatal calves", "PROBLEM", 179, 207], ["diarrhoea", "OBSERVATION", 179, 188]]], ["Hazards were higher when cows were not vaccinated (against a variety of specific agents), calvings needed assistance, cows were not clean, the building smelled of ammonia, and calfdiarrhoea incidence was >5% the previous year.", [["ammonia", "CHEMICAL", 163, 170], ["calfdiarrhoea", "DISEASE", 176, 189], ["ammonia", "CHEMICAL", 163, 170], ["cows", "ORGANISM", 25, 29], ["cows", "ORGANISM", 118, 122], ["ammonia", "SIMPLE_CHEMICAL", 163, 170], ["cows", "SPECIES", 25, 29], ["cows", "SPECIES", 118, 122], ["cows", "SPECIES", 25, 29], ["Hazards", "PROBLEM", 0, 7], ["specific agents", "TREATMENT", 72, 87], ["calfdiarrhoea incidence", "PROBLEM", 176, 199]]], ["However, we recommend use of the FCM if statistical inference is an intention.ConclusionFurthermore, the study of frailty allows us to distinguish between herds according to the fact that this component is an indicator of fragility.", [["the FCM", "TREATMENT", 29, 36], ["the study", "TEST", 101, 110], ["fragility", "PROBLEM", 222, 231], ["fragility", "OBSERVATION", 222, 231]]]], "PMC7492064": [["As Choy correctly points out, pulsatility could affect cortisol levels.", [["cortisol", "CHEMICAL", 55, 63], ["cortisol", "CHEMICAL", 55, 63], ["cortisol", "SIMPLE_CHEMICAL", 55, 63], ["Choy", "PROTEIN", 3, 7], ["pulsatility", "TEST", 30, 41], ["cortisol levels", "TEST", 55, 70]]], ["Gibbison and colleagues2 showed concordance of adrenocorticotropic hormone and cortisol pulses, crucially with significantly less pulsatility in critical illness compared with healthy volunteers.", [["Gibbison", "CHEMICAL", 0, 8], ["cortisol", "CHEMICAL", 79, 87], ["cortisol", "CHEMICAL", 79, 87], ["adrenocorticotropic hormone", "GENE_OR_GENE_PRODUCT", 47, 74], ["cortisol", "SIMPLE_CHEMICAL", 79, 87], ["volunteers", "ORGANISM", 184, 194], ["colleagues2", "TEST", 13, 24], ["adrenocorticotropic hormone", "TEST", 47, 74], ["cortisol pulses", "TEST", 79, 94], ["significantly less pulsatility in critical illness", "PROBLEM", 111, 161], ["adrenocorticotropic hormone", "OBSERVATION", 47, 74], ["illness", "OBSERVATION", 154, 161]]], ["This finding suggests that pulsatility might not have as great an effect on cortisol levels in critically ill patients as they would in healthy patients.", [["cortisol", "CHEMICAL", 76, 84], ["critically ill", "DISEASE", 95, 109], ["cortisol", "CHEMICAL", 76, 84], ["cortisol", "SIMPLE_CHEMICAL", 76, 84], ["patients", "ORGANISM", 110, 118], ["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 110, 118], ["patients", "SPECIES", 144, 152], ["pulsatility", "PROBLEM", 27, 38], ["cortisol levels", "TEST", 76, 91], ["pulsatility", "OBSERVATION", 27, 38]]]], "PMC7516386": [["Upper gastrointestinal bleeding (UGIB) is a common cause of hospital admissions worldwide.", [["gastrointestinal", "ANATOMY", 6, 22], ["Upper gastrointestinal bleeding", "DISEASE", 0, 31], ["UGIB", "DISEASE", 33, 37], ["Upper gastrointestinal", "ORGANISM_SUBDIVISION", 0, 22], ["Upper gastrointestinal bleeding", "PROBLEM", 0, 31], ["UGIB", "PROBLEM", 33, 37], ["gastrointestinal", "ANATOMY", 6, 22], ["bleeding", "OBSERVATION", 23, 31], ["UGIB", "OBSERVATION", 33, 37]]], ["While health care systems are under significant strain during the COVID-19 pandemic, it is logical to reduce hospital admissions for patients at very low risk of poor outcomes.", [["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 133, 141], ["significant strain", "PROBLEM", 36, 54], ["the COVID", "TEST", 62, 71], ["poor outcomes", "PROBLEM", 162, 175]]], ["Additionally, upper gastrointestinal endoscopy is recognized as an aerosol-generating procedure that should be restricted during the pandemic, because of the risk of spreading COVID-19 and the limited availability of personal protection equipment12.", [["upper gastrointestinal", "ANATOMY", 14, 36], ["upper gastrointestinal", "ORGANISM_SUBDIVISION", 14, 36], ["upper gastrointestinal endoscopy", "TEST", 14, 46], ["an aerosol-generating procedure", "TREATMENT", 64, 95], ["spreading COVID", "TEST", 166, 181], ["personal protection equipment", "TREATMENT", 217, 246], ["upper", "ANATOMY_MODIFIER", 14, 19], ["gastrointestinal", "ANATOMY", 20, 36]]], ["Therefore, elective and even urgent endoscopy has been suspended in many centers worldwide.", [["urgent endoscopy", "TEST", 29, 45]]], ["Current guidelines recommend the use of the Glasgow-Blatchford Score (GBS) for predicting the need for hospital-based intervention in patients with UGIB34.", [["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142], ["hospital-based intervention", "TREATMENT", 103, 130], ["UGIB34", "TREATMENT", 148, 154]]], ["Patients with GBS \u2264 1 are recognized to be at very low risk and can safely be managed as outpatients with no need for inpatient endoscopy34.", [["GBS", "DISEASE", 14, 17], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["GBS", "PROBLEM", 14, 17], ["inpatient endoscopy34", "TREATMENT", 118, 139]]]]}